{
  "id": "acr-html-b8df24",
  "title": "acr_html",
  "source": "acr_html.html",
  "blocks": [
    {
      "type": "image",
      "assetId": "asset_df87cfa437",
      "alt": "background image"
    },
    {
      "type": "image",
      "assetId": "asset_6a98f4f635",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ACR Manual on Contrast"
    },
    {
      "type": "paragraph",
      "text": "Media"
    },
    {
      "type": "paragraph",
      "text": "2025"
    },
    {
      "type": "paragraph",
      "text": "ACR Committee on Drugs and Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Copyright 2025 American College of Radiology"
    },
    {
      "type": "image",
      "assetId": "asset_befb7d559b",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE OF CONTENTS"
    },
    {
      "type": "paragraph",
      "text": "Topic"
    },
    {
      "type": "paragraph",
      "text": "Page"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Preface"
    },
    {
      "type": "paragraph",
      "text": "1"
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Version History"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Introduction"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Patient Selection and Preparation Strategies Before Contrast Medium Administration"
    },
    {
      "type": "paragraph",
      "text": "5"
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Fasting Prior to Intravascular Contrast Media Administration"
    },
    {
      "type": "paragraph",
      "text": "13"
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Safe Injection of Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "14"
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Extravasation of Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2022 Evidence Based Update"
    },
    {
      "type": "paragraph",
      "text": "17"
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "Allergic-Like and Physiologic Reactions to Intravascular Iodinated Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "26"
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Contrast Media Warming"
    },
    {
      "type": "paragraph",
      "text": "32"
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Post-Contrast Acute Kidney Injury and Contrast-Induced Nephropathy in Adults"
    },
    {
      "type": "paragraph",
      "text": "35"
    },
    {
      "type": "paragraph",
      "text": "11."
    },
    {
      "type": "paragraph",
      "text": "Metformin"
    },
    {
      "type": "paragraph",
      "text": "44"
    },
    {
      "type": "paragraph",
      "text": "12."
    },
    {
      "type": "paragraph",
      "text": "Contrast Media in Children"
    },
    {
      "type": "paragraph",
      "text": "47"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Ferumoxytol as MRI Contrast Medium"
    },
    {
      "type": "paragraph",
      "text": "(New 2024 addition)"
    },
    {
      "type": "paragraph",
      "text": "57"
    },
    {
      "type": "paragraph",
      "text": "13."
    },
    {
      "type": "paragraph",
      "text": "Gastrointestinal (GI) Contrast Media in Adults: Indications and Guidelines"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2024 Update"
    },
    {
      "type": "paragraph",
      "text": "61"
    },
    {
      "type": "paragraph",
      "text": "14."
    },
    {
      "type": "paragraph",
      "text": "ACR"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "ASNR Position Statement on the Use of Gadolinium Contrast Agents"
    },
    {
      "type": "paragraph",
      "text": "70"
    },
    {
      "type": "paragraph",
      "text": "15."
    },
    {
      "type": "paragraph",
      "text": "Adverse Reactions to Gadolinium-Based Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "71"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Gadolinium Pregnancy Screening Statement"
    },
    {
      "type": "paragraph",
      "text": "(2023 addition)"
    },
    {
      "type": "paragraph",
      "text": "74"
    },
    {
      "type": "paragraph",
      "text": "16."
    },
    {
      "type": "paragraph",
      "text": "Nephrogenic Systemic Fibrosis (NSF)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "("
    },
    {
      "type": "paragraph",
      "text": "2025 Update)"
    },
    {
      "type": "paragraph",
      "text": "75"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "ACR Manual Classification of Gadolinium-Based Agents Relative to Nephrogenic Systemic Fibrosis"
    },
    {
      "type": "paragraph",
      "text": "80"
    },
    {
      "type": "paragraph",
      "text": "17."
    },
    {
      "type": "paragraph",
      "text": "Ultrasound Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "81"
    },
    {
      "type": "paragraph",
      "text": "18."
    },
    {
      "type": "paragraph",
      "text": "Treatment of Contrast Reactions"
    },
    {
      "type": "paragraph",
      "text": "86"
    },
    {
      "type": "paragraph",
      "text": "19."
    },
    {
      "type": "paragraph",
      "text": "Administration of Contrast Media to Pregnant or Potentially Pregnant Patients"
    },
    {
      "type": "paragraph",
      "text": "88"
    },
    {
      "type": "paragraph",
      "text": "20."
    },
    {
      "type": "paragraph",
      "text": "Administration of Contrast Media to Patients Who are Breast-Feeding"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2024 Evidenced Based Update"
    },
    {
      "type": "paragraph",
      "text": "92"
    },
    {
      "type": "paragraph",
      "text": "Table 1"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Categories of Acute Reactions"
    },
    {
      "type": "paragraph",
      "text": "95"
    },
    {
      "type": "paragraph",
      "text": "Table 2"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Treatment Of Acute Reactions to Contrast Media In Children"
    },
    {
      "type": "paragraph",
      "text": "97"
    },
    {
      "type": "paragraph",
      "text": "Table 3"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Management Of Acute Reactions to Contrast Media In Adults"
    },
    {
      "type": "paragraph",
      "text": "104"
    },
    {
      "type": "paragraph",
      "text": "Table 4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Equipment For Contrast Reaction Kits in Radiology"
    },
    {
      "type": "paragraph",
      "text": "112"
    },
    {
      "type": "paragraph",
      "text": "Appendix A"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Contrast Media Specifications"
    },
    {
      "type": "paragraph",
      "text": "114"
    },
    {
      "type": "image",
      "assetId": "asset_aaac0b5d49",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ACR MANUAL ON CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "PREFACE"
    },
    {
      "type": "paragraph",
      "text": "1"
    },
    {
      "type": "paragraph",
      "text": "PREFACE"
    },
    {
      "type": "paragraph",
      "text": "This edition of the"
    },
    {
      "type": "paragraph",
      "text": "ACR Manual on Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "replaces all earlier editions. It is being published as a web-based document"
    },
    {
      "type": "paragraph",
      "text": "only so it can be updated as frequently as needed."
    },
    {
      "type": "paragraph",
      "text": "This manual was developed by the ACR Committee on Drugs and Contrast Media of the ACR Commission on Quality and"
    },
    {
      "type": "paragraph",
      "text": "Safety as a guide for radiologists to enhance the safe and effective use of contrast media. The Committee offers this document"
    },
    {
      "type": "paragraph",
      "text": "to practicing radiologists as a consensus of scientific evidence and clinical experience concerning the use of contrast media."
    },
    {
      "type": "paragraph",
      "text": "Suggestions for patient screening, premedication, recognition of adverse reactions, and emergency treatment of such reactions"
    },
    {
      "type": "paragraph",
      "text": "are emphasized. Its major purpose is to provide useful information regarding contrast media used in daily practice."
    },
    {
      "type": "paragraph",
      "text": "The editorial staff sincerely thanks all who have contributed their knowledge and valuable time to this publication."
    },
    {
      "type": "paragraph",
      "text": "Members of the ACR Committee on Drugs and Contrast Media are:"
    },
    {
      "type": "paragraph",
      "text": "Carolyn Wang, MD, Chair"
    },
    {
      "type": "paragraph",
      "text": "Pranay Krishnan, MD"
    },
    {
      "type": "paragraph",
      "text": "Daniella Asch, MD"
    },
    {
      "type": "paragraph",
      "text": "Robert J. McDonald, MD"
    },
    {
      "type": "paragraph",
      "text": "Kirk G. Banerian, MD, FACR"
    },
    {
      "type": "paragraph",
      "text": "Jennifer McDonald, PhD"
    },
    {
      "type": "paragraph",
      "text": "Mustafa Shadi Rifaat Bashir, MD"
    },
    {
      "type": "paragraph",
      "text": "Benjamin Mervak, MD"
    },
    {
      "type": "paragraph",
      "text": "Michael James Callahan, MD"
    },
    {
      "type": "paragraph",
      "text": "Jeffrey Newhouse, MD, FACR"
    },
    {
      "type": "paragraph",
      "text": "Jonathan Dillman, MD, MSc"
    },
    {
      "type": "paragraph",
      "text": "Jay Pahade, MD"
    },
    {
      "type": "paragraph",
      "text": "James Ellis, MD, FACR"
    },
    {
      "type": "paragraph",
      "text": "Jennifer G. Schopp, MD"
    },
    {
      "type": "paragraph",
      "text": "Monica Forbes-Amrhein, MD"
    },
    {
      "type": "paragraph",
      "text": "Prasad R. Shankar, MD"
    },
    {
      "type": "paragraph",
      "text": "Leah Gilligan, MD"
    },
    {
      "type": "paragraph",
      "text": "Kerry L. Thomas, MD"
    },
    {
      "type": "paragraph",
      "text": "Finally, the committee wishes to recognize the efforts of supporting members of the ACR staff."
    },
    {
      "type": "paragraph",
      "text": "The manual is copyright protected and the property of the American College of Radiology. Any reproduction or attempt to"
    },
    {
      "type": "paragraph",
      "text": "sell this manual is strictly prohibited absent the express permission of the American College of Radiology."
    },
    {
      "type": "image",
      "assetId": "asset_92e8119fb9",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ACR MANUAL ON CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "VERSION HISTORY"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "VERSION HISTORY"
    },
    {
      "type": "paragraph",
      "text": "2025"
    },
    {
      "type": "paragraph",
      "text": "Version 2025 of the ACR Manual on Contrast Media was published as a web-based product. Content changes may take place as"
    },
    {
      "type": "paragraph",
      "text": "a result of changes in technology, clinical treatment, or other evidence-based decisions from the contrast committee."
    },
    {
      "type": "paragraph",
      "text": "The following changes have been made:"
    },
    {
      "type": "paragraph",
      "text": "Last Updated"
    },
    {
      "type": "paragraph",
      "text": "Chapter"
    },
    {
      "type": "paragraph",
      "text": "Change"
    },
    {
      "type": "paragraph",
      "text": "2010"
    },
    {
      "type": "paragraph",
      "text": "Introduction"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2013"
    },
    {
      "type": "paragraph",
      "text": "Chapter 7"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Allergic-like and Physiologic Reactions to Intravascular Iodinated Contrast"
    },
    {
      "type": "paragraph",
      "text": "Media"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2013"
    },
    {
      "type": "paragraph",
      "text": "Chapter 8"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Contrast Media in Children"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2013"
    },
    {
      "type": "paragraph",
      "text": "Chapter 12"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Gastrointestinal (GI) Contrast Media in Adults: indications and"
    },
    {
      "type": "paragraph",
      "text": "Guidelines"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2013"
    },
    {
      "type": "paragraph",
      "text": "Chapter 19 - Administration of Contrast Media to Women Who Are Breast-Feeding"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2014"
    },
    {
      "type": "paragraph",
      "text": "Chapter 11- Contrast Media in Children"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2014"
    },
    {
      "type": "paragraph",
      "text": "Appendix A"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2015"
    },
    {
      "type": "paragraph",
      "text": "Preface"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2016"
    },
    {
      "type": "paragraph",
      "text": "Chapter 13"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "ACR-ASNR Position Statement on the Use of Gadolinium Contrast"
    },
    {
      "type": "paragraph",
      "text": "Agents"
    },
    {
      "type": "paragraph",
      "text": "A collaborative statement on"
    },
    {
      "type": "paragraph",
      "text": "gadolinium deposition was added to the"
    },
    {
      "type": "paragraph",
      "text": "manual"
    },
    {
      "type": "paragraph",
      "text": "2016"
    },
    {
      "type": "paragraph",
      "text": "Table 1"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Indications for Use of Iodinated Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Deleted"
    },
    {
      "type": "paragraph",
      "text": "2016"
    },
    {
      "type": "paragraph",
      "text": "Table 2"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Organ and System-Specific Adverse Effects from the Administration of"
    },
    {
      "type": "paragraph",
      "text": "Iodine-Based or Gadolinium-Based Contrast Agents"
    },
    {
      "type": "paragraph",
      "text": "Deleted"
    },
    {
      "type": "paragraph",
      "text": "2016"
    },
    {
      "type": "paragraph",
      "text": "Chapter 9"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Metformin"
    },
    {
      "type": "paragraph",
      "text": "Updated footnote based on new FDA advisory"
    },
    {
      "type": "paragraph",
      "text": "2016"
    },
    {
      "type": "paragraph",
      "text": "Chapter 14"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Injection of Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "New section on intra-osseous injection"
    },
    {
      "type": "paragraph",
      "text": "2016"
    },
    {
      "type": "paragraph",
      "text": "Chapter 13"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "ACR-ASNR Position Statement on the Use of Gadolinium Contrast"
    },
    {
      "type": "paragraph",
      "text": "Agents"
    },
    {
      "type": "paragraph",
      "text": "New Chapter added"
    },
    {
      "type": "paragraph",
      "text": "2017"
    },
    {
      "type": "paragraph",
      "text": "Chapter 15"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Nephrogenic Systemic Fibrosis"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2017"
    },
    {
      "type": "paragraph",
      "text": "Chapter 4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Patient Selection and Preparation Strategies"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2017"
    },
    {
      "type": "paragraph",
      "text": "Chapter 17"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Ultrasound Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "New chapter added"
    },
    {
      "type": "paragraph",
      "text": "2017"
    },
    {
      "type": "paragraph",
      "text": "Chapter 19"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Administration of Contrast Media to Pregnant or Potentially Pregnant"
    },
    {
      "type": "paragraph",
      "text": "Patients"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2018"
    },
    {
      "type": "paragraph",
      "text": "Chapter 5"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Injection of Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2018"
    },
    {
      "type": "paragraph",
      "text": "Chapter 6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Extravasation of Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2020"
    },
    {
      "type": "paragraph",
      "text": "Chapter 18"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Treatment of Contrast Reactions"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2020"
    },
    {
      "type": "paragraph",
      "text": "Table 4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Equipment for Contrast Reaction Kits in Radiology"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "image",
      "assetId": "asset_8117d6f7d8",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ACR MANUAL ON CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "VERSION HISTORY"
    },
    {
      "type": "paragraph",
      "text": "3"
    },
    {
      "type": "paragraph",
      "text": "2020"
    },
    {
      "type": "paragraph",
      "text": "Appendix (Approved Contrast Media Agents)"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2021"
    },
    {
      "type": "paragraph",
      "text": "Chapter 5 - Fasting Prior to Intravascular Contrast Media Administration"
    },
    {
      "type": "paragraph",
      "text": "New added chapter"
    },
    {
      "type": "paragraph",
      "text": "2021"
    },
    {
      "type": "paragraph",
      "text": "Chapter 10 - Post-Contrast Acute Kidney Injury and Contrast-Induced"
    },
    {
      "type": "paragraph",
      "text": "Nephropathy in Adults"
    },
    {
      "type": "paragraph",
      "text": "ACR-NKF Consensus language harmonization"
    },
    {
      "type": "paragraph",
      "text": "update with chapter title change"
    },
    {
      "type": "paragraph",
      "text": "2021"
    },
    {
      "type": "paragraph",
      "text": "Chapter 16 - Nephrogenic Systemic Fibrosis (NSF)"
    },
    {
      "type": "paragraph",
      "text": "ACR-NKF Consensus language harmonization"
    },
    {
      "type": "paragraph",
      "text": "update"
    },
    {
      "type": "paragraph",
      "text": "2022"
    },
    {
      "type": "paragraph",
      "text": "Chapter 7"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Extravasation of Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Evidence based update with recommendations"
    },
    {
      "type": "paragraph",
      "text": "and strength of evidence"
    },
    {
      "type": "paragraph",
      "text": "2022"
    },
    {
      "type": "paragraph",
      "text": "Chapter 15 - Adverse Reactions To Gadolinium-Based Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "New Gadolinium Pregnancy Screening"
    },
    {
      "type": "paragraph",
      "text": "Statement"
    },
    {
      "type": "paragraph",
      "text": "2023"
    },
    {
      "type": "paragraph",
      "text": "Chapter 16 - Nephrogenic Systemic Fibrosis (NSF)"
    },
    {
      "type": "paragraph",
      "text": "Updated Calculating eGFR for Adults"
    },
    {
      "type": "paragraph",
      "text": "2023"
    },
    {
      "type": "paragraph",
      "text": "TABLE 1. ACR Manual Classification of Gadolinium-Based Agents Relative to"
    },
    {
      "type": "paragraph",
      "text": "Nephrogenic Systemic Fibrosis"
    },
    {
      "type": "paragraph",
      "text": "Gadopiclenol Update"
    },
    {
      "type": "paragraph",
      "text": "2023"
    },
    {
      "type": "paragraph",
      "text": "Appendix A"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Contrast Media Specifications"
    },
    {
      "type": "paragraph",
      "text": "Gadopiclenol Update"
    },
    {
      "type": "paragraph",
      "text": "2024"
    },
    {
      "type": "paragraph",
      "text": "TABLE 1. ACR Manual Classification of Gadolinium-Based Agents Relative to"
    },
    {
      "type": "paragraph",
      "text": "Nephrogenic Systemic Fibrosis"
    },
    {
      "type": "paragraph",
      "text": "Eovist Update"
    },
    {
      "type": "paragraph",
      "text": "2024"
    },
    {
      "type": "paragraph",
      "text": "Chapter 12"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Contrast Media in Children"
    },
    {
      "type": "paragraph",
      "text": "Update and New Ferumoxytol addition"
    },
    {
      "type": "paragraph",
      "text": "2024"
    },
    {
      "type": "paragraph",
      "text": "Chapter 13 - Gastrointestinal (GI) Contrast Media in Adults: indications and"
    },
    {
      "type": "paragraph",
      "text": "Guidelines"
    },
    {
      "type": "paragraph",
      "text": "Updated"
    },
    {
      "type": "paragraph",
      "text": "2024"
    },
    {
      "type": "paragraph",
      "text": "Chapter 20 - Administration of Contrast Media to Women Who are Breast-Feeding"
    },
    {
      "type": "paragraph",
      "text": "Evidence based update with recommendations"
    },
    {
      "type": "paragraph",
      "text": "and strength of evidence"
    },
    {
      "type": "paragraph",
      "text": "2025"
    },
    {
      "type": "paragraph",
      "text": "Chapter 16 - Nephrogenic Systemic Fibrosis (NSF)"
    },
    {
      "type": "paragraph",
      "text": "Clarification on gadolinium-based contrast"
    },
    {
      "type": "paragraph",
      "text": "agent groups"
    },
    {
      "type": "image",
      "assetId": "asset_067f087fab",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ACR MANUAL ON CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "INTRODUCTION"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "INTRODUCTION"
    },
    {
      "type": "paragraph",
      "text": "Various forms of contrast media have been used to improve medical imaging. Their value has long been recognized, as"
    },
    {
      "type": "paragraph",
      "text": "attested to by their common daily use in imaging departments worldwide. Like all other pharmaceuticals, however, these"
    },
    {
      "type": "paragraph",
      "text": "agents are not completely devoid of risk. The major purpose of this manual is to assist radiologists in recognizing and"
    },
    {
      "type": "paragraph",
      "text": "managing the small but real risks inherent in the use of contrast media."
    },
    {
      "type": "paragraph",
      "text": "Adverse side effects from the administration of contrast media vary from minor physiological disturbances to rare severe"
    },
    {
      "type": "paragraph",
      "text": "life-threatening situations. Preparation for prompt treatment of contrast media reactions must include preparation for the"
    },
    {
      "type": "paragraph",
      "text": "entire spectrum of potential adverse events and include prearranged response planning with availability of appropriately"
    },
    {
      "type": "paragraph",
      "text": "trained personnel, equipment, and medications. Therefore, such preparation is best accomplished prior to approving and"
    },
    {
      "type": "paragraph",
      "text": "performing these examinations. Additionally, an ongoing quality assurance and quality improvement program for all"
    },
    {
      "type": "paragraph",
      "text": "radiologists and technologists and the requisite equipment are recommended. Thorough familiarity with the presentation"
    },
    {
      "type": "paragraph",
      "text": "and emergency treatment of contrast media reactions must be part of the environment in which all intravascular contrast"
    },
    {
      "type": "paragraph",
      "text": "media are administered."
    },
    {
      "type": "paragraph",
      "text": "Millions of radiological examinations assisted by intravascular contrast media are conducted each year in North America."
    },
    {
      "type": "paragraph",
      "text": "Although adverse side effects are infrequent, a detailed knowledge of the variety of side effects, their likelihood in"
    },
    {
      "type": "paragraph",
      "text": "relationship to pre-existing conditions, and their treatment is required to insure optimal patient care."
    },
    {
      "type": "paragraph",
      "text": "As would be appropriate with any diagnostic procedure, preliminary considerations for the referring physician and the"
    },
    {
      "type": "paragraph",
      "text": "radiologist include:"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Assessment of patient risk versus potential benefit of the contrast-assisted examination."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Imaging alternatives that would provide the same or better diagnostic information."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Assurance of a valid clinical indication for each contrast medium administration."
    },
    {
      "type": "paragraph",
      "text": "Because of the documented low incidence of adverse events, intravenous injection of contrast media may be exempted from"
    },
    {
      "type": "paragraph",
      "text": "the need for informed consent, but this decision should be based on state law, institutional policy, and departmental policy."
    },
    {
      "type": "paragraph",
      "text": "Usage Note:"
    },
    {
      "type": "paragraph",
      "text": "In this manual, the term low"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "osmolality in reference to radiographic iodinated contrast media is intended to"
    },
    {
      "type": "paragraph",
      "text": "encompass both low-osmolality and iso-osmolality media, the former having osmolality approximately twice that of human"
    },
    {
      "type": "paragraph",
      "text": "serum, and the latter having osmolality approximately that of human serum at conventionally used iodine concentrations for"
    },
    {
      "type": "paragraph",
      "text": "vascular injection. Also, unless otherwise obvious in context, this manual focuses on issues concerning radiographic"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast media."
    },
    {
      "type": "image",
      "assetId": "asset_bec865cdc5",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "PATIENT SELECTION AND PREPARATION STRATEGIES BEFORE CONTRAST MEDIUM ADMINISTRATION"
    },
    {
      "type": "paragraph",
      "text": "5"
    },
    {
      "type": "paragraph",
      "text": "PATIENT SELECTION AND PREPARATION STRATEGIES BEFORE"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIUM ADMINISTRATION"
    },
    {
      "type": "paragraph",
      "text": "General Considerations"
    },
    {
      "type": "paragraph",
      "text": "The approach to patients about to undergo a contrast-enhanced examination has four general goals:"
    },
    {
      "type": "paragraph",
      "text": "1)"
    },
    {
      "type": "paragraph",
      "text": "Ensure that the administration of contrast is appropriate for the patient and the indication"
    },
    {
      "type": "paragraph",
      "text": "2)"
    },
    {
      "type": "paragraph",
      "text": "Balance the likelihood of an adverse event with the benefit of the examination"
    },
    {
      "type": "paragraph",
      "text": "3)"
    },
    {
      "type": "paragraph",
      "text": "Promote efficient and accurate diagnosis and treatment"
    },
    {
      "type": "paragraph",
      "text": "4)"
    },
    {
      "type": "paragraph",
      "text": "Be prepared to treat a reaction should one occur (see"
    },
    {
      "type": "paragraph",
      "text": "Tables 2"
    },
    {
      "type": "paragraph",
      "text": ", and"
    },
    {
      "type": "paragraph",
      "text": "3"
    },
    {
      "type": "paragraph",
      "text": ")"
    },
    {
      "type": "paragraph",
      "text": "Achieving these aims depends on obtaining an appropriate and adequate history for each patient, considering the risks and"
    },
    {
      "type": "paragraph",
      "text": "benefit of using or avoiding contrast medium, preparing the patient appropriately for the examination, having equipment"
    },
    {
      "type": "paragraph",
      "text": "available to treat reactions, and ensuring that personnel with sufficient expertise are available to treat severe reactions."
    },
    {
      "type": "paragraph",
      "text": "The history obtained should focus on identification of factors that may indicate either a contraindication to contrast media use"
    },
    {
      "type": "paragraph",
      "text": "or an increased likelihood of an adverse event. Screening questions should include historical elements that will affect decision-"
    },
    {
      "type": "paragraph",
      "text": "making in the patient selection and preparation period."
    },
    {
      "type": "paragraph",
      "text": "Risk Factors for Adverse Reactions to Intravenous"
    },
    {
      "type": "paragraph",
      "text": "Contrast Media Primary Considerations"
    },
    {
      "type": "paragraph",
      "text": "Allergic-like reactions to modern iodinated and gadolinium-based contrast medium are uncommon (iodinated: 0.6% aggregate"
    },
    {
      "type": "paragraph",
      "text": "[1], 0.04% severe [2]; gadolinium-based: 0.01-0.22% aggregate [2], 0.008% severe) [3]. Risk factors exist that increase the risk"
    },
    {
      "type": "paragraph",
      "text": "of a contrast reaction. These generally increase the likelihood of a reaction by less than one order of magnitude, effectively"
    },
    {
      "type": "paragraph",
      "text": "increasing the risk that an uncommon event will occur, but not guaranteeing a reaction will take place. The following are some"
    },
    {
      "type": "paragraph",
      "text": "examples:"
    },
    {
      "type": "paragraph",
      "text": "Allergy:"
    },
    {
      "type": "paragraph",
      "text": "Patients who have had a prior allergic-like reaction or unknown-type reaction (i.e., a reaction of unknown"
    },
    {
      "type": "paragraph",
      "text": "manifestation) to contrast medium have an approximately 5-fold increased risk of developing a future allergic-like reaction if"
    },
    {
      "type": "paragraph",
      "text": "exposed to the same class of contrast medium again [2]. A prior allergic-like or unknown type reaction to the same class of"
    },
    {
      "type": "paragraph",
      "text": "contrast medium is considered the greatest risk factor for predicting future adverse events."
    },
    {
      "type": "paragraph",
      "text": "In general, patients with unrelated allergies are at a 2- to 3-fold increased risk of an allergic-like contrast reaction, but due to"
    },
    {
      "type": "paragraph",
      "text": "the modest increased risk, restricting contrast medium use or premedicating solely on the basis of unrelated allergies is not"
    },
    {
      "type": "paragraph",
      "text": "recommended. Patients with shellfish or povidone-iodine (e.g., Betadine"
    },
    {
      "type": "paragraph",
      "text": "(R)"
    },
    {
      "type": "paragraph",
      "text": ") allergies are at no greater risk from iodinated contrast"
    },
    {
      "type": "paragraph",
      "text": "medium than are patients with other allergies (i.e., neither is a significant risk factor) [4,5]."
    },
    {
      "type": "paragraph",
      "text": "There is no cross-reactivity between different classes of contrast medium. For example, a prior reaction to gadolinium-based"
    },
    {
      "type": "paragraph",
      "text": "contrast medium does not predict a future reaction to iodinated contrast medium, or vice versa, more than any other unrelated"
    },
    {
      "type": "paragraph",
      "text": "allergy."
    },
    {
      "type": "paragraph",
      "text": "Asthma:"
    },
    {
      "type": "paragraph",
      "text": "A history of asthma increases the likelihood of an allergic-like contrast reaction [2,6]."
    },
    {
      "type": "paragraph",
      "text": "Patients with asthma may be more prone to develop bronchospasm. Due to the modest increased risk, restricting contrast"
    },
    {
      "type": "paragraph",
      "text": "medium use or premedicating solely on the basis of a history of asthma is not recommended."
    },
    {
      "type": "paragraph",
      "text": "Renal Insufficiency:"
    },
    {
      "type": "paragraph",
      "text": "Screening and selection strategies to mitigate the possible risks of the non-allergic adverse events of"
    },
    {
      "type": "paragraph",
      "text": "contrast-induced nephrotoxicity (CIN) and nephrogenic systemic fibrosis (NSF) can be found in the Chapters on"
    },
    {
      "type": "paragraph",
      "text": "Post-Contrast"
    },
    {
      "type": "paragraph",
      "text": "Acute Kidney Injury and Contrast Induced Nephropathy in Adults"
    },
    {
      "type": "paragraph",
      "text": "and"
    },
    {
      "type": "paragraph",
      "text": "Nephrogenic Systemic Fibrosis."
    },
    {
      "type": "paragraph",
      "text": "Cardiac Status:"
    },
    {
      "type": "paragraph",
      "text": "Patients with severe cardiac disease may be at increased risk of a non-allergic cardiac event if an allergic-like"
    },
    {
      "type": "paragraph",
      "text": "or non-allergic contrast reaction occurs. These include symptomatic patients (e.g., patients with angina or congestive heart"
    },
    {
      "type": "paragraph",
      "text": "failure symptoms with minimal exertion) and also patients with severe aortic stenosis, cardiac arrhythmias, primary pulmonary"
    },
    {
      "type": "image",
      "assetId": "asset_8d735af874",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "PATIENT SELECTION AND PREPARATION STRATEGIES BEFORE CONTRAST MEDIUM ADMINISTRATION"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "hypertension, or severe but compensated cardiomyopathy. Due to the modest increased risk, restricting contrast medium use"
    },
    {
      "type": "paragraph",
      "text": "or premedicating solely on the basis of a patients cardiac status is not recommended."
    },
    {
      "type": "paragraph",
      "text": "Anxiety:"
    },
    {
      "type": "paragraph",
      "text": "There is some evidence that contrast reactions are more common in anxious patients [7]. Reassuring an anxious"
    },
    {
      "type": "paragraph",
      "text": "patient before contrast medium injection may mitigate the likelihood of a mild contrast reaction."
    },
    {
      "type": "paragraph",
      "text": "Other Historical and Pre-Procedure Considerations"
    },
    {
      "type": "paragraph",
      "text": "Age and Gender:"
    },
    {
      "type": "paragraph",
      "text": "Infants, neonates, children, and the elderly have lower reaction rates than middle-aged patients [1,8]. Male"
    },
    {
      "type": "paragraph",
      "text": "patients have lower reaction rates than female patients. Due to the modest increased risk, restricting contrast medium use or"
    },
    {
      "type": "paragraph",
      "text": "premedicating solely on the basis of patient age or gender is not recommended."
    },
    {
      "type": "paragraph",
      "text": "Beta-Blockers:"
    },
    {
      "type": "paragraph",
      "text": "Some have suggested that use of beta-blockers lowers the threshold for contrast reactions, increases the"
    },
    {
      "type": "paragraph",
      "text": "severity of contrast reactions, and reduces the responsiveness of treatment with epinephrine [9]. Due to the modest increased"
    },
    {
      "type": "paragraph",
      "text": "risk, restricting contrast medium use or premedicating solely on the basis of beta-blocker use is not recommended. Patients"
    },
    {
      "type": "paragraph",
      "text": "on beta-blocker therapy do not need to discontinue their medication(s) prior to contrast medium administration."
    },
    {
      "type": "paragraph",
      "text": "Sickle-Cell Trait/Disease:"
    },
    {
      "type": "paragraph",
      "text": "Some have suggested that contrast medium exposure to patients with sickle cell trait or sickle"
    },
    {
      "type": "paragraph",
      "text": "cell disease might increase the risk of an acute sickle crisis; however, there is no evidence this occurs with modern"
    },
    {
      "type": "paragraph",
      "text": "iodinated or gadolinium-based contrast medium [10]. Therefore, restricting contrast medium use or premedicating solely"
    },
    {
      "type": "paragraph",
      "text": "on the basis of sickle cell trait or sickle cell disease is not recommended."
    },
    {
      "type": "paragraph",
      "text": "Pheochromocytoma:"
    },
    {
      "type": "paragraph",
      "text": "There is no evidence that IV administration of modern iodinated or gadolinium-based contrast medium"
    },
    {
      "type": "paragraph",
      "text": "increases the risk of hypertensive crisis in patients with pheochromocytoma [11]. Therefore, restricting contrast medium use"
    },
    {
      "type": "paragraph",
      "text": "or premedicating solely on the basis of a history of pheochromocytoma is not recommended. Direct injection of any type of"
    },
    {
      "type": "paragraph",
      "text": "contrast medium into the adrenal or renal arteries in a patient with pheochromocytoma has not been adequately studied and is"
    },
    {
      "type": "paragraph",
      "text": "of unknown risk."
    },
    {
      "type": "paragraph",
      "text": "Myasthenia Gravis:"
    },
    {
      "type": "paragraph",
      "text": "There is a questionable relationship between IV iodinated contrast medium and exacerbations of"
    },
    {
      "type": "paragraph",
      "text": "myasthenic symptoms in patients with myasthenia gravis. While one retrospective study showed no immediate increase in"
    },
    {
      "type": "paragraph",
      "text": "myasthenic symptoms following the administration of iodinated or gadolinium-based contrast medium [12], another that"
    },
    {
      "type": "paragraph",
      "text": "searched for myasthenic exacerbations occurring up to 45 days after a CT scan found that IV non-ionic iodinated contrast"
    },
    {
      "type": "paragraph",
      "text": "medium was associated with an acute (within 1 day of contrast administration) myasthenic exacerbation in approximately 6%"
    },
    {
      "type": "paragraph",
      "text": "of patients (compared to a 1% acute exacerbation rate in patients who had undergone non-contrast CT,"
    },
    {
      "type": "paragraph",
      "text": "p=0.01"
    },
    {
      "type": "paragraph",
      "text": ") [13]. However,"
    },
    {
      "type": "paragraph",
      "text": "that study was retrospective, and the number of events was small. Premedication is not recommended solely on the basis of a"
    },
    {
      "type": "paragraph",
      "text": "history of myasthenia gravis. It is controversial whether iodinated contrast medium should be considered a relative"
    },
    {
      "type": "paragraph",
      "text": "contraindication in patients with myasthenia gravis."
    },
    {
      "type": "paragraph",
      "text": "Hyperthyroidism:"
    },
    {
      "type": "paragraph",
      "text": "Patients with a history of hyperthyroidism can develop thyrotoxicosis after exposure to iodinated contrast"
    },
    {
      "type": "paragraph",
      "text": "medium, but this complication is rare [14]. Therefore, restricting contrast medium use or premedicating solely on the basis of"
    },
    {
      "type": "paragraph",
      "text": "a history of hyperthyroidism is not recommended. However, two special situations may affect this:"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "In patients with acute thyroid storm, iodinated contrast medium exposure can potentiate thyrotoxicosis; in such"
    },
    {
      "type": "paragraph",
      "text": "patients, iodinated contrast medium should be avoided. Corticosteroid premedication in this setting is unlikely to"
    },
    {
      "type": "paragraph",
      "text": "be helpful."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "In patients considering radioactive iodine therapy or in patients undergoing radioactive iodine imaging of the"
    },
    {
      "type": "paragraph",
      "text": "thyroid gland, administration of iodinated contrast medium can interfere with uptake of the treatment and diagnostic"
    },
    {
      "type": "paragraph",
      "text": "dose. If iodinated contrast medium was administered, a washout period is suggested to minimize this interaction."
    },
    {
      "type": "paragraph",
      "text": "The washout period is ideally 3-4 weeks for patients with hyperthyroidism, and 6 weeks for patients with"
    },
    {
      "type": "paragraph",
      "text": "hypothyroidism [15,16]."
    },
    {
      "type": "paragraph",
      "text": "Normal Thyroid Function:"
    },
    {
      "type": "paragraph",
      "text": "Iodinated contrast medium does not affect thyroid function test results in patients with a"
    },
    {
      "type": "paragraph",
      "text": "normally functioning thyroid gland [14]. Multiple studies have shown that a single dose of iodinated contrast medium"
    },
    {
      "type": "paragraph",
      "text": "administered to a pregnant mother has no effect on neonatal thyroid function."
    },
    {
      "type": "image",
      "assetId": "asset_9b575e74ca",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "PATIENT SELECTION AND PREPARATION STRATEGIES BEFORE CONTRAST MEDIUM ADMINISTRATION"
    },
    {
      "type": "paragraph",
      "text": "7"
    },
    {
      "type": "paragraph",
      "text": "Angiography:"
    },
    {
      "type": "paragraph",
      "text": "Iso-osmolality contrast media (IOCM) are associated with the least amount of vasospasm and the least"
    },
    {
      "type": "paragraph",
      "text": "peripheral discomfort for peripheral angiograms [17]. Concomitant use of iodinated contrast medium with certain intra-"
    },
    {
      "type": "paragraph",
      "text": "arterial medications (e.g., papaverine) may lead to precipitation of contrast medium and crystal or thrombus formation."
    },
    {
      "type": "paragraph",
      "text": "Decisions about the use and timing of such medication are outside the scope of this document."
    },
    {
      "type": "paragraph",
      "text": "Pretesting"
    },
    {
      "type": "paragraph",
      "text": "Intradermal skin testing with contrast media to predict the likelihood of adverse reactions has not been shown to be useful"
    },
    {
      "type": "paragraph",
      "text": "in minimizing reaction risk [18-20]."
    },
    {
      "type": "paragraph",
      "text": "Corticosteroid Premedication"
    },
    {
      "type": "paragraph",
      "text": "The purpose of corticosteroid premedication is to mitigate the likelihood of an allergic-like reaction in high- risk patients."
    },
    {
      "type": "paragraph",
      "text": "Etiology of Hypersensitivity Contrast Reactions:"
    },
    {
      "type": "paragraph",
      "text": "The etiological mechanism of most immediate hypersensitivity contrast"
    },
    {
      "type": "paragraph",
      "text": "reactions is incompletely understood [21]. It is known, however, that approximately 90% of such adverse reactions are"
    },
    {
      "type": "paragraph",
      "text": "associated with direct release of histamine and other mediators from circulating basophils and eosinophils. It is also generally"
    },
    {
      "type": "paragraph",
      "text": "accepted that most adverse allergic-like reactions are not associated with the presence of increased IgE, and therefore are"
    },
    {
      "type": "paragraph",
      "text": "unlikely to be typical IgE-mediated hypersensitivity reactions. However, some studies show evidence of IgE mediation [18]."
    },
    {
      "type": "paragraph",
      "text": "No antibodies to IV contrast media have been consistently identified, and according to skin testing and basophil activation,"
    },
    {
      "type": "paragraph",
      "text": "IgE-mediated allergy is uncommon, for example occurring in 4% of patients having anaphylaxis symptoms [19]. This likely"
    },
    {
      "type": "paragraph",
      "text": "explains why patients who have never been exposed to contrast media can experience a severe hypersensitivity reaction on"
    },
    {
      "type": "paragraph",
      "text": "first exposure. Prior sensitization is not required for a contrast reaction to occur."
    },
    {
      "type": "paragraph",
      "text": "Pathophysiologic explanations for allergic-like hypersensitivity reactions include activation of mast cells and basophils"
    },
    {
      "type": "paragraph",
      "text": "releasing histamine, activation of the contact and complement systems, conversion of L-arginine into nitric oxide, activation"
    },
    {
      "type": "paragraph",
      "text": "of the XII clotting system leading to production of bradykinin [10]"
    },
    {
      "type": "paragraph",
      "text": ", and development of pseudoantigens"
    },
    {
      "type": "paragraph",
      "text": "[22]."
    },
    {
      "type": "paragraph",
      "text": "The osmolality of the contrast medium as well as the size and complexity of the molecule has potential influence on the"
    },
    {
      "type": "paragraph",
      "text": "likelihood of contrast reactions. Hyperosmolality is associated with stimulation of histamine release from basophils and mast"
    },
    {
      "type": "paragraph",
      "text": "cells. Increase in the size and complexity of the contrast molecule may potentiate the release of histamine [23,24]. There is"
    },
    {
      "type": "paragraph",
      "text": "some evidence to suggest that low-osmolality nonionic monomers produce lower levels of histamine release from basophils"
    },
    {
      "type": "paragraph",
      "text": "compared with high-osmolality ionic monomers, low-osmolality ionic dimers and iso-osmolality nonionic dimers [24]. Low-"
    },
    {
      "type": "paragraph",
      "text": "osmolality monomeric contrast media also are associated with a reduced likelihood of physiologic reactions following"
    },
    {
      "type": "paragraph",
      "text": "intravenous administration (i.e., non-allergic-like; e.g., nausea and vomiting). In general, non-ionic iodinated contrast media"
    },
    {
      "type": "paragraph",
      "text": "are associated with less adverse events than ionic contrast media (iodinated and gadolinium- based) [2,25]."
    },
    {
      "type": "paragraph",
      "text": "Benefits of Premedication:"
    },
    {
      "type": "paragraph",
      "text": "A randomized trial showed that premedication of average-risk patients prior to high- osmolality"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast medium administration reduces the likelihood of immediate adverse events of all severity [21]. However,"
    },
    {
      "type": "paragraph",
      "text": "high-osmolality contrast medium is no longer used for intravascular purposes."
    },
    {
      "type": "paragraph",
      "text": "Another randomized trial showed that premedication of average-risk patients prior to modern low- osmolality iodinated contrast"
    },
    {
      "type": "paragraph",
      "text": "medium administration reduce the likelihood of mild and aggregate immediate adverse events, but the trial was underpowered"
    },
    {
      "type": "paragraph",
      "text": "to evaluate the effect on moderate and severe reactions [26]."
    },
    {
      "type": "paragraph",
      "text": "Both of these randomized trials of premedication did not study the effect of premedication in high-risk patients who are"
    },
    {
      "type": "paragraph",
      "text": "usually premedicated today, and neither study was sufficiently powered to evaluate the efficacy of premedication in the"
    },
    {
      "type": "paragraph",
      "text": "prevention of moderate or severe reactions [21,26]."
    },
    {
      "type": "paragraph",
      "text": "Nonetheless, many experts believe that premedication does reduce the likelihood of a reaction in high- risk patients receiving"
    },
    {
      "type": "paragraph",
      "text": "low-osmolality iodinated contrast medium [26], although the number needed to treat to prevent a reaction is high [27,28]."
    },
    {
      "type": "paragraph",
      "text": "One study estimated that the number needed to premedicate to prevent one reaction in high-risk patients was 69 for a reaction"
    },
    {
      "type": "paragraph",
      "text": "of any severity and 569 for a severe reaction [27]. Another study estimated the number needed to treat to prevent a lethal"
    },
    {
      "type": "paragraph",
      "text": "reaction in high-risk patients to be 50,000 [28]."
    },
    {
      "type": "paragraph",
      "text": "There are no studies evaluating the efficacy of premedication prior to oral contrast medium administration or gadolinium-"
    },
    {
      "type": "image",
      "assetId": "asset_df15e03544",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "PATIENT SELECTION AND PREPARATION STRATEGIES BEFORE CONTRAST MEDIUM ADMINISTRATION"
    },
    {
      "type": "paragraph",
      "text": "8"
    },
    {
      "type": "paragraph",
      "text": "based contrast medium administration in high-risk patients. Premedication strategies in these patients are based on"
    },
    {
      "type": "paragraph",
      "text": "extrapolated data from patients receiving intravascular iodinated media."
    },
    {
      "type": "paragraph",
      "text": "Risks of Premedication:"
    },
    {
      "type": "paragraph",
      "text": "The direct risks of premedication are small [29] and include transient leukocytosis, transient (24-"
    },
    {
      "type": "paragraph",
      "text": "48h) and usually asymptomatic hyperglycemia (non-diabetics: +20-80 mg/dL, diabetics: +100-150 mg/dL) [30,31], and a"
    },
    {
      "type": "paragraph",
      "text": "questionable infection risk, among other things. Diphenhydramine may cause drowsiness and should not be taken shortly"
    },
    {
      "type": "paragraph",
      "text": "before operating a vehicle. Some patients have experienced allergies to the individual medications used in premedication."
    },
    {
      "type": "paragraph",
      "text": "The largest risk of premedication is indirect and related to the delay in diagnosis imparted by the multi- hour duration of"
    },
    {
      "type": "paragraph",
      "text": "premedication [30]. In one retrospective cohort study of 2829 subjects, 13-hour oral premedication of high-risk inpatients was"
    },
    {
      "type": "paragraph",
      "text": "associated with increased hospital length of stay (median:"
    },
    {
      "type": "paragraph",
      "text": "+25h), increased time to CT (median: +25h), increased hospital-acquired infection risk, and increased costs compared to non-"
    },
    {
      "type": "paragraph",
      "text": "premedicated controls [30]. The indirect harms of premedication likely overshadow the benefits of premedication in some"
    },
    {
      "type": "paragraph",
      "text": "vulnerable populations."
    },
    {
      "type": "paragraph",
      "text": "Breakthrough Contrast Reactions:"
    },
    {
      "type": "paragraph",
      "text": "Premedication does not prevent all contrast reactions [27,32,33]. Allergic- like contrast"
    },
    {
      "type": "paragraph",
      "text": "reactions that occur despite premedication are called breakthrough reactions"
    },
    {
      "type": "paragraph",
      "text": "[32]. Physiologic reactions are not mitigated"
    },
    {
      "type": "paragraph",
      "text": "by premedication and are not considered breakthrough reactions, even if they occur following premedication."
    },
    {
      "type": "paragraph",
      "text": "Patients premedicated for a prior contrast reaction have a breakthrough reaction rate (2.1%) that is 3-4 times the ordinary"
    },
    {
      "type": "paragraph",
      "text": "reaction rate in the general population, while patients premedicated for other indications have a breakthrough reaction rate"
    },
    {
      "type": "paragraph",
      "text": "close to 0% [27]. In most cases (~81%), breakthrough reaction severity is similar to index reaction severity [32,33]. Patients"
    },
    {
      "type": "paragraph",
      "text": "with a mild index reaction have a very low risk (<1%) of developing a severe breakthrough reaction [27]."
    },
    {
      "type": "paragraph",
      "text": "The majority (~88%) of contrast injections in premedicated patients with a prior breakthrough reaction will not result in a"
    },
    {
      "type": "paragraph",
      "text": "repeat breakthrough reaction [32,33]. Repeat breakthrough reactions, if they occur, usually are of similar severity to prior"
    },
    {
      "type": "paragraph",
      "text": "breakthrough reactions. Therefore, patients who have had a prior moderate or severe breakthrough reaction are at the highest"
    },
    {
      "type": "paragraph",
      "text": "risk for developing a future moderate or severe breakthrough reaction [32,33]."
    },
    {
      "type": "paragraph",
      "text": "Premedication Strategies:"
    },
    {
      "type": "paragraph",
      "text": "Oral premedication is preferable to IV premedication in most settings due to lower cost, more"
    },
    {
      "type": "paragraph",
      "text": "convenience, and greater evidentiary support in the literature [21,26]. The randomized trials of premedication in average-risk"
    },
    {
      "type": "paragraph",
      "text": "patients were conducted with oral methylprednisolone [21,26]. Uncontrolled studies in high-risk patients were conducted with"
    },
    {
      "type": "paragraph",
      "text": "oral prednisone [34,35]."
    },
    {
      "type": "paragraph",
      "text": "Supplemental administration of a non-selective antihistamine (e.g., diphenhydramine) orally or intravenously 1 hour prior to"
    },
    {
      "type": "paragraph",
      "text": "contrast medium administration may reduce the frequency of urticaria, angioedema, and respiratory symptoms. Use of selective"
    },
    {
      "type": "paragraph",
      "text": "anti-histamines (i.e., selective H2 blockers) has not been well studied [34]."
    },
    {
      "type": "paragraph",
      "text": "The minimum duration of premedication necessary for efficacy is unknown. Lasser et al [26] showed that one dose of 32 mg"
    },
    {
      "type": "paragraph",
      "text": "oral methylprednisolone 2 hours prior to IV high-osmolality iodinated contrast medium administration in average-risk patients"
    },
    {
      "type": "paragraph",
      "text": "was not effective, while two doses administered at 2- and 12-hours before contrast medium administration were effective"
    },
    {
      "type": "paragraph",
      "text": "[26]."
    },
    {
      "type": "paragraph",
      "text": "A dose-response study of single-dose IV methylprednisolone (1 mg/kg) [36] in 11 volunteers showed a reduction in circulating"
    },
    {
      "type": "paragraph",
      "text": "basophils and eosinophils by the end of the first post-injection hour, reaching statistical significance compared with controls"
    },
    {
      "type": "paragraph",
      "text": "by the end of the second hour and a concomitant reduction in histamine in sedimented leukocytes by 4 hours. Most of these"
    },
    {
      "type": "paragraph",
      "text": "effects reached their peak at 8 hours."
    },
    {
      "type": "paragraph",
      "text": "There is no evidence to support a premedication duration of 2 hours or less (oral or IV; corticosteroid- or antihistamine-"
    },
    {
      "type": "paragraph",
      "text": "based)."
    },
    {
      "type": "paragraph",
      "text": "An IV corticosteroid regimen with a minimum duration of 4-5 hours may be efficacious [10,26,29,36]."
    },
    {
      "type": "paragraph",
      "text": "Indications for Premedication"
    },
    {
      "type": "image",
      "assetId": "asset_f3fda536e3",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "PATIENT SELECTION AND PREPARATION STRATEGIES BEFORE CONTRAST MEDIUM ADMINISTRATION"
    },
    {
      "type": "paragraph",
      "text": "9"
    },
    {
      "type": "paragraph",
      "text": "Given that premedication does not prevent all reactions, has not been confirmed to reduce the incidence of moderate or severe"
    },
    {
      "type": "paragraph",
      "text": "reactions or reaction-related deaths, has limited supporting efficacy in high-risk patients, and is accompanied by direct and"
    },
    {
      "type": "paragraph",
      "text": "indirect harms, the utility of premedication in high- risk patients is uncertain. Given the tradeoffs between what is known and"
    },
    {
      "type": "paragraph",
      "text": "not known with respect to the benefits and harms of premedication, premedication may be considered in the following settings"
    },
    {
      "type": "paragraph",
      "text": "and scenarios:"
    },
    {
      "type": "paragraph",
      "text": "12- or 13-hour oral premedication may be considered in the following settings:"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Outpatient with a prior allergic-like or unknown-type contrast reaction to the same class of contrast medium (e.g.,"
    },
    {
      "type": "paragraph",
      "text": "iodinated"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "iodinated)."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Emergency department patient or inpatient with a prior allergic-like or unknown-type contrast reaction to the same"
    },
    {
      "type": "paragraph",
      "text": "class of contrast medium (e.g., iodinated"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "iodinated) in whom the use of premedication is not anticipated to"
    },
    {
      "type": "paragraph",
      "text": "adversely delay care decisions or treatment."
    },
    {
      "type": "paragraph",
      "text": "Accelerated IV premedication may be considered in the following settings:"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Outpatient with a prior allergic-like or unknown-type contrast reaction to the same class of contrast medium (e.g.,"
    },
    {
      "type": "paragraph",
      "text": "iodinated"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "iodinated) who has arrived for a contrast-enhanced examination but has not been premedicated and"
    },
    {
      "type": "paragraph",
      "text": "whose examination cannot be easily rescheduled."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Emergency department patient or inpatient with a prior allergic-like or unknown-type contrast reaction to the same"
    },
    {
      "type": "paragraph",
      "text": "class of contrast medium (e.g., iodinated"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "iodinated) in whom the use of 12- or 13-hour premedication is anticipated"
    },
    {
      "type": "paragraph",
      "text": "to adversely delay care decisions or treatment."
    },
    {
      "type": "paragraph",
      "text": "In rare clinical situations, the urgency of a contrast-enhanced examination may outweigh the benefits of prophylaxis,"
    },
    {
      "type": "paragraph",
      "text": "regardless of duration, necessitating that contrast medium be administered to a high-risk patient in the absence of"
    },
    {
      "type": "paragraph",
      "text": "premedication. This determination is best made jointly by the radiology team, the referring service, and potentially the patient"
    },
    {
      "type": "paragraph",
      "text": "(if feasible). In such cases, a team of individuals skilled in resuscitation should be available during the injection to monitor"
    },
    {
      "type": "paragraph",
      "text": "for and appropriately manage any developing reaction."
    },
    {
      "type": "paragraph",
      "text": "Regardless of patient status, history of a prior severe contrast reaction is considered a relative contraindication to receiving"
    },
    {
      "type": "paragraph",
      "text": "the same class of contrast medium in the future. If the same class of contrast medium is necessary and there are no alternatives,"
    },
    {
      "type": "paragraph",
      "text": "premedication should be considered, if feasible."
    },
    {
      "type": "paragraph",
      "text": "Routine premedication or avoidance of contrast medium for other indications, such as allergic reactions to other substances"
    },
    {
      "type": "paragraph",
      "text": "(including shellfish or contrast media from another class [e.g., gadolinium-based"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "iodinated]), asthma, seasonal allergies, or"
    },
    {
      "type": "paragraph",
      "text": "multiple drug and food allergies is not recommended."
    },
    {
      "type": "paragraph",
      "text": "Specific Recommended Premedication Regimens"
    },
    {
      "type": "paragraph",
      "text": "Elective Premedication (12- or 13-hour oral premedication)"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Prednisone-based: 50 mg prednisone by mouth at 13 hours, 7 hours, and 1 hour before contrast medium"
    },
    {
      "type": "paragraph",
      "text": "administration, plus 50 mg diphenhydramine intravenously, intramuscularly, or by mouth 1 hour before contrast"
    },
    {
      "type": "paragraph",
      "text": "medium administration [21]."
    },
    {
      "type": "paragraph",
      "text": "Or"
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Methylprednisolone-based: 32 mg methylprednisolone by mouth 12 hours and 2 hours before contrast medium"
    },
    {
      "type": "paragraph",
      "text": "administration. 50 mg diphenhydramine may be added as in option 1 [37]."
    },
    {
      "type": "paragraph",
      "text": "Although never formally compared, both regimens are considered similarly effective. The presence of"
    },
    {
      "type": "paragraph",
      "text": "diphenhydramine in regimen 1 and not in regimen 2 is historical and not evidence-based. Therefore,"
    },
    {
      "type": "paragraph",
      "text": "diphenhydramine may be considered optional."
    },
    {
      "type": "image",
      "assetId": "asset_5a2220fdfd",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "PATIENT SELECTION AND PREPARATION STRATEGIES BEFORE CONTRAST MEDIUM ADMINISTRATION"
    },
    {
      "type": "paragraph",
      "text": "10"
    },
    {
      "type": "paragraph",
      "text": "If a patient is unable to take oral medication, option 1 may be used substituting 200 mg hydrocortisone IV for each dose of oral"
    },
    {
      "type": "paragraph",
      "text": "prednisone [38]. If a patient is allergic to diphenhydramine in a situation where diphenhydramine would otherwise be"
    },
    {
      "type": "paragraph",
      "text": "considered, an alternate anti-histamine without cross-reactivity may be considered, or the anti-histamine portion of the regimen"
    },
    {
      "type": "paragraph",
      "text": "may be dropped."
    },
    {
      "type": "paragraph",
      "text": "Accelerated IV Premedication (in decreasing order of desirability)"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Methylprednisolone sodium succinate (e.g., Solu-Medrol"
    },
    {
      "type": "paragraph",
      "text": "(R)"
    },
    {
      "type": "paragraph",
      "text": ") 40 mg IV or hydrocortisone sodium succinate (e.g., Solu-"
    },
    {
      "type": "paragraph",
      "text": "Cortef"
    },
    {
      "type": "paragraph",
      "text": "(R)"
    },
    {
      "type": "paragraph",
      "text": ") 200 mg IV immediately, and then every 4 hours until contrast medium administration, plus"
    },
    {
      "type": "paragraph",
      "text": "diphenhydramine 50 mg IV 1 hour before contrast medium administration. This regimen usually is 4-5 hours in"
    },
    {
      "type": "paragraph",
      "text": "duration."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Dexamethasone sodium sulfate (e.g., Decadron"
    },
    {
      "type": "paragraph",
      "text": "(R)"
    },
    {
      "type": "paragraph",
      "text": ") 7.5 mg IV immediately, and then every 4 hours until contrast"
    },
    {
      "type": "paragraph",
      "text": "medium administration, plus diphenhydramine 50 mg IV 1 hour before contrast medium administration. This"
    },
    {
      "type": "paragraph",
      "text": "regimen may be useful in patients with an allergy to methylprednisolone and is also usually 4-5 hours in duration."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Methylprednisolone sodium succinate (e.g., Solu-Medrol"
    },
    {
      "type": "paragraph",
      "text": "(R)"
    },
    {
      "type": "paragraph",
      "text": ") 40 mg IV or hydrocortisone sodium succinate (e.g., Solu-"
    },
    {
      "type": "paragraph",
      "text": "Cortef"
    },
    {
      "type": "paragraph",
      "text": "(R)"
    },
    {
      "type": "paragraph",
      "text": ") 200 mg IV, plus diphenhydramine 50 mg IV, each 1 hour before contrast medium administration. This"
    },
    {
      "type": "paragraph",
      "text": "regimen, and all other regimens with a duration less than 4-5 hours, has no evidence of efficacy. It may be considered"
    },
    {
      "type": "paragraph",
      "text": "in emergent situations when there are no alternatives."
    },
    {
      "type": "paragraph",
      "text": "Note:"
    },
    {
      "type": "paragraph",
      "text": "Premedication regimens less than 4-5 hours in duration (oral or IV) have not been shown to be effective. The"
    },
    {
      "type": "paragraph",
      "text": "accelerated 4-5-hour regimen listed as Accelerated IV option 1 is supported by a case series and by a retrospective"
    },
    {
      "type": "paragraph",
      "text": "cohort study with 828 subjects [38]."
    },
    {
      "type": "paragraph",
      "text": "Missing One or More Doses of Premedication"
    },
    {
      "type": "paragraph",
      "text": "Sometimes, patients undergoing premedication present for a contrast-enhanced scan without completing their premedication"
    },
    {
      "type": "paragraph",
      "text": "regimen. In such cases, there is no evidence base to guide decision-making, so management should be individualized."
    },
    {
      "type": "paragraph",
      "text": "Generally speaking, if premedication is being used, a guiding principle is to have a minimum of 4-5 hours of corticosteroid"
    },
    {
      "type": "paragraph",
      "text": "therapy prior to contrast medium exposure, with repeat doses every 4-8 hours. Diphenhydramine administration is optional."
    },
    {
      "type": "paragraph",
      "text": "Premedication in Patients Undergoing Chronic Corticosteroid Therapy"
    },
    {
      "type": "paragraph",
      "text": "In patients who have had a prior allergic-like reaction to contrast medium and who are also on chronic corticosteroid therapy,"
    },
    {
      "type": "paragraph",
      "text": "premedication dosing may be modified. In this circumstance, there is no evidence base to guide decision-making, so"
    },
    {
      "type": "paragraph",
      "text": "management should be individualized. Generally speaking, if corticosteroid premedication is being used, a guiding principle"
    },
    {
      "type": "paragraph",
      "text": "is to reduce the dose of the chosen premedication dose regimen by an amount equivalent to the patients chronic therapeutic"
    },
    {
      "type": "paragraph",
      "text": "corticosteroid dose. If the patient is on simple replacement (not therapeutic) corticosteroids, the premedication dosing regimen"
    },
    {
      "type": "paragraph",
      "text": "may not need to be adjusted."
    },
    {
      "type": "paragraph",
      "text": "Changing Contrast Media Within the Same Class"
    },
    {
      "type": "paragraph",
      "text": "In patients with a prior allergic-like or unknown-type contrast reaction to a known contrast medium, changing contrast media"
    },
    {
      "type": "paragraph",
      "text": "within the same class (e.g., one iodinated medium for another) may help reduce the likelihood of a subsequent contrast reaction"
    },
    {
      "type": "paragraph",
      "text": "[39,40]. Some studies have shown that the effect size of switching contrast media actually may be greater than that of"
    },
    {
      "type": "paragraph",
      "text": "premedication alone, but combining premedication with a change in agent seems to have the greatest effect [39,40]."
    },
    {
      "type": "paragraph",
      "text": "Unfortunately, many patients do not know which specific agent they have reacted to in the past; they simply remember they"
    },
    {
      "type": "paragraph",
      "text": "had a reaction. In the future, through improved electronic medical records, routine linking of reactions to specific contrast"
    },
    {
      "type": "paragraph",
      "text": "media is likely to add value. In the current state, investigating which agent was responsible for one or more prior reactions"
    },
    {
      "type": "paragraph",
      "text": "often is not possible."
    },
    {
      "type": "paragraph",
      "text": "Premedication Is Not a Panacea"
    },
    {
      "type": "paragraph",
      "text": "No premedication strategy is a substitute for pre-administration preparedness. Contrast reactions occur despite premedication"
    },
    {
      "type": "paragraph",
      "text": "[32], and radiology teams must be prepared to treat breakthrough reactions when they occur. Patients should receive"
    },
    {
      "type": "image",
      "assetId": "asset_eddfeb4b9b",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "PATIENT SELECTION AND PREPARATION STRATEGIES BEFORE CONTRAST MEDIUM ADMINISTRATION"
    },
    {
      "type": "paragraph",
      "text": "11"
    },
    {
      "type": "paragraph",
      "text": "information concerning their risk of a reaction according to local policy and practice."
    },
    {
      "type": "paragraph",
      "text": "REFERENCES"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Wang CL, Cohan RH, Ellis JH, Caoili EM, Wang G, Francis IR. Frequency, outcome, and appropriateness of treatment of nonionic iodinated"
    },
    {
      "type": "paragraph",
      "text": "contrast media reactions. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2008;191:409-15."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from"
    },
    {
      "type": "paragraph",
      "text": "the Japanese Committee on the Safety of Contrast Media. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1990;175:621-8."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Jung JW, Kang HR, Kim MH, et al. Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2012;264:414-22."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Beaty AD, Lieberman PL, Slavin RG. Seafood allergy and radiocontrast media: are physicians propagating a myth? Am J Med"
    },
    {
      "type": "paragraph",
      "text": "2008;121:158.e1-"
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Boehm I. Seafood allergy and radiocontrast media: are physicians propagating a myth? Am J Med"
    },
    {
      "type": "paragraph",
      "text": "2008;121:e19."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Shehadi WH. Adverse reactions to intravascularly administered contrast media. A comprehensive study based on a prospective survey. Am J"
    },
    {
      "type": "paragraph",
      "text": "Roentgenol Radium Ther Nucl Med"
    },
    {
      "type": "paragraph",
      "text": "1975;124:145-52."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Lalli AF. Urographic contrast media reactions and anxiety. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1974;112:267-71."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "Callahan MJ, Poznauskis L, Zurakowski D, Taylor GA. Nonionic iodinated intravenous contrast material-related reactions: incidence in large"
    },
    {
      "type": "paragraph",
      "text": "urban children's hospital--retrospective analysis of data in 12,494 patients. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2009;250:674-81."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Lang DM, Alpern MB, Visintainer PF, Smith ST. Elevated risk of anaphylactoid reaction from radiographic contrast media is associated with"
    },
    {
      "type": "paragraph",
      "text": "both beta-blocker exposure and cardiovascular disorders. Arch Intern Med"
    },
    {
      "type": "paragraph",
      "text": "1993;153:2033-40."
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Morcos SK. Review article: Acute serious and fatal reactions to contrast media: our current understanding. Br J Radiol"
    },
    {
      "type": "paragraph",
      "text": "2005;78:686-93."
    },
    {
      "type": "paragraph",
      "text": "11."
    },
    {
      "type": "paragraph",
      "text": "Mukherjee JJ, Peppercorn PD, Reznek RH, et al. Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine"
    },
    {
      "type": "paragraph",
      "text": "levels. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1997;202:227-31."
    },
    {
      "type": "paragraph",
      "text": "12."
    },
    {
      "type": "paragraph",
      "text": "Mehrizi M, Pascuzzi RM. Complications of radiologic contrast in patients with myasthenia gravis. Muscle Nerve"
    },
    {
      "type": "paragraph",
      "text": "2014;50:443-4."
    },
    {
      "type": "paragraph",
      "text": "13."
    },
    {
      "type": "paragraph",
      "text": "Somashekar DK, Davenport MS, Cohan RH, Dillman JR, Ellis JH. Effect of intravenous low-osmolality iodinated contrast media on patients"
    },
    {
      "type": "paragraph",
      "text": "with myasthenia gravis. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2013;267:727-34."
    },
    {
      "type": "paragraph",
      "text": "14."
    },
    {
      "type": "paragraph",
      "text": "van der Molen AJ, Thomsen HS, Morcos SK. Effect of iodinated contrast media on thyroid function in adults. Eur Radiol"
    },
    {
      "type": "paragraph",
      "text": "2004;14:902-7."
    },
    {
      "type": "paragraph",
      "text": "15."
    },
    {
      "type": "paragraph",
      "text": "Silberstein EB, Alavi A, Balon HR, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med"
    },
    {
      "type": "paragraph",
      "text": "2012;53:1633-"
    },
    {
      "type": "paragraph",
      "text": "51."
    },
    {
      "type": "paragraph",
      "text": "16."
    },
    {
      "type": "paragraph",
      "text": "Society of Nuclear Medicine. Therapy of Thyroid Disease with Iodine-131 v2.0. Available at:"
    },
    {
      "type": "paragraph",
      "text": "http://interactive.snm.org/docs/Therapy%20of%20Thyroid%20Disease%20with%20Iodine-131%20v2.0.pdf"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "17."
    },
    {
      "type": "paragraph",
      "text": "Palena LM, Sacco ZD, Brigato C, et al. Discomfort assessment in peripheral angiography: randomized clinical trial of Iodixanol 270 versus"
    },
    {
      "type": "paragraph",
      "text": "Ioversol 320 in diabetics with critical limb ischemia. Catheter Cardiovasc Interv"
    },
    {
      "type": "paragraph",
      "text": "2014;84:1019-25."
    },
    {
      "type": "paragraph",
      "text": "18."
    },
    {
      "type": "paragraph",
      "text": "Laroche D, Aimone-Gastin I, Dubois F, et al. Mechanisms of severe, immediate reactions to iodinated contrast material. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1998;209:183-90."
    },
    {
      "type": "paragraph",
      "text": "19."
    },
    {
      "type": "paragraph",
      "text": "Trcka J, Schmidt C, Seitz CS, Brcker EB, Gross GE, Trautmann A. Anaphylaxis to iodinated contrast material: nonallergic hypersensitivity or"
    },
    {
      "type": "paragraph",
      "text": "IgE-mediated allergy? AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2008;190:666-70."
    },
    {
      "type": "paragraph",
      "text": "20."
    },
    {
      "type": "paragraph",
      "text": "Yamaguchi K, Katayama H, Takashima T, Kozuka T, Seez P, Matsuura K. Prediction of severe adverse reactions to ionic and nonionic contrast"
    },
    {
      "type": "paragraph",
      "text": "media in Japan: evaluation of pretesting. A report from the Japanese Committee on the Safety of Contrast Media. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1991;178:363-7."
    },
    {
      "type": "paragraph",
      "text": "21."
    },
    {
      "type": "paragraph",
      "text": "Lasser EC, Berry CC, Talner LB, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med"
    },
    {
      "type": "paragraph",
      "text": "1987;317:845-9."
    },
    {
      "type": "paragraph",
      "text": "22."
    },
    {
      "type": "paragraph",
      "text": "Lasser EC. The multipotential pseudoantigenicity of X-ray contrast media. Pseudoantigen excess may downregulate the release of hypotensive"
    },
    {
      "type": "paragraph",
      "text": "mediators. Int Arch Allergy Immunol"
    },
    {
      "type": "paragraph",
      "text": "2000;123:282-90."
    },
    {
      "type": "paragraph",
      "text": "23."
    },
    {
      "type": "paragraph",
      "text": "Paton WD. Histamine release by compounds of simple chemical structure. Pharmacol Rev"
    },
    {
      "type": "paragraph",
      "text": "1957;9:269-328."
    },
    {
      "type": "paragraph",
      "text": "24."
    },
    {
      "type": "paragraph",
      "text": "Peachell PT, Morcos SK. Effect of radiographic contrast media on histamine release from human mast cells and basophils. Br J Radiol"
    },
    {
      "type": "paragraph",
      "text": "1998;71:24-30."
    },
    {
      "type": "paragraph",
      "text": "25."
    },
    {
      "type": "paragraph",
      "text": "Lasser EC, Berry CC, Mishkin MM, Williamson B, Zheutlin N, Silverman JM. Pretreatment with corticosteroids to prevent adverse reactions to"
    },
    {
      "type": "paragraph",
      "text": "nonionic contrast media. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "1994;162:523-6."
    },
    {
      "type": "paragraph",
      "text": "26."
    },
    {
      "type": "paragraph",
      "text": "O'Malley RB, Cohan RH, Ellis JH, et al. A survey on the use of premedication prior to iodinated and gadolinium-based contrast material"
    },
    {
      "type": "paragraph",
      "text": "administration. J Am Coll Radiol"
    },
    {
      "type": "paragraph",
      "text": "2011;8:345-54."
    },
    {
      "type": "paragraph",
      "text": "27."
    },
    {
      "type": "paragraph",
      "text": "Mervak BM, Davenport MS, Ellis JH, Cohan RH. Rates of Breakthrough Reactions in Inpatients at High Risk Receiving Premedication Before"
    },
    {
      "type": "paragraph",
      "text": "Contrast-Enhanced CT. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2015;205:77-84."
    },
    {
      "type": "paragraph",
      "text": "28."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS, Mervak BM, Ellis JH, Dillman JR, Dunnick NR, Cohan RH. Indirect Cost and Harm Attributable to Oral 13-Hour Inpatient"
    },
    {
      "type": "paragraph",
      "text": "Corticosteroid Prophylaxis before Contrast-enhanced CT. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2016;279:492-501."
    },
    {
      "type": "paragraph",
      "text": "29."
    },
    {
      "type": "paragraph",
      "text": "Lasser EC. Pretreatment with corticosteroids to prevent reactions to i.v. contrast material: overview and implications. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "1988;150:257-9."
    },
    {
      "type": "paragraph",
      "text": "30."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS, Cohan RH, Caoili EM, Ellis JH. Hyperglycemic consequences of corticosteroid premedication in an outpatient population. AJR"
    },
    {
      "type": "paragraph",
      "text": "Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2010;194:W483-8."
    },
    {
      "type": "paragraph",
      "text": "31."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS, Cohan RH, Khalatbari S, Myles J, Caoili EM, Ellis JH. Hyperglycemia in hospitalized patients receiving corticosteroid"
    },
    {
      "type": "paragraph",
      "text": "premedication before the administration of radiologic contrast medium. Acad Radiol"
    },
    {
      "type": "paragraph",
      "text": "2011;18:384-90."
    },
    {
      "type": "paragraph",
      "text": "32."
    },
    {
      "type": "paragraph",
      "text": "Freed KS, Leder RA, Alexander C, DeLong DM, Kliewer MA. Breakthrough adverse reactions to low-osmolar contrast media after steroid"
    },
    {
      "type": "paragraph",
      "text": "premedication. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2001;176:1389-92."
    },
    {
      "type": "paragraph",
      "text": "33."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS, Cohan RH, Caoili EM, Ellis JH. Repeat contrast medium reactions in premedicated patients: frequency and severity. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2009;253:372-9."
    },
    {
      "type": "paragraph",
      "text": "34."
    },
    {
      "type": "paragraph",
      "text": "Greenberger PA, Patterson R, Tapio CM. Prophylaxis against repeated radiocontrast media reactions in 857 cases. Adverse experience with"
    },
    {
      "type": "paragraph",
      "text": "cimetidine and safety of beta-adrenergic antagonists. Arch Intern Med"
    },
    {
      "type": "paragraph",
      "text": "1985;145:2197-200."
    },
    {
      "type": "image",
      "assetId": "asset_9e41af7228",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "PATIENT SELECTION AND PREPARATION STRATEGIES BEFORE CONTRAST MEDIUM ADMINISTRATION"
    },
    {
      "type": "paragraph",
      "text": "12"
    },
    {
      "type": "paragraph",
      "text": "35."
    },
    {
      "type": "paragraph",
      "text": "Greenberger PA, Patterson R, Radin RC. Two pretreatment regimens for high-risk patients receiving radiographic contrast media. J Allergy Clin"
    },
    {
      "type": "paragraph",
      "text": "Immunol"
    },
    {
      "type": "paragraph",
      "text": "1984;74:540-3."
    },
    {
      "type": "paragraph",
      "text": "36."
    },
    {
      "type": "paragraph",
      "text": "Dunsky EH, Zweiman B, Fischler E, Levy DA. Early effects of corticosteroids on basophils, leukocyte histamine, and tissue histamine. J Allergy"
    },
    {
      "type": "paragraph",
      "text": "Clin Immunol"
    },
    {
      "type": "paragraph",
      "text": "1979;63:426-32."
    },
    {
      "type": "paragraph",
      "text": "37."
    },
    {
      "type": "paragraph",
      "text": "Greenberger PA, Patterson R. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J Allergy Clin"
    },
    {
      "type": "paragraph",
      "text": "Immunol"
    },
    {
      "type": "paragraph",
      "text": "1991;87:867-72."
    },
    {
      "type": "paragraph",
      "text": "38."
    },
    {
      "type": "paragraph",
      "text": "Mervak BM, Cohan RH, Ellis JH, Khalatbari S, Davenport MS. Intravenous Corticosteroid Premedication Administered 5 Hours before CT"
    },
    {
      "type": "paragraph",
      "text": "Compared with a Traditional 13-Hour Oral Regimen. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2017;285:425-33."
    },
    {
      "type": "paragraph",
      "text": "39."
    },
    {
      "type": "paragraph",
      "text": "Abe S, Fukuda H, Tobe K, Ibukuro K. Protective effect against repeat adverse reactions to iodinated contrast medium: Premedication vs."
    },
    {
      "type": "paragraph",
      "text": "changing the contrast medium. Eur Radiol"
    },
    {
      "type": "paragraph",
      "text": "2016;26:2148-54."
    },
    {
      "type": "paragraph",
      "text": "40."
    },
    {
      "type": "paragraph",
      "text": "Park HJ, Park JW, Yang MS, et al. Re-exposure to low osmolar iodinated contrast media in patients with prior moderate-to-severe"
    },
    {
      "type": "paragraph",
      "text": "hypersensitivity reactions: A multicentre retrospective cohort study. Eur Radiol"
    },
    {
      "type": "paragraph",
      "text": "2017;27:2886-93."
    },
    {
      "type": "image",
      "assetId": "asset_fe077d5898",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "FASTING PRIOR TO INTRAVASCULAR CONTRAST MEDIA ADMINISTRATION"
    },
    {
      "type": "paragraph",
      "text": "13"
    },
    {
      "type": "paragraph",
      "text": "Fasting Prior to Intravascular Contrast Media Administration"
    },
    {
      "type": "paragraph",
      "text": "To decrease the likelihood of vomiting and aspiration, some practices request that patients fast prior to administration on"
    },
    {
      "type": "paragraph",
      "text": "intravenous contrast media [1]. However, currently used low- and iso-osmolality nonionic iodinated contrast media used for"
    },
    {
      "type": "paragraph",
      "text": "CT, and gadolinium-based contrast media (GBCM) used for MRI, have much lower risk of vomiting compared to the"
    },
    {
      "type": "paragraph",
      "text": "previously used ionic high-osmolality iodinated contrast media [2-9]. Furthermore, pre-procedure fasting may have negative"
    },
    {
      "type": "paragraph",
      "text": "effects including scheduling limitations, hypoglycemic risk in patients with diabetes mellitus, and general discomfort."
    },
    {
      "type": "paragraph",
      "text": "A 2012 meta-analysis of 13 studies and 2,001 patients exposed to intravascular iodinated contrast media found that, despite"
    },
    {
      "type": "paragraph",
      "text": "heterogeneous fasting practices (including many with no restrictions), there were no cases of aspiration pneumonia attributable"
    },
    {
      "type": "paragraph",
      "text": "to iodinated contrast media [1]. A 2009 study of 158,439 injections of GBCM demonstrated that only 0.03% resulted in mild"
    },
    {
      "type": "paragraph",
      "text": "adverse events including nausea, vomiting, or mild rash [10]. No assessment of the risk aspiration pneumonia attributable to"
    },
    {
      "type": "paragraph",
      "text": "GBCM has been performed. Data indicate there is no preventive effect of fasting prior to modern iodinated and gadolinium-"
    },
    {
      "type": "paragraph",
      "text": "based intravascular contrast media administration on risk of nausea, vomiting, or aspiration [11]."
    },
    {
      "type": "paragraph",
      "text": "Given the potential for negative consequences due to fasting and a lack of evidence that supports the need for fasting, fasting is"
    },
    {
      "type": "paragraph",
      "text": "not required prior to routine intravascular contrast material administration. However, for patients receiving conscious sedation,"
    },
    {
      "type": "paragraph",
      "text": "anesthesia guidelines should be consulted (e.g., the American Society of Anesthesiology [ASA] Practice Guidelines for"
    },
    {
      "type": "paragraph",
      "text": "Preoperative Fasting in Health Patients Undergoing Elective Procedures) [12]."
    },
    {
      "type": "paragraph",
      "text": "References"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Lee BY, Ok JJ, Abdelaziz Elsayed AA, Kim Y, Han DH. Preparative fasting for contrast-enhanced CT: reconsideration."
    },
    {
      "type": "paragraph",
      "text": "Radiology."
    },
    {
      "type": "paragraph",
      "text": "2012;263(2):444-450."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Bush WH, Swanson DP. Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J"
    },
    {
      "type": "paragraph",
      "text": "Roentgenol."
    },
    {
      "type": "paragraph",
      "text": "1991;157(6):1153-1161."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report"
    },
    {
      "type": "paragraph",
      "text": "from the Japanese Committee on the Safety of Contrast Media."
    },
    {
      "type": "paragraph",
      "text": "Radiology."
    },
    {
      "type": "paragraph",
      "text": "1990;175(3):621-628."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Murphy KJ, Brunberg JA, Cohan RH. Adverse reactions to gadolinium contrast media: a review of 36 cases."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgenol."
    },
    {
      "type": "paragraph",
      "text": "1996;167(4):847-849."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Runge VM. Safety of approved MR contrast media for intravenous injection."
    },
    {
      "type": "paragraph",
      "text": "J Magn Reson Imaging."
    },
    {
      "type": "paragraph",
      "text": "2000;12(2):205-213."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Runge VM. Safety of magnetic resonance contrast media."
    },
    {
      "type": "paragraph",
      "text": "Top Magn Reson Imaging."
    },
    {
      "type": "paragraph",
      "text": "2001;12(4):309-314."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Murphy KP, Szopinski KT, Cohan RH, Mermillod B, Ellis JH. Occurrence of adverse reactions to gadolinium-based contrast material and"
    },
    {
      "type": "paragraph",
      "text": "management of patients at increased risk: a survey of the American Society of Neuroradiology Fellowship Directors."
    },
    {
      "type": "paragraph",
      "text": "Acad Radiol."
    },
    {
      "type": "paragraph",
      "text": "1999;6(11):656-664."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "Barbosa P, Bitencourt AGV, Tyng CJ, et al. JOURNAL CLUB: Preparative Fasting for Contrast-Enhanced CT in a Cancer Center: A New"
    },
    {
      "type": "paragraph",
      "text": "Approach."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgenol."
    },
    {
      "type": "paragraph",
      "text": "2018;210(5):941-947."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Wagner HJ, Evers JP, Hoppe M, Klose KJ. [Must the patient fast before intravascular injection of a non-ionic contrast medium? Results of a"
    },
    {
      "type": "paragraph",
      "text": "controlled study]."
    },
    {
      "type": "paragraph",
      "text": "Rofo."
    },
    {
      "type": "paragraph",
      "text": "1997;166(5):370-375."
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Hunt CH, Hartman RP, Hesley GK. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective"
    },
    {
      "type": "paragraph",
      "text": "review of 456,930 doses."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgenol."
    },
    {
      "type": "paragraph",
      "text": "2009;193(4):1124-1127."
    },
    {
      "type": "paragraph",
      "text": "11."
    },
    {
      "type": "paragraph",
      "text": "Neeman Z, Abu Ata M, Touma E, et al. Is fasting still necessary prior to contrast-enhanced computed tomography? A randomized clinical"
    },
    {
      "type": "paragraph",
      "text": "study."
    },
    {
      "type": "paragraph",
      "text": "Eur Radiol."
    },
    {
      "type": "paragraph",
      "text": "2020."
    },
    {
      "type": "paragraph",
      "text": "12."
    },
    {
      "type": "paragraph",
      "text": "Anonymous. Practice Guidelines for Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration:"
    },
    {
      "type": "paragraph",
      "text": "Application to Healthy Patients Undergoing Elective Procedures: An Updated Report by the American Society of Anesthesiologists Task Force"
    },
    {
      "type": "paragraph",
      "text": "on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration*."
    },
    {
      "type": "paragraph",
      "text": "Anesthesiology."
    },
    {
      "type": "paragraph",
      "text": "2017;126(3):376-"
    },
    {
      "type": "paragraph",
      "text": "393."
    },
    {
      "type": "image",
      "assetId": "asset_9a37001158",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "SAFE INJECTION OF CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "14"
    },
    {
      "type": "paragraph",
      "text": "SAFE INJECTION OF CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "General Considerations"
    },
    {
      "type": "paragraph",
      "text": "Injection methods vary depending on vascular access, differential diagnosis, and imaging examination type. The mode and"
    },
    {
      "type": "paragraph",
      "text": "method of delivery, either by hand or by power injector, also vary by procedure. Subject to the requirements of state law, a"
    },
    {
      "type": "paragraph",
      "text": "radiologist, radiologic technologist, or nurse may administer contrast media. Stable intravenous (IV) access is necessary. For"
    },
    {
      "type": "paragraph",
      "text": "current American College of Radiology (ACR) recommendations regarding injection of contrast media (including"
    },
    {
      "type": "paragraph",
      "text": "radiopharmaceuticals), see the"
    },
    {
      "type": "paragraph",
      "text": "ACR"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "SPR Practice Parameter for the Use of Intravascular Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "Referring to FDA package inserts may be appropriate in determining contrast media doses and concentrations (see"
    },
    {
      "type": "paragraph",
      "text": "Appendix"
    },
    {
      "type": "paragraph",
      "text": "A"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Contrast Media Specifications)."
    },
    {
      "type": "paragraph",
      "text": "It is important to avoid prolonged admixture of blood and contrast media in syringes and"
    },
    {
      "type": "paragraph",
      "text": "catheters whenever possible due to the risk of clot formation. In general, unless known to be safe, the admixture of contrast"
    },
    {
      "type": "paragraph",
      "text": "media and any medication should be avoided. However, heparin may be combined with contrast media."
    },
    {
      "type": "paragraph",
      "text": "Mechanical Injection of Intravenous Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Bolus or power injection of IV contrast material is superior to drip infusion for enhancing normal and abnormal structures"
    },
    {
      "type": "paragraph",
      "text": "during body computed tomography (CT). Radiology personnel must recognize the need for proper technique to avoid the"
    },
    {
      "type": "paragraph",
      "text": "potentially serious complications of contrast media extravasation and air embolism. (See the Chapter on"
    },
    {
      "type": "paragraph",
      "text": "Extravasation of"
    },
    {
      "type": "paragraph",
      "text": "Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "). When proper technique is used, contrast medium can be safely administered intravenously by power injector"
    },
    {
      "type": "paragraph",
      "text": "in the vast majority of patients, even at high-flow rates."
    },
    {
      "type": "paragraph",
      "text": "Technique"
    },
    {
      "type": "paragraph",
      "text": "To"
    },
    {
      "type": "paragraph",
      "text": "avoid potential complications, the patients cooperation should be obtained whenever possible. Communicating with the"
    },
    {
      "type": "paragraph",
      "text": "patient before the examination and during the injection may reduce the risk of contrast medium extravasation. If the patient"
    },
    {
      "type": "paragraph",
      "text": "reports pain or the sensation of swelling at the injection site, injection should be discontinued."
    },
    {
      "type": "paragraph",
      "text": "Intravenous contrast media should be administered by power injector through a flexible plastic cannula. Use of metal needles"
    },
    {
      "type": "paragraph",
      "text": "for power injection should be avoided whenever possible. In addition, the flow rate should be appropriate for the gauge of the"
    },
    {
      "type": "paragraph",
      "text": "catheter used. Although 22-gauge catheters may be able to tolerate flow rates up to 5 ml/sec, a 20-gauge or larger catheter is"
    },
    {
      "type": "paragraph",
      "text": "preferable for flow rates of 3 ml/sec or greater. An antecubital or large forearm vein is the preferred venous access site for"
    },
    {
      "type": "paragraph",
      "text": "power injection. If a more peripheral (e.g., hand or wrist) venipuncture site must be used, flow rates should be reduced if"
    },
    {
      "type": "paragraph",
      "text": "feasible (e.g., 1-2 mL/sec)."
    },
    {
      "type": "paragraph",
      "text": "Careful preparation of the power injection apparatus is essential to minimize the risk of contrast medium extravasation or air"
    },
    {
      "type": "paragraph",
      "text": "embolism. Standard procedures should be used to clear the syringe and pressure tubing of air, after which the syringe should"
    },
    {
      "type": "paragraph",
      "text": "be reoriented with the tubing directed downward. Several maneuvers can be performed to confirm the proper intravenous"
    },
    {
      "type": "paragraph",
      "text": "location of an inserted catheter. The catheter to be used can be checked for backflow of blood into the tubing, although"
    },
    {
      "type": "paragraph",
      "text": "backflow is not always noted, even in an appropriately positioned intravenous line. A saline test flush can be performed by"
    },
    {
      "type": "paragraph",
      "text": "hand or once the tubing is connected to a power injector. Direct monitoring of the site during injection can be performed if"
    },
    {
      "type": "paragraph",
      "text": "feasible, but direct monitoring often is not feasible, particularly when CT arteriography is performed or when automatic"
    },
    {
      "type": "paragraph",
      "text": "triggering programs are employed. If the venipuncture site is found to be tender or infiltrated during any of these maneuvers,"
    },
    {
      "type": "paragraph",
      "text": "an alternative site should be sought. In all instances, the power injector and its tubing should be positioned to allow adequate"
    },
    {
      "type": "paragraph",
      "text": "table movement without tension on the intravenous line."
    },
    {
      "type": "paragraph",
      "text": "A means of easy communication between the technologist and the patient is required at all times prior to, during, and following"
    },
    {
      "type": "paragraph",
      "text": "a contrast media injection. This initially can occur via direct contact and then by use of an intercom or television system."
    },
    {
      "type": "paragraph",
      "text": "When feasible, the patient should be notified of the presence of such a system and instructed to notify the technologist for any"
    },
    {
      "type": "paragraph",
      "text": "changes in sensation, including increasing pain or swelling at the injection site."
    },
    {
      "type": "paragraph",
      "text": "It should not be assumed that power injection can be performed in all central venous catheters. However, power injection of"
    },
    {
      "type": "paragraph",
      "text": "contrast media through some central venous catheters can be performed safely provided that certain precautions are followed."
    },
    {
      "type": "paragraph",
      "text": "Before connecting the catheter to the injector system tubing, the catheter tip position should be tested for venous backflow."
    },
    {
      "type": "paragraph",
      "text": "Occasionally backflow will not be obtained because the catheter tip is positioned against the wall of the vein in which it is"
    },
    {
      "type": "paragraph",
      "text": "located. If saline can be injected through the catheter without abnormal resistance, contrast media can be administered through"
    },
    {
      "type": "paragraph",
      "text": "the catheter safely. If abnormal resistance or discomfort is encountered, an alternative venous access site should be sought."
    },
    {
      "type": "paragraph",
      "text": "Injection with large-bore (9.5-F to 10-F) central venous catheters using flow rates of up to 2.5 ml/ sec has been shown to"
    },
    {
      "type": "image",
      "assetId": "asset_b0c41f9bf6",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "SAFE INJECTION OF CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "15"
    },
    {
      "type": "paragraph",
      "text": "generate pressures below manufacturers specified limits. For power injection of contrast media through some central venous"
    },
    {
      "type": "paragraph",
      "text": "catheters, the radiologist should consult manufacturers recommendations. Contrast media should not be administered by"
    },
    {
      "type": "paragraph",
      "text": "power injector through small-bore, peripheral (e.g., arm) access central venous catheters unless permitted by the"
    },
    {
      "type": "paragraph",
      "text": "manufacturers specifications because of the risk of catheter breakage. Such catheters will usually have a specific rating th"
    },
    {
      "type": "paragraph",
      "text": "at"
    },
    {
      "type": "paragraph",
      "text": "indicates they can be used for power injection up to a specified flow rate."
    },
    {
      "type": "paragraph",
      "text": "Air Embolism"
    },
    {
      "type": "paragraph",
      "text": "Clinically significant large-volume venous air embolism is a potentially fatal but rare complication of IV contrast media"
    },
    {
      "type": "paragraph",
      "text": "injection. However, small-volume clinically insignificant venous air embolism commonly occurs. Using care when using"
    },
    {
      "type": "paragraph",
      "text": "power injection for contrast-enhanced CT minimizes the risk of clinically significant air embolism. On CT, venous air"
    },
    {
      "type": "paragraph",
      "text": "embolism is most commonly identified as air bubbles or air-fluid levels in the intrathoracic veins, main pulmonary artery, or"
    },
    {
      "type": "paragraph",
      "text": "right ventricle, although it can conceivably be visualized in any vessel downstream of the injection (e.g, intracranial veins)."
    },
    {
      "type": "paragraph",
      "text": "Inadvertent injection of large amounts of air into the venous system may result in air hunger, dyspnea, cough, chest pain,"
    },
    {
      "type": "paragraph",
      "text": "pulmonary edema, tachycardia, hypotension, and expiratory wheezing. Neurologic deficits may result from stroke due to"
    },
    {
      "type": "paragraph",
      "text": "decreased cardiac output or paradoxical air embolism. Patients with right-to-left intracardiac shunts or pulmonary"
    },
    {
      "type": "paragraph",
      "text": "arteriovenous malformations are at a higher risk of having a neurological deficit develop from small volumes of air embolism."
    },
    {
      "type": "paragraph",
      "text": "Treatment of venous air embolism includes administration of 100% oxygen and placing the patient in the left lateral decubitus"
    },
    {
      "type": "paragraph",
      "text": "position (i.e., left side down). Hyperbaric oxygen has been recommended to reduce the size of air bubbles and to restore"
    },
    {
      "type": "paragraph",
      "text": "circulation and oxygenation. If cardio-pulmonary arrest occurs, closed-chest cardiopulmonary resuscitation should be initiated"
    },
    {
      "type": "paragraph",
      "text": "immediately."
    },
    {
      "type": "paragraph",
      "text": "Intra-osseous Injection"
    },
    {
      "type": "paragraph",
      "text": "Intra-osseous (IO) catheters allow rapid intravascular access for the administration of fluids and medications in critically ill"
    },
    {
      "type": "paragraph",
      "text": "patients without intravenous access. Over the last two decades, there have been improvements in product design and speed"
    },
    {
      "type": "paragraph",
      "text": "of line placement that have translated into a low reported complication rate [1-3]. Three common devices on the market in"
    },
    {
      "type": "paragraph",
      "text": "the United States include: The Bone Insertion Gun (BIG) (WaisMed, Israel); the First Access in Shock and Trauma (FAST1)"
    },
    {
      "type": "paragraph",
      "text": "(Pyng Medical Corporation, Richmond, Canada); and the EZ-IO (Vidacare, San Antonio, USA), which uses a battery-"
    },
    {
      "type": "paragraph",
      "text": "powered driver (similar to a hand-held drill) to place the specially designed needle [1,2]. Humeral placement is now the"
    },
    {
      "type": "paragraph",
      "text": "preferred site of access secondary to quick line placement and higher achievable flow rates compared to tibial access [1,4,5]."
    },
    {
      "type": "paragraph",
      "text": "High pressures are needed to infuse through IO lines because of high intramedullary compartmental pressures. Power"
    },
    {
      "type": "paragraph",
      "text": "injection is possible for CT and MRI; however, the rates for injection and pressure settings are not well studied in humans."
    },
    {
      "type": "paragraph",
      "text": "While no large studies looking at IO access for administration of contrast media exist, several case reports document"
    },
    {
      "type": "paragraph",
      "text": "successful acquisition of contrast-enhanced CT with no reported complications using injection rates up to 5 ml/sec (max PSI"
    },
    {
      "type": "paragraph",
      "text": "of 300) [4,6-9]. Intra-osseous injection of gadolinium-based contrast media has not been studied, but there is no reason to"
    },
    {
      "type": "paragraph",
      "text": "believe it would behave differently."
    },
    {
      "type": "paragraph",
      "text": "A local anesthetic is needed in non-sedated patients prior to infusion of any substance through IO access. A few small studies"
    },
    {
      "type": "paragraph",
      "text": "have looked at different lidocaine algorithms to minimize the pain of infusion [1,5,10]. One suggested pretreatment reported"
    },
    {
      "type": "paragraph",
      "text": "from a single institution with the EZ-IO device is 40 mg 2% (2 ml) of epinephrine-free lidocaine slowly infused over 2"
    },
    {
      "type": "paragraph",
      "text": "minutes after the line is primed with 1 ml lidocaine. The medication was allowed to dwell for one minute, and then the line"
    },
    {
      "type": "paragraph",
      "text": "was flushed with 5-10 ml of saline followed by another 20 mg (1 ml) of lidocaine infused over one minute. For pediatric"
    },
    {
      "type": "paragraph",
      "text": "patients the same algorithm would be used, with 0.5 mg/kg as the initial dose (not to exceed 40 mg), followed by a 2-5 ml"
    },
    {
      "type": "paragraph",
      "text": "saline flush and a second 0.25 mg/kg lidocaine dose [4]. If a radiology practice is not familiar with IO infusions, consult the"
    },
    {
      "type": "paragraph",
      "text": "local trauma team for advice on how and whether to prime the line with anesthetic using local protocols."
    },
    {
      "type": "paragraph",
      "text": "Revision History"
    },
    {
      "type": "paragraph",
      "text": "21 December 2017: Minor revision"
    },
    {
      "type": "paragraph",
      "text": "10 June 2016: Major revision"
    },
    {
      "type": "paragraph",
      "text": "29 October 2008: Major revisions"
    },
    {
      "type": "paragraph",
      "text": "8 March 2004 (First version)"
    },
    {
      "type": "paragraph",
      "text": "References"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Sum W, Ridley LJ. Recognition and management of contrast media extravasation."
    },
    {
      "type": "paragraph",
      "text": "Australas Radiol."
    },
    {
      "type": "paragraph",
      "text": "2006; 50(6):549-552."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Park KS, Kim SH, Park JH, Han MC, Kim DY, Kim SJ. Methods for mitigating soft-tissue injury after subcutaneous injection of water-soluble"
    },
    {
      "type": "paragraph",
      "text": "contrast media."
    },
    {
      "type": "paragraph",
      "text": "Invest Radiol."
    },
    {
      "type": "paragraph",
      "text": "1993;28(4):332-334."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Cohan RH, Leder RA, Herzberg AJ, et al. Treatment of injuries produced by extravasation of radiographic contrast media. Presented at the 39th"
    },
    {
      "type": "image",
      "assetId": "asset_88469a0169",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "SAFE INJECTION OF CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "16"
    },
    {
      "type": "paragraph",
      "text": "Annual Meeting of the Association of University Radiologists. 1990; Minneapolis, MN."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase."
    },
    {
      "type": "paragraph",
      "text": "Am J Emerg Med."
    },
    {
      "type": "paragraph",
      "text": "2012;30(9):2102 e2101-2103."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Hanrahan K. Hyaluronidase for treatment of intravenous extravasations: implementation of an evidence-based guideline in a pediatric population."
    },
    {
      "type": "paragraph",
      "text": "J Spec Pediatr Nurs."
    },
    {
      "type": "paragraph",
      "text": "2013;18(3):253-262."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Berson EL. Experimental and therapeutic aspects of photic damage to the retina."
    },
    {
      "type": "paragraph",
      "text": "Invest Ophthalmol."
    },
    {
      "type": "paragraph",
      "text": "1973;12(1):35-44."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Upton J, Mulliken JB, Murray JE. Major intravenous extravasation injuries."
    },
    {
      "type": "paragraph",
      "text": "Am J Surg."
    },
    {
      "type": "paragraph",
      "text": "1979;137(4):497-506."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "Lewis GB, Hecker JF. Radiological examination of failure of intravenous infusions."
    },
    {
      "type": "paragraph",
      "text": "Br J Surg."
    },
    {
      "type": "paragraph",
      "text": "1991;78(4):500-501."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Wei K, Mulvagh SL, Carson L, et al. The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383"
    },
    {
      "type": "paragraph",
      "text": "administered contrast doses."
    },
    {
      "type": "paragraph",
      "text": "J Am Soc Echocardiogr."
    },
    {
      "type": "paragraph",
      "text": "2008;21(11):1202-1206."
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Piscaglia F, Bolondi L, Italian Society for Ultrasound in M, Biology Study Group on Ultrasound Contrast A. The safety of Sonovue in abdominal"
    },
    {
      "type": "paragraph",
      "text": "applications: retrospective analysis of 23188 investigations."
    },
    {
      "type": "paragraph",
      "text": "Ultrasound Med Biol."
    },
    {
      "type": "paragraph",
      "text": "2006;32(9):1369-1375."
    },
    {
      "type": "paragraph",
      "text": "Suggested Reading"
    },
    {
      "type": "paragraph",
      "text": "(Articles that the Committee recommends for further reading on this topic are provided here)."
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Carlson JE, Hedlund LJ, Trenkner SW, Ritenour R, Halvorsen RA, Jr. Safety considerations in the power injection of contrast media via central"
    },
    {
      "type": "paragraph",
      "text": "venous catheters during computed tomographic examinations."
    },
    {
      "type": "paragraph",
      "text": "Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": "1992; 27:337-340."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Coyle D, Bloomgarden D, Beres R, Patel S, Sane S, Hurst E. Power injection of contrast media via peripherally inserted central catheters for"
    },
    {
      "type": "paragraph",
      "text": "CT."
    },
    {
      "type": "paragraph",
      "text": "J Vasc Interv Radiol"
    },
    {
      "type": "paragraph",
      "text": "2004; 15:809-814."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Herts BR, Cohen MA, McInroy B, Davros WJ, Zepp RC, Einstein DM. Power injection of intravenous contrast material through central venous"
    },
    {
      "type": "paragraph",
      "text": "catheters for CT: in vitro evaluation. Radiology 1996; 200:731-735."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Kizer KW, Goodman PC. Radiographic manifestations of venous air embolism."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1982; 144:35-39."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "McCarthy S, Moss AA. The use of a flow rate injector for contrast-enhanced computed tomography."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1984; 151:800."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Murphy BP, Harford FJ, Cramer FS. Cerebral air embolism resulting from invasive medical procedures. Treatment with hyperbaric oxygen."
    },
    {
      "type": "paragraph",
      "text": "Ann Surg"
    },
    {
      "type": "paragraph",
      "text": "1985; 201:242-245."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Price DB, Nardi P, Teitcher J. Venous air embolization as a complication of pressure injection of contrast media: CT findings."
    },
    {
      "type": "paragraph",
      "text": "J Comput Assist Tomog"
    },
    {
      "type": "paragraph",
      "text": "r 1987; 11:294-295."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "Rubinstein D, Dangleis K, Damiano TR. Venous air emboli identified on head and neck CT scans."
    },
    {
      "type": "paragraph",
      "text": "J Comput Assist Tomogr"
    },
    {
      "type": "paragraph",
      "text": "1996; 20:559-562."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Ruess L, Bulas DI, Rivera O, Markle BM. In-line pressures generated in small-bore central venous catheters during power injection of CT"
    },
    {
      "type": "paragraph",
      "text": "contrast media."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1997; 203:625-629."
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Shuman WP, Adam JL, Schoenecker SA, Tazioli PR, Moss AA. Use of a power injector during dynamic computed tomography."
    },
    {
      "type": "paragraph",
      "text": "J Comput Assist Tomogr"
    },
    {
      "type": "paragraph",
      "text": "1986; 10:1000-1002."
    },
    {
      "type": "paragraph",
      "text": "11."
    },
    {
      "type": "paragraph",
      "text": "Williamson EE, McKinney JM. Assessing the adequacy of peripherally inserted central catheters for power injection of intravenous contrast"
    },
    {
      "type": "paragraph",
      "text": "agents for CT."
    },
    {
      "type": "paragraph",
      "text": "J Comput Assist Tomogr"
    },
    {
      "type": "paragraph",
      "text": "2001; 25:932-937."
    },
    {
      "type": "paragraph",
      "text": "12."
    },
    {
      "type": "paragraph",
      "text": "Woodring JH, Fried AM. Nonfatal venous air embolism after contrast-enhanced CT."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1988; 167:405-407."
    },
    {
      "type": "image",
      "assetId": "asset_c3fc4de703",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "EXTRAVASATION OF CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "17"
    },
    {
      "type": "paragraph",
      "text": "Extravasation Bullet Points and Recommendations with Associated Strength of Evidence"
    },
    {
      "type": "paragraph",
      "text": "Below is a summary of the recommendations related to contrast extravasation and the associated strength of evidence for"
    },
    {
      "type": "paragraph",
      "text": "those recommendations using the"
    },
    {
      "type": "paragraph",
      "text": "ACR Appropriateness Criteria(R) Methodology"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "Frequency"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "0.1-1.2% of CT injections result in extravasations [1-9]."
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Most extravasations resolve without complication [6, 7, 11, 13, 14]; severe extravasation injuries, including"
    },
    {
      "type": "paragraph",
      "text": "compartment syndrome (most common [11]) and skin ulceration / necrosis, are very rare (<<1% of"
    },
    {
      "type": "paragraph",
      "text": "extravasations) [7, 8, 11]."
    },
    {
      "type": "paragraph",
      "text": "Risks"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Extravasations and severe extravasation injuries are more common in patients who 1) are uncommunicative, 2) have"
    },
    {
      "type": "paragraph",
      "text": "altered circulation in the injected extremity, 3) have had radiation of the injected extremity, or 4) are injected in the hand,"
    },
    {
      "type": "paragraph",
      "text": "foot, or ankle [1, 32]."
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Extravasations are also more common in patients injected with more viscous contrast material [6, 8, 35]."
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "The risk of extravasation can be minimized by 1) using angiocatheters rather than butterfly needles, 2) performing"
    },
    {
      "type": "paragraph",
      "text": "meticulous intravenous catheter insertion technique (confirming intravenous location by aspirating blood through an"
    },
    {
      "type": "paragraph",
      "text": "inserted catheter and flushing the inserted catheter with a test injection), 3) and carefully securing an inserted catheter"
    },
    {
      "type": "paragraph",
      "text": "[41]."
    },
    {
      "type": "paragraph",
      "text": "Evaluation and treatment"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "A health care provider should examine any patient in whom a contrast-media extravasation occurs; physical"
    },
    {
      "type": "paragraph",
      "text": "examination should include assessment of tenderness, swelling, erythema, paresthesia, active and passive range of"
    },
    {
      "type": "paragraph",
      "text": "finger motion, and perfusion [22]."
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "There is no known effective treatment for contrast medium extravasation, although initial steps should include"
    },
    {
      "type": "paragraph",
      "text": "elevation of the affected extremity above the level or the heart [22, 24], and use of cold or warm compresses [22-"
    },
    {
      "type": "paragraph",
      "text": "25]. No medical interventions have been deemed helpful [15, 22, 28, 29]."
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Since severe extravasation injuries can develop slowly (up to hours after an extravasation), all discharged"
    },
    {
      "type": "paragraph",
      "text": "outpatients should be given clear instructions concerning where and when to seek additional medical care"
    },
    {
      "type": "paragraph",
      "text": "(including for worsening pain, development of paresthesia, diminished range of motion, and new skin ulceration"
    },
    {
      "type": "paragraph",
      "text": "or blistering) [22]."
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Surgical consultation should be obtained whenever there is concern for a severe extravasation injury [11, 22]; this"
    },
    {
      "type": "paragraph",
      "text": "can be suspected if the patient develops severe pain, progressive swelling or pain, decreased capillary refill,"
    },
    {
      "type": "paragraph",
      "text": "change in sensation, worsening active or passive range of motion in the elbow, wrist, or fingers, or skin ulceration"
    },
    {
      "type": "paragraph",
      "text": "or blistering [17]; reliance on an extravasation volume threshold to trigger surgical consultation is not"
    },
    {
      "type": "paragraph",
      "text": "recommended [11, 13, 18]."
    },
    {
      "type": "paragraph",
      "text": "Power-injection through central venous catheters and peripherally inserted central catheters (PICCs)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Contrast material can only be power-injected into central venous catheters [38] or PICCs [39] if these catheters"
    },
    {
      "type": "paragraph",
      "text": "have been certified for such use, with the flow-rate limit provided. All manufacturer recommendations should be"
    },
    {
      "type": "paragraph",
      "text": "followed."
    },
    {
      "type": "paragraph",
      "text": "Gadolinium-based contrast media"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Extravasation injuries after injection of gadolinium-based contrast media are much less common than those seen after"
    },
    {
      "type": "paragraph",
      "text": "injection of iodinated contrast material [20], likely due, in part, to less toxicity [21] and the low volumes of gadolinium-"
    },
    {
      "type": "paragraph",
      "text": "based contrast media that are injected."
    },
    {
      "type": "image",
      "assetId": "asset_552b83321f",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "EXTRAVASATION OF CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "18"
    },
    {
      "type": "paragraph",
      "text": "Summary Questions and Answers"
    },
    {
      "type": "paragraph",
      "text": "(Study Quality = SQ)"
    },
    {
      "type": "paragraph",
      "text": "Question 1. What actions can be performed to minimize the likelihood of an extravasation?"
    },
    {
      "type": "paragraph",
      "text": "Recommendation 1: Extravasation risk is minimized by 1) using angiocatheters over butterflies, 2) performing meticulous"
    },
    {
      "type": "paragraph",
      "text": "intravenous insertion technique (confirming intravenous location by aspirating blood through an inserted catheter and flushing the"
    },
    {
      "type": "paragraph",
      "text": "inserted catheter with a test injection), 3) and carefully securing an inserted catheter."
    },
    {
      "type": "paragraph",
      "text": "Strength of evidence: Limited 1"
    },
    {
      "type": "paragraph",
      "text": "Reference #"
    },
    {
      "type": "paragraph",
      "text": "Original SQ"
    },
    {
      "type": "paragraph",
      "text": "Reassessed SQ"
    },
    {
      "type": "paragraph",
      "text": "Final SQ"
    },
    {
      "type": "paragraph",
      "text": "41"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "Question 2: What risk factors should clinicians take into consideration in determining the likelihood of a contrast"
    },
    {
      "type": "paragraph",
      "text": "extravasation?"
    },
    {
      "type": "paragraph",
      "text": "Recommendation 1: Clinicians should consider patient related factors such as history of altered circulation in the injected"
    },
    {
      "type": "paragraph",
      "text": "extremity, prior radiation to the injected extremity, or uncommunicative patients."
    },
    {
      "type": "paragraph",
      "text": "Strength of evidence: Limited 1"
    },
    {
      "type": "paragraph",
      "text": "Reference #"
    },
    {
      "type": "paragraph",
      "text": "Original SQ"
    },
    {
      "type": "paragraph",
      "text": "Reassessed SQ"
    },
    {
      "type": "paragraph",
      "text": "Final SQ"
    },
    {
      "type": "paragraph",
      "text": "1"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "32"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "Recommendation 2: Clinicians should consider contrast and injection parameters such as viscosity of contrast material and"
    },
    {
      "type": "paragraph",
      "text": "location of injection other than non-antecubital fossa regions (such as hand, foot, and ankle more at risk)"
    },
    {
      "type": "paragraph",
      "text": "Strength of evidence: Viscosity = Strong 3"
    },
    {
      "type": "paragraph",
      "text": "Reference #"
    },
    {
      "type": "paragraph",
      "text": "Original SQ"
    },
    {
      "type": "paragraph",
      "text": "Reassessed SQ"
    },
    {
      "type": "paragraph",
      "text": "Final SQ"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "8"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "35"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "Strength of evidence: Location of injection = Strong 3"
    },
    {
      "type": "paragraph",
      "text": "Reference #"
    },
    {
      "type": "paragraph",
      "text": "Original SQ"
    },
    {
      "type": "paragraph",
      "text": "Reassessed SQ"
    },
    {
      "type": "paragraph",
      "text": "Final SQ"
    },
    {
      "type": "paragraph",
      "text": "1"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "20"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "36"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "Question 3: How should clinicians evaluate patients for potential contrast extravasation?"
    },
    {
      "type": "paragraph",
      "text": "Recommendation 1: Clinicians should do a physical exam of the affected extremity to evaluate for tenderness, swelling,"
    },
    {
      "type": "paragraph",
      "text": "erythema, paresthesia, active and passive range of finger motion, and perfusion."
    },
    {
      "type": "paragraph",
      "text": "Strength of evidence: Limited 3"
    },
    {
      "type": "paragraph",
      "text": "Reference #"
    },
    {
      "type": "paragraph",
      "text": "Original SQ"
    },
    {
      "type": "paragraph",
      "text": "Reassessed SQ"
    },
    {
      "type": "paragraph",
      "text": "Final SQ"
    },
    {
      "type": "paragraph",
      "text": "22"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "image",
      "assetId": "asset_6f585c3186",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "EXTRAVASATION OF CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "19"
    },
    {
      "type": "paragraph",
      "text": "Question 4: How should contrast extravasations be treated?"
    },
    {
      "type": "paragraph",
      "text": "Recommendation 1: Elevation of the affected extremity above the heart."
    },
    {
      "type": "paragraph",
      "text": "Strength of evidence: Limited 3"
    },
    {
      "type": "paragraph",
      "text": "Reference #"
    },
    {
      "type": "paragraph",
      "text": "Original SQ"
    },
    {
      "type": "paragraph",
      "text": "Reassessed SQ"
    },
    {
      "type": "paragraph",
      "text": "Final SQ"
    },
    {
      "type": "paragraph",
      "text": "22"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "24"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "Recommendation 2: Cold compresses or ice packs should initially be applied to the extravasation site (rather than warm"
    },
    {
      "type": "paragraph",
      "text": "compresses)"
    },
    {
      "type": "paragraph",
      "text": "Strength of evidence: Limited 1"
    },
    {
      "type": "paragraph",
      "text": "Reference #"
    },
    {
      "type": "paragraph",
      "text": "Original SQ"
    },
    {
      "type": "paragraph",
      "text": "Reassessed SQ"
    },
    {
      "type": "paragraph",
      "text": "Final SQ"
    },
    {
      "type": "paragraph",
      "text": "22"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "23"
    },
    {
      "type": "paragraph",
      "text": "Inadequate"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Inadequate"
    },
    {
      "type": "paragraph",
      "text": "24"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "25"
    },
    {
      "type": "paragraph",
      "text": "1"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "1"
    },
    {
      "type": "paragraph",
      "text": "Recommendation 3: Routine use of hyaluronidase or corticosteroid injections or aspiration of the affected limb is not"
    },
    {
      "type": "paragraph",
      "text": "recommended."
    },
    {
      "type": "paragraph",
      "text": "Strength of evidence: Limited 1"
    },
    {
      "type": "paragraph",
      "text": "Reference #"
    },
    {
      "type": "paragraph",
      "text": "Original SQ"
    },
    {
      "type": "paragraph",
      "text": "Reassessed SQ"
    },
    {
      "type": "paragraph",
      "text": "Final SQ"
    },
    {
      "type": "paragraph",
      "text": "15"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "22"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "28"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "29"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "Recommendation 4: All discharged outpatients should be given clear instructions concerning where and when to seek additional"
    },
    {
      "type": "paragraph",
      "text": "medical care (including for worsening pain, development of paresthesia, diminished range of motion, and new skin ulceration or"
    },
    {
      "type": "paragraph",
      "text": "blistering) as severe extravasation could develop several hours later."
    },
    {
      "type": "paragraph",
      "text": "Strength of evidence: Limited 3"
    },
    {
      "type": "paragraph",
      "text": "Reference #"
    },
    {
      "type": "paragraph",
      "text": "Original SQ"
    },
    {
      "type": "paragraph",
      "text": "Reassessed SQ"
    },
    {
      "type": "paragraph",
      "text": "Final SQ"
    },
    {
      "type": "paragraph",
      "text": "11"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "3"
    },
    {
      "type": "paragraph",
      "text": "3"
    },
    {
      "type": "paragraph",
      "text": "22"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "Question 5: When should surgical consultation be placed?"
    },
    {
      "type": "paragraph",
      "text": "Recommendation 1: Surgical consultation should not be routinely requested based on volume alone."
    },
    {
      "type": "paragraph",
      "text": "Strength of evidence: Strong 3"
    },
    {
      "type": "paragraph",
      "text": "Reference #"
    },
    {
      "type": "paragraph",
      "text": "Original SQ"
    },
    {
      "type": "paragraph",
      "text": "Reassessed SQ"
    },
    {
      "type": "paragraph",
      "text": "Final SQ"
    },
    {
      "type": "paragraph",
      "text": "11"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "3"
    },
    {
      "type": "paragraph",
      "text": "3"
    },
    {
      "type": "paragraph",
      "text": "13"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "18"
    },
    {
      "type": "paragraph",
      "text": "1"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "1"
    },
    {
      "type": "paragraph",
      "text": "14"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "image",
      "assetId": "asset_add682e711",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "EXTRAVASATION OF CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "20"
    },
    {
      "type": "paragraph",
      "text": "Recommendation 2: Surgical consultation should be requested whenever there is concern for a severe extravasation injury; this"
    },
    {
      "type": "paragraph",
      "text": "can be suspected if the patient develops severe pain, progressive swelling or pain, decreased capillary refill, change in sensation,"
    },
    {
      "type": "paragraph",
      "text": "worsening active or passive range of motion in the elbow, wrist, or fingers, or skin ulceration or blistering."
    },
    {
      "type": "paragraph",
      "text": "Strength of evidence: Limited 3"
    },
    {
      "type": "paragraph",
      "text": "Reference #"
    },
    {
      "type": "paragraph",
      "text": "Original SQ"
    },
    {
      "type": "paragraph",
      "text": "Reassessed SQ"
    },
    {
      "type": "paragraph",
      "text": "Final SQ"
    },
    {
      "type": "paragraph",
      "text": "11"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "3"
    },
    {
      "type": "paragraph",
      "text": "3"
    },
    {
      "type": "paragraph",
      "text": "22"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "Question 6: Can automated (power) injectors be utilized for injections in central venous or PICC lines?"
    },
    {
      "type": "paragraph",
      "text": "Recommendation 1: Use central venous catheter to power inject contrast or PICCs if the catheters have been certified for such"
    },
    {
      "type": "paragraph",
      "text": "use, with the flow-rate limit provided. All manufacturer recommendations should be followed."
    },
    {
      "type": "paragraph",
      "text": "Strength of evidence: Limited 1"
    },
    {
      "type": "paragraph",
      "text": "Reference #"
    },
    {
      "type": "paragraph",
      "text": "Original SQ"
    },
    {
      "type": "paragraph",
      "text": "Reassessed SQ"
    },
    {
      "type": "paragraph",
      "text": "Final SQ"
    },
    {
      "type": "paragraph",
      "text": "38"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "39"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "Question 7: What is the extravasation risk from injection of gadolinium-based contrast media?"
    },
    {
      "type": "paragraph",
      "text": "Recommendation 1: Extravasation injuries are extremely unlikely during gadolinium-based contrast media injection, likely due"
    },
    {
      "type": "paragraph",
      "text": "to lower toxicity than iodinated contrast agents and lower total volumes of injected contrast media."
    },
    {
      "type": "paragraph",
      "text": "Strength of evidence: Limited 3"
    },
    {
      "type": "paragraph",
      "text": "Reference #"
    },
    {
      "type": "paragraph",
      "text": "Original SQ"
    },
    {
      "type": "paragraph",
      "text": "Reassessed SQ"
    },
    {
      "type": "paragraph",
      "text": "Final SQ"
    },
    {
      "type": "paragraph",
      "text": "20"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "21"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "image",
      "assetId": "asset_ce10ea6ffe",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "EXTRAVASATION OF CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "21"
    },
    {
      "type": "paragraph",
      "text": "EXTRAVASATION OF CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "Frequency"
    },
    {
      "type": "paragraph",
      "text": "The reported incidence of intravenous (IV) contrast media extravasation in adults and children related to power injection for"
    },
    {
      "type": "paragraph",
      "text": "CT has ranged from 0.1% to 1.2% [41-49] (1/1,000 patients to 1/83 patients). Extravasation can also occur during hand"
    },
    {
      "type": "paragraph",
      "text": "injections. Extravasations may occur at both low and high flow rates [50]. Extravasation occurring with dynamic bolus CT may"
    },
    {
      "type": "paragraph",
      "text": "involve large volumes of contrast media [51]."
    },
    {
      "type": "paragraph",
      "text": "Initial Signs and Symptoms"
    },
    {
      "type": "paragraph",
      "text": "Most extravasations are limited to the immediately adjacent soft tissues (typically the skin and subcutaneous tissues)."
    },
    {
      "type": "paragraph",
      "text": "Although most patients complain of initial swelling or tightness, and/or stinging or burning pain at the site of extravasation,"
    },
    {
      "type": "paragraph",
      "text": "some experience little or no discomfort [51,52]. On physical examination, the extravasation site may be edematous,"
    },
    {
      "type": "paragraph",
      "text": "erythematous, and tender [51]."
    },
    {
      "type": "paragraph",
      "text": "Extravasation of Iodinated Contrast Material"
    },
    {
      "type": "paragraph",
      "text": "In most patients, initial swelling and tenderness resolves within hours to days after the extravasation. The vast majority of"
    },
    {
      "type": "paragraph",
      "text": "patients in whom extravasations occur recover without clinically important sequelae [46,47,51,53,54]. However, in some"
    },
    {
      "type": "paragraph",
      "text": "patients, extravasated iodinated contrast media can result in injury to surrounding tissues, particularly the skin, producing an"
    },
    {
      "type": "paragraph",
      "text": "acute local inflammatory response that peaks at 24 to 48 hours [55]. Most of the time there are no lasting complications. Only"
    },
    {
      "type": "paragraph",
      "text": "rarely will a low-osmolality contrast media (LOCM) extravasation injury proceed to a severe adverse event [51]. Acute tissue"
    },
    {
      "type": "paragraph",
      "text": "injury resulting from extravasation of iodinated contrast media is probably related at least in part to its hyperosmolality [56,57]."
    },
    {
      "type": "paragraph",
      "text": "Several large series have illustrated the infrequency of severe injuries after LOCM extravasation. In one single institutional"
    },
    {
      "type": "paragraph",
      "text": "study, all 321 extravasation injuries were mild [48]. In another single institutional study [51], only one of 442 adult LOCM"
    },
    {
      "type": "paragraph",
      "text": "extravasations resulted in a severe injury (a compartment syndrome). Three other patients developed blisters or ulcerations that"
    },
    {
      "type": "paragraph",
      "text": "were successfully treated locally. In a third study, utilizing a practice quality improvement database established by the American"
    },
    {
      "type": "paragraph",
      "text": "College of Radiology [47] only six of 1,085 reported extravasations resulted in severe injuries, and only one patient required"
    },
    {
      "type": "paragraph",
      "text": "surgical intervention."
    },
    {
      "type": "paragraph",
      "text": "The most commonly reported severe injury after LOCM extravasation is compartment syndrome [51]. Compartment syndrome"
    },
    {
      "type": "paragraph",
      "text": "results from mechanical compression and is probably more likely to occur after extravasation of larger volumes of contrast"
    },
    {
      "type": "paragraph",
      "text": "media; however, it also has been observed after extravasation of small volumes, especially when these occur in less capacious"
    },
    {
      "type": "paragraph",
      "text": "areas (such as over the ventral or dorsal surfaces of the wrist) [51]. Compartment syndrome may develop soon after an"
    },
    {
      "type": "paragraph",
      "text": "extravasation [51] or result from swelling that sometimes occurs hours after the extravasation [58]."
    },
    {
      "type": "paragraph",
      "text": "Less commonly encountered severe injuries include skin ulceration and tissue necrosis [59]. These can occur within hours or"
    },
    {
      "type": "paragraph",
      "text": "days of the extravasation event."
    },
    {
      "type": "paragraph",
      "text": "Extravasation of Gadolinium Based Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Extravasation of gadolinium-based contrast media is less common (i.e., approximately one-sixth as often) than iodinated"
    },
    {
      "type": "paragraph",
      "text": "contrast media [60]. The difference is likely the due to much lower volumes of administered gadolinium-based contrast media"
    },
    {
      "type": "paragraph",
      "text": "for most clinical indications. Additionally, on a cc to cc basis, gadolinium-based contrast media may also have less toxicity"
    },
    {
      "type": "paragraph",
      "text": "than iodinated contrast agents [61]."
    },
    {
      "type": "paragraph",
      "text": "Evaluation of Patients in Whom Extravasations Occur"
    },
    {
      "type": "paragraph",
      "text": "A responsible health care provider should be summoned to examine any patient in whom an extravasation of contrast material"
    },
    {
      "type": "paragraph",
      "text": "has occurred. The patient should be asked about symptoms of pain and paresthesias. A brief examination should be performed"
    },
    {
      "type": "paragraph",
      "text": "and should include assessment of extremity tenderness, swelling, erythema, paresthesia, active and passive range of motion of"
    },
    {
      "type": "paragraph",
      "text": "the fingers, and perfusion [62]."
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Studies evaluating potential treatments of extravasation injuries are generally of low quality [63]. Given the absence of any"
    },
    {
      "type": "paragraph",
      "text": "studies demonstrating definite efficacy of any specific treatment regimen, the optimum treatment of extravasation events has"
    },
    {
      "type": "image",
      "assetId": "asset_152a3e7447",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "EXTRAVASATION OF CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "22"
    },
    {
      "type": "paragraph",
      "text": "not been determined. Our limited guidance is to suggest treatments that have a low risk of harm, but that might have some"
    },
    {
      "type": "paragraph",
      "text": "efficacy."
    },
    {
      "type": "paragraph",
      "text": "Extravasations that resolve rapidly probably need no treatment other than brief observation and discharge instructions (see"
    },
    {
      "type": "paragraph",
      "text": "section entitled Discharging Patients in Whom Extravasations Occur, below). More symptomatic extravasations may be treated"
    },
    {
      "type": "paragraph",
      "text": "with extremity elevation above the level of the heart (to decrease capillary hydrostatic pressure and thereby promote resorption"
    },
    {
      "type": "paragraph",
      "text": "of extravasated fluid [22, 24]) and either warm or cold compresses that an outpatient may continue intermittently at home until"
    },
    {
      "type": "paragraph",
      "text": "symptoms resolve, along with discharge instructions, or may be continued on the wards for inpatients. Controlled studies"
    },
    {
      "type": "paragraph",
      "text": "demonstrating the efficacy of these interventions are lacking, however [25]. There is no clear evidence favoring the use of"
    },
    {
      "type": "paragraph",
      "text": "warm over cold compresses or vice versa [64]. Some surgeons empirically recommend initial use of cold compresses to promote"
    },
    {
      "type": "paragraph",
      "text": "vasoconstriction and diminish inflowing blood and swelling [62,65]."
    },
    {
      "type": "paragraph",
      "text": "Severe cases in which there is concern for neurologic or vascular compromise or skin ulceration and necrosis require surgical"
    },
    {
      "type": "paragraph",
      "text": "consultation to assess the need for operative management (see next section)."
    },
    {
      "type": "paragraph",
      "text": "There is no consistent evidence that the effects of an extravasation can be mitigated by trying to aspirate the extravasated"
    },
    {
      "type": "paragraph",
      "text": "contrast medium through an inserted needle or angiocatheter [62,66]. When such attempts are made, usually little or no"
    },
    {
      "type": "paragraph",
      "text": "extravasated contrast material can be successfully aspirated. Therefore, aspiration is not recommended."
    },
    {
      "type": "paragraph",
      "text": "Some have suggested that the extravasation site can be treated by performing multiple punctures around the extravasation site"
    },
    {
      "type": "paragraph",
      "text": "and then manually squeezing the site [67,68]; however, the effectiveness of this approach has not been validated and it is not"
    },
    {
      "type": "paragraph",
      "text": "recommended."
    },
    {
      "type": "paragraph",
      "text": "Topical application of silver sulfadiazine ointment and steroid cream three to four times daily has been recommended by some"
    },
    {
      "type": "paragraph",
      "text": "as an approach to soothe irritated skin, reduce inflammation, and to prevent infection should any blistering occur, although the"
    },
    {
      "type": "paragraph",
      "text": "efficacy of this treatment is unknown [52]."
    },
    {
      "type": "paragraph",
      "text": "There is no consistent evidence that local injection of potentially therapeutic agents, such as corticosteroids or hyalurinidase is"
    },
    {
      "type": "paragraph",
      "text": "beneficial [55,69,70]. Hyaluronidase has been used in the management of extravasation events for medications unrelated to"
    },
    {
      "type": "paragraph",
      "text": "contrast media, and there are a few case reports in which it was attempted following a contrast material extravasation event [71-"
    },
    {
      "type": "paragraph",
      "text": "73]. However, no adequate studies confirm efficacy of hyaluronidase after contrast media extravasation [68]. Therefore, use of"
    },
    {
      "type": "paragraph",
      "text": "hyaluronidase for the management of contrast material extravasation is not recommended [62]."
    },
    {
      "type": "paragraph",
      "text": "Surgical Consultation"
    },
    {
      "type": "paragraph",
      "text": "Urgent surgical consultation should be obtained whenever there is concern for a severe extravasation injury [11,22]. Although"
    },
    {
      "type": "paragraph",
      "text": "consultation can prolong length of stay (eg, by 2.5 hours in one ED population [14]), it should be obtained for any patient in"
    },
    {
      "type": "paragraph",
      "text": "whom one or more of the following extravasation-related signs or symptoms develops: severe pain; progressive swelling or"
    },
    {
      "type": "paragraph",
      "text": "pain; altered tissue perfusion as evidenced by decreased capillary refill; change in sensation in the affected limb; worsening"
    },
    {
      "type": "paragraph",
      "text": "passive or active range of motion; and skin ulceration or blistering [17]."
    },
    {
      "type": "paragraph",
      "text": "Reliance on an extravasation volume threshold (such as estimated volumes exceeding 100 or 150 mL) to indicate the need for"
    },
    {
      "type": "paragraph",
      "text": "surgical consultation has been recommended by some [51,53]. Although a severe injury is probably more likely when larger"
    },
    {
      "type": "paragraph",
      "text": "volumes are involved, most patients with large volume extravasation do not develop severe complications, even when distal to"
    },
    {
      "type": "paragraph",
      "text": "the elbow [53]. Because of this, surgical consultation should be based on signs and symptoms rather than an absolute volume"
    },
    {
      "type": "paragraph",
      "text": "threshold. If the patient is asymptomatic or has only mild symptoms, appropriate evaluation and clinical follow-ups are usually"
    },
    {
      "type": "paragraph",
      "text": "sufficient."
    },
    {
      "type": "paragraph",
      "text": "Discharging Patients in Whom Extravasations Occur"
    },
    {
      "type": "paragraph",
      "text": "Outpatients who have suffered contrast media extravasation should be released from the radiology department only after an"
    },
    {
      "type": "paragraph",
      "text": "initial period of observation, provided the radiologist is satisfied that any signs and symptoms that were present initially have"
    },
    {
      "type": "paragraph",
      "text": "improved or that new symptoms have not developed during the observation period. Clear instructions should be given to the"
    },
    {
      "type": "paragraph",
      "text": "patient to seek additional medical care for severe pain, progressive pain, numbness or tingling, diminished range of motion"
    },
    {
      "type": "paragraph",
      "text": "(active or passive), skin ulceration, or other neurologic or circulatory symptoms [62]. This is because initial symptoms of a"
    },
    {
      "type": "paragraph",
      "text": "serious compartment syndrome may be absent or relatively mild (such as limited to the development of focal paresthesia) [58]."
    },
    {
      "type": "image",
      "assetId": "asset_c0b7ebee80",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "EXTRAVASATION OF CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "23"
    },
    {
      "type": "paragraph",
      "text": "Other Considerations"
    },
    {
      "type": "paragraph",
      "text": "Patients at Increased Risk for Extravasations"
    },
    {
      "type": "paragraph",
      "text": "Extravasations are more common in patients who cannot communicate effectively (e.g., the elderly, infants and children, and"
    },
    {
      "type": "paragraph",
      "text": "patients with altered consciousness), severely ill or debilitated patients, and patients with abnormal circulation in the limb to be"
    },
    {
      "type": "paragraph",
      "text": "injected [74]. Patients with altered circulation include those with atherosclerotic peripheral vascular disease, diabetic vascular"
    },
    {
      "type": "paragraph",
      "text": "disease, Raynauds disease, venous thrombosis or insufficiency, or prior radiation therapy or extensive surgery (e.g., axilla"
    },
    {
      "type": "paragraph",
      "text": "ry"
    },
    {
      "type": "paragraph",
      "text": "lymph node dissection or saphenous vein graft harvesting) in the limb to be injected. Women may have a mild increased risk of"
    },
    {
      "type": "paragraph",
      "text": "extravasation [63]. Some of these conditions are systemic and cannot be avoided by choosing a different injection site."
    },
    {
      "type": "paragraph",
      "text": "Certain intravenous access sites (e.g., hand, wrist, foot, and ankle) are more likely to result in extravasation and should be"
    },
    {
      "type": "paragraph",
      "text": "avoided, when possible [41]. However, use of these alternate injection sites may be necessary due to lack of availability of the"
    },
    {
      "type": "paragraph",
      "text": "more traditional locations."
    },
    {
      "type": "paragraph",
      "text": "In some studies, extravasations were more common in patients injected through small-bore (22 gauge) catheters compared to"
    },
    {
      "type": "paragraph",
      "text": "larger-bore catheters (2.2% versus 1.0-1.1%) [41]."
    },
    {
      "type": "paragraph",
      "text": "While some reviews have found that injection at higher flow rates likely increases the risk of extravasation [48], in others, no"
    },
    {
      "type": "paragraph",
      "text": "such difference has been detected [41,75]. In fact, it has been shown that flow rates of up to 3 and 5 mL/sec can be safely achieved"
    },
    {
      "type": "paragraph",
      "text": "through 22 gauge and 20 gauge intravenous catheters, respectively, in the vast majority of patients, provided that there is no"
    },
    {
      "type": "paragraph",
      "text": "increased resistance or pain during a rapid test injection [75]."
    },
    {
      "type": "paragraph",
      "text": "Patients injected with more viscous contrast material may be more likely to have extravasations than are patients injected with"
    },
    {
      "type": "paragraph",
      "text": "less viscous contrast material [46,48,76]."
    },
    {
      "type": "paragraph",
      "text": "This effect may be mitigated for viscous media by extrinsic warming to human body"
    },
    {
      "type": "paragraph",
      "text": "temperature prior to injection [76]."
    },
    {
      "type": "paragraph",
      "text": "The risk of extravasation also appears to be increased in patients in whom deep brachial intravenous access is achieved under"
    },
    {
      "type": "paragraph",
      "text": "ultrasound guidance, a practice used more often in Emergency Departments for patients in whom IV access is otherwise difficult"
    },
    {
      "type": "paragraph",
      "text": "[77]."
    },
    {
      "type": "paragraph",
      "text": "In one series, contrast media extravasation occurred during CT in 0.3% of all patients, but in 3.6% of patients who were"
    },
    {
      "type": "paragraph",
      "text": "injected through ultrasound-guided peripheral intravenous catheters [78]. That difference is likely in part due to selection bias"
    },
    {
      "type": "paragraph",
      "text": "(patients requiring ultrasound-guided access likely have more difficult venous access)."
    },
    {
      "type": "paragraph",
      "text": "Extravasation Risk of Injection through Indwelling Central Venous Catheters"
    },
    {
      "type": "paragraph",
      "text": "All central venous catheter port sites can be utilized for venous access if gentle hand injections are performed; however, only"
    },
    {
      "type": "paragraph",
      "text": "certain central venous catheter port sites are certified for use with mechanical injectors. Prior to using a central venous line"
    },
    {
      "type": "paragraph",
      "text": "for power injection, it is important to ensure that the port site is certified as power-injectable, and the flow limit should be"
    },
    {
      "type": "paragraph",
      "text": "noted. If this process is followed, it can be safe. In one report of 142 injections through certified power port sites (11 at high"
    },
    {
      "type": "paragraph",
      "text": "rates up to 5 mL/second), there were no extravasations [79]."
    },
    {
      "type": "paragraph",
      "text": "Mechanical injections can also be performed through some pressure-injectable peripherally inserted central catheters"
    },
    {
      "type": "paragraph",
      "text": "(PICCs). Manufacturer recommendations should be followed. There have been isolated reports of PICC tip migrations"
    },
    {
      "type": "paragraph",
      "text": "following pressure injections through these catheters [80]."
    },
    {
      "type": "paragraph",
      "text": "Patients at Increased Risk for a Severe Extravasation Injury Once an Extravasation Occurs"
    },
    {
      "type": "paragraph",
      "text": "A severe extravasation injury may be more likely to result from an extravasation in certain patients, such as those with arterial"
    },
    {
      "type": "paragraph",
      "text": "insufficiency or compromised venous or lymphatic drainage in the affected extremity. In addition, extravasations involving"
    },
    {
      "type": "paragraph",
      "text": "larger volumes of contrast media and those occurring in the dorsum of the hand, foot, or ankle are more likely to result in"
    },
    {
      "type": "paragraph",
      "text": "severe injury [22, 32]."
    },
    {
      "type": "paragraph",
      "text": "Preventing Extravasation Injuries"
    },
    {
      "type": "paragraph",
      "text": "Methods for reducing the risk of extravasation include: meticulous intravenous line insertion technique, using angiocatheters"
    },
    {
      "type": "paragraph",
      "text": "instead of butterfly catheters, confirming position by aspirating blood (although failure to aspirate blood does not exclude the"
    },
    {
      "type": "paragraph",
      "text": "possibility of proper catheter location), flushing an inserted catheter with a test injection of saline to ensure proper flow into"
    },
    {
      "type": "paragraph",
      "text": "the accessed vein, and carefully securing the inserted catheter [81]."
    },
    {
      "type": "paragraph",
      "text": "Low-risk intravenous line insertion sites are preferred when feasible. If not feasible, higher risk sites may be considered"
    },
    {
      "type": "paragraph",
      "text": "depending on the risks and benefits of administrating contrast media for the examination indication. Use of a preliminary"
    },
    {
      "type": "image",
      "assetId": "asset_d32ee5ad27",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "EXTRAVASATION OF CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "24"
    },
    {
      "type": "paragraph",
      "text": "saline flush to assess injection pressure prior to contrast media administration has been advocated by a few investigators [82];"
    },
    {
      "type": "paragraph",
      "text": "however, this has not been adopted by most institutions. Some have recommended use of a hand-held alarm, which the patient"
    },
    {
      "type": "paragraph",
      "text": "can press should any new symptoms develop [52]."
    },
    {
      "type": "paragraph",
      "text": "Interestingly, the practice quality improvement project created by the ACR"
    },
    {
      "type": "paragraph",
      "text": "to assist practices in identifying improvements that could be made to reduce the frequency of extravasations did not find that"
    },
    {
      "type": "paragraph",
      "text": "any significant improvement could be achieved, even when risk factors for extravasations were identified and attempts were"
    },
    {
      "type": "paragraph",
      "text": "made to reduce the extravasation risk in advance [47]."
    },
    {
      "type": "paragraph",
      "text": "Documentation"
    },
    {
      "type": "paragraph",
      "text": "All extravasation events and their treatment should be documented in the medical record. In addition, the referring provider"
    },
    {
      "type": "paragraph",
      "text": "should be notified following any symptomatic extravasation."
    },
    {
      "type": "paragraph",
      "text": "Revision History"
    },
    {
      "type": "paragraph",
      "text": "23 January 2018 (Minor Revision)"
    },
    {
      "type": "paragraph",
      "text": "October 2021 (Evidence Based Update)"
    },
    {
      "type": "paragraph",
      "text": "References"
    },
    {
      "type": "paragraph",
      "text": "1. Wienbeck S, Fischbach R, Kloska SP, et al. Prospective study of access site complications of automated contrast injection with peripheral venous"
    },
    {
      "type": "paragraph",
      "text": "access in MDCT. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2010;195:825-9."
    },
    {
      "type": "paragraph",
      "text": "2. Sistrom CL, Gay SB, Peffley L. Extravasation of iopamidol and iohexol during contrast-enhanced CT: report of 28 cases. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1991;180:707-"
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "3. Sinan T, Al-Khawari H, Chishti FA, Al Saeed OM, Sheikh M. Contrast media extravasation: manual versus power injector. Med Princ Pract"
    },
    {
      "type": "paragraph",
      "text": "2005;14:107-10."
    },
    {
      "type": "paragraph",
      "text": "4. Jacobs JE, Birnbaum BA, Langlotz CP. Contrast media reactions and extravasation: relationship to intravenous injection rates. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1998;209:411-6."
    },
    {
      "type": "paragraph",
      "text": "5. Federle MP, Chang PJ, Confer S, Ozgun B. Frequency and effects of extravasation of ionic and nonionic CT contrast media during rapid bolus"
    },
    {
      "type": "paragraph",
      "text": "injection. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1998;206:637-40."
    },
    {
      "type": "paragraph",
      "text": "6. Barrera CA, White AM, Shepherd AM, et al. Contrast Extravasation using Power Injectors for Contrast-Enhanced Computed Tomography in"
    },
    {
      "type": "paragraph",
      "text": "Children: Frequency and Injury Severity. Academic radiology"
    },
    {
      "type": "paragraph",
      "text": "2019;26:1668-74."
    },
    {
      "type": "paragraph",
      "text": "7. Dykes TM, Bhargavan-Chatfield M, Dyer RB. Intravenous contrast extravasation during CT: a national data registry and practice quality"
    },
    {
      "type": "paragraph",
      "text": "improvement initiative. Journal of the American College of Radiology : JACR"
    },
    {
      "type": "paragraph",
      "text": "2015;12:183-91."
    },
    {
      "type": "paragraph",
      "text": "8. Hwang EJ, Shin CI, Choi YH, Park CM. Frequency, outcome, and risk factors of contrast media extravasation in 142,651 intravenous contrast-"
    },
    {
      "type": "paragraph",
      "text": "enhanced CT scans. European radiology"
    },
    {
      "type": "paragraph",
      "text": "2018;28:5368-75."
    },
    {
      "type": "paragraph",
      "text": "9. Kingston RJ, Young N, Sindhusake DP, Truong M. Study of patients with intravenous contrast extravasation on CT studies, with radiology staff"
    },
    {
      "type": "paragraph",
      "text": "and ward staff cannulations. Journal of medical imaging and radiation oncology"
    },
    {
      "type": "paragraph",
      "text": "2012;56:163-7."
    },
    {
      "type": "paragraph",
      "text": "10. Cohan RH, Bullard MA, Ellis JH, et al. Local reactions after injection of iodinated contrast material: detection, management, and outcome."
    },
    {
      "type": "paragraph",
      "text": "Academic radiology"
    },
    {
      "type": "paragraph",
      "text": "1997;4:711-8."
    },
    {
      "type": "paragraph",
      "text": "11. Wang CL, Cohan RH, Ellis JH, Adusumilli S, Dunnick NR. Frequency, management, and outcome of extravasation of nonionic iodinated contrast"
    },
    {
      "type": "paragraph",
      "text": "medium in 69,657 intravenous injections. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2007;243:80-7."
    },
    {
      "type": "paragraph",
      "text": "12. Ko CH, Tay SY, Chang HC, Chan WP. Large-volume iodinated contrast medium extravasation: low frequency and good outcome after"
    },
    {
      "type": "paragraph",
      "text": "conservative management in a single-centre cohort of more than 67,000 patients. European radiology"
    },
    {
      "type": "paragraph",
      "text": "2018;28:5376-83."
    },
    {
      "type": "paragraph",
      "text": "13. Sbitany H, Koltz PF, Mays C, Girotto JA, Langstein HN. CT contrast extravasation in the upper extremity: strategies for management. International"
    },
    {
      "type": "paragraph",
      "text": "journal of surgery (London, England)"
    },
    {
      "type": "paragraph",
      "text": "2010;8:384-6."
    },
    {
      "type": "paragraph",
      "text": "14. Sonis JD, Gottumukkala RV, Glover M, et al. Implications of iodinated contrast media extravasation in the emergency department. American"
    },
    {
      "type": "paragraph",
      "text": "Journal of Emergency Medicine"
    },
    {
      "type": "paragraph",
      "text": "2018;36:29T 296."
    },
    {
      "type": "paragraph",
      "text": "15. McAlister WH, Palmer K. The histologic effects of four commonly used media for excretory urography and an attempt to modify the responses."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1971;99:511-6."
    },
    {
      "type": "paragraph",
      "text": "16. McAlister WH, Kissane JM. Comparison of soft tissue effects of conventional ionic, low osmolar ionic and nonionic iodine containing contrast"
    },
    {
      "type": "paragraph",
      "text": "material in experimental animals. Pediatric radiology"
    },
    {
      "type": "paragraph",
      "text": "1990;20:170-4."
    },
    {
      "type": "paragraph",
      "text": "17. Cohan RH, Leder RA, Bolick D, et al. Extravascular extravasation of radiographic contrast media. Effects of conventional and low-osmolar agents"
    },
    {
      "type": "paragraph",
      "text": "in the rat thigh. Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": "1990;25:504-10."
    },
    {
      "type": "paragraph",
      "text": "18. Memolo M, Dyer R, Zagoria RJ. Extravasation injury with nonionic contrast material. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "1993;160:203-4."
    },
    {
      "type": "paragraph",
      "text": "19. Pond GD, Dorr RT, McAleese KA. Skin ulceration from extravasation of low-osmolality contrast medium: a complication of automation. AJR Am"
    },
    {
      "type": "paragraph",
      "text": "J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "1992;158:915-6."
    },
    {
      "type": "paragraph",
      "text": "20. Heshmatzadeh Behzadi A, Farooq Z, Newhouse JH, Prince MR. MRI and CT contrast media extravasation: A systematic review. Medicine"
    },
    {
      "type": "paragraph",
      "text": "2018;97:e0055."
    },
    {
      "type": "paragraph",
      "text": "21. Cohan RH, Leder RA, Herzberg AJ, et al. Extravascular toxicity of two magnetic resonance contrast agents. Preliminary experience in the rat."
    },
    {
      "type": "paragraph",
      "text": "Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": "1991;26:224-26."
    },
    {
      "type": "paragraph",
      "text": "22. Cohan RH, Ellis JH, Garner WL. Extravasation of radiographic contrast material: recognition, prevention, and treatment. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1996;200:593-"
    },
    {
      "type": "paragraph",
      "text": "604."
    },
    {
      "type": "paragraph",
      "text": "23. Ding S, Meystre NR, Campeanu C, Gullo G. Contrast media extravasations in patients undergoing computerized tomography scanning: a"
    },
    {
      "type": "paragraph",
      "text": "systematic review and meta-analysis of risk factors and interventions. JBI database of systematic reviews and implementation reports"
    },
    {
      "type": "paragraph",
      "text": "2018;16:87-"
    },
    {
      "type": "paragraph",
      "text": "116."
    },
    {
      "type": "paragraph",
      "text": "24. Bellin MF, Jakobsen JA, Tomassin I, et al. Contrast medium extravasation injury: guidelines for prevention and management. European radiology"
    },
    {
      "type": "paragraph",
      "text": "2002;12:2807-12."
    },
    {
      "type": "image",
      "assetId": "asset_44598cd2e8",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "EXTRAVASATION OF CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "25"
    },
    {
      "type": "paragraph",
      "text": "25. Hastings-Tolsma MT, Yucha CB, Tompkins J, Robson L, Szeverenyi N. Effect of warm and cold applications on the resolution of i.v. infiltrations."
    },
    {
      "type": "paragraph",
      "text": "Research in nursing & health"
    },
    {
      "type": "paragraph",
      "text": "1993;16:171-8."
    },
    {
      "type": "paragraph",
      "text": "26. Sum W, Ridley LJ. Recognition and management of contrast media extravasation. Australas Radiol"
    },
    {
      "type": "paragraph",
      "text": "2006;50:549-52."
    },
    {
      "type": "paragraph",
      "text": "27. Kim SM, Cook KH, Lee IJ, Park DH, Park MC. Computed tomography contrast media extravasation: treatment algorithm and immediate treatment"
    },
    {
      "type": "paragraph",
      "text": "by squeezing with multiple slit incisions. International wound journal"
    },
    {
      "type": "paragraph",
      "text": "2017;14:430-34."
    },
    {
      "type": "paragraph",
      "text": "28. Mandlik V, Prantl L, Schreyer AG. Contrast Media Extravasation in CT and MRI - A Literature Review and Strategies for Therapy. RoFo :"
    },
    {
      "type": "paragraph",
      "text": "Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin"
    },
    {
      "type": "paragraph",
      "text": "2019;191:25-32."
    },
    {
      "type": "paragraph",
      "text": "29. Park KS, Kim SH, Park JH, Han MC, Kim DY, Kim SJ. Methods for mitigating soft-tissue injury after subcutaneous injection of water soluble"
    },
    {
      "type": "paragraph",
      "text": "contrast media. Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": "1993;28:332-4."
    },
    {
      "type": "paragraph",
      "text": "30. Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. The American journal of emergency medicine"
    },
    {
      "type": "paragraph",
      "text": "2012;30:2102.e1-3."
    },
    {
      "type": "paragraph",
      "text": "31. Hanrahan K. Hyaluronidase for treatment of intravenous extravasations: implementation of an evidence-based guideline in a pediatric population."
    },
    {
      "type": "paragraph",
      "text": "Journal for specialists in pediatric nursing : JSPN"
    },
    {
      "type": "paragraph",
      "text": "2013;18:253-62."
    },
    {
      "type": "paragraph",
      "text": "32. Upton J, Mulliken JB, Murray JE. Major intravenous extravasation injuries. American journal of surgery"
    },
    {
      "type": "paragraph",
      "text": "1979;137:497-506."
    },
    {
      "type": "paragraph",
      "text": "33. Lewis GB, Hecker JF. Radiological examination of failure of intravenous infusions. Br J Surg"
    },
    {
      "type": "paragraph",
      "text": "1991;78:500-1."
    },
    {
      "type": "paragraph",
      "text": "34. Schwab SA, Uder M, Anders K, Heinrich MC, Kuefner MA. Peripheral intravenous power injection of iodinated contrast media through 22G and"
    },
    {
      "type": "paragraph",
      "text": "20G cannulas: can high flow rates be achieved safely? A clinical feasibility study. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der"
    },
    {
      "type": "paragraph",
      "text": "Nuklearmedizin"
    },
    {
      "type": "paragraph",
      "text": "2009;181:355-61."
    },
    {
      "type": "paragraph",
      "text": "35. Davenport MS, Wang CL, Bashir MR, Neville AM, Paulson EK. Rate of contrast material extravasations and allergic-like reactions: effect of"
    },
    {
      "type": "paragraph",
      "text": "extrinsic warming of low-osmolality iodinated CT contrast material to 37 degrees C. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2012;262:475-84."
    },
    {
      "type": "paragraph",
      "text": "36. Hardie AD, Kereshi B. Incidence of intravenous contrast extravasation: increased risk for patients with deep brachial catheter placement from the"
    },
    {
      "type": "paragraph",
      "text": "emergency department. Emergency radiology"
    },
    {
      "type": "paragraph",
      "text": "2014;21:235-8."
    },
    {
      "type": "paragraph",
      "text": "37. Rupp JD, Ferre RM, Boyd JS, et al. Extravasation Risk Using Ultrasound-guided Peripheral Intravenous Catheters for Computed Tomography"
    },
    {
      "type": "paragraph",
      "text": "Contrast Administration. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine"
    },
    {
      "type": "paragraph",
      "text": "2016;23:918-21."
    },
    {
      "type": "paragraph",
      "text": "38. Alexander MD, Morrison HL. Power-injectable ports: safety during placement, therapeutic use, and contrast administration during computed"
    },
    {
      "type": "paragraph",
      "text": "tomography procedures. The journal of vascular access"
    },
    {
      "type": "paragraph",
      "text": "2012;13:432-7."
    },
    {
      "type": "paragraph",
      "text": "39. Craigie M, Meehan L, Harper J. Tip Migration Post-Contrast Pressure Injection Through Pressure-Injectable Peripherally Inserted Central Catheters"
    },
    {
      "type": "paragraph",
      "text": "Causing Vascular Injury: A Report of 3 Cases. Cardiovascular and interventional radiology"
    },
    {
      "type": "paragraph",
      "text": "2018;41:509-12."
    },
    {
      "type": "paragraph",
      "text": "40. Kadom N, Hashim HD, Olsen C, Cefaratti M, Bulas D, Shalaby-Rana E. Nursing role model for computed tomography contrast injection decreases"
    },
    {
      "type": "paragraph",
      "text": "extravasation rates. Journal of pediatric nursing"
    },
    {
      "type": "paragraph",
      "text": "2012;27:113-8."
    },
    {
      "type": "paragraph",
      "text": "41. Abe S, Mizuno N, Tani S, et al. Effectiveness of the new injection program 'saline test injection mode' for use power injector in pediatric contrast"
    },
    {
      "type": "paragraph",
      "text": "CT. Australasian physical & engineering sciences in medicine"
    },
    {
      "type": "paragraph",
      "text": "2013;36:347-54."
    },
    {
      "type": "image",
      "assetId": "asset_ff71715e6d",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ALLERGIC-LIKE AND PHYSIOLOGIC REACTIONS TO INTRAVASCULAR IODINATED CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "26"
    },
    {
      "type": "paragraph",
      "text": "ALLERGIC-LIKE AND PHYSIOLOGIC REACTIONS TO"
    },
    {
      "type": "paragraph",
      "text": "INTRAVASCULAR IODINATED CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "The frequency of allergic-like and physiologic adverse events related to the intravascular administration of iodinated contrast"
    },
    {
      "type": "paragraph",
      "text": "media (ICM) is low and has decreased considerably with changes in usage from ionic high- osmolality contrast media"
    },
    {
      "type": "paragraph",
      "text": "(HOCM) to nonionic low-osmolality contrast media (LOCM) [1-11]. The majority of adverse side effects to LOCM are mild"
    },
    {
      "type": "paragraph",
      "text": "non-life-threatening events that usually require only observation, reassurance, and/or supportive measures [3,12,13]. Severe"
    },
    {
      "type": "paragraph",
      "text": "and potentially life-threatening adverse events continue to occur rarely and unpredictably. Nearly all life-threatening contrast"
    },
    {
      "type": "paragraph",
      "text": "reactions occur within the first 20 minutes after contrast medium injection."
    },
    {
      "type": "paragraph",
      "text": "All personnel who inject intravascular contrast media should be prepared to: 1) recognize the variety of adverse events that"
    },
    {
      "type": "paragraph",
      "text": "may occur following ICM administration and 2) institute appropriate measures to manage the reaction. These measures"
    },
    {
      "type": "paragraph",
      "text": "include notifying the supervising radiologist (or his/her designee), monitoring the patient, administering certain medications,"
    },
    {
      "type": "paragraph",
      "text": "and/or calling for additional assistance (emergency service providers, code team, etc.)."
    },
    {
      "type": "paragraph",
      "text": "Acute Adverse Events"
    },
    {
      "type": "paragraph",
      "text": "Classification of Acute Adverse Events"
    },
    {
      "type": "paragraph",
      "text": "Acute adverse events can be categorized as either allergic-like or physiologic and organized into three general categories of"
    },
    {
      "type": "paragraph",
      "text": "severity (mild, moderate, or severe). A suggested classification system (which can be utilized for both ICM and gadolinium-"
    },
    {
      "type": "paragraph",
      "text": "based contrast media [GBCM]), stratifying adverse events by severity and type, is presented in"
    },
    {
      "type": "paragraph",
      "text": "Table 1"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "A standardized classification system is important to minimize variation between published reports. It is of particular"
    },
    {
      "type": "paragraph",
      "text": "importance to avoid contaminating the reported incidence of allergic-like reactions with that of physiologic reactions,"
    },
    {
      "type": "paragraph",
      "text": "because the management of patients experiencing these reaction types is different (e.g., patients who experience allergic-like"
    },
    {
      "type": "paragraph",
      "text": "reactions may require future premedication prior to ICM- enhanced studies, while patients who experience physiologic"
    },
    {
      "type": "paragraph",
      "text": "reactions would not)."
    },
    {
      "type": "paragraph",
      "text": "Allergic-Like Reactions"
    },
    {
      "type": "paragraph",
      "text": "Allergic-like reactions to ICM manifest similarly to true allergic reactions seen with other drugs and allergens, but because"
    },
    {
      "type": "paragraph",
      "text": "an antigen-antibody response cannot be always identified, allergic-"
    },
    {
      "type": "paragraph",
      "text": "like contrast reactions are classified as anaphylactoid,"
    },
    {
      "type": "paragraph",
      "text": "allergic"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "like, or idiosyncratic [2,3,12,13]. Treatment of an allergic"
    },
    {
      "type": "paragraph",
      "text": "-like contrast reaction is identical to that of an"
    },
    {
      "type": "paragraph",
      "text": "equivalent allergic reaction. Allergic-like contrast reactions are likely independent of dose and concentration above a certain"
    },
    {
      "type": "paragraph",
      "text": "unknown threshold [3]."
    },
    {
      "type": "paragraph",
      "text": "The pathogenesis of most allergic-like reactions is unclear. There are multiple possible mechanisms that result in activation"
    },
    {
      "type": "paragraph",
      "text": "of immunologic effectors [14]. It is believed that some allergic-like contrast reactions may involve activation, deactivation,"
    },
    {
      "type": "paragraph",
      "text": "or inhibition of a variety of vasoactive substances or mediators (such as histamine, complement, and the kinin system) [3,12-"
    },
    {
      "type": "paragraph",
      "text": "15]. ICM are known to directly cause histamine release from basophils and mast cells [9]. Histamine release must have"
    },
    {
      "type": "paragraph",
      "text": "occurred when patients develop urticaria, but the precise cause and pathway of histamine release are not known [3,12,13]."
    },
    {
      "type": "paragraph",
      "text": "Skin and intradermal testing are positive in a minority of individuals, indicating that an allergic IgE-mediated etiology may"
    },
    {
      "type": "paragraph",
      "text": "be responsible for some reactions [16], but this is the minority of cases."
    },
    {
      "type": "paragraph",
      "text": "Additives or contaminants, such as calcium-chelating substances or substances eluted from rubber stoppers in bottles or"
    },
    {
      "type": "paragraph",
      "text": "syringes, have been suggested as contributory in some allergic-like contrast reactions [12,13]."
    },
    {
      "type": "paragraph",
      "text": "Physiologic Reactions"
    },
    {
      "type": "paragraph",
      "text": "Physiologic reactions to ICM likely relate to specific molecular attributes that lead to direct chemotoxicity [3,12,13],"
    },
    {
      "type": "paragraph",
      "text": "osmotoxicity (adverse effects due to hyperosmolality) [14], or molecular binding to certain activators [9]. Physiologic"
    },
    {
      "type": "paragraph",
      "text": "reactions are frequently dose and concentration dependent [3]."
    },
    {
      "type": "paragraph",
      "text": "Cardiac arrhythmias, depressed myocardial contractility, cardiogenic pulmonary edema, and seizures are very rare,"
    },
    {
      "type": "paragraph",
      "text": "potentially serious physiologic reactions to ICM [3,9,12,13]. These phenomena are likely related to either contrast media-"
    },
    {
      "type": "paragraph",
      "text": "related hyperosmolality and/or calcium binding leading to functional hypocalcemia [3,9,12,13]. Cardiac adverse events are"
    },
    {
      "type": "paragraph",
      "text": "much more common during angiocardiography than intravenous ICM administration."
    },
    {
      "type": "image",
      "assetId": "asset_83391a80cd",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ALLERGIC-LIKE AND PHYSIOLOGIC REACTIONS TO INTRAVASCULAR IODINATED CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "27"
    },
    {
      "type": "paragraph",
      "text": "Cardiovascular effects are more frequent and significant in patients with underlying cardiac disease. For example, patients"
    },
    {
      "type": "paragraph",
      "text": "with left heart failure are less able to compensate for the osmotic load and minor negative chronotropic effects of ICM. As"
    },
    {
      "type": "paragraph",
      "text": "a result, there is an increased risk of developing acute pulmonary edema. Noncardiogenic pulmonary edema can also very"
    },
    {
      "type": "paragraph",
      "text": "rarely occur following intravascular ICM administration [16], although it is unclear whether this represents a physiologic or"
    },
    {
      "type": "paragraph",
      "text": "allergic-like reaction."
    },
    {
      "type": "paragraph",
      "text": "Vasovagal reactions are relatively common and characterized by hypotension with bradycardia. While the exact pathogenesis"
    },
    {
      "type": "paragraph",
      "text": "is unknown, this particular response is thought to be the result of increased vagal tone arising from the central nervous"
    },
    {
      "type": "paragraph",
      "text": "system. The effects of increased vagal tone include depressed sinoatrial and atrioventricular nodal activity, inhibition of"
    },
    {
      "type": "paragraph",
      "text": "atrioventricular conduction, and peripheral vasodilatation [3]. Vasovagal reactions may be related to anxiety and can occur"
    },
    {
      "type": "paragraph",
      "text": "while informed consent is being obtained, during placement of a needle or catheter for contrast medium injection, or during"
    },
    {
      "type": "paragraph",
      "text": "intravascular administration of contrast media. Such reactions commonly present with a feeling of apprehension and"
    },
    {
      "type": "paragraph",
      "text": "accompanying diaphoresis [3]."
    },
    {
      "type": "paragraph",
      "text": "While most vagal reactions are mild and self-limited, close patient observation is recommended until symptoms resolve"
    },
    {
      "type": "paragraph",
      "text": "fully. Severe hypotension may very rarely cause loss of consciousness, cardiovascular collapse, angina, or seizures [3]."
    },
    {
      "type": "paragraph",
      "text": "Patient anxiety may also contribute to or exacerbate nonvagal adverse events. Similar to allergic-like reactions, some additives"
    },
    {
      "type": "paragraph",
      "text": "and contaminants have been associated with physiologic reactions [12,13]."
    },
    {
      "type": "paragraph",
      "text": "For a discussion of renal failure, please see the separate chapter on"
    },
    {
      "type": "paragraph",
      "text": "Contrast-Induced Nephrotoxicity"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "Frequency of Acute Adverse Events"
    },
    {
      "type": "paragraph",
      "text": "The frequency of acute adverse events after the administration of intravascular ICM is difficult to determine with precision"
    },
    {
      "type": "paragraph",
      "text": "because similar signs and symptoms may arise from concomitant medical conditions, medications, anxiety, etc."
    },
    {
      "type": "paragraph",
      "text": "Underreporting and variation in the classification of acute adverse reactions have affected the reported incidence of these"
    },
    {
      "type": "paragraph",
      "text": "events."
    },
    {
      "type": "paragraph",
      "text": "Historically, acute adverse events occurred in 5% to 15% of all patients who received HOCM. Many patients receiving"
    },
    {
      "type": "paragraph",
      "text": "intravascular HOCM experienced physiologic disturbances (e.g., generalized warmth, nausea, or emesis), and this was often"
    },
    {
      "type": "paragraph",
      "text": "documented as a contrast reaction. HOCM are now rarely or never used for intravascular purposes because of their greater"
    },
    {
      "type": "paragraph",
      "text": "adverse event profile compared to LOCM."
    },
    {
      "type": "paragraph",
      "text": "LOCM are associated with a very low incidence of acute adverse events, and the bulk of these are not life- threatening."
    },
    {
      "type": "paragraph",
      "text": "Cochran et al [17] reported an overall acute adverse reaction rate (allergic-like + physiologic) of 0.2% for nonionic LOCM"
    },
    {
      "type": "paragraph",
      "text": "administered at a single institution. A slightly higher overall frequency of 0.7% (allergic-like + physiologic) was reported"
    },
    {
      "type": "paragraph",
      "text": "from another institution upon review of 29,508 patients given iopromide over a 2-year period [18]. Wang et al [19] reported"
    },
    {
      "type": "paragraph",
      "text": "an overall acute allergic-like reaction frequency of 0.6% in 84,928 adult patients who received iohexol, iopromide, or"
    },
    {
      "type": "paragraph",
      "text": "iodixanol."
    },
    {
      "type": "paragraph",
      "text": "A single institutional study of pediatric patients receiving intravenous LOCM by Dillman et al [20] demonstrated a frequency"
    },
    {
      "type": "paragraph",
      "text": "of acute allergic-like reactions of 0.18%. Another single institutional study in children by Callahan et al [21] demonstrated"
    },
    {
      "type": "paragraph",
      "text": "an overall acute adverse reaction rate of 0.46% (allergic-like + physiologic)."
    },
    {
      "type": "paragraph",
      "text": "Serious acute reactions to IV LOCM are rare, with an historical rate of approximately four in 10,000 (0.04%) [6]."
    },
    {
      "type": "paragraph",
      "text": "The mortality incidence related to intravascular ICM is unknown. In a large Japanese study by Katayama et al [6], no fatal"
    },
    {
      "type": "paragraph",
      "text": "reactions were attributed to LOCM despite greater than 170,000 injections. The conservative estimate of 1 fatality per"
    },
    {
      "type": "paragraph",
      "text": "170,000 contrast media administrations is thus often quoted. Fatal reactions to LOCM have been reported [4,17,18,22,23]."
    },
    {
      "type": "paragraph",
      "text": "A meta-analysis performed by Caro et al [4] documented a fatality rate of 0.9 per 100,000 injections of LOCM. A review of"
    },
    {
      "type": "paragraph",
      "text": "U.S. FDA and drug manufacturer data from 1990 to 1994 demonstrated 2.1 fatalities per 1 million contrast-enhanced studies"
    },
    {
      "type": "paragraph",
      "text": "using LOCM [7]."
    },
    {
      "type": "paragraph",
      "text": "Common Risk Factors for Acute Contrast Reactions"
    },
    {
      "type": "paragraph",
      "text": "Although it is clear that certain patients are at increased risk of experiencing an adverse event to intravascular ICM, contrast"
    },
    {
      "type": "paragraph",
      "text": "reactions remain sporadic and unpredictable."
    },
    {
      "type": "image",
      "assetId": "asset_e2d01ccfe1",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ALLERGIC-LIKE AND PHYSIOLOGIC REACTIONS TO INTRAVASCULAR IODINATED CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "28"
    },
    {
      "type": "paragraph",
      "text": "A prior allergic-like reaction to ICM is the most substantial risk factor for a recurrent allergic-like adverse event"
    },
    {
      "type": "paragraph",
      "text": "[1,2,6,18,24]. Such a history is not an absolute predictor, and the incidence of recurrent allergic-like reactions in high-risk"
    },
    {
      "type": "paragraph",
      "text": "nonpremedicated patients is unknown. It is estimated to range from 10 to 35% [6,25,26]. The estimated risk in high-risk"
    },
    {
      "type": "paragraph",
      "text": "premedicated patients is estimated to be approximately 10% [26,27]. Atopic individuals (particularly those with multiple"
    },
    {
      "type": "paragraph",
      "text": "severe allergies) and asthmatics are also at increased risk for allergic-like contrast reactions, although probably not to as"
    },
    {
      "type": "paragraph",
      "text": "great an extent [3,6,9,12,13,24,25,28]. Those with a history of prior allergic-like reaction to GBCM are at no greater risk for"
    },
    {
      "type": "paragraph",
      "text": "allergic-like reaction to ICM than other patients with a similar number of allergies and other risk factors (e.g., asthma). A"
    },
    {
      "type": "paragraph",
      "text": "prospective study by Kopp et al [24] of over 74,000 patients who received iopromide demonstrated that certain age and"
    },
    {
      "type": "paragraph",
      "text": "gender combinations (e.g., young females) may have a higher incidence of allergic-like reactions compared to the general"
    },
    {
      "type": "paragraph",
      "text": "population. A retrospective case-control study by Lang et al [28] showed that individuals with asthma and those receiving"
    },
    {
      "type": "paragraph",
      "text": "beta-adrenergic blocker therapy may be at increased risk for moderate and severe reactions; however, this study did not"
    },
    {
      "type": "paragraph",
      "text": "match patients based on underlying diseases and it is possible that beta- blocker therapy merely indicated those patients with"
    },
    {
      "type": "paragraph",
      "text": "more comorbid conditions."
    },
    {
      "type": "paragraph",
      "text": "Pre-existing medical conditions may increase the risk of certain adverse events. For example, bronchospasm is a common"
    },
    {
      "type": "paragraph",
      "text": "adverse event among patients with a history of asthma. Hemodynamic changes are more common in patients with"
    },
    {
      "type": "paragraph",
      "text": "significant cardiovascular disease, such as aortic stenosis or severe congestive heart failure."
    },
    {
      "type": "paragraph",
      "text": "The effects of dose, route (intravenous vs. intra-arterial vs. other), and rate of delivery of contrast media on the incidence of"
    },
    {
      "type": "paragraph",
      "text": "adverse events are not entirely clear. Studies have shown that a test injection does not decrease the incidence of severe"
    },
    {
      "type": "paragraph",
      "text": "allergic-like reactions [29,30], and may actually increase it. Non-"
    },
    {
      "type": "paragraph",
      "text": "reaction to a test injection does not indicate that an"
    },
    {
      "type": "paragraph",
      "text": "allergic-like reaction will not occur with a standard injection [25]. Test injections are not recommended for predicting which"
    },
    {
      "type": "paragraph",
      "text": "patients will react to ICM."
    },
    {
      "type": "paragraph",
      "text": "Patients with Myasthenia Gravis"
    },
    {
      "type": "paragraph",
      "text": "Myasthenia gravis has historically been considered a relative contraindication to intravascular iodinated contrast material"
    },
    {
      "type": "paragraph",
      "text": "exposure based on experimental and largely anecdotal clinical data with respect to HOCM. Due to a lack of clear evidence"
    },
    {
      "type": "paragraph",
      "text": "showing adverse effects for LOCM in this setting, only a few contrast material manufacturers continue to suggest precaution"
    },
    {
      "type": "paragraph",
      "text": "in patients with myasthenia gravis."
    },
    {
      "type": "paragraph",
      "text": "However, Somashekar et al [31] in 2013 studied 267 patients with clinically confirmed myasthenia gravis who underwent"
    },
    {
      "type": "paragraph",
      "text": "CT (112 with LOCM (CE-CT), 155 without LOCM (NC-CT)), and showed a significantly greater fraction of disease-related"
    },
    {
      "type": "paragraph",
      "text": "symptom exacerbations within 24 hours in the CE-CT group (6.3% [7/112] for CE-CT vs. 0.6% [1/155] for NC-CT, p ="
    },
    {
      "type": "paragraph",
      "text": "0.01). These findings suggest that intravascular LOCM may be relatively contraindicated in patients with myasthenia gravis."
    },
    {
      "type": "paragraph",
      "text": "This is the first evidence of such a relationship in the medical literature, and confirmatory studies will be needed before a"
    },
    {
      "type": "paragraph",
      "text": "more definitive recommendation can be made."
    },
    {
      "type": "paragraph",
      "text": "Other Risk Factors"
    },
    {
      "type": "paragraph",
      "text": "Drug package inserts suggest precautions are necessary to avoid adverse events in patients with known or suspected"
    },
    {
      "type": "paragraph",
      "text": "pheochromocytoma, thyrotoxicosis, dysproteinemias, or sickle-cell disease. There are scant data, however, to support the"
    },
    {
      "type": "paragraph",
      "text": "need for specific precautions in these patients when LOCM is used (See the Chapter on"
    },
    {
      "type": "paragraph",
      "text": "Patient Selection and Preparation"
    },
    {
      "type": "paragraph",
      "text": "Strategies"
    },
    {
      "type": "paragraph",
      "text": "). For example, a small retrospective study by Bessell-"
    },
    {
      "type": "paragraph",
      "text": "Browne and OMalley [32] demonstrated no adverse events"
    },
    {
      "type": "paragraph",
      "text": "following IV LOCM administration to patients with pheochromocytomas and paragangliomas."
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "The proper treatment of an acute contrast reaction varies depending on the presentation. A variety of scenarios and possible"
    },
    {
      "type": "paragraph",
      "text": "treatment algorithms are discussed in"
    },
    {
      "type": "paragraph",
      "text": "Tables 2"
    },
    {
      "type": "paragraph",
      "text": "and"
    },
    {
      "type": "paragraph",
      "text": "3"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "Delayed Adverse Events to Iodinated Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Timing"
    },
    {
      "type": "paragraph",
      "text": "Delayed allergic-like and non-allergic-like adverse events that occur following ICM exposure have long been a source of"
    },
    {
      "type": "paragraph",
      "text": "concern. Such reactions are most commonly cutaneous and may develop from 30 to 60 minutes to up to one week following"
    },
    {
      "type": "paragraph",
      "text": "contrast material exposure, with the majority occurring between three hours and two days [25,33]."
    },
    {
      "type": "image",
      "assetId": "asset_015f77e7d3",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ALLERGIC-LIKE AND PHYSIOLOGIC REACTIONS TO INTRAVASCULAR IODINATED CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "29"
    },
    {
      "type": "paragraph",
      "text": "Incidence"
    },
    {
      "type": "paragraph",
      "text": "The incidence of delayed allergic-like reactions has been reported to range from 0.5% to 14% [33,34]. A prospective study"
    },
    {
      "type": "paragraph",
      "text": "of 258 individuals receiving intravenous iohexol demonstrated a delayed reaction rate of 14.3% compared to 2.5% in a"
    },
    {
      "type": "paragraph",
      "text": "control group undergoing imaging without intravascular contrast material [34]. In that same study, 26 of 37 delayed adverse"
    },
    {
      "type": "paragraph",
      "text": "reactions were cutaneous in nature [34]. For several reasons (lack of awareness of such adverse events, usual practice"
    },
    {
      "type": "paragraph",
      "text": "patterns, relatively low frequency of serious outcomes), such reactions are often not brought to the attention of the radiologist."
    },
    {
      "type": "paragraph",
      "text": "Delayed reactions are more common in patients treated with interleukin-2 (IL-2) therapy [33,35,36]."
    },
    {
      "type": "paragraph",
      "text": "There is some evidence that the iso-osmolar dimer iodixanol may have a slightly higher rate of delayed cutaneous adverse"
    },
    {
      "type": "paragraph",
      "text": "events when compared to other LOCM [36]. A prospective study by Schild et al [37] demonstrated an increased frequency"
    },
    {
      "type": "paragraph",
      "text": "of delayed cutaneous adverse events to nonionic dimeric contrast material compared to nonionic monomeric contrast"
    },
    {
      "type": "paragraph",
      "text": "material."
    },
    {
      "type": "paragraph",
      "text": "Symptoms"
    },
    {
      "type": "paragraph",
      "text": "The most frequent delayed adverse events following ICM administration are allergic-like and cutaneous [2,33,34,36]. They"
    },
    {
      "type": "paragraph",
      "text": "occur more often than is generally recognized, can recur or have serious sequelae, and are often inadvertently ascribed to"
    },
    {
      "type": "paragraph",
      "text": "causes other than ICM."
    },
    {
      "type": "paragraph",
      "text": "Delayed cutaneous reactions commonly manifest as urticaria and/or a persistent rash [2,33,34,36], presenting as a"
    },
    {
      "type": "paragraph",
      "text": "maculopapular exanthem that varies widely in size and distribution [2,25,33,38], or a generalized exanthematous pustulosis"
    },
    {
      "type": "paragraph",
      "text": "[39]. Urticaria and/or angioedema may also occur, and is usually associated with pruritus [25,33]. Occasionally, pruritis may"
    },
    {
      "type": "paragraph",
      "text": "occur in the absence of urticaria."
    },
    {
      "type": "paragraph",
      "text": "Severe cutaneous reactions have also been described in individuals with systemic lupus erythematosus (SLE) [36,40,41]. A"
    },
    {
      "type": "paragraph",
      "text": "study by Mikkonen et al [42] suggested that delayed cutaneous adverse events may occur at an increased frequency during"
    },
    {
      "type": "paragraph",
      "text": "certain times of the year, and most commonly affect sun-exposed areas of the body. Cases have been also reported in which"
    },
    {
      "type": "paragraph",
      "text": "the reaction manifests similar to Stevens-Johnson syndrome [41,43], toxic epidermal necrolysis, or cutaneous vasculitis."
    },
    {
      "type": "paragraph",
      "text": "Rare fatalities have been described [40,41]."
    },
    {
      "type": "paragraph",
      "text": "A variety of delayed non-cutaneous symptoms and signs have been also reported. These include nausea, vomiting, fever,"
    },
    {
      "type": "paragraph",
      "text": "drowsiness, and headache. Severe delayed noncutaneous contrast reactions, while extremely rare, have been described,"
    },
    {
      "type": "paragraph",
      "text": "including severe hypotension [44] and cardiopulmonary arrest; however, at least some of the events may have been due to"
    },
    {
      "type": "paragraph",
      "text": "etiologies other than ICM."
    },
    {
      "type": "paragraph",
      "text": "Other Rare Delayed Adverse Events"
    },
    {
      "type": "paragraph",
      "text": "Iodide mumps (iodine"
    },
    {
      "type": "paragraph",
      "text": "-related sialoadenopathy or salivary gland swelling) [45,46] and acute polyarthropathy [47] are two"
    },
    {
      "type": "paragraph",
      "text": "additional delayed contrast reactions that have been reported rarely after ICM administration. These reactions may be more"
    },
    {
      "type": "paragraph",
      "text": "frequent in patients with renal dysfunction."
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Since delayed reactions are generally self-limited, most require no or minimal therapy [36]. Treatment is usually supportive,"
    },
    {
      "type": "paragraph",
      "text": "with antihistamines and/or corticosteroids used for cutaneous symptoms, antipyretics for fever, antiemetics for nausea, and"
    },
    {
      "type": "paragraph",
      "text": "fluid resuscitation for hypotension. If manifestations are progressive or widespread, or if there are noteworthy associated"
    },
    {
      "type": "paragraph",
      "text": "symptoms, consultation with an allergist and/or dermatologist may be helpful."
    },
    {
      "type": "paragraph",
      "text": "Recurrence Rates and Prophylaxis"
    },
    {
      "type": "paragraph",
      "text": "The precise recurrence rate of delayed contrast reactions is not known but anecdotally may be 25% or more [36]. Based on"
    },
    {
      "type": "paragraph",
      "text": "this tendency to recur, at least some of these reactions may be due to T cell-mediated hypersensitivity [2,33,34,36,38,48]."
    },
    {
      "type": "paragraph",
      "text": "The efficacy of corticosteroid and/or antihistamine prophylaxis is unknown, though some have suggested this practice [36]."
    },
    {
      "type": "paragraph",
      "text": "However, given the likely differing mechanisms between acute and delayed reactions, as well as the extreme rarity or"
    },
    {
      "type": "paragraph",
      "text": "nonexistence of severe delayed reactions, premedication prior to future contrast-enhanced studies is not specifically"
    },
    {
      "type": "paragraph",
      "text": "advocated in patients with solely a prior history of mild delayed cutaneous reaction."
    },
    {
      "type": "image",
      "assetId": "asset_5127e7df34",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ALLERGIC-LIKE AND PHYSIOLOGIC REACTIONS TO INTRAVASCULAR IODINATED CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "30"
    },
    {
      "type": "paragraph",
      "text": "References"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Bettmann MA, Heeren T, Greenfield A, Goudey C. Adverse events with radiographic contrast agents: results of the SCVIR Contrast Agent"
    },
    {
      "type": "paragraph",
      "text": "Registry."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1997; 203:611-620."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Brockow K. Contrast media hypersensitivity--scope of the problem."
    },
    {
      "type": "paragraph",
      "text": "Toxicology"
    },
    {
      "type": "paragraph",
      "text": "2005; 209:189-192."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Bush WH, Swanson DP. Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment."
    },
    {
      "type": "paragraph",
      "text": "AJR"
    },
    {
      "type": "paragraph",
      "text": "1991;"
    },
    {
      "type": "paragraph",
      "text": "157:1153-1161."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Caro JJ, Trindade E, McGregor M. The risks of death and of severe nonfatal reactions with high- vs low-osmolality contrast media: a meta-"
    },
    {
      "type": "paragraph",
      "text": "analysis."
    },
    {
      "type": "paragraph",
      "text": "AJR"
    },
    {
      "type": "paragraph",
      "text": "1991; 156:825-832."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Ellis JH, Cohan RH, Sonnad SS, Cohan NS. Selective use of radiographic low-osmolality contrast media in the 1990s."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1996; 200:297-311."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report"
    },
    {
      "type": "paragraph",
      "text": "from the Japanese Committee on the Safety of Contrast Media."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1990; 175:621-628."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1997; 203:605-610."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "Lawrence V, Matthai W, Hartmaier S. Comparative safety of high-osmolality and low-osmolality radiographic contrast agents. Report of a"
    },
    {
      "type": "paragraph",
      "text": "multidisciplinary working group."
    },
    {
      "type": "paragraph",
      "text": "Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": "1992; 27:2-28."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Lieberman PL, Seigle RL. Reactions to radiocontrast material. Anaphylactoid events in radiology."
    },
    {
      "type": "paragraph",
      "text": "Clin Rev Allergy Immunol"
    },
    {
      "type": "paragraph",
      "text": "1999; 17:469-496."
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Siegle RL. Rates of idiosyncratic reactions. Ionic versus nonionic contrast media."
    },
    {
      "type": "paragraph",
      "text": "Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": "1993; 28 Suppl 5: S95-98; discussion S99."
    },
    {
      "type": "paragraph",
      "text": "11."
    },
    {
      "type": "paragraph",
      "text": "Wolf GL, Arenson RL, Cross AP. A prospective trial of ionic vs nonionic contrast agents in routine clinical practice: comparison of adverse"
    },
    {
      "type": "paragraph",
      "text": "effects."
    },
    {
      "type": "paragraph",
      "text": "AJR"
    },
    {
      "type": "paragraph",
      "text": "1989; 152:939-944."
    },
    {
      "type": "paragraph",
      "text": "12."
    },
    {
      "type": "paragraph",
      "text": "Cohan RH, Dunnick NR. Intravascular contrast media: adverse reactions."
    },
    {
      "type": "paragraph",
      "text": "AJR"
    },
    {
      "type": "paragraph",
      "text": "1987; 149:665-670."
    },
    {
      "type": "paragraph",
      "text": "13."
    },
    {
      "type": "paragraph",
      "text": "Dunnick NR, Cohan RH. Cost, corticosteroids, and contrast media."
    },
    {
      "type": "paragraph",
      "text": "AJR"
    },
    {
      "type": "paragraph",
      "text": "1994; 162:527-529."
    },
    {
      "type": "paragraph",
      "text": "14."
    },
    {
      "type": "paragraph",
      "text": "Almen T. The etiology of contrast medium reactions."
    },
    {
      "type": "paragraph",
      "text": "Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": "1994; 29 Suppl 1: S37-45."
    },
    {
      "type": "paragraph",
      "text": "15."
    },
    {
      "type": "paragraph",
      "text": "Lasser EC. A coherent biochemical basis for increased reactivity to contrast material in allergic patients: a novel concept."
    },
    {
      "type": "paragraph",
      "text": "AJR"
    },
    {
      "type": "paragraph",
      "text": "1987; 149:1281-1285."
    },
    {
      "type": "paragraph",
      "text": "16."
    },
    {
      "type": "paragraph",
      "text": "Bouachour G, Varache N, Szapiro N,"
    },
    {
      "type": "paragraph",
      "text": "LHoste"
    },
    {
      "type": "paragraph",
      "text": "P, Harry P, Alquier P. Noncardiogenic pulmonary edema resulting from intravascular"
    },
    {
      "type": "paragraph",
      "text": "administration of contrast material."
    },
    {
      "type": "paragraph",
      "text": "AJR"
    },
    {
      "type": "paragraph",
      "text": "1991; 157:255-256."
    },
    {
      "type": "paragraph",
      "text": "17."
    },
    {
      "type": "paragraph",
      "text": "Cochran ST, Bomyea K, Sayre JW. Trends in adverse events after IV administration of contrast media."
    },
    {
      "type": "paragraph",
      "text": "AJR"
    },
    {
      "type": "paragraph",
      "text": "2001; 176:1385-1388."
    },
    {
      "type": "paragraph",
      "text": "18."
    },
    {
      "type": "paragraph",
      "text": "Mortele KJ, Oliva MR, Ondategui S, Ros PR, Silverman SG. Universal use of nonionic iodinated contrast medium for CT: evaluation of safety"
    },
    {
      "type": "paragraph",
      "text": "in a large urban teaching hospital."
    },
    {
      "type": "paragraph",
      "text": "AJR"
    },
    {
      "type": "paragraph",
      "text": "2005; 184:31-34."
    },
    {
      "type": "paragraph",
      "text": "19."
    },
    {
      "type": "paragraph",
      "text": "Wang CL, Cohan RH, Ellis JH, Caoili EM, Wang G, Francis IR. Frequency, outcome, and appropriateness of treatment of nonionic iodinated"
    },
    {
      "type": "paragraph",
      "text": "contrast media reactions."
    },
    {
      "type": "paragraph",
      "text": "AJR"
    },
    {
      "type": "paragraph",
      "text": "2008; 191:409-415."
    },
    {
      "type": "paragraph",
      "text": "20."
    },
    {
      "type": "paragraph",
      "text": "Dillman JR, Strouse PJ, Ellis JH, Cohan RH, Jan SC. Incidence and severity of acute allergic-like reactions to i.v. nonionic iodinated contrast"
    },
    {
      "type": "paragraph",
      "text": "material in children."
    },
    {
      "type": "paragraph",
      "text": "AJR"
    },
    {
      "type": "paragraph",
      "text": "2007; 188:1643-1647."
    },
    {
      "type": "paragraph",
      "text": "21."
    },
    {
      "type": "paragraph",
      "text": "Callahan MJ, Poznauskis L, Zurakowski D, Taylor GA. Nonionic iodinated intravenous contrast material-related reactions: incidence in large"
    },
    {
      "type": "paragraph",
      "text": "urban childrens hospital"
    },
    {
      "type": "paragraph",
      "text": "--retrospective analysis of data in 12,494 patients."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "2009; 250:674-681."
    },
    {
      "type": "paragraph",
      "text": "22."
    },
    {
      "type": "paragraph",
      "text": "Curry NS, Schabel SI, Reiheld CT, Henry WD, Savoca WJ. Fatal reactions to intravenous nonionic contrast material."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1991; 178:361-362."
    },
    {
      "type": "paragraph",
      "text": "23."
    },
    {
      "type": "paragraph",
      "text": "Spring DB, Bettmann MA, Barkan HE. Deaths related to iodinated contrast media reported spontaneously to the U.S. Food and Drug"
    },
    {
      "type": "paragraph",
      "text": "Administration, 1978-1994: effect of the availability of low-osmolality contrast media."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1997; 204:333-337."
    },
    {
      "type": "paragraph",
      "text": "24."
    },
    {
      "type": "paragraph",
      "text": "Kopp AF, Mortele KJ, Cho YD, Palkowitsch P, Bettmann MA, Claussen CD. Prevalence of acute reactions to iopromide: postmarketing"
    },
    {
      "type": "paragraph",
      "text": "surveillance study of 74,717 patients."
    },
    {
      "type": "paragraph",
      "text": "Acta Radiol"
    },
    {
      "type": "paragraph",
      "text": "2008; 49:902-911."
    },
    {
      "type": "paragraph",
      "text": "25."
    },
    {
      "type": "paragraph",
      "text": "Meth MJ, Maibach HI. Current understanding of contrast media reactions and implications for clinical management."
    },
    {
      "type": "paragraph",
      "text": "Drug Saf"
    },
    {
      "type": "paragraph",
      "text": "2006; 29:133-141."
    },
    {
      "type": "paragraph",
      "text": "26."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS, Cohan RH, Caoili EM, Ellis JH. Repeat contrast medium reactions in premedicated patients: frequency and severity."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "2009; 253:372-379."
    },
    {
      "type": "paragraph",
      "text": "27."
    },
    {
      "type": "paragraph",
      "text": "Freed KS, Leder RA, Alexander C, DeLong DM, Kliewer MA. Breakthrough adverse reactions to low-osmolar contrast media after steroid"
    },
    {
      "type": "paragraph",
      "text": "premedication."
    },
    {
      "type": "paragraph",
      "text": "AJR"
    },
    {
      "type": "paragraph",
      "text": "2001; 176:1389-1392."
    },
    {
      "type": "paragraph",
      "text": "28."
    },
    {
      "type": "paragraph",
      "text": "Lang DM, Alpern MB, Visintainer PF, Smith ST. Increased risk for anaphylactoid reaction from contrast media in patients on beta- adrenergic"
    },
    {
      "type": "paragraph",
      "text": "blockers or with asthma."
    },
    {
      "type": "paragraph",
      "text": "Ann Intern Med"
    },
    {
      "type": "paragraph",
      "text": "1991; 115:270-276."
    },
    {
      "type": "paragraph",
      "text": "29."
    },
    {
      "type": "paragraph",
      "text": "Fischer HW, Doust VL. An evaluation of pretesting in the problem of serious and fatal reactions to excretory urography."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1972; 103:497-501."
    },
    {
      "type": "paragraph",
      "text": "30."
    },
    {
      "type": "paragraph",
      "text": "Yamaguchi K, Katayama H, Takashima T, Kozuka T, Seez P, Matsuura K. Prediction of severe adverse reactions to ionic and"
    },
    {
      "type": "paragraph",
      "text": "nonionic contrast media in Japan: evaluation of pretesting. A report from the Japanese Committee on the Safety of Contrast Media."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1991; 178:363-367."
    },
    {
      "type": "paragraph",
      "text": "31."
    },
    {
      "type": "paragraph",
      "text": "Somashekar DK, Davenport MS, Cohan RH, Dillman JR, Ellis JH. Effect of Intravenous Low-Osmolality Iodinated Contrast Media on Patients"
    },
    {
      "type": "paragraph",
      "text": "with Myasthenia Gravis."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "2013."
    },
    {
      "type": "paragraph",
      "text": "32."
    },
    {
      "type": "paragraph",
      "text": "Bessell-"
    },
    {
      "type": "paragraph",
      "text": "Browne R, OMalley ME. CT of pheochromocytoma and paraganglioma: risk of adverse events with i.v. administration"
    },
    {
      "type": "paragraph",
      "text": "of nonionic"
    },
    {
      "type": "paragraph",
      "text": "contrast material."
    },
    {
      "type": "paragraph",
      "text": "AJR"
    },
    {
      "type": "paragraph",
      "text": "2007; 188:970-974."
    },
    {
      "type": "paragraph",
      "text": "33."
    },
    {
      "type": "paragraph",
      "text": "Christiansen C, Pichler WJ, Skotland T. Delayed allergy-like reactions to X-ray contrast media: mechanistic considerations."
    },
    {
      "type": "paragraph",
      "text": "Eur Radiol"
    },
    {
      "type": "paragraph",
      "text": "2000; 10:1965-1975."
    },
    {
      "type": "paragraph",
      "text": "34."
    },
    {
      "type": "paragraph",
      "text": "Loh S, Bagheri S, Katzberg RW, Fung MA, Li CS. Delayed adverse reaction to contrast-enhanced CT: a prospective single- center study"
    },
    {
      "type": "paragraph",
      "text": "comparison to control group without enhancement."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "2010; 255:764-771."
    },
    {
      "type": "paragraph",
      "text": "35."
    },
    {
      "type": "paragraph",
      "text": "Choyke PL, Miller DL, Lotze MT, Whiteis JM, Ebbitt B, Rosenberg SA. Delayed reactions to contrast media after interleukin-2 immunotherapy."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1992; 183:111-114."
    },
    {
      "type": "paragraph",
      "text": "36."
    },
    {
      "type": "paragraph",
      "text": "Webb JA, Stacul F, Thomsen HS, Morcos SK. Late adverse reactions to intravascular iodinated contrast media."
    },
    {
      "type": "paragraph",
      "text": "Eur Radiol"
    },
    {
      "type": "paragraph",
      "text": "2003; 13:181-184."
    },
    {
      "type": "image",
      "assetId": "asset_6e62a25d30",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ALLERGIC-LIKE AND PHYSIOLOGIC REACTIONS TO INTRAVASCULAR IODINATED CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "31"
    },
    {
      "type": "paragraph",
      "text": "37."
    },
    {
      "type": "paragraph",
      "text": "Schild HH, Kuhl CK, Hubner-Steiner U, Bohm I, Speck U. Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT:"
    },
    {
      "type": "paragraph",
      "text": "a prospective randomized controlled trial."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "2006; 240:56-64."
    },
    {
      "type": "paragraph",
      "text": "38."
    },
    {
      "type": "paragraph",
      "text": "Vernassiere C, Trechot P, Commun N, Schmutz JL, Barbaud A. Low negative predictive value of skin tests in investigating delayed reactions to"
    },
    {
      "type": "paragraph",
      "text": "radio-contrast media."
    },
    {
      "type": "paragraph",
      "text": "Contact Dermatitis"
    },
    {
      "type": "paragraph",
      "text": "2004; 50:359-366."
    },
    {
      "type": "paragraph",
      "text": "39."
    },
    {
      "type": "paragraph",
      "text": "Peterson A, Katzberg RW, Fung MA, Wootton-Gorges SL, Dager W. Acute generalized exanthematous pustulosis as a delayed dermatotoxic"
    },
    {
      "type": "paragraph",
      "text": "reaction to IV-administered nonionic contrast media."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2006; 187: W198-201."
    },
    {
      "type": "paragraph",
      "text": "40."
    },
    {
      "type": "paragraph",
      "text": "Goodfellow T, Holdstock GE, Brunton FJ, Bamforth J. Fatal acute vasculitis after high-dose urography with iohexol."
    },
    {
      "type": "paragraph",
      "text": "Br J Radiol"
    },
    {
      "type": "paragraph",
      "text": "1986; 59:620-621."
    },
    {
      "type": "paragraph",
      "text": "41."
    },
    {
      "type": "paragraph",
      "text": "Savill JS, Barrie R, Ghosh S, Muhlemann M, Dawson P, Pusey CD. Fatal Stevens-Johnson syndrome following urography with iopamidol in"
    },
    {
      "type": "paragraph",
      "text": "systemic lupus erythematosus."
    },
    {
      "type": "paragraph",
      "text": "Postgrad Med J"
    },
    {
      "type": "paragraph",
      "text": "1988; 64:392-394."
    },
    {
      "type": "paragraph",
      "text": "42."
    },
    {
      "type": "paragraph",
      "text": "Mikkonen R, Vehmas T, Granlund H, Kivisaari L. Seasonal variation in the occurrence of late adverse skin reactions to iodine- based contrast"
    },
    {
      "type": "paragraph",
      "text": "media."
    },
    {
      "type": "paragraph",
      "text": "Acta Radiol"
    },
    {
      "type": "paragraph",
      "text": "2000; 41:390-393."
    },
    {
      "type": "paragraph",
      "text": "43."
    },
    {
      "type": "paragraph",
      "text": "Laffitte E, Nenadov Beck M, Hofer M, Hohl D, Panizzon RG. Severe Stevens-Johnson syndrome induced by contrast medium iopentol"
    },
    {
      "type": "paragraph",
      "text": "(Imagopaque)."
    },
    {
      "type": "paragraph",
      "text": "Br J Dermatol"
    },
    {
      "type": "paragraph",
      "text": "2004; 150:376-378."
    },
    {
      "type": "paragraph",
      "text": "44."
    },
    {
      "type": "paragraph",
      "text": "Newman B. Delayed adverse reaction to nonionic contrast agents."
    },
    {
      "type": "paragraph",
      "text": "Pediatr Radiol"
    },
    {
      "type": "paragraph",
      "text": "2001; 31:597-599."
    },
    {
      "type": "paragraph",
      "text": "45."
    },
    {
      "type": "paragraph",
      "text": "Berman HL, Delaney V. Iodide mumps due to low-osmolality contrast material."
    },
    {
      "type": "paragraph",
      "text": "AJR"
    },
    {
      "type": "paragraph",
      "text": "1992; 159:1099-1100."
    },
    {
      "type": "paragraph",
      "text": "46."
    },
    {
      "type": "paragraph",
      "text": "Gilgen-Anner Y, Heim M, Ledermann HP, Bircher AJ. Iodide mumps after contrast media imaging: a rare adverse effect to iodine. Ann Allergy"
    },
    {
      "type": "paragraph",
      "text": "Asthma Immunol 2007; 99:93-98."
    },
    {
      "type": "paragraph",
      "text": "47."
    },
    {
      "type": "paragraph",
      "text": "Donnelly PK, Williams B, Watkin EM. Polyarthropathy--a delayed reaction to low osmolality angiographic contrast medium in patients with"
    },
    {
      "type": "paragraph",
      "text": "end stage renal disease. Eur J Radiol 1993; 17:130-132."
    },
    {
      "type": "paragraph",
      "text": "48."
    },
    {
      "type": "paragraph",
      "text": "Brockow K, Christiansen C, Kanny G, et al. Management of hypersensitivity reactions to iodinated contrast media. Allergy 2005; 60:150-158."
    },
    {
      "type": "image",
      "assetId": "asset_44338f7790",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA WARMING"
    },
    {
      "type": "paragraph",
      "text": "32"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA WARMING"
    },
    {
      "type": "paragraph",
      "text": "This chapter will discuss the relevant literature pertaining to the extrinsic warming of contrast media and provide suggestions"
    },
    {
      "type": "paragraph",
      "text": "of cases in which extrinsic warming of contrast media may be beneficial in the care of patients."
    },
    {
      "type": "paragraph",
      "text": "Introduction"
    },
    {
      "type": "paragraph",
      "text": "Contrast media viscosity, like that of many other liquids, is related to temperature. As the temperature of a given contrast"
    },
    {
      "type": "paragraph",
      "text": "medium increases, there is a concomitant decrease in its dynamic viscosity [1]. Therefore, warmed contrast media are less"
    },
    {
      "type": "paragraph",
      "text": "viscous than room temperature contrast media. When a warmed contrast medium is hand- or power-injected into an"
    },
    {
      "type": "paragraph",
      "text": "intravenous (IV) or intra-arterial (IA) catheter, there will be less resistance than if the contrast medium had not been warmed."
    },
    {
      "type": "paragraph",
      "text": "The relationship between viscosity and flow for contrast medium injections is typically non-linear because the flow through"
    },
    {
      "type": "paragraph",
      "text": "small bore IV catheters is turbulent and does not obey traditional laminar flow kinetics (Poiseuilles law) [2]."
    },
    {
      "type": "paragraph",
      "text": "Iodinated Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Contrast Material Warming and Injection Kinetics"
    },
    {
      "type": "paragraph",
      "text": "Several investigators have studied the effects of extrinsic warming of iodinated contrast media on IV and IA injection kinetics"
    },
    {
      "type": "paragraph",
      "text": "[1-9]."
    },
    {
      "type": "paragraph",
      "text": "Halsell [5] studied the in vitro flow rates through different sized angiographic catheters with and without extrinsic contrast"
    },
    {
      "type": "paragraph",
      "text": "media warming (37"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C). Contrast warming resulted in a flow rate improvement of 8% or more only when using high-viscosity"
    },
    {
      "type": "paragraph",
      "text": "contrast media (a highly concentrated ionic high-osmolality monomer and an ionic low-osmolality dimer from among the"
    },
    {
      "type": "paragraph",
      "text": "tested agents) through 4 to 5F catheters. Lower viscosity contrast media (including a nonionic monomer at 300 mg I/mL) and"
    },
    {
      "type": "paragraph",
      "text": "larger catheters did not show this flow improvement."
    },
    {
      "type": "paragraph",
      "text": "Hughes and Bisset [2] measured the iodine delivery rates for a variety of low-osmolality contrast media (LOCM) at both"
    },
    {
      "type": "paragraph",
      "text": "room (24"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C) and human body temperature (37"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C) and concluded that extrinsic warming to 37"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C improved iodine delivery"
    },
    {
      "type": "paragraph",
      "text": "rates for forceful hand injection through a 5F angiocatheter by 20% to 27% (average of 23.5%). They also found that the"
    },
    {
      "type": "paragraph",
      "text": "iodine delivery rates closely mimicked the dynamic viscosity of the tested contrast media. Contrast media with a greater"
    },
    {
      "type": "paragraph",
      "text": "viscosity tended to be delivered at substantially fewer milligrams of iodine per second compared to those with a lesser"
    },
    {
      "type": "paragraph",
      "text": "viscosity. The authors suggested that vascular opacification with forceful hand injection, such as that used during catheter"
    },
    {
      "type": "paragraph",
      "text": "angiography, could be maximized by reducing the viscosity of the utilized contrast media, either by using a lower viscosity"
    },
    {
      "type": "paragraph",
      "text": "contrast material or by extrinsic warming."
    },
    {
      "type": "paragraph",
      "text": "Roth et al [3] tested four different ionic and nonionic iodinated contrast media through 12 different-sized catheters at both"
    },
    {
      "type": "paragraph",
      "text": "human body (37"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C) and room temperature (20"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C), and measured the power injection pressure of each combination using a 7"
    },
    {
      "type": "paragraph",
      "text": "mL injection at 3 mL/second with an electronic pressure transducer. Their results supported some of Halsells [5] findings by"
    },
    {
      "type": "paragraph",
      "text": "showing that warmed contrast media have a lower viscosity, and this viscosity translates into a reduction in injection pressure,"
    },
    {
      "type": "paragraph",
      "text": "but primarily for smaller diameter (< 6 French) catheters."
    },
    {
      "type": "paragraph",
      "text": "Busch et al [4] studied the iodine delivery rates of four different contrast media through five different catheters used for"
    },
    {
      "type": "paragraph",
      "text": "coronary angiography at power injections of 100, 200, and 400 psi. Iodine delivery rates were treated as a surrogate for"
    },
    {
      "type": "paragraph",
      "text": "vascular opacification. The iodine delivery rate improved with increasing pressure, increasing iodine content (mg I/mL) and"
    },
    {
      "type": "paragraph",
      "text": "decreasing contrast media viscosity. Although the authors did not test the effect of extrinsic warming, they speculated that"
    },
    {
      "type": "paragraph",
      "text": "the reduction in viscosity associated with warming may be a method by which iodine delivery rates might be improved. This"
    },
    {
      "type": "paragraph",
      "text": "benefit might be greatest for lower pressure injections, such as hand injections."
    },
    {
      "type": "paragraph",
      "text": "Hazirolan et al [8] randomized patients undergoing cardiac CT angiography into two groups: 1) 32 patients receiving warmed"
    },
    {
      "type": "paragraph",
      "text": "(37"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C) iohexol 350 mg I/mL and 2) 32 patients receiving non-warmed (24"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C) iohexol 350 mg I/mL, and then compared the"
    },
    {
      "type": "paragraph",
      "text": "timing and degree of subsequent arterial opacification for a test bolus injection rate of 5 mL/second through an 18-gauge"
    },
    {
      "type": "paragraph",
      "text": "peripheral IV catheter. They found that the degree of maximal enhancement within the ascending aorta, descending aorta,"
    },
    {
      "type": "paragraph",
      "text": "and pulmonary arteries was significantly greater (p = 0.005) for group 1. They also found that group 1 patients reached 100"
    },
    {
      "type": "paragraph",
      "text": "Hounsfield Units of enhancement within the ascending aorta significantly faster than group 2 patients (p = 0.03). The authors"
    },
    {
      "type": "paragraph",
      "text": "concluded that extrinsic warming of the relatively viscous iohexol 350 improved the speed and degree of enhancement for"
    },
    {
      "type": "paragraph",
      "text": "high-rate cardiac CT angiography. However, their data was solely based on the test injection (not the diagnostic injection)."
    },
    {
      "type": "image",
      "assetId": "asset_0a08999dd2",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA WARMING"
    },
    {
      "type": "paragraph",
      "text": "33"
    },
    {
      "type": "paragraph",
      "text": "Schwab et al [9] tested the maximum injection pressures of iopamidol 300, iomeprol 350, and iomeprol 400 at both room"
    },
    {
      "type": "paragraph",
      "text": "(20"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C) and human body temperature (37"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C) through 18, 20 and 22-gauge IV catheters using a variety of injection rates (1 to"
    },
    {
      "type": "paragraph",
      "text": "9 mL/second) with a pressure-limited (300-psi) power injector. They concluded that warming of contrast media led to"
    },
    {
      "type": "paragraph",
      "text": "significant (p < 0.001) reductions in injection pressures across all tested media. De"
    },
    {
      "type": "paragraph",
      "text": "spite the fact that the manufacturers"
    },
    {
      "type": "paragraph",
      "text": "recommended pressure thresholds were exceeded with high- rate injections (e.g., 8 mL/second), there were no instances of"
    },
    {
      "type": "paragraph",
      "text": "IV catheter malfunction."
    },
    {
      "type": "paragraph",
      "text": "Iodinated Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Contrast Material Warming and Adverse Events"
    },
    {
      "type": "paragraph",
      "text": "Although there is good evidence that warming of contrast media changes the bolus kinetics and injection pressure of iodinated"
    },
    {
      "type": "paragraph",
      "text": "contrast media, there has been little evidence that it affects clinical adverse event rates in a meaningful way [10-12]."
    },
    {
      "type": "paragraph",
      "text": "In 1982, Turner et al [10] randomly assigned 100 patients in a double-blind fashion to receive either room temperature (20 to"
    },
    {
      "type": "paragraph",
      "text": "24"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C) or human body temperature (37"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C) ionic high osmolality contrast media (HOCM), and then compared the"
    },
    {
      "type": "paragraph",
      "text": "anaphylactoid and non-anaphylactoid adverse event rates between these two groups. The authors were unable to show a"
    },
    {
      "type": "paragraph",
      "text": "significant difference, although their study was likely underpowered for a non-inferiority design. They did not report"
    },
    {
      "type": "paragraph",
      "text": "extravasation events."
    },
    {
      "type": "paragraph",
      "text": "Vergara et al [11] conducted a non-randomized prospective study of 4,936 IV injections of iodinated contrast media in which"
    },
    {
      "type": "paragraph",
      "text": "each group of patients received a specific contrast media and temperature combination. These groups were then compared"
    },
    {
      "type": "paragraph",
      "text": "with respect to their allergic-like and physiologic adverse events. Again, extravasation rates were not assessed. The authors"
    },
    {
      "type": "paragraph",
      "text": "showed a small but significant reduction in overall adverse events for warmed (37"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C) ionic HOCM compared to the same"
    },
    {
      "type": "paragraph",
      "text": "non-warmed (22"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C) ionic HOCM (89/894 [10.0%] vs. 204/1607 [12.7%]). The dominant effect was a reduction in mild"
    },
    {
      "type": "paragraph",
      "text": "adverse events (49/894 [5.5%] vs. 138/1607 [8.6%]) rather than a reduction in adverse events that were moderate (36/894"
    },
    {
      "type": "paragraph",
      "text": "[4.0%] vs. 59/1607 [3.7%]) or severe (4/894 [0.45%] vs. 7/1607 [0.44%])."
    },
    {
      "type": "paragraph",
      "text": "Based on the above work, as well as the package inserts for many iodinated contrast media, many institutions heat their"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast media (both HOCM and LOCM) to human body temperature (37"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C) prior to routine clinical intravascular"
    },
    {
      "type": "paragraph",
      "text": "administration. In most instances, this is performed using an external incubator in which the bottles of contrast media are"
    },
    {
      "type": "paragraph",
      "text": "placed. The temperature of the device is typically kept at or near human body temperature (37"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C). In addition to these stand-"
    },
    {
      "type": "paragraph",
      "text": "alone warming machines, there also"
    },
    {
      "type": "paragraph",
      "text": "exist warming sleeves that can be used to keep pre"
    },
    {
      "type": "paragraph",
      "text": "-warmed bottles (or syringes filled"
    },
    {
      "type": "paragraph",
      "text": "from pre-warmed bottles) of contrast media at a stable (warmed) temperature for approximately one hour or more in cases"
    },
    {
      "type": "paragraph",
      "text": "where the contrast media is removed from the warming device but not immediately injected. These sleeves can be a"
    },
    {
      "type": "paragraph",
      "text": "component to the power injector itself or can function independently."
    },
    {
      "type": "paragraph",
      "text": "Because contrast media are designated as medications, the warming of contrast media has fallen under the regulation of The"
    },
    {
      "type": "paragraph",
      "text": "Joint Commission, which mandates that if contrast media are to be extrinsically warmed, there must be both a daily"
    },
    {
      "type": "paragraph",
      "text": "temperature log for each warmer and evidence of regular maintenance for the warming device(s). This regulation has led"
    },
    {
      "type": "paragraph",
      "text": "some institutions to reconsider the use of these warming devices and reevaluate whether warming iodinated contrast media"
    },
    {
      "type": "paragraph",
      "text": "to human body temperature has a significant practical, rather than just a theoretical, benefit for IV LOCM administration."
    },
    {
      "type": "paragraph",
      "text": "Although some institutions have discontinued the routine use of contrast media warmers for low-rate (< 5 mL/second), non-"
    },
    {
      "type": "paragraph",
      "text": "angiographic, non-cardiac applications, there are little published data investigating what effect this may have on patient"
    },
    {
      "type": "paragraph",
      "text": "adverse events."
    },
    {
      "type": "paragraph",
      "text": "The largest study investigating the effect of extrinsic warming on IV LOCM adverse events was published in 2012 [12]. In"
    },
    {
      "type": "paragraph",
      "text": "this non-inferiority retrospective analysis of 24,830 power-injections (< 6 mL/ second) of IV LOCM, the authors compared"
    },
    {
      "type": "paragraph",
      "text": "the rates of allergic-like reactions and extravasations before and after the discontinuation of contrast media warming at a"
    },
    {
      "type": "paragraph",
      "text": "single institution for both iopamidol 300 (dynamic viscosity: 8.8 centiPoise (cP) at 20C and 4.7 cP at 37C) and the more"
    },
    {
      "type": "paragraph",
      "text": "viscous iopamidol 370 (dynamic viscosity: 20.9 cP at 20C and 9.4 cP at 37C). Discontinuation of contrast media warming"
    },
    {
      "type": "paragraph",
      "text": "had no significant effect on the allergic-like reaction or extravasation rates of iopamidol 300. However, it did result in nearly"
    },
    {
      "type": "paragraph",
      "text": "tripling of the extravasation rate (0.27% [five of 1851] vs. 0.87% [18 of 2074], p = 0.05) and combined allergic- like and"
    },
    {
      "type": "paragraph",
      "text": "extravasation event rate (0.43% [eight of 1851] vs 1.25% [26 of 2074], p = 0.02) for iopamidol 370. These results suggest"
    },
    {
      "type": "paragraph",
      "text": "that contrast media warming may not be needed for iopamidol 300 but may be needed for iopamidol 370 (and possibly other"
    },
    {
      "type": "paragraph",
      "text": "similarly viscous contrast media) if the primary goal is to minimize contrast media-related adverse events. However, the"
    },
    {
      "type": "paragraph",
      "text": "authors did note that there was no difference in clinical outcome between the warmed and non-warmed iopamidol 370 groups,"
    },
    {
      "type": "paragraph",
      "text": "likely because the vast majority of extravasation events and allergic-like reactions do not result in long-term morbidity or"
    },
    {
      "type": "paragraph",
      "text": "mortality. The authors did not have any data to permit evaluation of the effect of extrinsic contrast media warming on patient"
    },
    {
      "type": "image",
      "assetId": "asset_0963374fad",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA WARMING"
    },
    {
      "type": "paragraph",
      "text": "34"
    },
    {
      "type": "paragraph",
      "text": "comfort or physiologic (e.g., nausea, vomiting, sensation of warmth) adverse events."
    },
    {
      "type": "paragraph",
      "text": "Warming of Iodinated Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Suggestions"
    },
    {
      "type": "paragraph",
      "text": "Based on the available literature, the validity of extrinsic warmers seems predicated on the intended outcome."
    },
    {
      "type": "paragraph",
      "text": "Extrinsic warming of iodinated contrast material to human body temperature (37C) may be helpful to minimize"
    },
    {
      "type": "paragraph",
      "text": "complications and improve vascular opacification in the following circumstances:"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "For high-rate (> 5 mL/second) IV LOCM power injections"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "For injections of viscous iodinated contrast (e.g., iopamidol 370, and presumably other contrast media with a"
    },
    {
      "type": "paragraph",
      "text": "similar or higher viscosity)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "For direct arterial injections through small-caliber catheters (5 French or smaller)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "For intravenously injected arterial studies in which timing and peak enhancement are critical features"
    },
    {
      "type": "paragraph",
      "text": "Extrinsic warming of iodinated contrast material may not be needed or beneficial in the following circumstances:"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "For low-"
    },
    {
      "type": "paragraph",
      "text": "rate (<= 5 mL/second) IV LOCM power injections or hand injections"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "For injections of iodinated contrast media with a relatively low viscosity (e.g., iopamidol 300, and presumably"
    },
    {
      "type": "paragraph",
      "text": "other contrast media with a similar or lower viscosity)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "For direct arterial injections through large-bore catheters (6 French or larger)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "For IV injections in which peak opacification and timing are not critical (e.g., routine portal venous phase"
    },
    {
      "type": "paragraph",
      "text": "chest/abdomen/pelvis CT imaging)"
    },
    {
      "type": "paragraph",
      "text": "Package inserts for iodinated contrast media contain information about recommended storage temperatures."
    },
    {
      "type": "paragraph",
      "text": "Warming of Gadolinium-Based Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Suggestions"
    },
    {
      "type": "paragraph",
      "text": "Gadolinium-based contrast media are administered at room temperature (15 to 30"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "C [59 to 86"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "F]) and according to"
    },
    {
      "type": "paragraph",
      "text": "package inserts, should not be externally warmed for routine clinical applications."
    },
    {
      "type": "paragraph",
      "text": "References"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Brunette J, Mongrain R, Rodes-Cabau J, et al. Comparative rheology of low- and iso-osmolarity contrast agents at different temperatures."
    },
    {
      "type": "paragraph",
      "text": "Cath and Cardiov Interv"
    },
    {
      "type": "paragraph",
      "text": "2008; 71:78-83."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Hughes PM, Bisset R. Non-ionic contrast media: a comparison of iodine delivery rates during manual injection angiography."
    },
    {
      "type": "paragraph",
      "text": "Brit J Radiol"
    },
    {
      "type": "paragraph",
      "text": "1991; 64:417-419."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Roth R, Akin M, Deligonul U, Kern MJ. Influence of radiographic contrast media viscosity to flow through coronary angiographic"
    },
    {
      "type": "paragraph",
      "text": "catheters."
    },
    {
      "type": "paragraph",
      "text": "Cathet Cardiovasc Diagn"
    },
    {
      "type": "paragraph",
      "text": "1991; 22(4):290-294."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Busch HP, Stocker KP. Iodine delivery rate in catheter angiography under pressure conditions in manual injection."
    },
    {
      "type": "paragraph",
      "text": "Aktuelle Radiol"
    },
    {
      "type": "paragraph",
      "text": "1998; 8:232-235."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Halsell RD. Heating contrast media: role in contemporary angiography."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1987; 164:276-278."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Pugh ND. Haemodynamic and rheological effects of contrast media: the role of viscosity and osmolality."
    },
    {
      "type": "paragraph",
      "text": "Eur Radiol"
    },
    {
      "type": "paragraph",
      "text": "1996; 6: S13- S15."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Bae KT. Intravenous contrast medium administration and scan timing at CT: considerations and approaches."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "2010; 256:32-61."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "Hazirolan T, Turkbey B, Akpinar E, et al. The impact of warmed intravenous contrast media on the bolus geometry of coronary CT"
    },
    {
      "type": "paragraph",
      "text": "angiography applications."
    },
    {
      "type": "paragraph",
      "text": "Korean J Radiol"
    },
    {
      "type": "paragraph",
      "text": "2009; 10:150-155."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Schwab SA, Kuefner MA, Anders K, et al. Peripheral intravenous power injection of iodinated contrast media: the impact of temperature"
    },
    {
      "type": "paragraph",
      "text": "on maximum injection pressures at different cannula sizes."
    },
    {
      "type": "paragraph",
      "text": "Acad Radiol"
    },
    {
      "type": "paragraph",
      "text": "2009; 16:1502-1508."
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Turner E, Kentor P, Melamed JL, et al. Frequency of anaphylactoid reactions during intravenous urography with radiographic contrast"
    },
    {
      "type": "paragraph",
      "text": "media at two different temperatures."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1982; 143:327-329."
    },
    {
      "type": "paragraph",
      "text": "11."
    },
    {
      "type": "paragraph",
      "text": "Vergara M, Seguel S. Adverse reactions to contrast media in CT: effects of temperature and ionic property."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1996; 199:363-"
    },
    {
      "type": "paragraph",
      "text": "366."
    },
    {
      "type": "paragraph",
      "text": "12."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS, Wang CL, Bashir MR, et al. Rate of contrast media extravasations and allergic-like reactions: effect of extrinsic warming"
    },
    {
      "type": "paragraph",
      "text": "of low-osmolality iodinated CT contrast media to 37oC."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "2012; 262:475-484."
    },
    {
      "type": "image",
      "assetId": "asset_f468a2ccd1",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "POST-CONTRAST ACUTE KIDNEY INJURY AND CONTRAST-INDUCED NEPHROPATHY IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "35"
    },
    {
      "type": "paragraph",
      "text": "POST-CONTRAST ACUTE KIDNEY INJURY AND CONTRAST-INDUCED"
    },
    {
      "type": "paragraph",
      "text": "NEPHROPATHY IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "Definitions and Terminology"
    },
    {
      "type": "paragraph",
      "text": "Contrast-associated acute kidney injury (CA-AKI) (formerly known as post-contrast acute kidney injury (PC-AKI)) is a general"
    },
    {
      "type": "paragraph",
      "text": "term used to describe a sudden deterioration in renal function that occurs within 48 hours following the intravascular"
    },
    {
      "type": "paragraph",
      "text": "administration of iodinated contrast medium. CA-AKI may occur regardless of whether the contrast medium was the cause of the"
    },
    {
      "type": "paragraph",
      "text": "deterioration [1-12]."
    },
    {
      "type": "paragraph",
      "text": "CA-AKI is a correlative diagnosis."
    },
    {
      "type": "paragraph",
      "text": "Contrast-induced acute kidney injury (CI-AKI) (formerly known as contrast-induced nephropathy (CIN) is a specific term used"
    },
    {
      "type": "paragraph",
      "text": "to describe a sudden deterioration in renal function that is caused by the intravascular administration of iodinated contrast medium;"
    },
    {
      "type": "paragraph",
      "text": "therefore, CI-AKI is a subgroup of CA-AKI [1-12]."
    },
    {
      "type": "paragraph",
      "text": "CI-AKI is a causative diagnosis."
    },
    {
      "type": "paragraph",
      "text": "Unfortunately, very few published studies have a suitable control group to permit the separation of CI-AKI from CA-AKI [1-12]."
    },
    {
      "type": "paragraph",
      "text": "Therefore, the incidence of CA-AKI reported in clinical studies and the incidence of CA-AKI observed in clinical practice likely"
    },
    {
      "type": "paragraph",
      "text": "includes a combination of CI-AKI (i.e., AKI caused by contrast medium administration) and AKI unrelated to contrast medium"
    },
    {
      "type": "paragraph",
      "text": "administration (i.e., AKI coincident to but not caused by contrast medium administration)."
    },
    {
      "type": "paragraph",
      "text": "This document will address both CI-AKI and CA-AKI, but these terms are not interchangeable. CA-AKI is not synonymous with"
    },
    {
      "type": "paragraph",
      "text": "CI-AKI."
    },
    {
      "type": "paragraph",
      "text": "At the current time, it is the position of ACR Committee on Drugs and Contrast Media that CI-AKI is a real, albeit rare,"
    },
    {
      "type": "paragraph",
      "text": "entity."
    },
    {
      "type": "paragraph",
      "text": "Published studies on CI-AKI have been heavily contaminated by bias and conflation. Future investigations building on"
    },
    {
      "type": "paragraph",
      "text": "recent methodological advancements [3,4,7,9], are necessary to clarify the incidence and significance of this disease."
    },
    {
      "type": "paragraph",
      "text": "Pathogenesis"
    },
    {
      "type": "paragraph",
      "text": "CA-AKI may be caused by any nephrotoxic event (including CI-AKI) that is coincident to the intravascular administration of"
    },
    {
      "type": "paragraph",
      "text": "contrast material. Because the diagnosis of CA-AKI is based on changes in serum creatinine [2,13-15] physiologic fluctuation in"
    },
    {
      "type": "paragraph",
      "text": "this value can also contribute to its incidence, particularly in patients with chronic kidney disease. Patients who have an elevated"
    },
    {
      "type": "paragraph",
      "text": "serum creatinine at baseline have a greater variance in daily serum creatinine measurements than those with a normal baseline"
    },
    {
      "type": "paragraph",
      "text": "serum creatinine [10]."
    },
    {
      "type": "paragraph",
      "text": "The exact pathophysiology of CI-AKI is not understood. Etiologic factors that have been suggested include renal hemodynamic"
    },
    {
      "type": "paragraph",
      "text": "changes (vasoconstriction) and direct tubular toxicity, among others [16-26]. Both osmotic and chemotoxic mechanisms may be"
    },
    {
      "type": "paragraph",
      "text": "involved, and some investigations suggest agent-specific chemotoxicity. The nephrotoxic effect of iodinated contrast medium"
    },
    {
      "type": "paragraph",
      "text": "may be proportional to dose for cardiac angiography; there is no evidence of a dose-toxicity relationship following intravenous"
    },
    {
      "type": "paragraph",
      "text": "(IV) administration when administered at usual diagnostic doses. CI-AKI may occur in children, but if so, it is rare [27-30]."
    },
    {
      "type": "paragraph",
      "text": "Gadolinium-based contrast media either do not cause CI-AKI when administered at FDA-approved doses, or this event is"
    },
    {
      "type": "paragraph",
      "text": "exceptionally rare [31-35]. If administered at extreme above-FDA-label doses to achieve X-ray attenuating effects during"
    },
    {
      "type": "paragraph",
      "text": "angiography (not recommended), gadolinium-based contrast media are more nephrotoxic than iso-attenuating doses of iodinated"
    },
    {
      "type": "paragraph",
      "text": "contrast media [36-38]."
    },
    {
      "type": "paragraph",
      "text": "Diagnosis"
    },
    {
      "type": "paragraph",
      "text": "Kidney Disease Improving Global Outcomes (KDIGO) criteria are recommended for the diagnosis of CA-AKI and endorsed by"
    },
    {
      "type": "paragraph",
      "text": "the NKF Kidney Disease Outcomes Quality Initiative as a consensus definition for epidemiologic and clinical research"
    },
    {
      "type": "paragraph",
      "text": "applications [39-41]. The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for acute"
    },
    {
      "type": "paragraph",
      "text": "kidney injury were developed to assist practitioners caring for patients at risk for or with AKI following an explicit process of"
    },
    {
      "type": "paragraph",
      "text": "evidence review and appraisal [40,42]."
    },
    {
      "type": "paragraph",
      "text": "KDIGO Definition of Acute Kidney Injury"
    },
    {
      "type": "paragraph",
      "text": "The diagnosis of AKI is made according to the KDIGO criteria if one of the following occurs within 48 hours after a nephrotoxic"
    },
    {
      "type": "paragraph",
      "text": "event (e.g., intravascular iodinated contrast medium exposure) [40]:"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Absolute serum creatinine increase >=0.3 mg/dL (>26.4 mol/L)."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "A percentage increase in serum creatinine >= 50% (>=1.5"
    },
    {
      "type": "paragraph",
      "text": "-fold above baseline)."
    },
    {
      "type": "image",
      "assetId": "asset_21aa380a36",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "POST-CONTRAST ACUTE KIDNEY INJURY AND CONTRAST-INDUCED NEPHROPATHY IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "36"
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Urine output reduced to <= 0.5 mL/kg/hour for at least 6 hours."
    },
    {
      "type": "paragraph",
      "text": "This system has been advocated as a common definition of intrinsic acute kidney injury, regardless of etiology [40]. Therefore, it"
    },
    {
      "type": "paragraph",
      "text": "can be used to define the parameters of CA-AKI as well as CI-AKI. The KDIGO criteria also outline a system for staging the"
    },
    {
      "type": "paragraph",
      "text": "degree of renal injury that is present following the diagnosis of AKI; the interested reader is referred to the original manuscript"
    },
    {
      "type": "paragraph",
      "text": "[40]."
    },
    {
      "type": "paragraph",
      "text": "Elevations in serum creatinine are neither sensitive nor specific for individual types of AKI. Any serum creatinine-based criteria,"
    },
    {
      "type": "paragraph",
      "text": "used in isolation, will be unable to separate CI-AKI from generic CA-AKI. This applies to scientific studies lacking appropriate"
    },
    {
      "type": "paragraph",
      "text": "control groups and to clinical evaluations of individual patients [2-4,7-9,11]."
    },
    {
      "type": "paragraph",
      "text": "Laboratory Tests of Renal Function"
    },
    {
      "type": "paragraph",
      "text": "Laboratory tests may be used both to estimate the risk of CI-AKI prior to administering contrast medium and to determine whether"
    },
    {
      "type": "paragraph",
      "text": "AKI has occurred after contrast medium administration. Serum creatinine concentration is the most commonly used measure of"
    },
    {
      "type": "paragraph",
      "text": "renal function, but it has limitations as an accurate measure of glomerular filtration rate (GFR) [43-47]. Serum creatinine is"
    },
    {
      "type": "paragraph",
      "text": "considerably influenced by the patients gender, muscle mass, nutritional status, and age. Impaired renal function can exist"
    },
    {
      "type": "paragraph",
      "text": "when"
    },
    {
      "type": "paragraph",
      "text": "the"
    },
    {
      "type": "paragraph",
      "text": "serum creatinine is normal. Normal serum creatinine is maintained until the GFR -"
    },
    {
      "type": "paragraph",
      "text": "at least as reflected in creatinine clearance"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "is reduced by nearly 50%."
    },
    {
      "type": "paragraph",
      "text": "Calculated estimated glomerular filtration rate (eGFR) is more accurate than is serum creatinine at predicting true GFR [48]. As"
    },
    {
      "type": "paragraph",
      "text": "a result, eGFR is gaining attention as a potentially better marker of CI-AKI risk [49,50]."
    },
    {
      "type": "paragraph",
      "text": "Although the formula for estimating GFR has intrinsic error due to the reliance on serum creatinine, and lack of validation in"
    },
    {
      "type": "paragraph",
      "text": "patients with AKI, low muscle mass or patients on dialysis, it is the most accurate and least biased method commonly available"
    },
    {
      "type": "paragraph",
      "text": "to stratify KDIGO CKD stages."
    },
    {
      "type": "paragraph",
      "text": "Route of Contrast Administration"
    },
    {
      "type": "paragraph",
      "text": "In the last two decades, the CI-AKI literature has been dominated by reports of patients who have undergone cardiac angiography"
    },
    {
      "type": "paragraph",
      "text": "with iodinated contrast medium. Cardiac angiography differs from IV contrast medium administration in three major ways: 1) the"
    },
    {
      "type": "paragraph",
      "text": "injection is intra-arterial and supra-renal, 2) the injection requires a catheter that can dislodge atheroemboli, and 3) the contrast"
    },
    {
      "type": "paragraph",
      "text": "medium dose to the kidneys will be more abrupt and concentrated [2,6,51,52]."
    },
    {
      "type": "paragraph",
      "text": "The overall incidence of CA-AKI in studies of cardiac angiography is higher than it is in studies of patients who receive IV"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast medium. Therefore, data from cardiac angiography studies likely over-estimate the risk of CI-AKI for patients"
    },
    {
      "type": "paragraph",
      "text": "undergoing IV contrast-enhanced studies [2,6]."
    },
    {
      "type": "paragraph",
      "text": "CI-AKI Studies"
    },
    {
      "type": "paragraph",
      "text": "Much of the literature investigating the incidence of CI-AKI has failed to include a control group of patients not receiving contrast"
    },
    {
      "type": "paragraph",
      "text": "medium [8,12]. This is problematic because several studies have shown that the frequency and magnitude of serum creatinine"
    },
    {
      "type": "paragraph",
      "text": "change in patients who have not received contrast medium is similar to the changes in patients who have received it [7-9,53-60]."
    },
    {
      "type": "paragraph",
      "text": "In more than 30,000 patients at a single institution who did not receive any contrast medium, more than half showed a change in"
    },
    {
      "type": "paragraph",
      "text": "serum creatinine of at least 25%, and more than 40% showed a change of at least 0.4 mg/dL [10]. The authors noted that had some"
    },
    {
      "type": "paragraph",
      "text": "of these patients received iodinated contrast medium temporally related to the rise in serum creatinine, the rise would have been"
    },
    {
      "type": "paragraph",
      "text": "undoubtedly attributed to it, rather than to physiologic variation or another etiology."
    },
    {
      "type": "paragraph",
      "text": "Since 2007, an increasing number of published studies have included control groups of patients not exposed to iodinated contrast"
    },
    {
      "type": "paragraph",
      "text": "medium [53,55-60]. Most have found no evidence of CI-AKI, but most also utilized non- randomized non-matched controls who"
    },
    {
      "type": "paragraph",
      "text": "happened to receive unenhanced CT as part of routine clinical care [53,55-60]. The clinical population of patients imaged with"
    },
    {
      "type": "paragraph",
      "text": "unenhanced CT is enriched with patients who are at risk for AKI and therefore is contaminated by selection bias. This selection"
    },
    {
      "type": "paragraph",
      "text": "bias has been shown objectively in a meta-analysis by McDonald et al [8]."
    },
    {
      "type": "paragraph",
      "text": "Four large studies released in 2013 and 2014 (each with >10,000 patients) have addressed selection bias in the unenhanced CT"
    },
    {
      "type": "paragraph",
      "text": "population through use of propensity score adjustment and propensity score matching [3,4,7,9]. Although the conclusions from"
    },
    {
      "type": "paragraph",
      "text": "these studies differ somewhat, all four have shown that CI-AKI is much less common than previously believed. In patients with"
    },
    {
      "type": "paragraph",
      "text": "a stable baseline eGFR >=45 mL / min/1.73m2, IV iodinated contrast media are not an independent nephrotoxic risk factor [3,4,7"
    },
    {
      "type": "paragraph",
      "text": ",9],"
    },
    {
      "type": "paragraph",
      "text": "and in patients with a stable baseline eGFR 30-44 mL / min/1.73m2, IV iodinated contrast media are either not nephrotoxic or"
    },
    {
      "type": "image",
      "assetId": "asset_fd7f104363",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "POST-CONTRAST ACUTE KIDNEY INJURY AND CONTRAST-INDUCED NEPHROPATHY IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "37"
    },
    {
      "type": "paragraph",
      "text": "rarely so [3,4,7,9]."
    },
    {
      "type": "paragraph",
      "text": "Despite this common ground, there are differences among these studies [3,4,7,9] in the covariates chosen for inclusion, the method"
    },
    {
      "type": "paragraph",
      "text": "of controlling baseline renal function instability, the definitions of AKI, and the nuances of the statistical methodology. These"
    },
    {
      "type": "paragraph",
      "text": "differences likely explain the different conclusions drawn between these studies for patients with Stage IV and Stage V chronic"
    },
    {
      "type": "paragraph",
      "text": "kidney disease (eGFR <30 mL / min/1.73m2). In particular, two propensity-score matched studies [3,4] have shown that IV"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast material is an independent nephrotoxic risk factor in patients with Stage IV and Stage V chronic kidney disease,"
    },
    {
      "type": "paragraph",
      "text": "while two others were unable to find such evidence [7,9]."
    },
    {
      "type": "paragraph",
      "text": "Risk Factors"
    },
    {
      "type": "paragraph",
      "text": "Numerous studies have attempted to isolate risk factors for CI-AKI. There is consensus that the most important risk factor is pre-"
    },
    {
      "type": "paragraph",
      "text": "existing severe renal insufficiency [3,4,15,61,62]. Multiple other risk factors have been proposed, including diabetes mellitus,"
    },
    {
      "type": "paragraph",
      "text": "dehydration, cardiovascular disease, diuretic use, advanced age, hypertension, hyperuricemia, and multiple iodinated contrast"
    },
    {
      "type": "paragraph",
      "text": "medium doses in a short time interval (<24 hours) [3,4,15,61-64], but these have not been rigorously confirmed. In particular,"
    },
    {
      "type": "paragraph",
      "text": "multiple myeloma is not supported as a risk factor for CA-AKI [65-67]. Two studies have shown that CA-AKI may occur after"
    },
    {
      "type": "paragraph",
      "text": "two closely spaced doses of IV iodinated contrast medium [63,64], but neither study was designed to show that the risk was higher"
    },
    {
      "type": "paragraph",
      "text": "than after one or no dose of IV contrast medium."
    },
    {
      "type": "paragraph",
      "text": "Risk Thresholds"
    },
    {
      "type": "paragraph",
      "text": "There is no agreed-upon threshold of serum creatinine elevation or eGFR declination beyond which the risk of CI-AKI is"
    },
    {
      "type": "paragraph",
      "text": "considered so great that intravascular iodinated contrast medium should never be administered. In fact, since each contrast medium"
    },
    {
      "type": "paragraph",
      "text": "administration always implies a risk-benefit analysis for the patient, contrast medium administration for all patients should always"
    },
    {
      "type": "paragraph",
      "text": "be taken in the clinical context, considering all risks, benefits and alternatives [2,6]."
    },
    {
      "type": "paragraph",
      "text": "Some practices have advocated stratification of potential risk by eGFR instead of serum creatinine because it is a better indicator"
    },
    {
      "type": "paragraph",
      "text": "of baseline renal function [49,50]. This has been limited in the past by insufficient data [68-70], but there are now two large"
    },
    {
      "type": "paragraph",
      "text": "propensity score-adjusted studies that stratify CI-AKI risk by eGFR [3,7]. One showed no risk of CI-AKI from IV iodinated"
    },
    {
      "type": "paragraph",
      "text": "contrast material, regardless of baseline eGFR [7], while another identified patients with an eGFR <30 mL / min/1.73m2 to be at"
    },
    {
      "type": "paragraph",
      "text": "significant risk (patients with eGFR 30-44 mL / min/1.73m2 were at borderline but not statistically significant risk) [3]."
    },
    {
      "type": "paragraph",
      "text": "Herts et al [50] showed that when patients eGFR was calculated by the MDRD formula, a significantly higher percentage of"
    },
    {
      "type": "paragraph",
      "text": "patients presenting for contrast-enhanced CT scans had an eGFR <60 mL / min than had a serum creatinine of >1.4 mg/dL."
    },
    {
      "type": "paragraph",
      "text": "Davenport et al [49] showed that the use of eGFR thresholds (instead of serum creatinine-based thresholds) more appropriately"
    },
    {
      "type": "paragraph",
      "text": "identified patients who may be at risk for CI-AKI."
    },
    {
      "type": "paragraph",
      "text": "At the current time, there is very little evidence that IV iodinated contrast material is an independent risk factor for AKI in patients"
    },
    {
      "type": "paragraph",
      "text": "with eGFR >=30 mL / min/1.73m2. Therefore, if a threshold for CI"
    },
    {
      "type": "paragraph",
      "text": "-AKI risk is used at all, 30 mL / min/1.73m2 seems to be the"
    },
    {
      "type": "paragraph",
      "text": "one with the greatest level of evidence [3]. Any threshold put into practice must be weighed on an individual patient level with"
    },
    {
      "type": "paragraph",
      "text": "the benefits of administering contrast material."
    },
    {
      "type": "paragraph",
      "text": "Contrast-enhanced CT has superior diagnostic performance compared to unenhanced CT for a wide array of indications. Failure"
    },
    {
      "type": "paragraph",
      "text": "to diagnose an important clinical entity carries its own risk."
    },
    {
      "type": "paragraph",
      "text": "As previously stated, no serum creatinine or eGFR threshold is adequate to stratify risk for patients with AKI because serum"
    },
    {
      "type": "paragraph",
      "text": "creatinine in this setting is unreliable. However, in patients with AKI, the administration of iodinated contrast medium should"
    },
    {
      "type": "paragraph",
      "text": "only be undertaken with appropriate caution, and only if the benefit to the patient outweighs the risk. There have been no published"
    },
    {
      "type": "paragraph",
      "text": "series demonstrating that IV iodinated contrast medium administration to patients with AKI leads to worse or prolonged renal"
    },
    {
      "type": "paragraph",
      "text": "dysfunction than would occur in a control group. However, patients with AKI are particularly susceptible to nephrotoxin exposure"
    },
    {
      "type": "paragraph",
      "text": "and therefore it is probably prudent to avoid intravascular iodinated contrast medium in these patients when possible."
    },
    {
      "type": "paragraph",
      "text": "Anuric patients with end-stage renal disease who do not have a functioning transplant kidney are not at risk for CI-AKI because"
    },
    {
      "type": "paragraph",
      "text": "their kidneys are nonfunctional; these patients may receive intravascular iodinated contrast material without risk of additional"
    },
    {
      "type": "paragraph",
      "text": "renal injury (see Renal Dialysis Patients and the Use of Iodinated Contrast Medium, below)."
    },
    {
      "type": "paragraph",
      "text": "Screening"
    },
    {
      "type": "paragraph",
      "text": "Screening based on eGFR should be used to identify patients at potential risk of CI-AKI [61,71] . A variety of patient risk factors"
    },
    {
      "type": "image",
      "assetId": "asset_cf61e5317d",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "POST-CONTRAST ACUTE KIDNEY INJURY AND CONTRAST-INDUCED NEPHROPATHY IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "38"
    },
    {
      "type": "paragraph",
      "text": "have been investigated as screening data elements which vary in their sensitivity and specificity, although the most useful may be"
    },
    {
      "type": "paragraph",
      "text": "a personal history of kidney disease (i.e. CKD, remote AKI, kidney surgery, kidney ablation, albumineria) [72,73]. Diabetes"
    },
    {
      "type": "paragraph",
      "text": "mellitus may be an additional optional factor for screening [72,73]. Patient age and treated or untreated hypertension as"
    },
    {
      "type": "paragraph",
      "text": "independent triggers for kidney function assessment may result in a large false-positive rate in identifying patients with eGFR less"
    },
    {
      "type": "paragraph",
      "text": "than 30 mL/min/1.73 m2."
    },
    {
      "type": "paragraph",
      "text": "There is no agreed-upon acceptable maximum interval between baseline renal function assessment and contrast medium"
    },
    {
      "type": "paragraph",
      "text": "administration in at-risk patients. Some accept a 30-day interval in outpatients. It seems prudent to have a shorter interval for"
    },
    {
      "type": "paragraph",
      "text": "inpatients, those with a new risk factor, and those with a heightened risk of renal dysfunction."
    },
    {
      "type": "paragraph",
      "text": "Suggested Indications for Renal Function Assessment before the Intravascular Administration of Iodinated Contrast Medium"
    },
    {
      "type": "paragraph",
      "text": "The following is a suggested list of risk factors that may warrant renal function assessment (e.g., serum creatinine, eGFR) prior"
    },
    {
      "type": "paragraph",
      "text": "to the administration of intravascular iodinated contrast medium. This list should not be considered definitive and represents a"
    },
    {
      "type": "paragraph",
      "text": "blend of published data [73,74] and expert opinion:"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Personal history of renal disease, including:"
    },
    {
      "type": "paragraph",
      "text": "Known chronic kidney disease (CKD)"
    },
    {
      "type": "paragraph",
      "text": "Remote history of AKI"
    },
    {
      "type": "paragraph",
      "text": "Dialysis"
    },
    {
      "type": "paragraph",
      "text": "Kidney surgery"
    },
    {
      "type": "paragraph",
      "text": "Kidney ablation"
    },
    {
      "type": "paragraph",
      "text": "Albuminuria"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "History of diabetes mellitus (optional)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Metformin or metformin-containing drug combinations"
    },
    {
      "type": "paragraph",
      "text": "1"
    },
    {
      "type": "paragraph",
      "text": "Patients who are scheduled for a routine intravascular study but do not have one of the above risk factors do not require a baseline"
    },
    {
      "type": "paragraph",
      "text": "serum creatinine determination before iodinated contrast medium administration."
    },
    {
      "type": "paragraph",
      "text": "Morbidity and Mortality"
    },
    {
      "type": "paragraph",
      "text": "The clinical course of CA-AKI (and, presumably, CI-AKI) depends on baseline renal function, coexisting risk factors, degree"
    },
    {
      "type": "paragraph",
      "text": "of hydration, and other factors. However, the usual course consists of a transient asymptomatic elevation in serum creatinine."
    },
    {
      "type": "paragraph",
      "text": "Serum creatinine usually begins to rise within 24 hours of intravascular iodinated contrast medium administration, peaks"
    },
    {
      "type": "paragraph",
      "text": "within 4 days, and often returns to baseline within 7 to 10 days. It is unusual for patients to develop permanent renal"
    },
    {
      "type": "paragraph",
      "text": "dysfunction [68,70]."
    },
    {
      "type": "paragraph",
      "text": "Several studies have shown that patients with CA-AKI, including those with only transient injury, tend to have longer hospital"
    },
    {
      "type": "paragraph",
      "text": "stays, higher mortality, and higher incidences of cardiac and neurologic events than contrast medium-receiving patients whose"
    },
    {
      "type": "paragraph",
      "text": "kidney function remains stable [41,75-78]. These observations have led to widespread hesitance in the use of intravascular"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast medium when the risk of CI-AKI is felt to be high. However, many studies investigating CI-AKI and its"
    },
    {
      "type": "paragraph",
      "text": "consequences following intravascular iodinated contrast medium administration have failed to include a control group of patients"
    },
    {
      "type": "paragraph",
      "text": "not receiving contrast medium [76-78]; therefore, it is possible that much of the morbidity and mortality previously attributed to"
    },
    {
      "type": "paragraph",
      "text": "CI-AKI in the literature may in fact be due to other etiologies (i.e., contrast-independent causes of CA-AKI). Larger studies with"
    },
    {
      "type": "paragraph",
      "text": "proper control groups and longitudinal outcomes data are needed."
    },
    {
      "type": "paragraph",
      "text": "Prevention"
    },
    {
      "type": "paragraph",
      "text": "Prior to contrast medium administration, adequate patient assessment and communication between radiologist and referring"
    },
    {
      "type": "paragraph",
      "text": "clinician are important. Consideration of alternative imaging strategies and an individualized risk-benefit assessment are"
    },
    {
      "type": "paragraph",
      "text": "fundamental."
    },
    {
      "type": "paragraph",
      "text": "Avoidance of Iodinated Contrast Medium"
    },
    {
      "type": "paragraph",
      "text": "Concern for the development of CI-AKI is a relative but not absolute contraindication to the administration of intravascular"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast medium in at-risk patients that have AKI or an eGFR less than 30 mL/min/1.73 m2 and are not undergoing"
    },
    {
      "type": "paragraph",
      "text": "1"
    },
    {
      "type": "paragraph",
      "text": "Metformin does not confer an increased risk of CI-AKI. However, patients who develop AKI while taking metformin may be susceptible to"
    },
    {
      "type": "paragraph",
      "text": "the development of lactic acidosis."
    },
    {
      "type": "image",
      "assetId": "asset_a2d19bdaf5",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "POST-CONTRAST ACUTE KIDNEY INJURY AND CONTRAST-INDUCED NEPHROPATHY IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "39"
    },
    {
      "type": "paragraph",
      "text": "maintenance dialysis [3,4,70,79,80]. In these scenarios, the information that may be obtained by using no contrast medium (e.g.,"
    },
    {
      "type": "paragraph",
      "text": "non-contrast CT) and/or other modalities (e.g., ultrasound, non-contrast magnetic resonance imaging [MRI]) may be sufficiently"
    },
    {
      "type": "paragraph",
      "text": "useful that contrast medium administration can be avoided. (See the Chapter on Nephrogenic Systemic Fibrosis [NSF] for a full"
    },
    {
      "type": "paragraph",
      "text": "discussion of the use of gadolinium chelates in patients with renal disease.) In some clinical situations, the use of intravascular"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast medium may be necessary regardless of CI-AKI risk. Although there is data suggesting a directly proportional"
    },
    {
      "type": "paragraph",
      "text": "dose- toxicity relationship for intracardiac iodinated contrast medium [81], there is no analogous robust data for intravenous"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast media within the range of clinically administered doses. Therefore, it is not recommended to reduce doses to"
    },
    {
      "type": "paragraph",
      "text": "attempt to mitigate the risk of CI-AKI as this may result in suboptimal or nondiagnostic images. Instead, standard contrast dosing"
    },
    {
      "type": "paragraph",
      "text": "is recommended if the benefits have been deemed to outweigh the risks for intravenous iodinated contrast media administration"
    },
    {
      "type": "paragraph",
      "text": "in high-risk patients for CI-AKI."
    },
    {
      "type": "paragraph",
      "text": "One purported risk factor for the development of CI-AKI is the administration of multiple doses of intravascular iodinated contrast"
    },
    {
      "type": "paragraph",
      "text": "medium within a short period of time [63,64]. Most low-osmolality iodinated contrast media have a half-life of approximately"
    },
    {
      "type": "paragraph",
      "text": "two hours. Therefore, it takes approximately 20 hours for one administered dose of contrast medium to be eliminated in a patient"
    },
    {
      "type": "paragraph",
      "text": "with normal renal function. Therefore, it has long been suggested that dosing intervals shorter than 24 hours be avoided except in"
    },
    {
      "type": "paragraph",
      "text": "urgent situations."
    },
    {
      "type": "paragraph",
      "text": "We do not believe that there is sufficient evidence to specifically endorse the decision to withhold a repeat contrast medium"
    },
    {
      "type": "paragraph",
      "text": "injection until more than 24 hours have passed since the prior injection, nor to recommend a specific threshold of contrast medium"
    },
    {
      "type": "paragraph",
      "text": "volume beyond which additional contrast media should not be given within a 24-hour period."
    },
    {
      "type": "paragraph",
      "text": "Further, obtaining a serum creatinine measurement between two closely spaced iodinated contrast medium enhanced studies are"
    },
    {
      "type": "paragraph",
      "text": "unlikely to be of any benefit given the slow nature of change of serum creatinine in patients with AKI."
    },
    {
      "type": "paragraph",
      "text": "Therefore, the decision to administer closely spaced contrast-enhanced studies is clinical and subjective, with high-risk patients"
    },
    {
      "type": "paragraph",
      "text": "(e.g., Stage IV and Stage V chronic kidney disease, AKI) treated with greater caution than the general population."
    },
    {
      "type": "paragraph",
      "text": "Choice of Iodinated Contrast Medium"
    },
    {
      "type": "paragraph",
      "text": "Barrett and Carlisle [82] reported a meta-analysis of the literature concerning the relative nephrotoxicity of high osmolality"
    },
    {
      "type": "paragraph",
      "text": "contrast media (HOCM) and low osmolality contrast media (LOCM). They concluded that LOCM are less nephrotoxic than"
    },
    {
      "type": "paragraph",
      "text": "HOCM in patients with underlying renal insufficiency. LOCM were not shown to be significantly different in patients with normal"
    },
    {
      "type": "paragraph",
      "text": "renal function. Most centers no longer use intravascular HOCM due to the greater incidence of various adverse effects associated"
    },
    {
      "type": "paragraph",
      "text": "with its use."
    },
    {
      "type": "paragraph",
      "text": "Studies [83-86] have failed to establish a clear advantage of IV iso-osmolality iodixanol over IV LOCM with regard to CA-AKI"
    },
    {
      "type": "paragraph",
      "text": "or CI-AKI. A 2009 meta-analysis using data pooled from 25 trials found no difference in the rate of CA-AKI between iodixanol"
    },
    {
      "type": "paragraph",
      "text": "and low osmolality agents after intravenous administration [87]."
    },
    {
      "type": "paragraph",
      "text": "Volume Expansion"
    },
    {
      "type": "paragraph",
      "text": "The major preventive action to mitigate the risk of CI-AKI is to provide intravenous volume expansion prior to contrast medium"
    },
    {
      "type": "paragraph",
      "text": "administration [88-94]. The ideal infusion rate and volume is unknown, but isotonic fluid such as 0.9% normal saline (NS) is"
    },
    {
      "type": "paragraph",
      "text": "preferred. Typical prophylaxis regiments begin 1 hour prior to the exam and continue 3-12 hours after with longer regiments"
    },
    {
      "type": "paragraph",
      "text": "(approximately 12 hours) shown to lower the risk of CA-AKI compared with shorter regiments [61,95]. Typical doses may be"
    },
    {
      "type": "paragraph",
      "text": "fixed volume (e.g., 500 mL NS) before and after or weight-based volumes (1-3mL/kg per hour) [61,79]. Oral hydration has not"
    },
    {
      "type": "paragraph",
      "text": "been well studied for patients with eGFR less than 30 mL/min/1.73 m2 or in patients with AKI."
    },
    {
      "type": "paragraph",
      "text": "Not all clinical studies have shown dehydration to be a major risk factor for CA-AKI. However, in the dehydrated state, renal"
    },
    {
      "type": "paragraph",
      "text": "blood flow and GFR are decreased, the effect of iodinated contrast medium on these parameters is accentuated, and there is a"
    },
    {
      "type": "paragraph",
      "text": "theoretical concern of prolonged tubular exposure to iodinated contrast medium due to low tubular flow rates. Solomon et al [96]"
    },
    {
      "type": "paragraph",
      "text": "[86] studied adult patients with chronic kidney disease who underwent cardiac angiography. The reported incidence of CA-AKI"
    },
    {
      "type": "paragraph",
      "text": "was decreased by periprocedural IV volume expansion (0.45% or 0.9% saline, 100 mL/h, 12 hours before to 12 hours after"
    },
    {
      "type": "paragraph",
      "text": "intravascular contrast medium administration). In another study, IV volume expansion with 0.9% saline was superior to IV volume"
    },
    {
      "type": "paragraph",
      "text": "expansion with 0.45% saline in CA-AKI risk reduction [89]."
    },
    {
      "type": "paragraph",
      "text": "Prophylaxis is indicated for patients who have AKI or severe CKD with an eGFR less than 30 mL/min/1.73m2, although the risks"
    },
    {
      "type": "paragraph",
      "text": "of volume expansion (i.e., heart failure or other hypervolemic conditions) should be considered before initiation [97,98]."
    },
    {
      "type": "image",
      "assetId": "asset_39e24d3a33",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "POST-CONTRAST ACUTE KIDNEY INJURY AND CONTRAST-INDUCED NEPHROPATHY IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "40"
    },
    {
      "type": "paragraph",
      "text": "Prophylaxis is not indicated for the general population of patients with stable eGFR greater than or equal to 30 mL/min 1.73 m2"
    },
    {
      "type": "paragraph",
      "text": "or patients on chronic dialysis [98]. Prophylaxis may also be considered on an individual basis for high-risk circumstances (e.g."
    },
    {
      "type": "paragraph",
      "text": "numerous risk factors, recent AKI, borderline eGFR) in patients with an eGFR of 30-44 mL/min./1.73 m2 at the discretion of the"
    },
    {
      "type": "paragraph",
      "text": "ordering provider."
    },
    {
      "type": "paragraph",
      "text": "Sodium bicarbonate"
    },
    {
      "type": "paragraph",
      "text": "Some studies and meta-analyses of patients undergoing cardiac angiography have shown intravenous volume expansion with"
    },
    {
      "type": "paragraph",
      "text": "sodium bicarbonate to be superior to 0.9% saline in reducing the risk of CA-AKI [90,91], but these results have been challenged"
    },
    {
      "type": "paragraph",
      "text": "by other meta-analyses and studies [93,99]. Bicarbonate is likely similar to normal saline for the prevention of CA-AKI, but it is"
    },
    {
      "type": "paragraph",
      "text": "not preferred due to the additional requirement for pharmacist compounding."
    },
    {
      "type": "paragraph",
      "text": "N-acetylcysteine"
    },
    {
      "type": "paragraph",
      "text": "Recent randomized trial showed that N-acetylcysteine was no more effective than placebo at preventing CA-AKI for intra-arterial"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast media administration and is therefore not recommended for intravenous contrast media prophylaxis [99]."
    },
    {
      "type": "paragraph",
      "text": "Diuretics: Mannitol and Furosemide or Other Agents"
    },
    {
      "type": "paragraph",
      "text": "Solomon et al [100] reported no beneficial effects from the osmotic diuretic mannitol when it was added to IV saline solution in"
    },
    {
      "type": "paragraph",
      "text": "patients with or without diabetes mellitus. There was an exacerbation of renal dysfunction when the loop diuretic furosemide was"
    },
    {
      "type": "paragraph",
      "text": "used in addition to IV saline solution. Neither mannitol nor furosemide is recommended for CI-AKI risk reduction. Other"
    },
    {
      "type": "paragraph",
      "text": "theoretical renal-protective medications such as theophylline, endothelin-1, and fenoldopam are also not recommended for CI-"
    },
    {
      "type": "paragraph",
      "text": "AKI reduction as strong supporting data is lacking."
    },
    {
      "type": "paragraph",
      "text": "Renal Dialysis Patients and the Use of Iodinated Contrast Medium"
    },
    {
      "type": "paragraph",
      "text": "Patients with anuric end-stage chronic kidney disease who do not have a functioning transplant can receive intravascular iodinated"
    },
    {
      "type": "paragraph",
      "text": "contrast medium without risk of further renal damage because their kidneys are no longer functioning. However, there is a"
    },
    {
      "type": "paragraph",
      "text": "theoretical risk of converting an oliguric patient on dialysis to an anuric patient on dialysis by exposing him or her to intravascular"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast medium. This remains speculative, as there are no conclusive outcomes data in this setting. Therefore, patients"
    },
    {
      "type": "paragraph",
      "text": "undergoing dialysis who make more than 1-2 cups of urine/day (100 mL) should be considered nonanuric and treated as high-risk"
    },
    {
      "type": "paragraph",
      "text": "patients similar to patients with AKI or eGFR less than 30 mL/min/1.73m2 who are not undergoing hemodialysis."
    },
    {
      "type": "paragraph",
      "text": "Patients should not have acute dialysis nor continuous renal replacement therapy initiated or alter their schedule solely based on"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast media administration regardless of renal function due to the risks, costs and lack of benefit [39,61,72,79,80,101-"
    },
    {
      "type": "paragraph",
      "text": "103]."
    },
    {
      "type": "paragraph",
      "text": "The U.S. Food and Drug Administration (FDA) has issued guidelines and drug labeling for metformin since 1995, and the component of these FDA"
    },
    {
      "type": "paragraph",
      "text": "guidelines related to administration of iodinated contrast material in patients taking metformin has been made progressively less rigorous since the original"
    },
    {
      "type": "paragraph",
      "text": "version. The ACR Committee on Drugs and Contrast Media recognizes that the latest (as of this writing, dated 4-8-2016) FDA guidelines and drug labeling"
    },
    {
      "type": "paragraph",
      "text": "are still more restrictive than those in this chapter of the ACR Manual on Contrast Media. Nevertheless, the committee authoring this Manual has reviewed"
    },
    {
      "type": "paragraph",
      "text": "the evidence and believes that the prevailing weight of clinical evidence on this matter allows less stringent yet safe patient management which should"
    },
    {
      "type": "paragraph",
      "text": "reduce patient cost and inconvenience. This footnote is designed to alert readers that the ACR recommendations differ in case their personal philosophy or"
    },
    {
      "type": "paragraph",
      "text": "institutional policies necessitate adherence to the more restrictive FDA guidelines."
    },
    {
      "type": "paragraph",
      "text": "References"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Baumgarten DA, Ellis JH. Contrast-induced nephropathy: contrast material not required? AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2008;191:383-6."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS, Cohan RH, Khalatbari S, Ellis JH. The challenges in assessing contrast-induced nephropathy: where are we now? JR Am J"
    },
    {
      "type": "paragraph",
      "text": "Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2014;202:784-9."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS, Khalatbari S, Cohan RH, Dillman JR, Myles JD, Ellis JH. Contrast material-induced nephrotoxicity and intravenous low-"
    },
    {
      "type": "paragraph",
      "text": "osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2013;268:719-28."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS, Khalatbari S, Dillman JR, Cohan RH, Caoili EM, Ellis JH. Contrast material-induced nephrotoxicity and intravenous low-"
    },
    {
      "type": "paragraph",
      "text": "osmolality iodinated contrast material. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2013;267:94-105."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Ellis JH, Cohan RH. Reducing the risk of contrast-induced nephropathy: a perspective on the controversies. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2009;192:1544-9."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Katzberg RW, Newhouse JH. Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to"
    },
    {
      "type": "paragraph",
      "text": "believe? Radiology"
    },
    {
      "type": "paragraph",
      "text": "2010;256:21-8."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "McDonald JS, McDonald RJ, Carter RE, Katzberg RW, Kallmes DF, Williamson EE. Risk of intravenous contrast material-mediated acute"
    },
    {
      "type": "paragraph",
      "text": "kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2014;271:65-73."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "McDonald JS, McDonald RJ, Comin J, et al. Frequency of acute kidney injury following intravenous contrast medium administration: a"
    },
    {
      "type": "paragraph",
      "text": "systematic review and meta-analysis. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2013;267:119-28."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "McDonald RJ, McDonald JS, Bida JP, et al. Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology"
    },
    {
      "type": "paragraph",
      "text": "2013;267:106-18."
    },
    {
      "type": "image",
      "assetId": "asset_575f90c269",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "POST-CONTRAST ACUTE KIDNEY INJURY AND CONTRAST-INDUCED NEPHROPATHY IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "41"
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Newhouse JH, Kho D, Rao QA, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for"
    },
    {
      "type": "paragraph",
      "text": "studies of contrast nephrotoxicity. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2008;191:376-82."
    },
    {
      "type": "paragraph",
      "text": "11."
    },
    {
      "type": "paragraph",
      "text": "Newhouse JH, RoyChoudhury A. Quantitating contrast medium-induced nephropathy: controlling the controls. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2013;267:4-8."
    },
    {
      "type": "paragraph",
      "text": "12."
    },
    {
      "type": "paragraph",
      "text": "Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2006;239:392-7."
    },
    {
      "type": "paragraph",
      "text": "13."
    },
    {
      "type": "paragraph",
      "text": "Aurelio A, Durante A. Contrast-induced nephropathy in percutaneous coronary interventions: pathogenesis, risk factors, outcome, prevention and"
    },
    {
      "type": "paragraph",
      "text": "treatment. Cardiology"
    },
    {
      "type": "paragraph",
      "text": "2014;128:62-72."
    },
    {
      "type": "paragraph",
      "text": "14."
    },
    {
      "type": "paragraph",
      "text": "Slocum NK, Grossman PM, Moscucci M, et al. The changing definition of contrast-induced nephropathy and its clinical implications: insights"
    },
    {
      "type": "paragraph",
      "text": "from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). American heart journal"
    },
    {
      "type": "paragraph",
      "text": "2012;163:829-34."
    },
    {
      "type": "paragraph",
      "text": "15."
    },
    {
      "type": "paragraph",
      "text": "Stacul F, van der Molen AJ, Reimer P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines."
    },
    {
      "type": "paragraph",
      "text": "European radiology"
    },
    {
      "type": "paragraph",
      "text": "2011;21:2527-41."
    },
    {
      "type": "paragraph",
      "text": "16."
    },
    {
      "type": "paragraph",
      "text": "Deray G, Dubois M, Martinez F, et al. Renal effects of radiocontrast agents in rats: a new model of acute renal failure. American journal of"
    },
    {
      "type": "paragraph",
      "text": "nephrology"
    },
    {
      "type": "paragraph",
      "text": "1990;10:507-13."
    },
    {
      "type": "paragraph",
      "text": "17."
    },
    {
      "type": "paragraph",
      "text": "Gruskin AB, Oetliker OH, Wolfish NM, Gootman NL, Bernstein J, Edelmann CM, Jr. Effects of angiography on renal function and histology in"
    },
    {
      "type": "paragraph",
      "text": "infants and piglets. The Journal of pediatrics"
    },
    {
      "type": "paragraph",
      "text": "1970;76:41-8."
    },
    {
      "type": "paragraph",
      "text": "18."
    },
    {
      "type": "paragraph",
      "text": "Heinrich MC, Kuhlmann MK, Grgic A, Heckmann M, Kramann B, Uder M. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and"
    },
    {
      "type": "paragraph",
      "text": "nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2005;235:843-9."
    },
    {
      "type": "paragraph",
      "text": "19."
    },
    {
      "type": "paragraph",
      "text": "Heneghan M. Contrast-induced acute renal failure. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "1978;131:1113-5."
    },
    {
      "type": "paragraph",
      "text": "20."
    },
    {
      "type": "paragraph",
      "text": "Katzberg RW, Morris TW, Schulman G, et al. Reactions to intravenous contrast media. Part II: Acute renal response in euvolemic and dehydrated"
    },
    {
      "type": "paragraph",
      "text": "dogs. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1983;147:331-4."
    },
    {
      "type": "paragraph",
      "text": "21."
    },
    {
      "type": "paragraph",
      "text": "Liu ZZ, Viegas VU, Perlewitz A, et al. Iodinated contrast media differentially affect afferent and efferent arteriolar tone and reactivity in mice: a"
    },
    {
      "type": "paragraph",
      "text": "possible explanation for reduced glomerular filtration rate. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2012;265:762-71."
    },
    {
      "type": "paragraph",
      "text": "22."
    },
    {
      "type": "paragraph",
      "text": "Lund G, Einzig S, Rysavy J, et al. Role of ischemia in contrast-induced renal damage: an experimental study. Circulation"
    },
    {
      "type": "paragraph",
      "text": "1984;69:783-89."
    },
    {
      "type": "paragraph",
      "text": "23."
    },
    {
      "type": "paragraph",
      "text": "Porter GA, Kloster FE, Bristow JD. Sequential effect of angiographic contrast agent on canine renal and systemic hemodynamics. American heart"
    },
    {
      "type": "paragraph",
      "text": "journal"
    },
    {
      "type": "paragraph",
      "text": "1971;81:80-92."
    },
    {
      "type": "paragraph",
      "text": "24."
    },
    {
      "type": "paragraph",
      "text": "Sendeski M, Patzak A, Pallone TL, Cao C, Persson AE, Persson PB. Iodixanol, constriction of medullary descending vasa recta, and risk for"
    },
    {
      "type": "paragraph",
      "text": "contrast medium-induced nephropathy. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2009;251:697-704."
    },
    {
      "type": "paragraph",
      "text": "25."
    },
    {
      "type": "paragraph",
      "text": "Tadavarthy SM, Castaneda W, Amplatz K. Redistribution of renal blood flow caused by contrast media. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1977;122:343-8."
    },
    {
      "type": "paragraph",
      "text": "26."
    },
    {
      "type": "paragraph",
      "text": "Ziegler TW, Ludens JH, Fanestil DD, Talner LB. Inhibition of active sodium transport by radiographic contrast media. Kidney international"
    },
    {
      "type": "paragraph",
      "text": "1975;7:68-76."
    },
    {
      "type": "paragraph",
      "text": "27."
    },
    {
      "type": "paragraph",
      "text": "Ajami G, Derakhshan A, Amoozgar H, et al. Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac"
    },
    {
      "type": "paragraph",
      "text": "angiography: a prospective study. Pediatric cardiology"
    },
    {
      "type": "paragraph",
      "text": "2010;31:668-73."
    },
    {
      "type": "paragraph",
      "text": "28."
    },
    {
      "type": "paragraph",
      "text": "Haight AE, Kaste SC, Goloubeva OG, Xiong XP, Bowman LC. Nephrotoxicity of iopamidol in pediatric, adolescent, and young adult patients"
    },
    {
      "type": "paragraph",
      "text": "who have undergone allogeneic bone marrow transplantation. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2003;226:399-404."
    },
    {
      "type": "paragraph",
      "text": "29."
    },
    {
      "type": "paragraph",
      "text": "Noyan A, Kkosmanolu O, Yildizda D, Ozbarlas N, Anarat A, Anarat R. Evaluation of renal functions in children with"
    },
    {
      "type": "paragraph",
      "text": "congenital heart"
    },
    {
      "type": "paragraph",
      "text": "disease before and after cardiac angiography. The Turkish journal of pediatrics"
    },
    {
      "type": "paragraph",
      "text": "1998;40:97-101."
    },
    {
      "type": "paragraph",
      "text": "30."
    },
    {
      "type": "paragraph",
      "text": "Senthilnathan S, Gauvreau K, Marshall AC, Lock JE, Bergersen L. Contrast administration in pediatric cardiac catheterization: dose and adverse"
    },
    {
      "type": "paragraph",
      "text": "events. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions"
    },
    {
      "type": "paragraph",
      "text": "2009;73:814-"
    },
    {
      "type": "paragraph",
      "text": "20."
    },
    {
      "type": "paragraph",
      "text": "31."
    },
    {
      "type": "paragraph",
      "text": "Arsenault TM, King BF, Marsh JW, Jr., et al. Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: retrospective"
    },
    {
      "type": "paragraph",
      "text": "analysis of an initial experience. Mayo Clinic proceedings"
    },
    {
      "type": "paragraph",
      "text": "1996;71:1150-4."
    },
    {
      "type": "paragraph",
      "text": "32."
    },
    {
      "type": "paragraph",
      "text": "Hoffmann U, Fischereder M, Reil A, Fischer M, Link J, Krmer BK. Renal effects of gadopentetate dimeglumine in patients with normal and"
    },
    {
      "type": "paragraph",
      "text": "impaired renal function. European journal of medical research"
    },
    {
      "type": "paragraph",
      "text": "2005;10:149-54."
    },
    {
      "type": "paragraph",
      "text": "33."
    },
    {
      "type": "paragraph",
      "text": "Prince MR, Arnoldus C, Frisoli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. Journal of magnetic resonance"
    },
    {
      "type": "paragraph",
      "text": "imaging : JMRI"
    },
    {
      "type": "paragraph",
      "text": "1996;6:162-6."
    },
    {
      "type": "paragraph",
      "text": "34."
    },
    {
      "type": "paragraph",
      "text": "Tombach B, Bremer C, Reimer P, et al. Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results"
    },
    {
      "type": "paragraph",
      "text": "of a randomized study. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2001;218:651-7."
    },
    {
      "type": "paragraph",
      "text": "35."
    },
    {
      "type": "paragraph",
      "text": "Zhang HL, Ersoy H, Prince MR. Effects of gadopentetate dimeglumine and gadodiamide on serum calcium, magnesium, and creatinine"
    },
    {
      "type": "paragraph",
      "text": "measurements. Journal of magnetic resonance imaging : JMRI"
    },
    {
      "type": "paragraph",
      "text": "2006;23:383-7."
    },
    {
      "type": "paragraph",
      "text": "36."
    },
    {
      "type": "paragraph",
      "text": "Briguori C, Colombo A, Airoldi F, et al. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures."
    },
    {
      "type": "paragraph",
      "text": "Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions"
    },
    {
      "type": "paragraph",
      "text": "2006;67:175-80."
    },
    {
      "type": "paragraph",
      "text": "37."
    },
    {
      "type": "paragraph",
      "text": "Elmsthl B, Nyman U, Leander P, Chai CM, Frennby B, Almn T. Gadolinium contrast media are more nephrotoxic than a low osmolar iodine"
    },
    {
      "type": "paragraph",
      "text": "medium employing doses with equal X-ray attenuation in renal arteriography: an experimental study in pigs. Academic radiology"
    },
    {
      "type": "paragraph",
      "text": "2004;11:1219-"
    },
    {
      "type": "paragraph",
      "text": "28."
    },
    {
      "type": "paragraph",
      "text": "38."
    },
    {
      "type": "paragraph",
      "text": "Erley CM, Bader BD, Berger ED, et al. Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in"
    },
    {
      "type": "paragraph",
      "text": "azotaemic patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European"
    },
    {
      "type": "paragraph",
      "text": "Renal Association"
    },
    {
      "type": "paragraph",
      "text": "2004;19:2526-31."
    },
    {
      "type": "paragraph",
      "text": "39."
    },
    {
      "type": "paragraph",
      "text": "Palevsky PM, Liu KD, Brophy PD, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury."
    },
    {
      "type": "paragraph",
      "text": "American journal of kidney diseases : the official journal of the National Kidney Foundation"
    },
    {
      "type": "paragraph",
      "text": "2013;61:649-72."
    },
    {
      "type": "paragraph",
      "text": "40."
    },
    {
      "type": "paragraph",
      "text": "Section 2: AKI Definition. Kidney Int Suppl (2011)"
    },
    {
      "type": "paragraph",
      "text": "2012;2:19-36."
    },
    {
      "type": "paragraph",
      "text": "41."
    },
    {
      "type": "paragraph",
      "text": "Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Critical"
    },
    {
      "type": "paragraph",
      "text": "care (London, England)"
    },
    {
      "type": "paragraph",
      "text": "2007;11:R31."
    },
    {
      "type": "paragraph",
      "text": "42."
    },
    {
      "type": "paragraph",
      "text": "Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Critical care (London,"
    },
    {
      "type": "paragraph",
      "text": "England)"
    },
    {
      "type": "paragraph",
      "text": "2013;17:204."
    },
    {
      "type": "paragraph",
      "text": "43."
    },
    {
      "type": "paragraph",
      "text": "Endre ZH, Pickering JW. Outcome definitions in non-dialysis intervention and prevention trials in acute kidney injury (AKI). Nephrology"
    },
    {
      "type": "paragraph",
      "text": "Dialysis Transplantation"
    },
    {
      "type": "paragraph",
      "text": "2009;25:107-18."
    },
    {
      "type": "paragraph",
      "text": "44."
    },
    {
      "type": "paragraph",
      "text": "Charlton JR, Portilla D, Okusa MD. A basic science view of acute kidney injury biomarkers. Nephrology, dialysis, transplantation : official"
    },
    {
      "type": "paragraph",
      "text": "publication of the European Dialysis and Transplant Association - European Renal Association"
    },
    {
      "type": "paragraph",
      "text": "2014;29:1301-11."
    },
    {
      "type": "image",
      "assetId": "asset_6beec03905",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "POST-CONTRAST ACUTE KIDNEY INJURY AND CONTRAST-INDUCED NEPHROPATHY IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "42"
    },
    {
      "type": "paragraph",
      "text": "45."
    },
    {
      "type": "paragraph",
      "text": "de Geus HR, Betjes MG, Bakker J. Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future"
    },
    {
      "type": "paragraph",
      "text": "challenges. Clinical kidney journal"
    },
    {
      "type": "paragraph",
      "text": "2012;5:102-08."
    },
    {
      "type": "paragraph",
      "text": "46."
    },
    {
      "type": "paragraph",
      "text": "Waikar SS, Betensky RA, Emerson SC, Bonventre JV. Imperfect gold standards for kidney injury biomarker evaluation. Journal of the American"
    },
    {
      "type": "paragraph",
      "text": "Society of Nephrology : JASN"
    },
    {
      "type": "paragraph",
      "text": "2012;23:13-21."
    },
    {
      "type": "paragraph",
      "text": "47."
    },
    {
      "type": "paragraph",
      "text": "Ostermann M, Bellomo R, Burdmann EA, et al. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global"
    },
    {
      "type": "paragraph",
      "text": "Outcomes (KDIGO) Conference. Kidney international"
    },
    {
      "type": "paragraph",
      "text": "2020;98:294-309."
    },
    {
      "type": "paragraph",
      "text": "48."
    },
    {
      "type": "paragraph",
      "text": "Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum"
    },
    {
      "type": "paragraph",
      "text": "creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of internal medicine"
    },
    {
      "type": "paragraph",
      "text": "1999;130:461-70."
    },
    {
      "type": "paragraph",
      "text": "49."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS, Khalatbari S, Cohan RH, Ellis JH. Contrast medium-induced nephrotoxicity risk assessment in adult inpatients: a comparison of"
    },
    {
      "type": "paragraph",
      "text": "serum creatinine level- and estimated glomerular filtration rate-based screening methods. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2013;269:92-100."
    },
    {
      "type": "paragraph",
      "text": "50."
    },
    {
      "type": "paragraph",
      "text": "Herts BR, Schneider E, Poggio ED, Obuchowski NA, Baker ME. Identifying outpatients with renal insufficiency before contrast-enhanced CT by"
    },
    {
      "type": "paragraph",
      "text": "using estimated glomerular filtration rates versus serum creatinine levels. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2008;248:106-13."
    },
    {
      "type": "paragraph",
      "text": "51."
    },
    {
      "type": "paragraph",
      "text": "Karlsberg RP, Dohad SY, Sheng R. Contrast medium-induced acute kidney injury: comparison of intravenous and intraarterial administration of"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast medium. Journal of vascular and interventional radiology : JVIR"
    },
    {
      "type": "paragraph",
      "text": "2011;22:1159-65."
    },
    {
      "type": "paragraph",
      "text": "52."
    },
    {
      "type": "paragraph",
      "text": "Nyman U, Almn T, Jacobsson B, Aspelin P. Are intravenous injections of contrast media really less nephrotoxic than intra-arterial injections?"
    },
    {
      "type": "paragraph",
      "text": "European radiology"
    },
    {
      "type": "paragraph",
      "text": "2012;22:1366-71."
    },
    {
      "type": "paragraph",
      "text": "53."
    },
    {
      "type": "paragraph",
      "text": "Bruce RJ, Djamali A, Shinki K, Michel SJ, Fine JP, Pozniak MA. Background fluctuation of kidney function versus contrast-induced"
    },
    {
      "type": "paragraph",
      "text": "nephrotoxicity. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2009;192:711-8."
    },
    {
      "type": "paragraph",
      "text": "54."
    },
    {
      "type": "paragraph",
      "text": "Cramer BC, Parfrey PS, Hutchinson TA, et al. Renal function following infusion of radiologic contrast material. A prospective controlled study."
    },
    {
      "type": "paragraph",
      "text": "Archives of internal medicine"
    },
    {
      "type": "paragraph",
      "text": "1985;145:87-9."
    },
    {
      "type": "paragraph",
      "text": "55."
    },
    {
      "type": "paragraph",
      "text": "Heller CA, Knapp J, Halliday J, O'Connell D, Heller RF. Failure to demonstrate contrast nephrotoxicity. The Medical journal of Australia"
    },
    {
      "type": "paragraph",
      "text": "1991;155:329-32."
    },
    {
      "type": "paragraph",
      "text": "56."
    },
    {
      "type": "paragraph",
      "text": "Langner S, Stumpe S, Kirsch M, Petrik M, Hosten N. No increased risk for contrast-induced nephropathy after multiple CT perfusion studies of"
    },
    {
      "type": "paragraph",
      "text": "the brain with a nonionic, dimeric, iso-osmolal contrast medium. AJNR. American journal of neuroradiology"
    },
    {
      "type": "paragraph",
      "text": "2008;29:1525-9."
    },
    {
      "type": "paragraph",
      "text": "57."
    },
    {
      "type": "paragraph",
      "text": "Lima FO, Lev MH, Levy RA, et al. Functional Contrast-Enhanced CT for Evaluation of Acute Ischemic Stroke Does Not Increase the Risk of"
    },
    {
      "type": "paragraph",
      "text": "Contrast-Induced Nephropathy. American Journal of Neuroradiology"
    },
    {
      "type": "paragraph",
      "text": "2010;31:817-21."
    },
    {
      "type": "paragraph",
      "text": "58."
    },
    {
      "type": "paragraph",
      "text": "McGillicuddy EA, Schuster KM, Kaplan LJ, et al. Contrast-induced nephropathy in elderly trauma patients. The Journal of trauma"
    },
    {
      "type": "paragraph",
      "text": "2010;68:294-"
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "59."
    },
    {
      "type": "paragraph",
      "text": "Oleinik A, Romero JM, Schwab K, et al. CT angiography for intracerebral hemorrhage does not increase risk of acute nephropathy. Stroke"
    },
    {
      "type": "paragraph",
      "text": "2009;40:2393-7."
    },
    {
      "type": "paragraph",
      "text": "60."
    },
    {
      "type": "paragraph",
      "text": "Tremblay LN, Tien H, Hamilton P, et al. Risk and benefit of intravenous contrast in trauma patients with an elevated serum creatinine. The"
    },
    {
      "type": "paragraph",
      "text": "Journal of trauma"
    },
    {
      "type": "paragraph",
      "text": "2005;59:1162-6; discussion 66-7."
    },
    {
      "type": "paragraph",
      "text": "61."
    },
    {
      "type": "paragraph",
      "text": "Media ACoDaC. ACR Manual on Contrast Media."
    },
    {
      "type": "paragraph",
      "text": "https://www.acr.org/Clinical-Resources/Contrast-Manual"
    },
    {
      "type": "paragraph",
      "text": ". Accessed April 22, 2021."
    },
    {
      "type": "paragraph",
      "text": "62."
    },
    {
      "type": "paragraph",
      "text": "Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both."
    },
    {
      "type": "paragraph",
      "text": "A prospective controlled study. The New England journal of medicine"
    },
    {
      "type": "paragraph",
      "text": "1989;320:143-9."
    },
    {
      "type": "paragraph",
      "text": "63."
    },
    {
      "type": "paragraph",
      "text": "Abujudeh HH, Gee MS, Kaewlai R. In emergency situations, should serum creatinine be checked in all patients before performing second"
    },
    {
      "type": "paragraph",
      "text": "contrast CT examinations within 24 hours? Journal of the American College of Radiology : JACR"
    },
    {
      "type": "paragraph",
      "text": "2009;6:268-73."
    },
    {
      "type": "paragraph",
      "text": "64."
    },
    {
      "type": "paragraph",
      "text": "Trivedi H, Foley WD. Contrast-induced nephropathy after a second contrast exposure. Renal failure"
    },
    {
      "type": "paragraph",
      "text": "2010;32:796-801."
    },
    {
      "type": "paragraph",
      "text": "65."
    },
    {
      "type": "paragraph",
      "text": "Stacul F, Bertolotto M, Thomsen HS, et al. Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and"
    },
    {
      "type": "paragraph",
      "text": "ESUR Contrast Media Safety Committee guidelines. European radiology"
    },
    {
      "type": "paragraph",
      "text": "2018;28:683-91."
    },
    {
      "type": "paragraph",
      "text": "66."
    },
    {
      "type": "paragraph",
      "text": "Pahade JK, LeBedis CA, Raptopoulos VD, et al. Incidence of contrast-induced nephropathy in patients with multiple myeloma undergoing"
    },
    {
      "type": "paragraph",
      "text": "contrast-enhanced CT. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2011;196:1094-101."
    },
    {
      "type": "paragraph",
      "text": "67."
    },
    {
      "type": "paragraph",
      "text": "Crowley MP, Prabhakaran VN, Gilligan OM. Incidence of Contrast-Induced Nephropathy in Patients with Multiple Myeloma Undergoing"
    },
    {
      "type": "paragraph",
      "text": "Contrast-Enhanced Procedures. Pathology oncology research : POR"
    },
    {
      "type": "paragraph",
      "text": "2018;24:915-19."
    },
    {
      "type": "paragraph",
      "text": "68."
    },
    {
      "type": "paragraph",
      "text": "Kim SM, Cha RH, Lee JP, et al. Incidence and outcomes of contrast-induced nephropathy after computed tomography in patients with CKD: a"
    },
    {
      "type": "paragraph",
      "text": "quality improvement report. American journal of kidney diseases : the official journal of the National Kidney Foundation"
    },
    {
      "type": "paragraph",
      "text": "2010;55:1018-25."
    },
    {
      "type": "paragraph",
      "text": "69."
    },
    {
      "type": "paragraph",
      "text": "Thomsen HS, Morcos SK. Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT--a pooled analysis of two"
    },
    {
      "type": "paragraph",
      "text": "randomized trials. European radiology"
    },
    {
      "type": "paragraph",
      "text": "2009;19:891-7."
    },
    {
      "type": "paragraph",
      "text": "70."
    },
    {
      "type": "paragraph",
      "text": "Weisbord SD, Mor MK, Resnick AL, Hartwig KC, Palevsky PM, Fine MJ. Incidence and outcomes of contrast-induced AKI following computed"
    },
    {
      "type": "paragraph",
      "text": "tomography. Clinical journal of the American Society of Nephrology : CJASN"
    },
    {
      "type": "paragraph",
      "text": "2008;3:1274-81."
    },
    {
      "type": "paragraph",
      "text": "71."
    },
    {
      "type": "paragraph",
      "text": "Nyman U, Ahlkvist J, Aspelin P, et al. Preventing contrast medium-induced acute kidney injury : Side-by-side comparison of Swedish-ESUR"
    },
    {
      "type": "paragraph",
      "text": "guidelines. European radiology"
    },
    {
      "type": "paragraph",
      "text": "2018;28:5384-95."
    },
    {
      "type": "paragraph",
      "text": "72."
    },
    {
      "type": "paragraph",
      "text": "Too CW, Ng WY, Tan CC, Mahmood MI, Tay KH. Screening for impaired renal function in outpatients before iodinated contrast injection:"
    },
    {
      "type": "paragraph",
      "text": "Comparing the Choyke questionnaire with a rapid point-of-care-test. European journal of radiology"
    },
    {
      "type": "paragraph",
      "text": "2015;84:1227-31."
    },
    {
      "type": "paragraph",
      "text": "73."
    },
    {
      "type": "paragraph",
      "text": "Choyke PL, Cady J, DePollar SL, Austin H. Determination of serum creatinine prior to iodinated contrast media: is it necessary in all patients?"
    },
    {
      "type": "paragraph",
      "text": "Techniques in urology"
    },
    {
      "type": "paragraph",
      "text": "1998;4:65-9."
    },
    {
      "type": "paragraph",
      "text": "74."
    },
    {
      "type": "paragraph",
      "text": "Tippins RB, Torres WE, Baumgartner BR, Baumgarten DA. Are screening serum creatinine levels necessary prior to outpatient CT"
    },
    {
      "type": "paragraph",
      "text": "examinations? Radiology"
    },
    {
      "type": "paragraph",
      "text": "2000;216:481-4."
    },
    {
      "type": "paragraph",
      "text": "75."
    },
    {
      "type": "paragraph",
      "text": "Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and"
    },
    {
      "type": "paragraph",
      "text": "information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical"
    },
    {
      "type": "paragraph",
      "text": "care (London, England)"
    },
    {
      "type": "paragraph",
      "text": "2004;8:R204-12."
    },
    {
      "type": "paragraph",
      "text": "76."
    },
    {
      "type": "paragraph",
      "text": "Lakhal K, Ehrmann S, Chaari A, et al. Acute Kidney Injury Network definition of contrast-induced nephropathy in the critically ill: incidence and"
    },
    {
      "type": "paragraph",
      "text": "outcome. Journal of critical care"
    },
    {
      "type": "paragraph",
      "text": "2011;26:593-9."
    },
    {
      "type": "paragraph",
      "text": "77."
    },
    {
      "type": "paragraph",
      "text": "Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. American journal of kidney diseases : the official journal of the National"
    },
    {
      "type": "paragraph",
      "text": "Kidney Foundation"
    },
    {
      "type": "paragraph",
      "text": "2002;39:930-6."
    },
    {
      "type": "paragraph",
      "text": "78."
    },
    {
      "type": "paragraph",
      "text": "Valette X, Parienti JJ, Plaud B, Lehoux P, Samba D, Hanouz JL. Incidence, morbidity, and mortality of contrast-induced acute kidney injury in a"
    },
    {
      "type": "paragraph",
      "text": "surgical intensive care unit: a prospective cohort study. Journal of critical care"
    },
    {
      "type": "paragraph",
      "text": "2012;27:322.e1-5."
    },
    {
      "type": "image",
      "assetId": "asset_743b433c8d",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "POST-CONTRAST ACUTE KIDNEY INJURY AND CONTRAST-INDUCED NEPHROPATHY IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "43"
    },
    {
      "type": "paragraph",
      "text": "79."
    },
    {
      "type": "paragraph",
      "text": "Faucon AL, Bobrie G, Clment O. Nephrotoxicity of iodinated contrast media: From pathophysiology to prevention strategies. European journal"
    },
    {
      "type": "paragraph",
      "text": "of radiology"
    },
    {
      "type": "paragraph",
      "text": "2019;116:231-41."
    },
    {
      "type": "paragraph",
      "text": "80."
    },
    {
      "type": "paragraph",
      "text": "Subramaniam RM, Wilson RF, Turban S, et al. AHRQ Comparative Effectiveness Reviews."
    },
    {
      "type": "paragraph",
      "text": "Contrast-Induced Nephropathy: Comparative"
    },
    {
      "type": "paragraph",
      "text": "Effectiveness of Preventive Measures"
    },
    {
      "type": "paragraph",
      "text": ". Rockville (MD): Agency for Healthcare Research and Quality (US); 2016."
    },
    {
      "type": "paragraph",
      "text": "81."
    },
    {
      "type": "paragraph",
      "text": "Kooiman J, Seth M, Share D, Dixon S, Gurm HS. The association between contrast dose and renal complications post PCI across the continuum"
    },
    {
      "type": "paragraph",
      "text": "of procedural estimated risk. PloS one"
    },
    {
      "type": "paragraph",
      "text": "2014;9:e90233."
    },
    {
      "type": "paragraph",
      "text": "82."
    },
    {
      "type": "paragraph",
      "text": "Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1993;188:171-8."
    },
    {
      "type": "paragraph",
      "text": "83."
    },
    {
      "type": "paragraph",
      "text": "Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Lundkvist J. Cost-effectiveness of iodixanol in patients at high risk of contrast-"
    },
    {
      "type": "paragraph",
      "text": "induced nephropathy. American heart journal"
    },
    {
      "type": "paragraph",
      "text": "2005;149:298-303."
    },
    {
      "type": "paragraph",
      "text": "84."
    },
    {
      "type": "paragraph",
      "text": "Barrett BJ, Katzberg RW, Thomsen HS, et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed"
    },
    {
      "type": "paragraph",
      "text": "tomography: a double-blind comparison of iodixanol and iopamidol. Investigative radiology"
    },
    {
      "type": "paragraph",
      "text": "2006;41:815-21."
    },
    {
      "type": "paragraph",
      "text": "85."
    },
    {
      "type": "paragraph",
      "text": "Feldkamp T, Baumgart D, Elsner M, et al. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients. Clinical"
    },
    {
      "type": "paragraph",
      "text": "nephrology"
    },
    {
      "type": "paragraph",
      "text": "2006;66:322-30."
    },
    {
      "type": "paragraph",
      "text": "86."
    },
    {
      "type": "paragraph",
      "text": "Liss P, Persson PB, Hansell P, Lagerqvist B. Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar"
    },
    {
      "type": "paragraph",
      "text": "contrast media. Kidney international"
    },
    {
      "type": "paragraph",
      "text": "2006;70:1811-7."
    },
    {
      "type": "paragraph",
      "text": "87."
    },
    {
      "type": "paragraph",
      "text": "Heinrich MC, Hberle L, Mller V, Bautz W, Uder M. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast"
    },
    {
      "type": "paragraph",
      "text": "media: meta-analysis of randomized controlled trials. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2009;250:68-86."
    },
    {
      "type": "paragraph",
      "text": "88."
    },
    {
      "type": "paragraph",
      "text": "Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. The New England journal of medicine"
    },
    {
      "type": "paragraph",
      "text": "2006;354:379-86."
    },
    {
      "type": "paragraph",
      "text": "89."
    },
    {
      "type": "paragraph",
      "text": "Weisbord SD, Palevsky PM. Prevention of contrast-induced nephropathy with volume expansion. Clinical journal of the American Society of"
    },
    {
      "type": "paragraph",
      "text": "Nephrology : CJASN"
    },
    {
      "type": "paragraph",
      "text": "2008;3:273-80."
    },
    {
      "type": "paragraph",
      "text": "90."
    },
    {
      "type": "paragraph",
      "text": "Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial."
    },
    {
      "type": "paragraph",
      "text": "Jama"
    },
    {
      "type": "paragraph",
      "text": "2004;291:2328-34."
    },
    {
      "type": "paragraph",
      "text": "91."
    },
    {
      "type": "paragraph",
      "text": "Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a"
    },
    {
      "type": "paragraph",
      "text": "systematic review and meta-analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation"
    },
    {
      "type": "paragraph",
      "text": "2009;53:617-"
    },
    {
      "type": "paragraph",
      "text": "27."
    },
    {
      "type": "paragraph",
      "text": "92."
    },
    {
      "type": "paragraph",
      "text": "Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient"
    },
    {
      "type": "paragraph",
      "text": "vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest"
    },
    {
      "type": "paragraph",
      "text": "1998;114:1570-4."
    },
    {
      "type": "paragraph",
      "text": "93."
    },
    {
      "type": "paragraph",
      "text": "Zoungas S, Ninomiya T, Huxley R, et al. Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced"
    },
    {
      "type": "paragraph",
      "text": "nephropathy. Annals of internal medicine"
    },
    {
      "type": "paragraph",
      "text": "2009;151:631-8."
    },
    {
      "type": "paragraph",
      "text": "94."
    },
    {
      "type": "paragraph",
      "text": "Brar SS, Aharonian V, Mansukhani P, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney"
    },
    {
      "type": "paragraph",
      "text": "injury: the POSEIDON randomised controlled trial. Lancet (London, England)"
    },
    {
      "type": "paragraph",
      "text": "2014;383:1814-23."
    },
    {
      "type": "paragraph",
      "text": "95."
    },
    {
      "type": "paragraph",
      "text": "van der Molen AJ, Reimer P, Dekkers IA, et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other"
    },
    {
      "type": "paragraph",
      "text": "prophylactic measures, patients taking metformin and chronic dialysis patients : Recommendations for updated ESUR Contrast Medium Safety"
    },
    {
      "type": "paragraph",
      "text": "Committee guidelines. European radiology"
    },
    {
      "type": "paragraph",
      "text": "2018;28:2856-69."
    },
    {
      "type": "paragraph",
      "text": "96."
    },
    {
      "type": "paragraph",
      "text": "Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial"
    },
    {
      "type": "paragraph",
      "text": "of contrast-induced nephropathy in patients with chronic kidney disease. Circulation"
    },
    {
      "type": "paragraph",
      "text": "2007;115:3189-96."
    },
    {
      "type": "paragraph",
      "text": "97."
    },
    {
      "type": "paragraph",
      "text": "Nijssen EC, Nelemans PJ, Rennenberg RJ, Theunissen RA, van Ommen V, Wildberger JE. Prophylaxis in High-Risk Patients With eGFR < 30"
    },
    {
      "type": "paragraph",
      "text": "mL/min/1.73 m2: Get the Balance Right. Investigative radiology"
    },
    {
      "type": "paragraph",
      "text": "2019;54:580-88."
    },
    {
      "type": "paragraph",
      "text": "98."
    },
    {
      "type": "paragraph",
      "text": "Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in"
    },
    {
      "type": "paragraph",
      "text": "patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority"
    },
    {
      "type": "paragraph",
      "text": "trial. Lancet (London, England)"
    },
    {
      "type": "paragraph",
      "text": "2017;389:1312-22."
    },
    {
      "type": "paragraph",
      "text": "99."
    },
    {
      "type": "paragraph",
      "text": "Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. The New England journal"
    },
    {
      "type": "paragraph",
      "text": "of medicine"
    },
    {
      "type": "paragraph",
      "text": "2018;378:603-14."
    },
    {
      "type": "paragraph",
      "text": "100."
    },
    {
      "type": "paragraph",
      "text": "Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by"
    },
    {
      "type": "paragraph",
      "text": "radiocontrast agents. The New England journal of medicine"
    },
    {
      "type": "paragraph",
      "text": "1994;331:1416-20."
    },
    {
      "type": "paragraph",
      "text": "101."
    },
    {
      "type": "paragraph",
      "text": "Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. Jama"
    },
    {
      "type": "paragraph",
      "text": "2006;295:2765-79."
    },
    {
      "type": "paragraph",
      "text": "102."
    },
    {
      "type": "paragraph",
      "text": "Kawashima S, Takano H, Iino Y, Takayama M, Takano T. Prophylactic hemodialysis does not prevent contrast-induced nephropathy after"
    },
    {
      "type": "paragraph",
      "text": "cardiac catheterization in patients with chronic renal insufficiency. Circulation journal : official journal of the Japanese Circulation Society"
    },
    {
      "type": "paragraph",
      "text": "2006;70:553-8."
    },
    {
      "type": "paragraph",
      "text": "103."
    },
    {
      "type": "paragraph",
      "text": "Cruz DN, Goh CY, Marenzi G, Corradi V, Ronco C, Perazella MA. Renal replacement therapies for prevention of radiocontrast-induced"
    },
    {
      "type": "paragraph",
      "text": "nephropathy: a systematic review. The American journal of medicine"
    },
    {
      "type": "paragraph",
      "text": "2012;125:66-78.e3."
    },
    {
      "type": "paragraph",
      "text": "Revision History"
    },
    {
      "type": "paragraph",
      "text": "July 2021: Updated to reflect the ACR-NKF Consensus Statement"
    },
    {
      "type": "paragraph",
      "text": "19 November 2014: Major revisions"
    },
    {
      "type": "paragraph",
      "text": "15 April 2013: Minor revisions"
    },
    {
      "type": "paragraph",
      "text": "23 June 2010: Major revisions"
    },
    {
      "type": "paragraph",
      "text": "29 October 2008: First version"
    },
    {
      "type": "image",
      "assetId": "asset_6bd4ddbe64",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "METFORMIN"
    },
    {
      "type": "paragraph",
      "text": "44"
    },
    {
      "type": "paragraph",
      "text": "METFORMIN"
    },
    {
      "type": "paragraph",
      "text": "Metformin is a biguanide oral anti-hyperglycemic agent used primarily, but not exclusively, to treat patients with non-"
    },
    {
      "type": "paragraph",
      "text": "insulin-dependent diabetes mellitus [1-3]. It is available as a generic drug as well as in proprietary formulations, alone"
    },
    {
      "type": "paragraph",
      "text": "and in combination with other drugs (see"
    },
    {
      "type": "paragraph",
      "text": "Table A"
    },
    {
      "type": "paragraph",
      "text": "for some of the brand name formulations). The drug was approved in"
    },
    {
      "type": "paragraph",
      "text": "the United States in December of 1994 for use as monotherapy or combination therapy in patients with non-insulin-"
    },
    {
      "type": "paragraph",
      "text": "dependent diabetes mellitus whose hyperglycemia is not controlled by diet or sulfonylurea therapy alone."
    },
    {
      "type": "paragraph",
      "text": "Metformin is thought to act by decreasing hepatic glucose production and enhancing peripheral glucose uptake as a"
    },
    {
      "type": "paragraph",
      "text": "result of increased sensitivity of peripheral tissues to insulin. Only rarely does it cause hypoglycemia."
    },
    {
      "type": "paragraph",
      "text": "The most significant adverse effect of metformin therapy is the potential for the development of metformin-associated"
    },
    {
      "type": "paragraph",
      "text": "lactic acidosis in susceptible patients. This condition is estimated to occur at a rate of 0 to 0.084 cases per 1,000 patient"
    },
    {
      "type": "paragraph",
      "text": "years. Patient mortality in reported cases is about 50%. However, in almost all reported cases, lactic acidosis occurred"
    },
    {
      "type": "paragraph",
      "text": "because one or more patient-associated contraindications for the drug were overlooked. In one extensive 13-year"
    },
    {
      "type": "paragraph",
      "text": "retrospective study [4] of patients in Sweden, 16 cases were found, and all patients had several comorbid factors, most"
    },
    {
      "type": "paragraph",
      "text": "often cardiovascular or renal disease. There are no documented cases of metformin-associated lactic acidosis in properly"
    },
    {
      "type": "paragraph",
      "text": "selected patients."
    },
    {
      "type": "paragraph",
      "text": "Metformin is excreted unchanged by the kidneys, probably by both glomerular filtration and tubular excretion. The renal"
    },
    {
      "type": "paragraph",
      "text": "route eliminates approximately 90% of the absorbed drug within the first 24 hours. Metformin seems to cause increased"
    },
    {
      "type": "paragraph",
      "text": "lactic acid production by the intestines. Any factors that decrease metformin excretion or increase blood lactate levels are"
    },
    {
      "type": "paragraph",
      "text": "important risk factors for lactic acidosis. Renal insufficiency, then, is a major consideration for radiologists."
    },
    {
      "type": "paragraph",
      "text": "Also, factors that depress the ability to metabolize lactate, such as liver dysfunction or alcohol abuse, or that increase"
    },
    {
      "type": "paragraph",
      "text": "lactate production by increasing anaerobic metabolism (e.g., cardiac failure, cardiac or peripheral muscle ischemia, or"
    },
    {
      "type": "paragraph",
      "text": "severe infection) are contraindications to the use of metformin. Iodinated X-ray contrast media are not an independent"
    },
    {
      "type": "paragraph",
      "text": "risk factor for patients taking metformin but are a concern only if post-contrast acute kidney injury (AKI) should"
    },
    {
      "type": "paragraph",
      "text": "develop. Please refer to the chapter on Postcontrast Acute Kidney Injury and Contrast-Induced Nephropathy in Adults"
    },
    {
      "type": "paragraph",
      "text": "for information about the risk of these events."
    },
    {
      "type": "paragraph",
      "text": "The metformin package inserts approved by the U.S. Food and Drug Administration state that metformin should be"
    },
    {
      "type": "paragraph",
      "text": "withheld temporarily for patients undergoing radiological studies using IV iodinated contrast media. If acute kidney"
    },
    {
      "type": "paragraph",
      "text": "injury were to be caused by the iodinated contrast media, an accumulation of metformin could occur, with resultant"
    },
    {
      "type": "paragraph",
      "text": "lactate accumulation."
    },
    {
      "type": "paragraph",
      "text": "Management"
    },
    {
      "type": "paragraph",
      "text": "The management of patients taking metformin should be guided by the following:"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Patients taking metformin are not at higher risk than other patients for post-contrast acute kidney injury."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Iodinated contrast is a potential concern for furthering renal damage in patients with acute kidney injury, and in"
    },
    {
      "type": "paragraph",
      "text": "patients with severe chronic kidney disease (stage IV or stage V)."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "There have been no reports of lactic acidosis following intravenous iodinated contrast medium administration in"
    },
    {
      "type": "paragraph",
      "text": "patients properly selected for metformin administration."
    },
    {
      "type": "paragraph",
      "text": "The Committee recommends that patients taking metformin be classified into one of two categories based on the"
    },
    {
      "type": "paragraph",
      "text": "patients renal function (as measured by eGFR)."
    },
    {
      "type": "paragraph",
      "text": "Category I"
    },
    {
      "type": "paragraph",
      "text": "In patients with no evidence of AKI and with eGFR >=30 mL / min/1.73m"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": ", there is no need to discontinue metformin"
    },
    {
      "type": "paragraph",
      "text": "either prior to or following the intravenous administration of iodinated contrast media, nor is there an obligatory need to"
    },
    {
      "type": "image",
      "assetId": "asset_7ed144c7d2",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "METFORMIN"
    },
    {
      "type": "paragraph",
      "text": "45"
    },
    {
      "type": "paragraph",
      "text": "reassess the patients renal function following the test or procedure."
    },
    {
      "type": "paragraph",
      "text": "1"
    },
    {
      "type": "paragraph",
      "text": "Category II"
    },
    {
      "type": "paragraph",
      "text": "In patients taking metformin who are known to have acute kidney injury or severe chronic kidney disease (stage IV or"
    },
    {
      "type": "paragraph",
      "text": "stage V; i.e., eGFR< 30), or are undergoing arterial catheter studies that might result in emboli (atheromatous or other) to"
    },
    {
      "type": "paragraph",
      "text": "the renal arteries, metformin should be temporarily discontinued at the time of or prior to the procedure and withheld for"
    },
    {
      "type": "paragraph",
      "text": "48 hours subsequent to the procedure and reinstituted only after renal function has been re-evaluated and found to be"
    },
    {
      "type": "paragraph",
      "text": "normal."
    },
    {
      "type": "paragraph",
      "text": "Metformin and Gadolinium"
    },
    {
      "type": "paragraph",
      "text": "It is not necessary to discontinue metformin prior to contrast medium administration when the amount of gadolinium-"
    },
    {
      "type": "paragraph",
      "text": "based contrast material administered is in the usual dose range of 0.1 to 0.3 mmol per kg of body weight."
    },
    {
      "type": "paragraph",
      "text": "1The U.S. Food and Drug Administration (FDA) has issued guidelines and drug labeling for metformin since 1995, and the component of these"
    },
    {
      "type": "paragraph",
      "text": "FDA guidelines related to administration of iodinated contrast material in patients taking metformin has been made progressively less rigorous"
    },
    {
      "type": "paragraph",
      "text": "since the original version. The ACR Committee on Drugs and Contrast Media recognizes that the latest (as of this writing, dated 4-8-2016) FDA"
    },
    {
      "type": "paragraph",
      "text": "guidelines and drug labeling are still more restrictive than those in this chapter of the ACR Manual on Contrast Media. Nevertheless, the committee"
    },
    {
      "type": "paragraph",
      "text": "authoring this Manual has reviewed the evidence and believes that the prevailing weight of clinical evidence on this matter allows less stringent yet"
    },
    {
      "type": "paragraph",
      "text": "safe patient management which should reduce patient cost and inconvenience. This footnote is designed to alert readers that the ACR"
    },
    {
      "type": "paragraph",
      "text": "recommendations differ in case their personal philosophy or institutional policies necessitate adherence to the more restrictive FDA guidelines."
    },
    {
      "type": "paragraph",
      "text": "Table A"
    },
    {
      "type": "paragraph",
      "text": "Medications containing Metformin*"
    },
    {
      "type": "paragraph",
      "text": "Generic Ingredients"
    },
    {
      "type": "paragraph",
      "text": "Trade Names"
    },
    {
      "type": "paragraph",
      "text": "Metformin"
    },
    {
      "type": "paragraph",
      "text": "Glucophage"
    },
    {
      "type": "paragraph",
      "text": "Glucophage XR"
    },
    {
      "type": "paragraph",
      "text": "Fortamet"
    },
    {
      "type": "paragraph",
      "text": "Glumetza"
    },
    {
      "type": "paragraph",
      "text": "Riomet"
    },
    {
      "type": "paragraph",
      "text": "Glyburide/metformin"
    },
    {
      "type": "paragraph",
      "text": "Glucovance"
    },
    {
      "type": "paragraph",
      "text": "Glipizide/metformin"
    },
    {
      "type": "paragraph",
      "text": "Metaglip"
    },
    {
      "type": "paragraph",
      "text": "Linigliptin.metformin"
    },
    {
      "type": "paragraph",
      "text": "Jentadueto"
    },
    {
      "type": "paragraph",
      "text": "Pioglitazone/metformin"
    },
    {
      "type": "paragraph",
      "text": "ActoPlus Met"
    },
    {
      "type": "paragraph",
      "text": "ActoPlus Met XR"
    },
    {
      "type": "paragraph",
      "text": "Repaglinide/metformin"
    },
    {
      "type": "paragraph",
      "text": "Prandimet"
    },
    {
      "type": "paragraph",
      "text": "Rosiglitazone/metformin"
    },
    {
      "type": "paragraph",
      "text": "Avandamet"
    },
    {
      "type": "paragraph",
      "text": "Saxagliptin/metformin"
    },
    {
      "type": "paragraph",
      "text": "Kombiglyze XR"
    },
    {
      "type": "paragraph",
      "text": "Sitagliptin/metformin"
    },
    {
      "type": "paragraph",
      "text": "Janumet"
    },
    {
      "type": "paragraph",
      "text": "Janumet XR"
    },
    {
      "type": "paragraph",
      "text": "(Metformin and several of the combination drugs also available in generic versions) *List most recently revised on 4/17/2014"
    },
    {
      "type": "paragraph",
      "text": "References"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Bailey CJ, Turner RC. Metformin. The New England journal of medicine. 1996;334(9):574-579."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes"
    },
    {
      "type": "paragraph",
      "text": "mellitus. Drugs. 1995;49(5):721-749."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacological research: the official"
    },
    {
      "type": "paragraph",
      "text": "journal of the Italian Pharmacological Society. 1994;30(3):187-228."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Wiholm BE, Myrhed M. Metformin-associated lactic acidosis in Sweden 1977-1991. European journal of clinical pharmacology."
    },
    {
      "type": "paragraph",
      "text": "1993;44(6):589-591."
    },
    {
      "type": "paragraph",
      "text": "Revision History"
    },
    {
      "type": "paragraph",
      "text": "12 December 2014: Minor revisions"
    },
    {
      "type": "image",
      "assetId": "asset_bcde9b4d95",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "METFORMIN"
    },
    {
      "type": "paragraph",
      "text": "46"
    },
    {
      "type": "paragraph",
      "text": "29 June 2012: Minor revisions"
    },
    {
      "type": "paragraph",
      "text": "29 October 2008: First version"
    },
    {
      "type": "image",
      "assetId": "asset_2a592edcf6",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "47"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "Principles regarding contrast media utilization and associated adverse events are generally similar in children and adults. This"
    },
    {
      "type": "paragraph",
      "text": "section will address specific areas in which pediatric use of contrast medium differs from adult use and will attempt to avoid"
    },
    {
      "type": "paragraph",
      "text": "repeating recommendations that are similar for both patient populations."
    },
    {
      "type": "paragraph",
      "text": "Iodinated Intravascular Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Osmolality"
    },
    {
      "type": "paragraph",
      "text": "Osmolality, a measure of the concentration of a solution, is an important physical property of contrast media. There is variation"
    },
    {
      "type": "paragraph",
      "text": "in the osmolality of the nonionic iodinated contrast media approved for use in the United States, even when the iodine"
    },
    {
      "type": "paragraph",
      "text": "concentration is equivalent (see"
    },
    {
      "type": "paragraph",
      "text": "Appendix A"
    },
    {
      "type": "paragraph",
      "text": "). Contrast media osmolality is of particular importance in neonates and small"
    },
    {
      "type": "paragraph",
      "text": "children who are especially susceptible to fluid shifts and have a lower tolerance for intravascular and enteric osmotic loads"
    },
    {
      "type": "paragraph",
      "text": "compared to adults. Intravascular administration of hyperosmolar contrast medium can result in the shift of fluid from the"
    },
    {
      "type": "paragraph",
      "text": "extravascular space into the intravascular space, expanding blood volume [1,2]. If the fluid shift is large, cardiac failure and"
    },
    {
      "type": "paragraph",
      "text": "pulmonary edema can result; children with significant pre-existing cardiac dysfunction may be at particular risk."
    },
    {
      "type": "paragraph",
      "text": "Viscosity"
    },
    {
      "type": "paragraph",
      "text": "Viscosity, a measure of fluid resistance to stress, is another important physical property of contrast media and varies between"
    },
    {
      "type": "paragraph",
      "text": "different contrast media (see"
    },
    {
      "type": "paragraph",
      "text": "Appendix A"
    },
    {
      "type": "paragraph",
      "text": "). Contrast medium viscosity is especially relevant in pediatric patients due to the use"
    },
    {
      "type": "paragraph",
      "text": "of small gauge angiocatheters for contrast medium injection. Smaller gauge catheters and higher contrast medium viscosity both"
    },
    {
      "type": "paragraph",
      "text": "slow the injection flow rate per Poiseui"
    },
    {
      "type": "paragraph",
      "text": "lles law. If rapid injection of a high viscosity contrast medium through a small"
    },
    {
      "type": "paragraph",
      "text": "angiocatheter is attempted, catheter failure, vessel injury, or failure to achieve the desired rapid injection rate may result."
    },
    {
      "type": "paragraph",
      "text": "Viscosity of contrast media is inversely affected by temperature (see"
    },
    {
      "type": "paragraph",
      "text": "Appendix A"
    },
    {
      "type": "paragraph",
      "text": "). As temperature increases, viscosity"
    },
    {
      "type": "paragraph",
      "text": "decreases, thereby allowing for increased flow rates at lower pressures. However, there is a lack of data demonstrating the"
    },
    {
      "type": "paragraph",
      "text": "benefits of contrast media warming in children [3,4]."
    },
    {
      "type": "paragraph",
      "text": "Safe Intravascular Injection of Contrast Media in Children"
    },
    {
      "type": "paragraph",
      "text": "Several additional issues complicate the administration of intravascular contrast media to neonates and children, including the"
    },
    {
      "type": "paragraph",
      "text": "use of small volumes of contrast medium, small gauge angiocatheters, and unusual vascular access sites. First, very small"
    },
    {
      "type": "paragraph",
      "text": "volumes of contrast media are typically administered to neonates and infants (typically 1.5"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2 mL/kg) [5]. As a result, timing of"
    },
    {
      "type": "paragraph",
      "text": "image acquisition with regard to contrast medium administration may be important when performing certain imaging studies,"
    },
    {
      "type": "paragraph",
      "text": "such as CT angiography. In some instances, a slower injection rate (compared to that used in older children and adults) may be"
    },
    {
      "type": "paragraph",
      "text": "useful to prolong intravascular enhancement. Second, small-gauge angiocatheters (e.g., 24-gauge) located in very small"
    },
    {
      "type": "paragraph",
      "text": "peripheral veins (e.g., in the hand or foot) or other unusual vascular access sites are commonly utilized in neonates and infants."
    },
    {
      "type": "paragraph",
      "text": "A study by Amaral et al [6] showed that 24-gauge angiocatheters in a peripheral location can be safely power injected using a"
    },
    {
      "type": "paragraph",
      "text": "maximum flow rate of approximately 1.5 mL/sec and a maximum pressure of 150 psi. Recently, new small gauge intravenous"
    },
    {
      "type": "paragraph",
      "text": "catheter systems (e.g., BD Nexiva"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "Diffusics"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "closed IV catheter system) have been developed that allow injection rates and"
    },
    {
      "type": "paragraph",
      "text": "pressures higher than traditional peripheral intravenous cannulas, although there is a paucity of data describing their use in"
    },
    {
      "type": "paragraph",
      "text": "children undergoing power injection of contrast medium. When access is thought to be tenuous, careful hand injection of"
    },
    {
      "type": "paragraph",
      "text": "contrast medium should be strongly considered to minimize risk of vessel injury and extravasation, noting that smaller syringes"
    },
    {
      "type": "paragraph",
      "text": "can generate substantially greater injection pressures than larger syringes. Since some central venous catheters may not be"
    },
    {
      "type": "paragraph",
      "text": "approved for power injection, one should always verify in advance that any catheter to be utilized for bolus contrast material"
    },
    {
      "type": "paragraph",
      "text": "instillation can tolerate the anticipated injection and is appropriately positioned. It is also important to ensure that the pressure"
    },
    {
      "type": "paragraph",
      "text": "used does not exceed the catheters press"
    },
    {
      "type": "paragraph",
      "text": "ure rating."
    },
    {
      "type": "paragraph",
      "text": "Extravasation of Contrast Media in Children"
    },
    {
      "type": "paragraph",
      "text": "The frequency of contrast media extravasation in children is likely similar to that observed in the adult population, despite the"
    },
    {
      "type": "paragraph",
      "text": "use of lower intravascular contrast medium volumes. An extravasation rate of 0.3% was documented in a study of 554 children"
    },
    {
      "type": "paragraph",
      "text": "in which a power injector was used to administer iodinated contrast medium [6]. Another study of 2429 children who"
    },
    {
      "type": "paragraph",
      "text": "underwent intravenous power injection of iodinated contrast medium found an extravasation rate of 0.7% without an association"
    },
    {
      "type": "paragraph",
      "text": "with age [7]. Most extravasations in the pediatric population resolve without complication. A study by Wang et al [8] showed"
    },
    {
      "type": "paragraph",
      "text": "that 15 of 17 cases of contrast medium extravasation in children were mild in severity with minimal or no adverse effects. In the"
    },
    {
      "type": "paragraph",
      "text": "study by Barrera et al [7], none of the 18 children who experienced a contrast extravasation suffered a long-term substantial"
    },
    {
      "type": "image",
      "assetId": "asset_d0870c1b82",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "48"
    },
    {
      "type": "paragraph",
      "text": "injury or required surgery, although moderate and severe cases were documented. Furthermore, this study demonstrated positive"
    },
    {
      "type": "paragraph",
      "text": "associations between contrast media extravasation and both power injection peak pressure and flow rate."
    },
    {
      "type": "paragraph",
      "text": "Particular attention should be paid to the injection sites of neonates, infants, young children and developmentally delayed"
    },
    {
      "type": "paragraph",
      "text": "patients, as they cannot verbalize symptoms of an injection site complication. Please refer to the"
    },
    {
      "type": "paragraph",
      "text": "Extravasation of Contrast"
    },
    {
      "type": "paragraph",
      "text": "Media"
    },
    {
      "type": "paragraph",
      "text": "Chapter or download the"
    },
    {
      "type": "paragraph",
      "text": "ACR Guidance"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Contrast Reaction App"
    },
    {
      "type": "paragraph",
      "text": "for the treatment of a contrast extravasation, as"
    },
    {
      "type": "paragraph",
      "text": "treatment in a child is similar to that in an adult."
    },
    {
      "type": "paragraph",
      "text": "Physiologic Side Effects in Children"
    },
    {
      "type": "paragraph",
      "text": "Physiologic side effects to intravascular contrast medium administration in children have the potential for greater consequence"
    },
    {
      "type": "paragraph",
      "text": "than in adults [9]. For example, local warmth at the injection site or nausea may cause a child to move or cry. Such a response"
    },
    {
      "type": "paragraph",
      "text": "to contrast medium injection may result in a nondiagnostic imaging study, necessitating repeat imaging and additional exposure"
    },
    {
      "type": "paragraph",
      "text": "to contrast medium and possibly ionizing radiation. Management of physiologic side effects is generally supportive."
    },
    {
      "type": "paragraph",
      "text": "Incidence of Allergic-Like Reactions"
    },
    {
      "type": "paragraph",
      "text": "There are several difficulties in interpreting the available literature on the incidence of allergic-like reactions to IV iodinated"
    },
    {
      "type": "paragraph",
      "text": "contrast media in children. First, some studies have failed to discriminate between physiologic side effects and allergic-like"
    },
    {
      "type": "paragraph",
      "text": "reactions and have used heterogeneous definitions of what constitutes mild, moderate, or severe reactions. Second, there is a"
    },
    {
      "type": "paragraph",
      "text": "lack of controlled prospective pediatric studies on the topic. Prospective investigations are difficult to perform because allergic-"
    },
    {
      "type": "paragraph",
      "text": "like reactions to contrast media in children are rare, and large numbers of patients would be needed to acquire statistically"
    },
    {
      "type": "paragraph",
      "text": "meaningful results. Third, in some studies in the published literature, the methodology for tracking contrast reactions is such"
    },
    {
      "type": "paragraph",
      "text": "that it is difficult to guarantee that all adverse reactions were documented, and none were overlooked."
    },
    {
      "type": "paragraph",
      "text": "Therefore, the reported incidence of pediatric allergic-like reactions to contrast media is variable. It is generally agreed,"
    },
    {
      "type": "paragraph",
      "text": "however, that the incidence of allergic-like reactions in children is lower than that in adults [3,8-10]. A very large retrospective"
    },
    {
      "type": "paragraph",
      "text": "study by Katayama et al of more than 150,000 nonionic contrast medium administrations [10], when stratified by age, showed"
    },
    {
      "type": "paragraph",
      "text": "that patients less than 10 years of age and greater than 60 years of age have the lowest rates of adverse reactions overall; the rate"
    },
    {
      "type": "paragraph",
      "text": "of severe reactions was more uniform across age groups but the numbers were small. A study by Dillman et al [11]"
    },
    {
      "type": "paragraph",
      "text": "retrospectively reviewed more than 11,000 intravascular injections of low-osmolality nonionic iodinated contrast media in"
    },
    {
      "type": "paragraph",
      "text": "children and neonates and documented an allergic-like reaction rate of 0.18%. Of the 20 reactions documented in their study, 16"
    },
    {
      "type": "paragraph",
      "text": "were mild, one was moderate, and three were severe. A study by Callahan et al [12] of 12,494 consecutive patients up to 21"
    },
    {
      "type": "paragraph",
      "text": "years of age revealed a 0.46% incidence of adverse reactions to ioversol, the majority of which were mild and none of which"
    },
    {
      "type": "paragraph",
      "text": "were severe. A smaller study by Fjelldal et al [13] documented five allergic-like reactions to iohexol following a total of 547"
    },
    {
      "type": "paragraph",
      "text": "injections, for a rate of reaction of 0.9%. Although fatal reactions to contrast media in children are extremely rare (and may be"
    },
    {
      "type": "paragraph",
      "text": "due to co-morbid conditions), infants, young children, and developmentally delayed patients require close observation during"
    },
    {
      "type": "paragraph",
      "text": "and immediately following intravascular contrast medium administration, as they are unable to verbalize reaction-related"
    },
    {
      "type": "paragraph",
      "text": "discomfort or symptoms."
    },
    {
      "type": "paragraph",
      "text": "Prevention of Allergic-Like Reactions"
    },
    {
      "type": "paragraph",
      "text": "General guidelines for the prevention of allergic-like reactions in children are similar to those used for adult patients. However,"
    },
    {
      "type": "paragraph",
      "text": "it should be noted that there has been no prospective, controlled investigation performed to assess the efficacy of premedication"
    },
    {
      "type": "paragraph",
      "text": "for the prevention of allergic-like reactions to iodinated contrast media in children. A sample pediatric premedication regimen,"
    },
    {
      "type": "paragraph",
      "text": "using a combination of corticosteroid and antihistamine, is described in"
    },
    {
      "type": "paragraph",
      "text": "Table A"
    },
    {
      "type": "paragraph",
      "text": "at the end of this chapter. Allergic-like"
    },
    {
      "type": "paragraph",
      "text": "reactions following premedication may still occur, although the frequency of such reactions is unknown [11]."
    },
    {
      "type": "paragraph",
      "text": "Treatment of Allergic-Like Reactions"
    },
    {
      "type": "paragraph",
      "text": "General guidelines for the treatment of allergic-like reactions in children are similar to those used for adult patients. Pediatric"
    },
    {
      "type": "paragraph",
      "text": "medication dosages, however, may be significantly different from adult dosages used in the management of such reactions"
    },
    {
      "type": "paragraph",
      "text": "("
    },
    {
      "type": "paragraph",
      "text": "Table 2"
    },
    {
      "type": "paragraph",
      "text": "and"
    },
    {
      "type": "paragraph",
      "text": "Table 3"
    },
    {
      "type": "paragraph",
      "text": "). It can be helpful to have a pediatric medication chart with weight-based dosages placed on the"
    },
    {
      "type": "paragraph",
      "text": "emergency cart or posted in the rooms where intravascular contrast media is to be injected into children, noting that for IM"
    },
    {
      "type": "paragraph",
      "text": "epinephrine administration, most pediatric patients can be treated with an autoinjector (i.e., EpiPen(R) or EpiPen Jr(R)) to"
    },
    {
      "type": "paragraph",
      "text": "maximize speed of administration and minimize dosing errors. Dedicated pediatric emergency resuscitation equipment"
    },
    {
      "type": "paragraph",
      "text": "(including various sizes of supplemental oxygen facemasks) should be available in all such locations ("
    },
    {
      "type": "paragraph",
      "text": "Table 4"
    },
    {
      "type": "paragraph",
      "text": "). A separate box"
    },
    {
      "type": "paragraph",
      "text": "of pediatric airway equipment attached to the emergency cart may be useful in areas where both children and adults receive"
    },
    {
      "type": "paragraph",
      "text": "contrast media."
    },
    {
      "type": "image",
      "assetId": "asset_e3546ec36c",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "49"
    },
    {
      "type": "paragraph",
      "text": "Acute Kidney Injury after Iodinated Contrast Media Administration in Children"
    },
    {
      "type": "paragraph",
      "text": "Acute kidney injury (AKI) after contrast media administration is subdivided into two entities per the ACR-NKF consensus"
    },
    {
      "type": "paragraph",
      "text": "statement: contrast-induced acute kidney injury (CI-AKI), which implies a causal relationship between iodinated contrast"
    },
    {
      "type": "paragraph",
      "text": "material and AKI, and contrast-associated acute kidney injury (CA-AKI) [also referred to as post-contrast acute kidney injury"
    },
    {
      "type": "paragraph",
      "text": "(PC-AKI)], which represents a correlative relationship between iodinated contrast material (ICM) and acute kidney injury [14]."
    },
    {
      "type": "paragraph",
      "text": "Recent studies in which children exposed to intravenous iodinated contrast media were propensity score matched with groups of"
    },
    {
      "type": "paragraph",
      "text": "nonexposed control patients have showed no significant difference in the frequencies of subsequent acute kidney injury (CI-"
    },
    {
      "type": "paragraph",
      "text": "and CA-AKI) [15,16]. A study by Gilligan et al of 925 ICM-exposed children 18 years of age and younger propensity score"
    },
    {
      "type": "paragraph",
      "text": "matched to a group who underwent abdominal ultrasound showed no significant difference in the frequency of CI-AKI between"
    },
    {
      "type": "paragraph",
      "text": "the exposed and unexposed groups and found that, in children with an eGFR of 60 and greater, iodinated contrast medium"
    },
    {
      "type": "paragraph",
      "text": "exposure was not predictive of CI-AKI [15]. A similar large propensity score-based study by Calle-Toro et al. yielded similar"
    },
    {
      "type": "paragraph",
      "text": "findings [17]. A study by Guo et al of 192 ICM-exposed children 3-years-old or younger prior to cardiac surgery propensity"
    },
    {
      "type": "paragraph",
      "text": "score matched to a group without preoperative iodinated contrast media exposure found no significant difference in"
    },
    {
      "type": "paragraph",
      "text": "postoperative AKI [16]. A retrospective study of 211 trauma patients aged 15 years or younger (164 exposed to contrast, 47 not"
    },
    {
      "type": "paragraph",
      "text": "exposed to contrast) showed no significant difference in frequency of subsequent AKI [18]. The effects of contrast media on the"
    },
    {
      "type": "paragraph",
      "text": "kidneys are generally assumed to be similar between children and adults as no evidence currently available suggests otherwise."
    },
    {
      "type": "paragraph",
      "text": "A few key differences between CI-AKI and CA-AKI in children and adults are discussed below."
    },
    {
      "type": "paragraph",
      "text": "Measurement of Renal Function in Children"
    },
    {
      "type": "paragraph",
      "text": "Serum creatinine concentration reflects the balance between creatinine production and excretion. Creatinine is a breakdown"
    },
    {
      "type": "paragraph",
      "text": "product of skeletal muscle, and its rate of production is proportional to muscle mass. Muscle mass depends on a variety of"
    },
    {
      "type": "paragraph",
      "text": "factors, including patient age, gender, and level of physical activity. Normal serum creatinine concentrations, thus, are quite"
    },
    {
      "type": "paragraph",
      "text": "variable in pediatric patients. Normal pediatric serum creatinine concentrations increase with age, with the upper limits of"
    },
    {
      "type": "paragraph",
      "text": "normal typically less than adult values. Age-based normal serum creatinine concentrations also may vary slightly from"
    },
    {
      "type": "paragraph",
      "text": "laboratory to laboratory."
    },
    {
      "type": "paragraph",
      "text": "There are problems with using serum creatinine concentration as the sole marker of renal function. First, a normal serum"
    },
    {
      "type": "paragraph",
      "text": "creatinine value does not mean that renal function is preserved. For example, an increase in creatinine from 0.4 mg/dL to 0.8"
    },
    {
      "type": "paragraph",
      "text": "mg/dL in a 10-year-old child would be clinically important and suggest some degree of renal impairment, even though both"
    },
    {
      "type": "paragraph",
      "text": "measurements may be within acceptable limits for patient age. Serum creatinine concentration may not become abnormal until"
    },
    {
      "type": "paragraph",
      "text": "glomerular filtration has decreased substantially. Second, it may take several days in the setting of acute renal failure for serum"
    },
    {
      "type": "paragraph",
      "text": "creatinine concentration to rise. Therefore, a patient may have impaired renal function in the setting of a normal serum"
    },
    {
      "type": "paragraph",
      "text": "creatinine concentration. This phenomenon is not unique to the pediatric population."
    },
    {
      "type": "paragraph",
      "text": "Measurement of blood urea nitrogen (BUN) concentration is a poor indicator of renal function. BUN concentration depends on"
    },
    {
      "type": "paragraph",
      "text": "numerous variables in addition to renal function, including daily dietary protein intake, hepatic function, and patient hydration."
    },
    {
      "type": "paragraph",
      "text": "A more appropriate method by which to express renal function in children is the estimated glomerular filtration rate (eGFR). It"
    },
    {
      "type": "paragraph",
      "text": "is important to note that the formula used to calculate pediatric eGFR (see below) is different from that used in adults. eGFR"
    },
    {
      "type": "paragraph",
      "text": "calculation in children requires knowledge of patient serum creatinine concentration, height, and/or cystatin C. In addition, the"
    },
    {
      "type": "paragraph",
      "text": "assay used to measure serum creatinine concentration must be known."
    },
    {
      "type": "paragraph",
      "text": "EGFR Calculation in Children"
    },
    {
      "type": "paragraph",
      "text": "There is no perfect manner of estimating GFR in children. The National Kidney Disease Education Program, an initiative of the"
    },
    {
      "type": "paragraph",
      "text": "National Institutes of Health, provides an"
    },
    {
      "type": "paragraph",
      "text": "online calculator"
    },
    {
      "type": "paragraph",
      "text": "for estimating purposes and has published the following information"
    },
    {
      "type": "paragraph",
      "text": "regarding the estimation of GFR in children."
    },
    {
      "type": "paragraph",
      "text": "Currently, the best equation for estimating GFR from serum creatinine in children and young adults ages 1-25 years is the"
    },
    {
      "type": "paragraph",
      "text": "CKiD"
    },
    {
      "type": "paragraph",
      "text": "Under 25 (U25) eGFR"
    },
    {
      "type": "paragraph",
      "text": "[19]. This formula has improved validity across a broader age range compared to the previously"
    },
    {
      "type": "paragraph",
      "text": "recommended Bedside Schwartz Equation, which was developed using a narrow age range of 8-15 years old. The CKiD U25"
    },
    {
      "type": "paragraph",
      "text": "eGFR equation can be used with the serum creatinine level or with the IFCC-calibrated serum cystatin C level; both require age,"
    },
    {
      "type": "paragraph",
      "text": "sex, and height."
    },
    {
      "type": "image",
      "assetId": "asset_83fe3c7d6b",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "50"
    },
    {
      "type": "paragraph",
      "text": "Equation: CKiD U25 eGFR"
    },
    {
      "type": "paragraph",
      "text": "eGFR (mL/min/1.73 m2) = (K x height) / serum creatinine AND/OR"
    },
    {
      "type": "paragraph",
      "text": "eGFR (mL/min/1.73 m2) = K x (1/cystatin C)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "K is multiplier that is dependent on age and sex"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Height in cm"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Serum creatinine in mg/dL"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Cystatin C in mg/L"
    },
    {
      "type": "paragraph",
      "text": "It is also important to note that in the immediate newborn period (approximately the first 3 weeks of life), blood creatinine"
    },
    {
      "type": "paragraph",
      "text": "concentration represents at least in part the maternal creatinine concentration which freely crosses the placenta [20]. Thus,"
    },
    {
      "type": "paragraph",
      "text": "infant plasma creatinine is not a reliable measure of renal function or glomerular filtration rate. Iodinated contrast media can be"
    },
    {
      "type": "paragraph",
      "text": "generally considered safe in the neonate and infant regardless of serum creatinine and eGFR in the absence of known kidney"
    },
    {
      "type": "paragraph",
      "text": "disease [21]."
    },
    {
      "type": "paragraph",
      "text": "Prevention of Contrast-Induced and Contrast-Associated Acute Kidney Injury in At-Risk Children"
    },
    {
      "type": "paragraph",
      "text": "Risk factors for CI-AKI and CA-AKI in children are thought to be similar to those in adults. Unfortunately, there are no"
    },
    {
      "type": "paragraph",
      "text": "established evidence-based guidelines for the prevention of CI-AKI and CA-AKI in children with impaired renal function. As"
    },
    {
      "type": "paragraph",
      "text": "no pediatric-specific measures for the prevention of acute kidney injury have been established in the literature, strategies"
    },
    {
      "type": "paragraph",
      "text": "described in adults should be considered when using IV iodinated contrast media in children with renal dysfunction. Please"
    },
    {
      "type": "paragraph",
      "text": "refer to the chapter"
    },
    {
      "type": "paragraph",
      "text": "Post-Contrast Acute Kidney Injury And Contrast-Induced Nephropathy In Adults"
    },
    {
      "type": "paragraph",
      "text": ". A noncontrast imaging"
    },
    {
      "type": "paragraph",
      "text": "examination can be performed if the clinical question can be answered without intravascular iodinated contrast medium. In"
    },
    {
      "type": "paragraph",
      "text": "addition, the use of alternative imaging modalities, such as ultrasound (with or without intravenous microbubble contrast"
    },
    {
      "type": "paragraph",
      "text": "medium) and MRI (with or without intravenous gadolinium-based contrast medium) could also be considered."
    },
    {
      "type": "paragraph",
      "text": "Thyroid Dysfunction after Iodinated Contrast in Children"
    },
    {
      "type": "paragraph",
      "text": "Some published data suggests an increased risk of thyroid dysfunction after the administration of iodinated contrast media in"
    },
    {
      "type": "paragraph",
      "text": "particular pediatric cohorts, including infants with congenital heart disease and very low birth weight. Supraphysiologic levels"
    },
    {
      "type": "paragraph",
      "text": "of iodine can potentially result in suppression of thyroid hormone production, a phenomenon known as the Wolff-Chaikoff"
    },
    {
      "type": "paragraph",
      "text": "effect (a protective autoregulatory mechanism). This effect in most individuals is transient, and thyroid hormone production"
    },
    {
      "type": "paragraph",
      "text": "typically returns to normal after 1-2 weeks. However, it is thought that in particularly susceptible populations, some individuals"
    },
    {
      "type": "paragraph",
      "text": "are unable to escape the Wolff-Chaikoff effect, resulting in true hypothyroidism."
    },
    {
      "type": "paragraph",
      "text": "The United States Food and Drug Administration (FDA) issued a safety announcement in 2015 regarding 10 cases of"
    },
    {
      "type": "paragraph",
      "text": "hypothyroidism reported after ICM administration in infants less than 4 months of age that occurred between 1969 and 2012"
    },
    {
      "type": "paragraph",
      "text": "[22]. Each of those infants had congenital heart disease or a history of prematurity."
    },
    {
      "type": "paragraph",
      "text": "There is a small number of prospective studies that have evaluated the association between thyroid dysfunction and"
    },
    {
      "type": "paragraph",
      "text": "intravascular iodinated contrast media exposure in children. These studies have shown mixed results and are generally very"
    },
    {
      "type": "paragraph",
      "text": "small with regards to the number of participants, may or may not have a control group, and study specific pediatric cohorts"
    },
    {
      "type": "paragraph",
      "text": "which limit the generalizability of observations. There are some retrospective studies with larger (e.g., n >100) patient"
    },
    {
      "type": "paragraph",
      "text": "populations that also have assessed the impact of intravascular iodinated contrast media on thyroid function. These latter studies"
    },
    {
      "type": "paragraph",
      "text": "are also mostly limited due to a lack of control groups and/or a variety of biases and confounders. A review of this literature can"
    },
    {
      "type": "paragraph",
      "text": "be found in the"
    },
    {
      "type": "paragraph",
      "text": "ACR Statement on Use of Iodinated Contrast Material for Medical Imaging in Young Children and Need for"
    },
    {
      "type": "paragraph",
      "text": "Thyroid Monitoring"
    },
    {
      "type": "paragraph",
      "text": "[23]."
    },
    {
      "type": "paragraph",
      "text": "In summary, there is an overall lack of high-quality data available regarding the risk of thyroid dysfunction after intravascular"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast media exposure and further investigation is needed."
    },
    {
      "type": "paragraph",
      "text": "Thyroid Monitoring after Iodinated Contrast in Children"
    },
    {
      "type": "paragraph",
      "text": "The FDA issued an updated Drug Safety Communication in March 2022 recommending that newborns and children through 3"
    },
    {
      "type": "paragraph",
      "text": "years of age undergo thyroid monitoring within 3 weeks after receiving intravascular iodinated contrast media [24]. This"
    },
    {
      "type": "paragraph",
      "text": "announcement cited"
    },
    {
      "type": "paragraph",
      "text": "11 studies, nearly all of which have considerable limitations, as detailed in the section above. The ACRs"
    },
    {
      "type": "paragraph",
      "text": "position statement on this topic, referred to above, indicates that based on the available evidence the risk for clinically relevant"
    },
    {
      "type": "paragraph",
      "text": "hypothyroidism related to iodinated contrast media is quite low in children younger than 3 months and minimal to absent in"
    },
    {
      "type": "image",
      "assetId": "asset_c193028cfc",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "51"
    },
    {
      "type": "paragraph",
      "text": "children 3 months and older. Furthermore, the ACR statement suggests that universal testing in all young children is not"
    },
    {
      "type": "paragraph",
      "text": "currently supported by the published literature [23]."
    },
    {
      "type": "paragraph",
      "text": "Gadolinium-Based Intravascular Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Guidelines for intravenous (IV) use of gadolinium-based contrast media are generally similar in both the pediatric and adult"
    },
    {
      "type": "paragraph",
      "text": "populations. The prescribing information sheets from gadolinium-based contrast media approved for intravascular use in the"
    },
    {
      "type": "paragraph",
      "text": "United States show variable labeling with regards to the pediatric population, with differences between contrast media relating"
    },
    {
      "type": "paragraph",
      "text": "to indications (most often MRI of the brain and spine, and less often other parts of the body) and age of approval for usage. For"
    },
    {
      "type": "paragraph",
      "text": "example, for certain contrast media, safety and efficacy have been established for pediatric patients over 2 years of age but not"
    },
    {
      "type": "paragraph",
      "text": "for children under 2 years of age. No gadolinium-based contrast media has been approved for use in premature infants to date."
    },
    {
      "type": "paragraph",
      "text": "The prescribing information for gadoxetate disodium (Eovist), a hepatobiliary contrast media, does not specifically specify"
    },
    {
      "type": "paragraph",
      "text": "patient age for which the drug is approved. Instead, it indicates that an observational study was performed in patients aged >2"
    },
    {
      "type": "paragraph",
      "text": "months and <18 years and identified no safety issues. Based on the above information, it can be concluded that these contrast"
    },
    {
      "type": "paragraph",
      "text": "media are commonly used off-label in children in the U.S. with regards to patient age, clinical indication for imaging, or both."
    },
    {
      "type": "paragraph",
      "text": "Pediatric-specific issues regarding these contrast media are discussed below."
    },
    {
      "type": "paragraph",
      "text": "Osmolality and Viscosity"
    },
    {
      "type": "paragraph",
      "text": "As with iodinated contrast media, there are significant ranges in osmolality and viscosity of gadolinium- based contrast media"
    },
    {
      "type": "paragraph",
      "text": "(see"
    },
    {
      "type": "paragraph",
      "text": "Appendix A"
    },
    {
      "type": "paragraph",
      "text": "). For example, the osmolality of gadoteridol (ProHance) is 630 mosm/kg H2O, and the osmolality of"
    },
    {
      "type": "paragraph",
      "text": "gadobenate dimeglumine (MultiHance) is 1,970 mosm/kg H2O. Viscosities (at 37C) can also vary, for example from 1.19 cps"
    },
    {
      "type": "paragraph",
      "text": "for gadoxetate disodium (Eovist) to 5.3 cps for gadobenate dimeglumine (MultiHance). These physical properties, however,"
    },
    {
      "type": "paragraph",
      "text": "potentially are less important when using gadolinium-based contrast media in children compared to iodinated contrast agents."
    },
    {
      "type": "paragraph",
      "text": "The much smaller volumes of gadolinium-based contrast agents typically administered to pediatric patients likely result in only"
    },
    {
      "type": "paragraph",
      "text": "minimal fluid shifts. The slower injection flow rates generally used for gadolinium-based contrast result in lower injection-"
    },
    {
      "type": "paragraph",
      "text": "related pressures and decreased risk for vessel injury and extravasation. While there is a lack of published literature describing"
    },
    {
      "type": "paragraph",
      "text": "the frequency and clinical relevance of extravasation of these contrast media in children, it is usually of no or minimal clinical"
    },
    {
      "type": "paragraph",
      "text": "significance because of the small volumes injected."
    },
    {
      "type": "paragraph",
      "text": "Allergic-Like Reactions and Other Adverse Events"
    },
    {
      "type": "paragraph",
      "text": "Although uncommon, allergic-like reactions to IV gadolinium-based contrast media in children do occur. A study by Dillman et"
    },
    {
      "type": "paragraph",
      "text": "al [25] documented a 0.04% (48 reactions/13,344 injections) allergic-like reaction rate for these contrast media in children."
    },
    {
      "type": "paragraph",
      "text": "Another study by Davenport et al that included 15,706 administrations of gadolinium-based contrast media in children (under"
    },
    {
      "type": "paragraph",
      "text": "the age of 18 years) documented only eight allergic-like reactions, for a reaction rate of 0.05% [26]. A more recent study by"
    },
    {
      "type": "paragraph",
      "text": "Forbes-Amrhein et al. documented 21 allergic-like reactions in 32,365 pediatric gadolinium-based contrast media"
    },
    {
      "type": "paragraph",
      "text": "administrations [27]. Although mild reactions are most common, more significant reactions that require urgent medical"
    },
    {
      "type": "paragraph",
      "text": "management may occur [27]. Pediatric allergic-like reactions to contrast media are treated in the same manner as other allergic"
    },
    {
      "type": "paragraph",
      "text": "and allergic-like reactions, including similar reactions to iodinated contrast media ("
    },
    {
      "type": "paragraph",
      "text": "Table 2"
    },
    {
      "type": "paragraph",
      "text": "). While no investigation has studied"
    },
    {
      "type": "paragraph",
      "text": "the efficacy of corticosteroid and antihistamine premedication regimens for the prevention of allergic-like reactions to"
    },
    {
      "type": "paragraph",
      "text": "gadolinium-based contrast media in children, commonly used regimens, such as the ones presented in"
    },
    {
      "type": "paragraph",
      "text": "Tables A and B"
    },
    {
      "type": "paragraph",
      "text": "at the end"
    },
    {
      "type": "paragraph",
      "text": "of the chapter, are thought to provide some protective benefit."
    },
    {
      "type": "paragraph",
      "text": "A variety of physiologic side effects also may occur following administration of gadolinium-based contrast media, including"
    },
    {
      "type": "paragraph",
      "text": "coldness at the injection site, nausea, vomiting, headache, and dizziness (see prescribing information for different contrast"
    },
    {
      "type": "paragraph",
      "text": "media). There is no evidence for pediatric renal toxicity from gadolinium-based contrast media at approved doses, and there is"
    },
    {
      "type": "paragraph",
      "text": "no role for intravenous or oral hydration prior to IV administration of gadolinium-based contrast media."
    },
    {
      "type": "paragraph",
      "text": "Nephrogenic Systemic Fibrosis"
    },
    {
      "type": "paragraph",
      "text": "There are only a small number of reported cases of nephrogenic systemic fibrosis (NSF) in children. As of September 2012,"
    },
    {
      "type": "paragraph",
      "text": "there were only 23 unique pediatric NSF cases, and all patients were 6 years of age or older [28]. Seventeen of these children"
    },
    {
      "type": "paragraph",
      "text": "had documented exposure to a gadolinium-based contrast media. Thirteen of 13 children with available clinical data pertaining"
    },
    {
      "type": "paragraph",
      "text": "to renal disease had substantial renal dysfunction (acute kidney injury and/or chronic kidney disease), and 10 were on"
    },
    {
      "type": "paragraph",
      "text": "hemodialysis and/or peritoneal dialysis at the time of gadolinium-based contrast medium administration. Renal status was"
    },
    {
      "type": "paragraph",
      "text": "unknown in 10 children. There have been no published reports of NSF since 2012 in the pediatric population using currently"
    },
    {
      "type": "paragraph",
      "text": "approved contrast media."
    },
    {
      "type": "image",
      "assetId": "asset_9d804007c3",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "52"
    },
    {
      "type": "paragraph",
      "text": "As there are no pediatric-specific evidence-based guidelines for the prevention of NSF, we recommend that adult guidelines be"
    },
    {
      "type": "paragraph",
      "text": "followed for identifying at-risk patients and administering gadolinium-based contrast media in the presence of impaired renal"
    },
    {
      "type": "paragraph",
      "text": "function [see Chapter 16"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Nephrogenic Systemic Fibrosis"
    },
    {
      "type": "paragraph",
      "text": "]. If use of a Group I or III GBCA is being considered, children at risk"
    },
    {
      "type": "paragraph",
      "text": "for renal dysfunction should be identified (e.g., those with known medical renal disease [chronic kidney disease or acute kidney"
    },
    {
      "type": "paragraph",
      "text": "injury] or those with known renal/urinary tract structural abnormalities) and screened for impaired renal function. As in adults,"
    },
    {
      "type": "paragraph",
      "text": "the risks and benefits of gadolinium-based contrast media administration should be carefully considered in pediatric patients"
    },
    {
      "type": "paragraph",
      "text": "with acute kidney injury as well as chronic kidney disease with an eGFR less than 30 mL/min/1.73 m2. Although there has been"
    },
    {
      "type": "paragraph",
      "text": "no reported case of NSF in a very young child to date, some authors have urged caution with regards to administering these"
    },
    {
      "type": "paragraph",
      "text": "contrast media to preterm neonates and infants [29] due to renal immaturity and potential glomerular filtration rates under 30"
    },
    {
      "type": "paragraph",
      "text": "mL/min/1.73m2 [30]. However, as mentioned above, there have been no cases of NSF in neonates and infants, and these"
    },
    {
      "type": "paragraph",
      "text": "contrast media may be administered to these populations if clinically warranted. Similar to older pediatric patients both without"
    },
    {
      "type": "paragraph",
      "text": "and with impaired renal function, the use of IV gadolinium-based contrast media should be justified in very young children, and"
    },
    {
      "type": "paragraph",
      "text": "the benefit of administration should outweigh potential risks."
    },
    {
      "type": "paragraph",
      "text": "Gadolinium Retention in the Body"
    },
    {
      "type": "paragraph",
      "text": "Like adults, retention of gadolinium in the body has been observed by both imaging and/or pathology in children in multiple"
    },
    {
      "type": "paragraph",
      "text": "tissues (including the brain) and with a variety of gadolinium-based contrast media, including macrocyclic media [31-33]. The"
    },
    {
      "type": "paragraph",
      "text": "literature is conflicting and attributes these apparent signal alterations in the brain to a variety of causes including a particular"
    },
    {
      "type": "paragraph",
      "text": "contrast media, previous brain irradiation, and/or patient age [34-39]. Also, similar to adults, we believe that IV gadolinium-"
    },
    {
      "type": "paragraph",
      "text": "based contrast media can provide crucial diagnostic medical information. To date, no adverse health effects related to"
    },
    {
      "type": "paragraph",
      "text": "gadolinium retention have been confirmed in the pediatric population. Despite this fact, each time a contrast-enhanced MRI"
    },
    {
      "type": "paragraph",
      "text": "study is considered, it remains prudent to consider the clinical benefit of the diagnostic information that will be obtained while"
    },
    {
      "type": "paragraph",
      "text": "avoiding overutilization. Retention is of particular concern in children with chronic medical conditions that may receive"
    },
    {
      "type": "paragraph",
      "text": "multiple contrast-enhanced MRI studies over the course of their lifetimes. Reduced dose (e.g., half dose) contrast-enhanced"
    },
    {
      "type": "paragraph",
      "text": "MRI has been described as a method to further reduce contrast media exposure in children [40], although further investigations"
    },
    {
      "type": "paragraph",
      "text": "are needed before this practice can be commonplace. We will continue to assess the safety of these contrast media and modify"
    },
    {
      "type": "paragraph",
      "text": "our recommendations accordingly as new data become available. See Chapter 14"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "ACR-ASNR Position Statement on the Use"
    },
    {
      "type": "paragraph",
      "text": "of Gadolinium Contrast Agents"
    },
    {
      "type": "paragraph",
      "text": "for additional information."
    },
    {
      "type": "paragraph",
      "text": "Gastrointestinal and Urogenital Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Contrast media can be introduced into the gastrointestinal or urogenital tracts by mouth, rectum, vagina, urethra, urinary"
    },
    {
      "type": "paragraph",
      "text": "bladder, ostomy, or indwelling gastrointestinal or urinary tract catheter. The most commonly used contrast media for"
    },
    {
      "type": "paragraph",
      "text": "gastroenteric indications in infants, children, and adolescents are barium-based or water-soluble iodinated contrast media [41]"
    },
    {
      "type": "paragraph",
      "text": "("
    },
    {
      "type": "paragraph",
      "text": "Appendix A"
    },
    {
      "type": "paragraph",
      "text": "). Although iohexol is the only iodinated low osmolar contrast medium that is approved by the FDA for"
    },
    {
      "type": "paragraph",
      "text": "gastrointestinal administration, any iodinated contrast medium that is FDA-approved for intravascular use is safe to administer"
    },
    {
      "type": "paragraph",
      "text": "off-label into the gastrointestinal or urinary tract. Contrast media for urogenital imaging is typically iodine-based, although the"
    },
    {
      "type": "paragraph",
      "text": "use of ultrasound microbubble contrast medium is becoming increasingly more common for pediatric studies involving the"
    },
    {
      "type": "paragraph",
      "text": "urogenital tract."
    },
    {
      "type": "paragraph",
      "text": "Barium sulfate suspension is used in the assessment of the upper gastrointestinal tract and small bowel when there is no clinical"
    },
    {
      "type": "paragraph",
      "text": "concern for perforation or leak. Barium sulfate is insoluble in water and absorption by the gut into the body is negligible."
    },
    {
      "type": "paragraph",
      "text": "Barium has a high atomic number (Z=56) and attenuates more x-rays than water-soluble contrast, making it preferred for fine"
    },
    {
      "type": "paragraph",
      "text": "detail evaluation of the gastrointestinal system. Patients should be advised to stay well hydrated following an imaging study"
    },
    {
      "type": "paragraph",
      "text": "with barium due to its water insolubility and tendency to constipate. Barium should not be administered retrograde into a"
    },
    {
      "type": "paragraph",
      "text": "defunctionalized colon or bowel segment (e.g., mucous fistula or Hartman pouch), since intraluminal contents will likely not"
    },
    {
      "type": "paragraph",
      "text": "pass and barium can become inspissated and difficult to remove. Barium is generally contraindicated in patients with suspected"
    },
    {
      "type": "paragraph",
      "text": "or known gastrointestinal tract perforation because of the risk of peritonitis [42]. Barium contrast material is not directly toxic to"
    },
    {
      "type": "paragraph",
      "text": "the airways; however, it does have the potential to plug distal airways, resulting in post-obstructive pneumonia or diminishing"
    },
    {
      "type": "paragraph",
      "text": "the capacity for gas exchange [43]. Aspiration of large volumes of barium-based contrast can be fatal [44]. Allergic-like"
    },
    {
      "type": "paragraph",
      "text": "reactions to barium sulfate preparations are extremely rare and are likely related to the presence of additives to the commercial"
    },
    {
      "type": "paragraph",
      "text": "preparations rather than the barium sulfate [45]. Treatment of pediatric allergic-like reactions to enteric administration of"
    },
    {
      "type": "paragraph",
      "text": "barium sulfate suspension is the same as for allergic-like reactions to intravascular iodine-based and gadolinium-based contrast"
    },
    {
      "type": "paragraph",
      "text": "media and is outlined in"
    },
    {
      "type": "paragraph",
      "text": "Table 2"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "Iodinated contrast media are commonly used for infant, pediatric, and adolescent contrast enemas, postoperative gastrointestinal"
    },
    {
      "type": "paragraph",
      "text": "tract assessment, when there is concern for gastrointestinal tract perforation, and upper gastrointestinal tract studies in"
    },
    {
      "type": "image",
      "assetId": "asset_03cc7b2911",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "53"
    },
    {
      "type": "paragraph",
      "text": "premature and very-low-birthweight neonates. They are generally preferred in the setting of suspected gastrointestinal tract"
    },
    {
      "type": "paragraph",
      "text": "perforation because they are quickly resorbed through the peritoneal surface and have a low risk of inducing peritonitis. The"
    },
    {
      "type": "paragraph",
      "text": "exact iodinated contrast media used for a particular exam typically relates to a combination of availability, cost, iodine"
    },
    {
      "type": "paragraph",
      "text": "concentration, and safety profile related to the route of administration."
    },
    {
      "type": "paragraph",
      "text": "As with intravascular iodinated contrast media, osmolality should be considered when deciding which iodinated contrast media"
    },
    {
      "type": "paragraph",
      "text": "to administer via the gastrointestinal tract. Hyperosmolar, typically ionic iodinated contrast media such as diatrizoate"
    },
    {
      "type": "paragraph",
      "text": "meglumine (i.e., Gastrografin or Gastroview) within the gastrointestinal tract may result in dangerous fluid shifts into the bowel"
    },
    {
      "type": "paragraph",
      "text": "from the intravascular space and therefore are capable of causing dehydration and hypotension [46-50]. Neonates, infants of"
    },
    {
      "type": "paragraph",
      "text": "very low birthweight, and older children with cardiac and renal impairment may be most susceptible to such fluid shifts. In such"
    },
    {
      "type": "paragraph",
      "text": "patients, low-osmolality or iso-osmolality contrast media should be considered for imaging of the gastrointestinal tract. Higher"
    },
    {
      "type": "paragraph",
      "text": "osmolality water soluble contrast media can be administered into the upper gastrointestinal tract or per rectum to assist in the"
    },
    {
      "type": "paragraph",
      "text": "resolution of a bowel obstruction, such as in the setting of cystic fibrosis [51], adhesive bowel disease, or meconium ileus [52]."
    },
    {
      "type": "paragraph",
      "text": "Use of such contrast media is also commonly carried out only after some degree of dilution [53-55]. However, per mouth"
    },
    {
      "type": "paragraph",
      "text": "administration of high-osmolality iodinated contrast media should be generally avoided in children, in part due to the potential"
    },
    {
      "type": "paragraph",
      "text": "consequences of aspiration. This risk can be mitigated by using of a nasogastric tube to deliver the contrast material into the"
    },
    {
      "type": "paragraph",
      "text": "stomach. Aspirated hyperosmolality contrast medium may cause fluid shifts at the alveolar level and chemical pneumonitis with"
    },
    {
      "type": "paragraph",
      "text": "resultant pulmonary edema [44,56-58]. Aspiration of large volumes of iodinated oral contrast media rarely may be fatal [44]."
    },
    {
      "type": "paragraph",
      "text": "The taste of barium sulfate preparations is usually tolerated quite well by children, given the presence of flavoring and sugar"
    },
    {
      "type": "paragraph",
      "text": "substitutes in the formulation. Barium sulfate suspensions also lend themselves well to flavor-mix-ins, such as chocolate syrup,"
    },
    {
      "type": "paragraph",
      "text": "fruit syrups, or drink mix powders. The taste of some iodinated contrast media are bitter and can be a limitation in its oral"
    },
    {
      "type": "paragraph",
      "text": "acceptability in pediatric patients. In this circumstance, placement of an enteric tube for contrast material administration can be"
    },
    {
      "type": "paragraph",
      "text": "useful."
    },
    {
      "type": "paragraph",
      "text": "Urogenital contrast media typically include ionic iodine-based contrast media and ultrasound microbubble contrast media. The"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast media are utilized in the setting of fluoroscopy and CT, whereas the ultrasound microbubbles are utilized in"
    },
    {
      "type": "paragraph",
      "text": "the setting of contrast-enhanced voiding ultrasonography. Lumason(R) is the only ultrasound contrast media approved for"
    },
    {
      "type": "paragraph",
      "text": "pediatric urinary tract use (see"
    },
    {
      "type": "paragraph",
      "text": "Ultrasound Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "chapter). As with the gastrointestinal tract, any iodinated contrast"
    },
    {
      "type": "paragraph",
      "text": "medium that is FDA-approved for intravascular use is safe to administer into the vagina, urethra, urinary bladder, or renal"
    },
    {
      "type": "paragraph",
      "text": "collecting system."
    },
    {
      "type": "paragraph",
      "text": "Neutral oral contrast media are used for cross-sectional enterography imaging to promote distension of the bowel. These media"
    },
    {
      "type": "paragraph",
      "text": "demonstrate water or near water attenuation on CT and biphasic signal intensity on MRI. Commercially available preparations"
    },
    {
      "type": "paragraph",
      "text": "with imaging indications include a low-density barium sulfate suspension, which also contains sorbitol and a thickening agent"
    },
    {
      "type": "paragraph",
      "text": "(NeuLumEX [formerly VoLumen]; Bracco Diagnostics, Milan, Italy) and a lemon-lime flavored beverage containing sorbitol,"
    },
    {
      "type": "paragraph",
      "text": "mannitol, and a thickening agent (Breeza; Beckley Medical, Bristol, Conn). A study by Dillman et al showed that both media"
    },
    {
      "type": "paragraph",
      "text": "provide adequate bowel distension for imaging, but pediatric patients are more likely to consume the entirety of their prescribed"
    },
    {
      "type": "paragraph",
      "text": "oral preparation of Breeza versus NeuLumEX (VoLumen) due to the preferred flavor profile [59]. Other oral contrast media"
    },
    {
      "type": "paragraph",
      "text": "options for cross sectional enterography include water, methylcellulose, and polyethylene glycol electrolyte solution (Golytely;"
    },
    {
      "type": "paragraph",
      "text": "Braintree Laboratories, Inc, Braintree, Mass), each having unique advantages and disadvantages. Of these latter options,"
    },
    {
      "type": "paragraph",
      "text": "polyethylene glycol has been demonstrated to have bowel distension similar to low-density barium suspension [60]."
    },
    {
      "type": "image",
      "assetId": "asset_0b6d462c11",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "54"
    },
    {
      "type": "paragraph",
      "text": "Table A"
    },
    {
      "type": "paragraph",
      "text": "Sample Pediatric Corticosteroid and Antihistamine Premedication Regimen"
    },
    {
      "type": "paragraph",
      "text": "Dosage"
    },
    {
      "type": "paragraph",
      "text": "Timing"
    },
    {
      "type": "paragraph",
      "text": "Prednisone"
    },
    {
      "type": "paragraph",
      "text": "0.5"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "0.7 mg/kg PO (up to 50 mg)"
    },
    {
      "type": "paragraph",
      "text": "13, 7, and 1 hr prior to contrast injection"
    },
    {
      "type": "paragraph",
      "text": "Diphenhydramine"
    },
    {
      "type": "paragraph",
      "text": "1.25 mg/kg PO (up to 50 mg)"
    },
    {
      "type": "paragraph",
      "text": "1 hr prior to contrast injection"
    },
    {
      "type": "paragraph",
      "text": "Note: Appropriate intravenous doses may be substituted for patients who cannot ingest PO medication."
    },
    {
      "type": "paragraph",
      "text": "Table B"
    },
    {
      "type": "paragraph",
      "text": "Sample Pediatric Corticosteroid and Antihistamine Premedication Regimen for Urgent,"
    },
    {
      "type": "paragraph",
      "text": "ED, Inpatient, or NPO Patients"
    },
    {
      "type": "paragraph",
      "text": "Dosage"
    },
    {
      "type": "paragraph",
      "text": "Timing"
    },
    {
      "type": "paragraph",
      "text": "Hydrocortisone"
    },
    {
      "type": "paragraph",
      "text": "2 mg/kg IV (up to 200 mg)"
    },
    {
      "type": "paragraph",
      "text": "5 and 1 hr prior to contrast injection"
    },
    {
      "type": "paragraph",
      "text": "Diphenhydramine"
    },
    {
      "type": "paragraph",
      "text": "1 mg/kg IV, IM, or PO (up to 50 mg)"
    },
    {
      "type": "paragraph",
      "text": "1 hr prior to contrast injection"
    },
    {
      "type": "paragraph",
      "text": "Revision History"
    },
    {
      "type": "paragraph",
      "text": "July 2024: Major Revision"
    },
    {
      "type": "paragraph",
      "text": "2 June 2014: Minor revision"
    },
    {
      "type": "paragraph",
      "text": "15 April 2013: Minor revision"
    },
    {
      "type": "paragraph",
      "text": "29 June 2012: Minor revision"
    },
    {
      "type": "paragraph",
      "text": "29 October 2008: First version"
    },
    {
      "type": "paragraph",
      "text": "REFERENCES"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Standen JR, Nogrady MB, Dunbar JS, Goldbloom RB. The Osmotic Effects of Methylglucamine Diatrizoate (Renografin 60) in Intravenous"
    },
    {
      "type": "paragraph",
      "text": "Urography in Infants. Am J Roentgenol Radium Ther Nucl Med"
    },
    {
      "type": "paragraph",
      "text": "1965;93:473-9."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Morris TW, Harnish PP, Reece K, Katzberg RW. Tissue fluid shifts during renal arteriography with conventional and low osmolality agents."
    },
    {
      "type": "paragraph",
      "text": "Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": "1983;18:335-40."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Vergara M, Seguel S. Adverse reactions to contrast media in CT: effects of temperature and ionic property. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1996;199:363-6."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS, Wang CL, Bashir MR, Neville AM, Paulson EK. Rate of contrast material extravasations and allergic-like reactions: effect of"
    },
    {
      "type": "paragraph",
      "text": "extrinsic warming of low-osmolality iodinated CT contrast material to 37 degrees C. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2012;262:475-84."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Trout AT, Dillman JR, Ellis JH, Cohan RH, Strouse PJ. Patterns of intravenous contrast material use and corticosteroid premedication in"
    },
    {
      "type": "paragraph",
      "text": "children--a survey of Society of Chairs of Radiology in Children's Hospitals (SCORCH) member institutions. Pediatr Radiol"
    },
    {
      "type": "paragraph",
      "text": "2011;41:1272-83."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Amaral JG, Traubici J, BenDavid G, Reintamm G, Daneman A. Safety of power injector use in children as measured by incidence of"
    },
    {
      "type": "paragraph",
      "text": "extravasation. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2006;187:580-3."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Barrera CA, White AM, Shepherd AM, et al. Contrast Extravasation using Power Injectors for Contrast-Enhanced Computed Tomography in"
    },
    {
      "type": "paragraph",
      "text": "Children: Frequency and Injury Severity. Acad Radiol"
    },
    {
      "type": "paragraph",
      "text": "2019;26:1668-74."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "Wang CL, Cohan RH, Ellis JH, Adusumilli S, Dunnick NR. Frequency, management, and outcome of extravasation of nonionic iodinated"
    },
    {
      "type": "paragraph",
      "text": "contrast medium in 69,657 intravenous injections. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2007;243:80-7."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Cohen MD, Herman E, Herron D, White SJ, Smith JA. Comparison of intravenous contrast agents for CT studies in children. Acta Radiol"
    },
    {
      "type": "paragraph",
      "text": "1992;33:592-5."
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from"
    },
    {
      "type": "paragraph",
      "text": "the Japanese Committee on the Safety of Contrast Media. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1990;175:621-8."
    },
    {
      "type": "paragraph",
      "text": "11."
    },
    {
      "type": "paragraph",
      "text": "Dillman JR, Strouse PJ, Ellis JH, Cohan RH, Jan SC. Incidence and severity of acute allergic-like reactions to i.v. nonionic iodinated contrast"
    },
    {
      "type": "paragraph",
      "text": "material in children. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2007;188:1643-7."
    },
    {
      "type": "paragraph",
      "text": "12."
    },
    {
      "type": "paragraph",
      "text": "Callahan MJ, Poznauskis L, Zurakowski D, Taylor GA. Nonionic iodinated intravenous contrast material-related reactions: incidence in large"
    },
    {
      "type": "paragraph",
      "text": "urban children's hospital--retrospective analysis of data in 12,494 patients. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2009;250:674-81."
    },
    {
      "type": "paragraph",
      "text": "13."
    },
    {
      "type": "paragraph",
      "text": "Fjelldal A, Nordshus T, Eriksson J. Experiences with iohexol (Omnipaque) at urography. Pediatr Radiol"
    },
    {
      "type": "paragraph",
      "text": "1987;17:491-2."
    },
    {
      "type": "paragraph",
      "text": "14."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS, Perazella MA, Yee J, et al. Use of Intravenous Iodinated Contrast Media in Patients With Kidney Disease: Consensus Statements"
    },
    {
      "type": "paragraph",
      "text": "from the American College of Radiology and the National Kidney Foundation. Kidney Med"
    },
    {
      "type": "paragraph",
      "text": "2020;2:85-93."
    },
    {
      "type": "paragraph",
      "text": "15."
    },
    {
      "type": "paragraph",
      "text": "Gilligan LA, Davenport MS, Trout AT, et al. Risk of Acute Kidney Injury Following Contrast-enhanced CT in Hospitalized Pediatric Patients: A"
    },
    {
      "type": "paragraph",
      "text": "Propensity Score Analysis. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2020;294:548-56."
    },
    {
      "type": "paragraph",
      "text": "16."
    },
    {
      "type": "paragraph",
      "text": "Guo S, Bai L, Tong Y, et al. Contrast media exposure in the perioperative period confers no additional risk of acute kidney injury in infants and"
    },
    {
      "type": "paragraph",
      "text": "young children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Nephrol"
    },
    {
      "type": "paragraph",
      "text": "2021;36:2485-91."
    },
    {
      "type": "paragraph",
      "text": "17."
    },
    {
      "type": "paragraph",
      "text": "Calle-Toro J, Viteri B, Ballester L, et al. Risk of Acute Kidney Injury Following Contrast-"
    },
    {
      "type": "paragraph",
      "text": "enhanced CT in a Cohort of 10407 Children and"
    },
    {
      "type": "paragraph",
      "text": "Adolescents. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2022:210816."
    },
    {
      "type": "image",
      "assetId": "asset_a5eda7fc4f",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "55"
    },
    {
      "type": "paragraph",
      "text": "18."
    },
    {
      "type": "paragraph",
      "text": "Paul KM, 2nd, Johnson J, Garwe T, et al. Computed Tomography with Intravenous Contrast Is Not Associated with Development of Acute"
    },
    {
      "type": "paragraph",
      "text": "Kidney Injury in Severely Injured Pediatric Patients. Am Surg"
    },
    {
      "type": "paragraph",
      "text": "2019;85:e1-e5."
    },
    {
      "type": "paragraph",
      "text": "19."
    },
    {
      "type": "paragraph",
      "text": "Pierce CB, Muoz A, Ng DK, Warady BA, Furth SL, Schwartz GJ. Age- and sex-dependent clinical equations to estimate glomerular filtration"
    },
    {
      "type": "paragraph",
      "text": "rates in children and young adults with chronic kidney disease. Kidney Int"
    },
    {
      "type": "paragraph",
      "text": "2021;99:948-56."
    },
    {
      "type": "paragraph",
      "text": "20."
    },
    {
      "type": "paragraph",
      "text": "Guignard JP, Drukker A. Why do newborn infants have a high plasma creatinine? Pediatrics"
    },
    {
      "type": "paragraph",
      "text": "1999;103:e49."
    },
    {
      "type": "paragraph",
      "text": "21."
    },
    {
      "type": "paragraph",
      "text": "Bedoya MA, White AM, Edgar JC, Pradhan M, Raab EL, Meyer JS. Effect of Intravenous Administration of Contrast Media on Serum"
    },
    {
      "type": "paragraph",
      "text": "Creatinine Levels in Neonates. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2017;284:530-40."
    },
    {
      "type": "paragraph",
      "text": "22."
    },
    {
      "type": "paragraph",
      "text": "US Food and Drug Administration. FDA Drug Safety Communication: FDA advises of rare cases of underactive thyroid in infants given iodine-"
    },
    {
      "type": "paragraph",
      "text": "containing contrast agents for medical imaging. Available at:"
    },
    {
      "type": "paragraph",
      "text": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-"
    },
    {
      "type": "paragraph",
      "text": "communication-fda-advises-rare-cases-underactive-thyroid-infants-given-"
    },
    {
      "type": "paragraph",
      "text": "iodine#:~:text=11%2D17%2D2015%20Safety%20Announcement,and%20other%20medical%20imaging%20procedures"
    },
    {
      "type": "paragraph",
      "text": ". Accessed May, 2024."
    },
    {
      "type": "paragraph",
      "text": "23."
    },
    {
      "type": "paragraph",
      "text": "Dillman JR, Forbes-Amrhein MM, Wang CL, et al. ACR Statement on Use of Iodinated Contrast Material for Medical Imaging in Young"
    },
    {
      "type": "paragraph",
      "text": "Children and Need for Thyroid Monitoring. J Am Coll Radiol"
    },
    {
      "type": "paragraph",
      "text": "2022;19:849-53."
    },
    {
      "type": "paragraph",
      "text": "24."
    },
    {
      "type": "paragraph",
      "text": "US Food and Drug Administration. FDA recommends thyroid monitoring in babies and young children who receive injections of iodine-"
    },
    {
      "type": "paragraph",
      "text": "containing contrast media for medical imaging. Available at:"
    },
    {
      "type": "paragraph",
      "text": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-thyroid-"
    },
    {
      "type": "paragraph",
      "text": "monitoring-babies-and-young-children-who-receive-injections-iodine-"
    },
    {
      "type": "paragraph",
      "text": "containing#:~:text=Therefore%2C%20FDA%20recommends%20that%20newborns,many%20of%20the%20body's%20functions"
    },
    {
      "type": "paragraph",
      "text": ". Accessed"
    },
    {
      "type": "paragraph",
      "text": "May, 2024."
    },
    {
      "type": "paragraph",
      "text": "25."
    },
    {
      "type": "paragraph",
      "text": "Dillman JR, Ellis JH, Cohan RH, Strouse PJ, Jan SC. Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v."
    },
    {
      "type": "paragraph",
      "text": "contrast media in children and adults. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2007;189:1533-8."
    },
    {
      "type": "paragraph",
      "text": "26."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS, Dillman JR, Cohan RH, et al. Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of"
    },
    {
      "type": "paragraph",
      "text": "allergic-like reactions. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2013;266:773-82."
    },
    {
      "type": "paragraph",
      "text": "27."
    },
    {
      "type": "paragraph",
      "text": "Forbes-Amrhein MM, Dillman JR, Trout AT, et al. Frequency and Severity of Acute Allergic-Like Reactions to Intravenously Administered"
    },
    {
      "type": "paragraph",
      "text": "Gadolinium-Based Contrast Media in Children. Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": "2018;53:313-18."
    },
    {
      "type": "paragraph",
      "text": "28."
    },
    {
      "type": "paragraph",
      "text": "Nardone B, Saddleton E, Laumann AE, et al. Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatr Radiol"
    },
    {
      "type": "paragraph",
      "text": "2014;44:173-80."
    },
    {
      "type": "paragraph",
      "text": "29."
    },
    {
      "type": "paragraph",
      "text": "Penfield JG. Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. Pediatr Nephrol"
    },
    {
      "type": "paragraph",
      "text": "2008;23:2121-9."
    },
    {
      "type": "paragraph",
      "text": "30."
    },
    {
      "type": "paragraph",
      "text": "Smeets NJL, IntHout J, van der Burgh MJP, Schwartz GJ, Schreuder MF, de Wildt SN. Maturation of GFR in Term-Born Neonates: An"
    },
    {
      "type": "paragraph",
      "text": "Individual Participant Data Meta-Analysis. J Am Soc Nephrol"
    },
    {
      "type": "paragraph",
      "text": "2022;33:1277-92."
    },
    {
      "type": "paragraph",
      "text": "31."
    },
    {
      "type": "paragraph",
      "text": "Rossi Espagnet MC, Bernardi B, Pasquini L, Fig-Talamanca L, Tom P, Napolitano A. Signal intensity at unenhanced T1-weighted magnetic"
    },
    {
      "type": "paragraph",
      "text": "resonance in the globus pallidus and dentate nucleus after serial administrations of a macrocyclic gadolinium-based contrast agent in children."
    },
    {
      "type": "paragraph",
      "text": "Pediatr Radiol"
    },
    {
      "type": "paragraph",
      "text": "2017;47:1345-52."
    },
    {
      "type": "paragraph",
      "text": "32."
    },
    {
      "type": "paragraph",
      "text": "Topcuoglu ED, Topcuoglu OM, Semiz Oysu A, Bukte Y. Does Gadoterate Meglumine Cause Gadolinium Retention in the Brain of Children? A"
    },
    {
      "type": "paragraph",
      "text": "Case-Control Study. J Magn Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": "2020;51:1471-77."
    },
    {
      "type": "paragraph",
      "text": "33."
    },
    {
      "type": "paragraph",
      "text": "Ichikawa S, Omiya Y, Onishi H, Motosugi U. Linear gadolinium-based contrast agent (gadodiamide and gadopentetate dimeglumine)-induced"
    },
    {
      "type": "paragraph",
      "text": "high signal intensity on unenhanced T(1) -weighted images in pediatric patients. J Magn Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": "2019;49:1046-52."
    },
    {
      "type": "paragraph",
      "text": "34."
    },
    {
      "type": "paragraph",
      "text": "Pozeg P, Forget J, Meuli RA, Maeder P. Age, But Not Repeated Exposure to Gadoterate Meglumine, Is Associated With T1- and T2-Weighted"
    },
    {
      "type": "paragraph",
      "text": "Signal Intensity Changes in the Deep Brain Nuclei of Pediatric Patients. Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": "2019;54:537-48."
    },
    {
      "type": "paragraph",
      "text": "35."
    },
    {
      "type": "paragraph",
      "text": "Radbruch A, Haase R, Kickingereder P, et al. Pediatric Brain: No Increased Signal Intensity in the Dentate Nucleus on Unenhanced T1-weighted"
    },
    {
      "type": "paragraph",
      "text": "MR Images after Consecutive Exposure to a Macrocyclic Gadolinium-based Contrast Agent. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2017;283:828-36."
    },
    {
      "type": "paragraph",
      "text": "36."
    },
    {
      "type": "paragraph",
      "text": "Ryu YJ, Choi YH, Cheon JE, et al. Pediatric Brain: Gadolinium Deposition in Dentate Nucleus and Globus Pallidus on Unenhanced T1-"
    },
    {
      "type": "paragraph",
      "text": "Weighted Images Is Dependent on the Type of Contrast Agent. Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": "2018;53:246-55."
    },
    {
      "type": "paragraph",
      "text": "37."
    },
    {
      "type": "paragraph",
      "text": "Schneider GK, Stroeder J, Roditi G, et al. T1 Signal Measurements in Pediatric Brain: Findings after Multiple Exposures to Gadobenate"
    },
    {
      "type": "paragraph",
      "text": "Dimeglumine for Imaging of Nonneurologic Disease. AJNR Am J Neuroradiol"
    },
    {
      "type": "paragraph",
      "text": "2017;38:1799-806."
    },
    {
      "type": "paragraph",
      "text": "38."
    },
    {
      "type": "paragraph",
      "text": "Tamrazi B, Liu CJ, Cen SY, Nelson MB, Dhall G, Nelson MD. Brain Irradiation and Gadobutrol Administration in Pediatric Patients with Brain"
    },
    {
      "type": "paragraph",
      "text": "Tumors: Effect on MRI Brain Signal Intensity. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2018;289:188-94."
    },
    {
      "type": "paragraph",
      "text": "39."
    },
    {
      "type": "paragraph",
      "text": "Young JR, Orosz I, Franke MA, et al. Gadolinium deposition in the paediatric brain: T1-weighted hyperintensity within the dentate nucleus"
    },
    {
      "type": "paragraph",
      "text": "following repeated gadolinium-based contrast agent administration. Clin Radiol"
    },
    {
      "type": "paragraph",
      "text": "2018;73:290-95."
    },
    {
      "type": "paragraph",
      "text": "40."
    },
    {
      "type": "paragraph",
      "text": "Colafati GS, Rossi E, Carducci C, et al. Half-dose versus full-dose macrocyclic gadolinium at 3-T magnetic resonance imaging in paediatric bone"
    },
    {
      "type": "paragraph",
      "text": "and soft-tissue disease. Pediatr Radiol"
    },
    {
      "type": "paragraph",
      "text": "2018;48:1724-35."
    },
    {
      "type": "paragraph",
      "text": "41."
    },
    {
      "type": "paragraph",
      "text": "Callahan MJ, Talmadge JM, MacDougall RD, Kleinman PL, Taylor GA, Buonomo C. Selecting appropriate gastroenteric contrast media for"
    },
    {
      "type": "paragraph",
      "text": "diagnostic fluoroscopic imaging in infants and children: a practical approach. Pediatr Radiol"
    },
    {
      "type": "paragraph",
      "text": "2017;47:372-81."
    },
    {
      "type": "paragraph",
      "text": "42."
    },
    {
      "type": "paragraph",
      "text": "Yamamura M, Nishi M, Furubayashi H, Hioki K, Yamamoto M. Barium peritonitis. Report of a case and review of the literature. Dis Colon"
    },
    {
      "type": "paragraph",
      "text": "Rectum"
    },
    {
      "type": "paragraph",
      "text": "1985;28:347-52."
    },
    {
      "type": "paragraph",
      "text": "43."
    },
    {
      "type": "paragraph",
      "text": "Chiu CY, Wong KS, Tsai MH. Massive aspiration of barium sulfate during an upper gastrointestinal examination in a child with dysphagia. Int J"
    },
    {
      "type": "paragraph",
      "text": "Pediatr Otorhinolaryngol"
    },
    {
      "type": "paragraph",
      "text": "2005;69:541-4."
    },
    {
      "type": "paragraph",
      "text": "44."
    },
    {
      "type": "paragraph",
      "text": "McAlister WH, Siegel MJ. Fatal aspirations in infancy during gastrointestinal series. Pediatr Radiol"
    },
    {
      "type": "paragraph",
      "text": "1984;14:81-3."
    },
    {
      "type": "paragraph",
      "text": "45."
    },
    {
      "type": "paragraph",
      "text": "Skucas J. Anaphylactoid reactions with gastrointestinal contrast media. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "1997;168:962-4."
    },
    {
      "type": "paragraph",
      "text": "46."
    },
    {
      "type": "paragraph",
      "text": "Harris PD, Neuhauser EB, Gerth R. The Osmotic Effect of Water Soluble Contrast Media on Circulating Plasma Volume. Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "Radium Ther Nucl Med"
    },
    {
      "type": "paragraph",
      "text": "1964;91:694-8."
    },
    {
      "type": "paragraph",
      "text": "47."
    },
    {
      "type": "paragraph",
      "text": "Johansen JG, Kolmannskog S. Osmotic effect and solubility of amipaque (metrizamide) in the gastrointestinal tract. Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": "1978;13:93-7."
    },
    {
      "type": "paragraph",
      "text": "48."
    },
    {
      "type": "paragraph",
      "text": "Cohen MD. Choosing contrast media for the evaluation of the gastrointestinal tract of neonates and infants. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1987;162:447-56."
    },
    {
      "type": "paragraph",
      "text": "49."
    },
    {
      "type": "paragraph",
      "text": "Poole CA, Rowe MI. Clinical evidence of intestinal absorption of Gastrografin. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1976;118:151-3."
    },
    {
      "type": "paragraph",
      "text": "50."
    },
    {
      "type": "paragraph",
      "text": "Rowe MI, Seagram G, Weinberger M. Gastrografin-induced hypertonicity. The pathogenesis of a neonatal hazard. Am J Surg"
    },
    {
      "type": "paragraph",
      "text": "1973;125:185-8."
    },
    {
      "type": "paragraph",
      "text": "51."
    },
    {
      "type": "paragraph",
      "text": "Long AM, Jones IH, Knight M, McNally J. Early management of meconium ileus in infants with cystic fibrosis: A prospective population cohort"
    },
    {
      "type": "paragraph",
      "text": "study. J Pediatr Surg"
    },
    {
      "type": "paragraph",
      "text": "2021;56:1287-92."
    },
    {
      "type": "paragraph",
      "text": "52."
    },
    {
      "type": "paragraph",
      "text": "Rubalcava NS, Bence CM, Jensen AR, et al. Contrast Challenge Algorithms for Adhesive Small Bowel Obstructions Are Safe in Children: A"
    },
    {
      "type": "paragraph",
      "text": "Multi-Institutional Study. Ann Surg"
    },
    {
      "type": "paragraph",
      "text": "2023;277:e925-e32."
    },
    {
      "type": "image",
      "assetId": "asset_489d5e65ab",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "56"
    },
    {
      "type": "paragraph",
      "text": "53."
    },
    {
      "type": "paragraph",
      "text": "Koshinaga T, Inoue M, Ohashi K, Sugito K, Ikeda T, Tomita R. Therapeutic strategies of meconium obstruction of the small bowel in very-low-"
    },
    {
      "type": "paragraph",
      "text": "birthweight neonates. Pediatr Int"
    },
    {
      "type": "paragraph",
      "text": "2011;53:338-44."
    },
    {
      "type": "paragraph",
      "text": "54."
    },
    {
      "type": "paragraph",
      "text": "Shin J, Jeon GW. Successful Ultrasound-Guided Gastrografin Enema for Very Low Birth Weight Infants with Meconium-Related Ileus."
    },
    {
      "type": "paragraph",
      "text": "Neonatal Med"
    },
    {
      "type": "paragraph",
      "text": "2018;25:37-43."
    },
    {
      "type": "paragraph",
      "text": "55."
    },
    {
      "type": "paragraph",
      "text": "Mitani Y, Kubota A, Goda T, et al. Optimum therapeutic strategy for meconium-related ileus in very-low-birth-weight infants. J Pediatr Surg"
    },
    {
      "type": "paragraph",
      "text": "2021;56:1117-20."
    },
    {
      "type": "paragraph",
      "text": "56."
    },
    {
      "type": "paragraph",
      "text": "Frech RS, Davie JM, Adatepe M, Feldhaus R, McAlister WH. Comparison of barium sulfate and oral 40 per cent diatrizoate injected into the"
    },
    {
      "type": "paragraph",
      "text": "trachea of dogs. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1970;95:299-303."
    },
    {
      "type": "paragraph",
      "text": "57."
    },
    {
      "type": "paragraph",
      "text": "Friedman BI, Hartenberg MA, Mulroy JJ, Tong TK, Mickell JJ. Gastrografin aspiration in a 3 3/4-year-old girl. Pediatr Radiol"
    },
    {
      "type": "paragraph",
      "text": "1986;16:506-7."
    },
    {
      "type": "paragraph",
      "text": "58."
    },
    {
      "type": "paragraph",
      "text": "Reich SB. Production of pulmonary edema by aspiration of water-soluble nonabsorbable contrast media. Radiology"
    },
    {
      "type": "paragraph",
      "text": "1969;92:367-70."
    },
    {
      "type": "paragraph",
      "text": "59."
    },
    {
      "type": "paragraph",
      "text": "Dillman JR, Towbin AJ, Imbus R, Young J, Gates E, Trout AT. Comparison of Two Neutral Oral Contrast Agents in Pediatric Patients: A"
    },
    {
      "type": "paragraph",
      "text": "Prospective Randomized Study. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2018;288:245-51."
    },
    {
      "type": "paragraph",
      "text": "60."
    },
    {
      "type": "paragraph",
      "text": "Young BM, Fletcher JG, Booya F, et al. Head-to-head comparison of oral contrast agents for cross-sectional enterography: small bowel"
    },
    {
      "type": "paragraph",
      "text": "distention, timing, and side effects. J Comput Assist Tomogr"
    },
    {
      "type": "paragraph",
      "text": "2008;32:32-8."
    },
    {
      "type": "image",
      "assetId": "asset_a979f892b9",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "57"
    },
    {
      "type": "paragraph",
      "text": "Ferumoxytol as MRI Contrast Medium"
    },
    {
      "type": "paragraph",
      "text": "Ferumoxytol (Feraheme; AMAG Pharmaceuticals, Waltham, MA and ferumoxytol; Sandoz Inc., Princeton, NJ) is approved by"
    },
    {
      "type": "paragraph",
      "text": "the Food and Drug Administration (FDA) for intravenous (IV) treatment of iron deficiency anemia in adults [1-6]. However,"
    },
    {
      "type": "paragraph",
      "text": "off-label use of this iron oxide nanoparticle compound as a magnetic resonance imaging (MRI) contrast medium is growing"
    },
    {
      "type": "paragraph",
      "text": "[7,8]. Benefits of ferumoxytol as an intravenous MRI imaging medium include a prolonged blood pool phase and delayed"
    },
    {
      "type": "paragraph",
      "text": "intracellular uptake, allowing use as a pure intravascular contrast medium, and high T1 and T2 relaxivities compared to"
    },
    {
      "type": "paragraph",
      "text": "gadolinium-based contrast media [9]. Ferumoxytol has no known acute nephrotoxicity and may be considered in patients with"
    },
    {
      "type": "paragraph",
      "text": "severely impaired renal function [5,6]."
    },
    {
      "type": "paragraph",
      "text": "Uses"
    },
    {
      "type": "paragraph",
      "text": "Vascular imaging"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "The long circulating time of ferumoxytol, with a plasma half-life of 14"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "21 h [10], is exploited for"
    },
    {
      "type": "paragraph",
      "text": "cardiovascular [11,12] and peripheral vascular MRI examinations [13]. Ferumoxytol has been used in MRA of coronary artery"
    },
    {
      "type": "paragraph",
      "text": "stenosis [12], abdominal aortic aneurysms [12], renal artery stenosis [14], renal transplant [12], deep vein thrombosis [15],"
    },
    {
      "type": "paragraph",
      "text": "pulmonary thromboembolism [12], central venous occlusion [16], pediatric cardiovascular imaging, and peripheral arterial"
    },
    {
      "type": "paragraph",
      "text": "disease [8]. Ferumoxytol has also been used for steady-state [17-19] and dynamic [20] cerebral blood volume mapping of the"
    },
    {
      "type": "paragraph",
      "text": "brain."
    },
    {
      "type": "paragraph",
      "text": "Delayed phase imaging"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Slow leakage of ferumoxytol from blood vessels results in intracellular MRI signal changes peaking"
    },
    {
      "type": "paragraph",
      "text": "around 24 h after administration. Signal decrease on T2-weighted and T2*-weighted images may represent accumulation of iron"
    },
    {
      "type": "paragraph",
      "text": "stores, macrophage or phagocytic uptake, and/or sequestration in tissue interstitium. This characteristic has useful applications"
    },
    {
      "type": "paragraph",
      "text": "in central nervous system (CNS) lesions [21,22], abdominal organs [23], atherosclerotic plaques [24], and evaluation for"
    },
    {
      "type": "paragraph",
      "text": "endoleaks after aortic aneurysm stent-graft repair [12]. Macrophage uptake of ferumoxytol allows the assessment of"
    },
    {
      "type": "paragraph",
      "text": "macrophage activity and identify localized cellular inflammation [25]. Thus, the immune response to tumors, such as gliomas"
    },
    {
      "type": "paragraph",
      "text": "and lymphomas, may enable the imaging of tumor extent. Macrophage influx related to stem cell death or immune-mismatched"
    },
    {
      "type": "paragraph",
      "text": "stem cell transplants can be imaged in stem cell transplant rejection [26]. Similarly, ferumoxytol uptake in macrophages has"
    },
    {
      "type": "paragraph",
      "text": "been associated with instability and impending rupture of vascular lesions, including intracranial aneurysms, arteriovenous"
    },
    {
      "type": "paragraph",
      "text": "malformations, and carotid plaques [22]. Conversely, lymph nodes replaced by metastatic tumor may show reduced or absent"
    },
    {
      "type": "paragraph",
      "text": "uptake [27]."
    },
    {
      "type": "paragraph",
      "text": "Ferumoxytol administration for MRI Imaging"
    },
    {
      "type": "paragraph",
      "text": "Imaging with ferumoxytol can be performed at both 1.5 and 3 Tesla [28]."
    },
    {
      "type": "paragraph",
      "text": "Diagnostic imaging use of ferumoxytol differs from therapeutic use in two important ways: 1) lower total iron dose with"
    },
    {
      "type": "paragraph",
      "text": "dilution, and 2) lower average injection rate. Typical ferumoxytol doses for imaging range from 1 to 7.5 mg/kg, with most doses"
    },
    {
      "type": "paragraph",
      "text": "between 2 and 4 mg/kg in both adults and children [29,30]; whereas the standard therapeutic dose for anemia is 1020 mg (14.6"
    },
    {
      "type": "paragraph",
      "text": "mg/kg for a 70-kg adult over 3-8 day period)."
    },
    {
      "type": "paragraph",
      "text": "Injection rates reflect specific imaging indications and range from a slow infusion (for lymph node and steady-state imaging) to"
    },
    {
      "type": "paragraph",
      "text": "bolus injections of 3"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "15 sec for angiographic applications [30]. All reporting groups dilute the administered dose with saline"
    },
    {
      "type": "paragraph",
      "text": "(total volume of ~24"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "60 mL for adults). High injection rates and concentrations may be limited by artifacts from T2* effects."
    },
    {
      "type": "paragraph",
      "text": "In the therapeutic ferumoxytol boxed warning, the FDA recommends a slow intravenous infusion over at least 15 minutes of a"
    },
    {
      "type": "paragraph",
      "text": "diluted medium [31]. For imaging, the ferumoxytol is diluted to 1 part ferumoxytol in ~2-4 parts normal saline, resulting in a"
    },
    {
      "type": "paragraph",
      "text": "concentration of no higher than 10 mg/mL [30]. However, the infusion time varies depending on the imaging indication."
    },
    {
      "type": "paragraph",
      "text": "As with other contrast media, injection should be performed in a setting with personnel and therapies immediately available for"
    },
    {
      "type": "paragraph",
      "text": "the treatment of anaphylaxis and other hypersensitivity reactions [29]. For therapeutic ferumoxytol administration, FDA"
    },
    {
      "type": "paragraph",
      "text": "recommends close monitoring of patients for signs and symptoms of hypersensitivity reaction, including monitoring blood"
    },
    {
      "type": "paragraph",
      "text": "pressure and heart rate during the infusion and for at least 30 minutes after completion of the infusion [29,32]."
    },
    {
      "type": "paragraph",
      "text": "Pharmacodynamics and pharmacokinetics"
    },
    {
      "type": "paragraph",
      "text": "Ferumoxytol can be administered as a bolus, allowing dynamic imaging of the arterial vasculature and first-pass perfusion of"
    },
    {
      "type": "paragraph",
      "text": "the liver and kidneys [33]. There is slow migration of the ferumoxytol across the capillary endothelium (12-14 hours), so"
    },
    {
      "type": "paragraph",
      "text": "imaging in this time frame allows for venography [34]. The iron-oxide nanoparticles are then sequestered and cleared by the"
    },
    {
      "type": "image",
      "assetId": "asset_60257371b7",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "58"
    },
    {
      "type": "paragraph",
      "text": "mononuclear phagocytic system (MPS) [35], which includes liver, spleen, and bone marrow, and to a lesser extend lymph"
    },
    {
      "type": "paragraph",
      "text": "nodes. As the cells of MPS accumulated iron, they progressively lose T2- and T2*-weighted signal intensity. Iron deposition"
    },
    {
      "type": "paragraph",
      "text": "in the mononuclear phagocytic system (liver, spleen, and bone marrow) can cause signal change on MRI for up to 11 months"
    },
    {
      "type": "paragraph",
      "text": "[22,35,36], which may affect tissue and lesion characterization on subsequent MRI examinations."
    },
    {
      "type": "paragraph",
      "text": "The body has no active excretory pathways to remove excess iron from administration. For MRI, the amount of contrast"
    },
    {
      "type": "paragraph",
      "text": "administered (<4 mg/kg) is much lower than doses resulting in acute systemic toxicity (>60 mg/kg) or chronic iron overload"
    },
    {
      "type": "paragraph",
      "text": "[36]. However, evaluation for preexisting iron overload could be considered in high-risk groups, either through liver T2*"
    },
    {
      "type": "paragraph",
      "text": "measurements or serum ferritin levels."
    },
    {
      "type": "paragraph",
      "text": "As mentioned above, ferumoxytol is FDA approved for therapeutic use in adult patients with iron deficiency anemia in the"
    },
    {
      "type": "paragraph",
      "text": "setting of chronic kidney disease [6]. It is important for the radiologist to be aware of the common interactions of ferumoxytol"
    },
    {
      "type": "paragraph",
      "text": "and other intravenous iron formulations on subsequent MR imaging, particularly those studies that are performed within 72"
    },
    {
      "type": "paragraph",
      "text": "hours of administration."
    },
    {
      "type": "paragraph",
      "text": "Ferumoxytol and other ultrasmall superparamagnetic iron oxide compounds result in T1, T2, and T2* shortening effects on"
    },
    {
      "type": "paragraph",
      "text": "MRI. These phenomena are used clinically for vascular imaging and other specific clinical indications [37], but can also result"
    },
    {
      "type": "paragraph",
      "text": "in unwanted artifacts, and may impact image interpretation [38]. Maximum intravascular signal alterations occur within 2 days"
    },
    {
      "type": "paragraph",
      "text": "of administration. The effects of T1 shortening and prolonged intravascular half-life of ferumoxytol can also result in"
    },
    {
      "type": "paragraph",
      "text": "interactions with conventional gadolinium-based contrast media for MRI [39], occasionally rendering typical enhancement"
    },
    {
      "type": "paragraph",
      "text": "patterns undetectable if ferumoxytol was administered within 72 hours of the MR examination. The package insert for"
    },
    {
      "type": "paragraph",
      "text": "ferumoxytol warns of potential prolonged MR effects [40], and can increase the R2* signal in hematopoietic bone marrow for"
    },
    {
      "type": "paragraph",
      "text": "up to a period of 3 months and liver for up to 6 months [41], mimicking hemosiderosis."
    },
    {
      "type": "paragraph",
      "text": "Other parenteral iron formulations are available, but are not used as contrast media. These preparations can also affect MR"
    },
    {
      "type": "paragraph",
      "text": "signal, and recommended times between infusion and MR imaging have been published [41]. There may be usefulness in"
    },
    {
      "type": "paragraph",
      "text": "reimaging with MRI soon after parenteral iron administration, however, the interpreting radiologist should be aware that MR"
    },
    {
      "type": "paragraph",
      "text": "signal may be impacted in this time frame. In brain pathologies, enhancement can persist for several days following"
    },
    {
      "type": "paragraph",
      "text": "ferumoxytol administration [35]. Ferumoxytol has no effect on radiography, computed tomography, positron emission"
    },
    {
      "type": "paragraph",
      "text": "tomography, single photon emission computed tomography, ultrasound, or nuclear medicine imaging [42]."
    },
    {
      "type": "paragraph",
      "text": "Safety profile"
    },
    {
      "type": "paragraph",
      "text": "Serious and rarely fatal adverse reactions to therapeutic doses of ferumoxytol, including anaphylaxis associated with"
    },
    {
      "type": "paragraph",
      "text": "cardiac/cardiorespiratory arrest, have been reported. From 2009 to 2015, approximately 1.2 million therapeutic doses of"
    },
    {
      "type": "paragraph",
      "text": "ferumoxytol were administered for treatment of iron deficiency anemia. In March 2015, the US Food & Drug Administration"
    },
    {
      "type": "paragraph",
      "text": "(FDA) placed a boxed warning on ferumoxytol for serious, potentially fatal allergic reactions after the FDA Adverse Event"
    },
    {
      "type": "paragraph",
      "text": "Reporting System showed 79 anaphylactic reactions, with 18 fatalities despite immediate intervention [31]. Twenty-four"
    },
    {
      "type": "paragraph",
      "text": "percent of these patients had multiple drug allergies, and nearly half of these anaphylactic reactions occurred within 5 minutes"
    },
    {
      "type": "paragraph",
      "text": "of administration."
    },
    {
      "type": "paragraph",
      "text": "The largest experience for diagnostic use of ferumoxytol is a retrospective, observational study using data from the FeraSafeTM"
    },
    {
      "type": "paragraph",
      "text": "Multicenter MRI Registry, consisting of 11 institutional partners in the U.S. and U.K. [43]. Between 2003 and 2018, a total of"
    },
    {
      "type": "paragraph",
      "text": "3,215 unique patients (13% children, 87% adults) had 4,240 ferumoxytol injections for MRI. Ferumoxytol dose ranged from 1-"
    },
    {
      "type": "paragraph",
      "text": "11mg/kg (<=510mg Fe; rate <=45mg Fe/s). There were no systematic changes reported in heart rate, blood pressure or oxygen"
    },
    {
      "type": "paragraph",
      "text": "saturation following ferumoxytol administration. No severe, life-threatening, or fatal adverse events occurred. Eighty-three"
    },
    {
      "type": "paragraph",
      "text": "adverse events (1.9%) were related or possibly related to ferumoxytol infusions (1.8 % mild; 0.2% moderate). Thirty-one were"
    },
    {
      "type": "paragraph",
      "text": "classified as allergic-like using ACR criteria but were consistent with known minor infusion reactions observed with parenteral"
    },
    {
      "type": "paragraph",
      "text": "iron. Other studies have shown similar results of an overall adverse event rate of 2%, serious hypersensitivity reactions in"
    },
    {
      "type": "paragraph",
      "text": "0.01% of patients, and no reports of death [44]."
    },
    {
      "type": "paragraph",
      "text": "Similar to other contrast media, hypersensitivity/allergic-like reactions may occur after the first dose or subsequent doses, even"
    },
    {
      "type": "paragraph",
      "text": "in patients who have previously tolerated the drug [1]. Patients with a history of multiple medication allergies have an increased"
    },
    {
      "type": "paragraph",
      "text": "risk of hypersensitivity reaction to parenteral iron preparations, therefore, potential risks and benefits of ferumoxytol"
    },
    {
      "type": "paragraph",
      "text": "administration should be considered carefully in such patients. The current FDA recommendation is that ferumoxytol should"
    },
    {
      "type": "paragraph",
      "text": "not be administered to patients with a history of allergic reactions to IV iron preparations [29,45]."
    },
    {
      "type": "image",
      "assetId": "asset_ffd23c6165",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "59"
    },
    {
      "type": "paragraph",
      "text": "A study in pigs showed no significant differences in the brain MRI of pigs exposed to ferumoxytol doses of 5-10 mg/kg"
    },
    {
      "type": "paragraph",
      "text": "compared to unexposed pigs [15]. A study of 17 pediatric patients who received between one and four doses of ferumoxytol for"
    },
    {
      "type": "paragraph",
      "text": "evaluation of arteriovenous malformations were compared to control patients, and showed no differences in susceptibility and"
    },
    {
      "type": "paragraph",
      "text": "R* values of the deep gray structures of the brain between the two groups [46]."
    },
    {
      "type": "paragraph",
      "text": "Pregnant and breastfeeding patients"
    },
    {
      "type": "paragraph",
      "text": "There is insufficient available data about ferumoxytol use in pregnant women to make conclusions regarding any risk of adverse"
    },
    {
      "type": "paragraph",
      "text": "developmental outcomes. There are risks to the mother and fetus associated with maternal severe hypersensitivity reactions"
    },
    {
      "type": "paragraph",
      "text": "[47,48]. Severe adverse reactions, including severe hypotension and shock, may occur in pregnant women with parental iron"
    },
    {
      "type": "paragraph",
      "text": "products which may cause fetal bradycardia, especially during the second and third trimester [1,49]."
    },
    {
      "type": "paragraph",
      "text": "In animal studies, administration of ferumoxytol to pregnant rabbits at doses up to 2 times the estimated therapeutic human"
    },
    {
      "type": "paragraph",
      "text": "daily dose during organogenesis did not result in maternal or fetal effects [1]. In rabbits and rats, administration of ferumoxytol"
    },
    {
      "type": "paragraph",
      "text": "during organogenesis at approximately 6 times the estimated human daily dose caused adverse developmental outcomes"
    },
    {
      "type": "paragraph",
      "text": "including fetal malformations and decreased fetal weights [1]. One study that looked at ferumoxytol administration in rhesus"
    },
    {
      "type": "paragraph",
      "text": "macaques for MRI placental imaging showed placental ferumoxytol retention similar to levels of maternal liver ferumoxytol"
    },
    {
      "type": "paragraph",
      "text": "retention, which returned to baseline by day 4 post injection [50]. No increase in ferumoxytol was measured in the fetal tissues"
    },
    {
      "type": "paragraph",
      "text": "or maternal-fetal interface (decidua, placenta, fetal membranes) on MRI or post-delivery histopathologic evaluation, suggesting"
    },
    {
      "type": "paragraph",
      "text": "ferumoxytol may not enter the fetal circulation. Placental function, as measured by peripheral blood steroid hormone levels,"
    },
    {
      "type": "paragraph",
      "text": "was unaffected."
    },
    {
      "type": "paragraph",
      "text": "No data is available on the presence of ferumoxytol in human milk, the effects on breastfed children, or the effects on milk"
    },
    {
      "type": "paragraph",
      "text": "production."
    },
    {
      "type": "paragraph",
      "text": "REFERENCES"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "FDA. Full prescribing information: fereheme. Available at:"
    },
    {
      "type": "paragraph",
      "text": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022180s009lbl.pdf"
    },
    {
      "type": "paragraph",
      "text": "Accessed May, 2024."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Sandoz. Sandoz launches first generic high dose intravenous iron, Ferumoxytol Injection, to treat US patients with iron deficiency anemia."
    },
    {
      "type": "paragraph",
      "text": "Available at:"
    },
    {
      "type": "paragraph",
      "text": "https://www.sandoz.com/news/media-releases/sandoz-launches-first-generic-high-dose-intravenous-iron-ferumoxytol-injection"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "Accessed May, 2024."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "FDA. FDA-Approved Drug: Sandoz inc. Ferumoxytol. . Available at:"
    },
    {
      "type": "paragraph",
      "text": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/206604Orig1s000ltr.pdf"
    },
    {
      "type": "paragraph",
      "text": ". Accessed May, 2024."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol"
    },
    {
      "type": "paragraph",
      "text": "2008;19:1599-605."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis"
    },
    {
      "type": "paragraph",
      "text": "patients. Clin J Am Soc Nephrol"
    },
    {
      "type": "paragraph",
      "text": "2009;4:386-93."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner L. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis"
    },
    {
      "type": "paragraph",
      "text": "2008;52:907-15."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Mukai K, Burris NS, Mahadevan VS, Foster ED, Ordovas KG, Hope MD. 4D flow image quality with blood pool contrast: a comparison of"
    },
    {
      "type": "paragraph",
      "text": "gadofosveset trisodium and ferumoxytol. Int J Cardiovasc Imaging"
    },
    {
      "type": "paragraph",
      "text": "2018;34:273-79."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "Walker JP, Nosova E, Sigovan M, et al. Ferumoxytol-enhanced magnetic resonance angiography is a feasible method for the clinical evaluation"
    },
    {
      "type": "paragraph",
      "text": "of lower extremity arterial disease. Ann Vasc Surg"
    },
    {
      "type": "paragraph",
      "text": "2015;29:63-8."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Bashir MR, Bhatti L, Marin D, Nelson RC. Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": "2015;41:884-98."
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Pai AB, Nielsen JC, Kausz A, Miller P, Owen JS. Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects. Clin"
    },
    {
      "type": "paragraph",
      "text": "Pharmacol Ther"
    },
    {
      "type": "paragraph",
      "text": "2010;88:237-42."
    },
    {
      "type": "paragraph",
      "text": "11."
    },
    {
      "type": "paragraph",
      "text": "Prince MR, Zhang HL, Chabra SG, Jacobs P, Wang Y. A pilot investigation of new superparamagnetic iron oxide (ferumoxytol) as a contrast"
    },
    {
      "type": "paragraph",
      "text": "agent for cardiovascular MRI. J Xray Sci Technol"
    },
    {
      "type": "paragraph",
      "text": "2003;11:231-40."
    },
    {
      "type": "paragraph",
      "text": "12."
    },
    {
      "type": "paragraph",
      "text": "Hope MD, Hope TA, Zhu C, et al. Vascular Imaging With Ferumoxytol as a Contrast Agent. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2015;205:W366-73."
    },
    {
      "type": "paragraph",
      "text": "13."
    },
    {
      "type": "paragraph",
      "text": "Anzai Y, Prince MR, Chenevert TL, et al. MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent. J Magn Reson"
    },
    {
      "type": "paragraph",
      "text": "Imaging"
    },
    {
      "type": "paragraph",
      "text": "1997;7:209-14."
    },
    {
      "type": "paragraph",
      "text": "14."
    },
    {
      "type": "paragraph",
      "text": "Ersoy H, Jacobs P, Kent CK, Prince MR. Blood pool MR angiography of aortic stent-graft endoleak. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2004;182:1181-6."
    },
    {
      "type": "paragraph",
      "text": "15."
    },
    {
      "type": "paragraph",
      "text": "Bashir MR, Mody R, Neville A, et al. Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance"
    },
    {
      "type": "paragraph",
      "text": "venography in patients with endstage renal diseases. J Magn Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": "2014;40:113-8."
    },
    {
      "type": "paragraph",
      "text": "16."
    },
    {
      "type": "paragraph",
      "text": "Shahrouki P, Moriarty JM, Khan SN, et al. High resolution, 3-dimensional Ferumoxytol-enhanced cardiovascular magnetic resonance"
    },
    {
      "type": "paragraph",
      "text": "venography in central venous occlusion. J Cardiovasc Magn Reson"
    },
    {
      "type": "paragraph",
      "text": "2019;21:17."
    },
    {
      "type": "paragraph",
      "text": "17."
    },
    {
      "type": "paragraph",
      "text": "Christen T, Ni W, Qiu D, et al. High-resolution cerebral blood volume imaging in humans using the blood pool contrast agent ferumoxytol."
    },
    {
      "type": "paragraph",
      "text": "Magn Reson Med"
    },
    {
      "type": "paragraph",
      "text": "2013;70:705-10."
    },
    {
      "type": "paragraph",
      "text": "18."
    },
    {
      "type": "paragraph",
      "text": "Rivera-Rivera LA, Schubert T, Knobloch G, et al. Comparison of ferumoxytol-based cerebral blood volume estimates using quantitative R(1)"
    },
    {
      "type": "paragraph",
      "text": "and R2* relaxometry. Magn Reson Med"
    },
    {
      "type": "paragraph",
      "text": "2018;79:3072-81."
    },
    {
      "type": "paragraph",
      "text": "19."
    },
    {
      "type": "paragraph",
      "text": "Varallyay CG, Nesbit E, Fu R, et al. High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms"
    },
    {
      "type": "paragraph",
      "text": "using ferumoxytol, a superparamagnetic iron oxide nanoparticle. J Cereb Blood Flow Metab"
    },
    {
      "type": "paragraph",
      "text": "2013;33:780-6."
    },
    {
      "type": "paragraph",
      "text": "20."
    },
    {
      "type": "paragraph",
      "text": "Varallyay CG, Nesbit E, Horvath A, et al. Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI:"
    },
    {
      "type": "image",
      "assetId": "asset_a5e1d49e0b",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "60"
    },
    {
      "type": "paragraph",
      "text": "Comparison to standard of care. J Magn Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": "2018;48:441-48."
    },
    {
      "type": "paragraph",
      "text": "21."
    },
    {
      "type": "paragraph",
      "text": "Hamilton BE, Barajas R, Nesbit GM, et al. Ferumoxytol-Enhanced MRI Is Not Inferior to Gadolinium-Enhanced MRI in Detecting Intracranial"
    },
    {
      "type": "paragraph",
      "text": "Metastatic Disease and Metastasis Size. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2020;215:1436-42."
    },
    {
      "type": "paragraph",
      "text": "22."
    },
    {
      "type": "paragraph",
      "text": "Hasan DM, Amans M, Tihan T, et al. Ferumoxytol-enhanced MRI to Image Inflammation within Human Brain Arteriovenous Malformations: A"
    },
    {
      "type": "paragraph",
      "text": "Pilot Investigation. Transl Stroke Res"
    },
    {
      "type": "paragraph",
      "text": "2012;3:166-73."
    },
    {
      "type": "paragraph",
      "text": "23."
    },
    {
      "type": "paragraph",
      "text": "Shahrouki P, Felker ER, Raman SS, Jeong WK, Lu DS, Finn JP. Steady-state ferumoxytol-enhanced MRI: early observations in benign"
    },
    {
      "type": "paragraph",
      "text": "abdominal organ masses and clinical implications. Abdom Radiol (NY)"
    },
    {
      "type": "paragraph",
      "text": "2022;47:460-70."
    },
    {
      "type": "paragraph",
      "text": "24."
    },
    {
      "type": "paragraph",
      "text": "Smits LP, Tiessens F, Zheng KH, Stroes ES, Nederveen AJ, Coolen BF. Evaluation of ultrasmall superparamagnetic iron-oxide (USPIO)"
    },
    {
      "type": "paragraph",
      "text": "enhanced MRI with ferumoxytol to quantify arterial wall inflammation. Atherosclerosis"
    },
    {
      "type": "paragraph",
      "text": "2017;263:211-18."
    },
    {
      "type": "paragraph",
      "text": "25."
    },
    {
      "type": "paragraph",
      "text": "Stirrat CG, Alam SR, MacGillivray TJ, et al. Ferumoxytol-enhanced magnetic resonance imaging methodology and normal values at 1.5 and 3T."
    },
    {
      "type": "paragraph",
      "text": "J Cardiovasc Magn Reson"
    },
    {
      "type": "paragraph",
      "text": "2016;18:46."
    },
    {
      "type": "paragraph",
      "text": "26."
    },
    {
      "type": "paragraph",
      "text": "Nejadnik H, Tseng J, Daldrup-Link H. Magnetic resonance imaging of stem cell-macrophage interactions with ferumoxytol and ferumoxytol-"
    },
    {
      "type": "paragraph",
      "text": "derived nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol"
    },
    {
      "type": "paragraph",
      "text": "2019;11:e1552."
    },
    {
      "type": "paragraph",
      "text": "27."
    },
    {
      "type": "paragraph",
      "text": "Muehe AM, Siedek F, Theruvath AJ, et al. Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced"
    },
    {
      "type": "paragraph",
      "text": "PET/MRI. Theranostics"
    },
    {
      "type": "paragraph",
      "text": "2020;10:3612-21."
    },
    {
      "type": "paragraph",
      "text": "28."
    },
    {
      "type": "paragraph",
      "text": "Wells SA, Schubert T, Motosugi U, et al. Pharmacokinetics of Ferumoxytol in the Abdomen and Pelvis: A Dosing Study with 1.5- and 3.0-T"
    },
    {
      "type": "paragraph",
      "text": "MRI Relaxometry. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2020;294:108-16."
    },
    {
      "type": "paragraph",
      "text": "29."
    },
    {
      "type": "paragraph",
      "text": "Nguyen KL, Yoshida T, Han F, et al. MRI with ferumoxytol: A single center experience of safety across the age spectrum. J Magn Reson"
    },
    {
      "type": "paragraph",
      "text": "Imaging"
    },
    {
      "type": "paragraph",
      "text": "2017;45:804-12."
    },
    {
      "type": "paragraph",
      "text": "30."
    },
    {
      "type": "paragraph",
      "text": "Vasanawala SS, Nguyen KL, Hope MD, et al. Safety and technique of ferumoxytol administration for MRI. Magn Reson Med"
    },
    {
      "type": "paragraph",
      "text": "2016;75:2107-11."
    },
    {
      "type": "paragraph",
      "text": "31."
    },
    {
      "type": "paragraph",
      "text": "FDA. FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic"
    },
    {
      "type": "paragraph",
      "text": "reactions with anemia drug Feraheme (ferumoxytol). Available at:"
    },
    {
      "type": "paragraph",
      "text": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-"
    },
    {
      "type": "paragraph",
      "text": "communication-fda-strengthens-warnings-and-changes-prescribing-instructions-decrease"
    },
    {
      "type": "paragraph",
      "text": ". Accessed May, 2024."
    },
    {
      "type": "paragraph",
      "text": "32."
    },
    {
      "type": "paragraph",
      "text": "Iv M, Ng NN, Nair S, et al. Brain Iron Assessment after Ferumoxytol-enhanced MRI in Children and Young Adults with Arteriovenous"
    },
    {
      "type": "paragraph",
      "text": "Malformations: A Case-Control Study. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2020;297:438-46."
    },
    {
      "type": "paragraph",
      "text": "33."
    },
    {
      "type": "paragraph",
      "text": "Schubert T, Motosugi U, Kinner S, et al. Crossover comparison of ferumoxytol and gadobenate dimeglumine for abdominal MR-angiography at"
    },
    {
      "type": "paragraph",
      "text": "3.0 tesla: Effects of contrast bolus length and flip angle. J Magn Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": "2017;45:1617-26."
    },
    {
      "type": "paragraph",
      "text": "34."
    },
    {
      "type": "paragraph",
      "text": "Han F, Rapacchi S, Khan S, et al. Four-dimensional, multiphase, steady-state imaging with contrast enhancement (MUSIC) in the heart: a"
    },
    {
      "type": "paragraph",
      "text": "feasibility study in children. Magn Reson Med"
    },
    {
      "type": "paragraph",
      "text": "2015;74:1042-9."
    },
    {
      "type": "paragraph",
      "text": "35."
    },
    {
      "type": "paragraph",
      "text": "Storey P, Lim RP, Chandarana H, et al. MRI assessment of hepatic iron clearance rates after USPIO administration in healthy adults. Invest"
    },
    {
      "type": "paragraph",
      "text": "Radiol"
    },
    {
      "type": "paragraph",
      "text": "2012;47:717-24."
    },
    {
      "type": "paragraph",
      "text": "36."
    },
    {
      "type": "paragraph",
      "text": "Weinstein JS, Varallyay CG, Dosa E, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential"
    },
    {
      "type": "paragraph",
      "text": "therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab"
    },
    {
      "type": "paragraph",
      "text": "2010;30:15-35."
    },
    {
      "type": "paragraph",
      "text": "37."
    },
    {
      "type": "paragraph",
      "text": "Toth GB, Varallyay CG, Horvath A, et al. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney"
    },
    {
      "type": "paragraph",
      "text": "International"
    },
    {
      "type": "paragraph",
      "text": "2017;92:47-66."
    },
    {
      "type": "paragraph",
      "text": "38."
    },
    {
      "type": "paragraph",
      "text": "Schieda N. Parenteral ferumoxytol interaction with magnetic resonance imaging: a case report, review of the literature and advisory warning."
    },
    {
      "type": "paragraph",
      "text": "Insights Imaging"
    },
    {
      "type": "paragraph",
      "text": "2013;4:509-12."
    },
    {
      "type": "paragraph",
      "text": "39."
    },
    {
      "type": "paragraph",
      "text": "McCullough BJ, Kolokythas O, Maki JH, Green DE. Ferumoxytol in clinical practice: implications for MRI. J Magn Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": "2013;37:1476-9."
    },
    {
      "type": "paragraph",
      "text": "40."
    },
    {
      "type": "paragraph",
      "text": "Pharmaceuticals A. Feraheme (ferumoxytol) Prescribing Information. Available at:"
    },
    {
      "type": "paragraph",
      "text": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022180lbl.pdf"
    },
    {
      "type": "paragraph",
      "text": ". Accessed May, 2024."
    },
    {
      "type": "paragraph",
      "text": "41."
    },
    {
      "type": "paragraph",
      "text": "Rostoker G, Cohen Y. Magnetic Resonance Imaging Repercussions of Intravenous Iron Products Used for Iron-Deficiency Anemia and Dialysis-"
    },
    {
      "type": "paragraph",
      "text": "Associated Anemia. Journal of Computer Assisted Tomography"
    },
    {
      "type": "paragraph",
      "text": "2014;38:843-44."
    },
    {
      "type": "paragraph",
      "text": "42."
    },
    {
      "type": "paragraph",
      "text": "Pharmaceuticals A. Feraheme(R) (ferumoxytol injection) Important Safety Information - Radiologist Letter. Available at:"
    },
    {
      "type": "paragraph",
      "text": "https://www.feraheme.com/wp-content/uploads/2020/07/Radiologist-Letter.pdf"
    },
    {
      "type": "paragraph",
      "text": ". Accessed May, 2024."
    },
    {
      "type": "paragraph",
      "text": "43."
    },
    {
      "type": "paragraph",
      "text": "Nguyen KL, Yoshida T, Kathuria-Prakash N, et al. Multicenter Safety and Practice for Off-Label Diagnostic Use of Ferumoxytol in MRI."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "2019;293:554-64."
    },
    {
      "type": "paragraph",
      "text": "44."
    },
    {
      "type": "paragraph",
      "text": "Ahmad F, Treanor L, McGrath TA, Walker D, McInnes MDF, Schieda N. Safety of Off-Label Use of Ferumoxtyol as a Contrast Agent for MRI:"
    },
    {
      "type": "paragraph",
      "text": "A Systematic Review and Meta-Analysis of Adverse Events. J Magn Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": "2021;53:840-58."
    },
    {
      "type": "paragraph",
      "text": "45."
    },
    {
      "type": "paragraph",
      "text": "Varallyay CG, Toth GB, Fu R, et al. What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent."
    },
    {
      "type": "paragraph",
      "text": "AJNR Am J Neuroradiol"
    },
    {
      "type": "paragraph",
      "text": "2017;38:1297-302."
    },
    {
      "type": "paragraph",
      "text": "46."
    },
    {
      "type": "paragraph",
      "text": "Theruvath AJ, Aghighi M, Iv M, et al. Brain iron deposition after Ferumoxytol-enhanced MRI: A study of Porcine Brains. Nanotheranostics"
    },
    {
      "type": "paragraph",
      "text": "2020;4:195-200."
    },
    {
      "type": "paragraph",
      "text": "47."
    },
    {
      "type": "paragraph",
      "text": "McCall SJ, Bunch KJ, Brocklehurst P, et al. The incidence, characteristics, management and outcomes of anaphylaxis in pregnancy: a"
    },
    {
      "type": "paragraph",
      "text": "population-based descriptive study. Bjog"
    },
    {
      "type": "paragraph",
      "text": "2018;125:965-71."
    },
    {
      "type": "paragraph",
      "text": "48."
    },
    {
      "type": "paragraph",
      "text": "McCall SJ, Bonnet MP, yrs O, et al. Anaphylaxis in pregnancy: a population-based multinational European study. Anaesthesia"
    },
    {
      "type": "paragraph",
      "text": "2020;75:1469-"
    },
    {
      "type": "paragraph",
      "text": "75."
    },
    {
      "type": "paragraph",
      "text": "49."
    },
    {
      "type": "paragraph",
      "text": "Woodward T, Kay T, Rucklidge M. Fetal bradycardia following maternal administration of low-molecular-weight intravenous iron. Int J Obstet"
    },
    {
      "type": "paragraph",
      "text": "Anesth"
    },
    {
      "type": "paragraph",
      "text": "2015;24:196-7."
    },
    {
      "type": "paragraph",
      "text": "50."
    },
    {
      "type": "paragraph",
      "text": "Nguyen SM, Wiepz GJ, Schotzko M, et al. Impact of ferumoxytol magnetic resonance imaging on the rhesus macaque maternal-"
    },
    {
      "type": "paragraph",
      "text": "fetal interface."
    },
    {
      "type": "paragraph",
      "text": "Biol Reprod"
    },
    {
      "type": "paragraph",
      "text": "2020;102:434-44."
    },
    {
      "type": "image",
      "assetId": "asset_8913ca0700",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "GASTROINTESTINAL (GI) CONTRAST MEDIA IN ADULTS: INDICATIONS AND GUIDELINES"
    },
    {
      "type": "paragraph",
      "text": "61"
    },
    {
      "type": "paragraph",
      "text": "GASTROINTESTINAL (GI) CONTRAST MEDIA IN ADULTS:"
    },
    {
      "type": "paragraph",
      "text": "INDICATIONS AND GUIDELINES"
    },
    {
      "type": "paragraph",
      "text": "Introduction"
    },
    {
      "type": "paragraph",
      "text": "This chapter discusses indications, contraindications, and adverse reactions resulting from the administration of contrast agents"
    },
    {
      "type": "paragraph",
      "text": "used to assess the gastrointestinal system. Barium, iodinated, and negative GI contrast agents will be primarily discussed."
    },
    {
      "type": "paragraph",
      "text": "Ancillary drugs utilized in gastrointestinal tract imaging will also be reviewed along with contraindications and risks. Allergic-"
    },
    {
      "type": "paragraph",
      "text": "like reactions and premedication strategies are covered at the end of the chapter."
    },
    {
      "type": "paragraph",
      "text": "Barium-based and iodinated contrast agents are commonly used to opacify the bowel lumen during fluoroscopic, computed"
    },
    {
      "type": "paragraph",
      "text": "tomography (CT), or magnetic resonance imaging (MRI) of the gastrointestinal system. Oral or rectal administration may be"
    },
    {
      "type": "paragraph",
      "text": "during the study (e.g., during fluoroscopic examinations), or in advance (e.g., prior to CT or MRI). Less commonly, contrast"
    },
    {
      "type": "paragraph",
      "text": "media can enter the bowel following intravenous injection and hepatobiliary clearance (e.g., with vicarious excretion of iodinated"
    },
    {
      "type": "paragraph",
      "text": "contrast, or following injection of gadobenate dimeglumine or gadoxetate disodium), or after direct injection of contrast media"
    },
    {
      "type": "paragraph",
      "text": "into the biliary and pancreatic ducts (e.g., during ERCP)."
    },
    {
      "type": "paragraph",
      "text": "Barium Sulfate Enteric Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Barium sulfate is a micropulverized white powder that is supplied in various forms, including in bulk for mixing with distilled or"
    },
    {
      "type": "paragraph",
      "text": "tap water, in prepackaged aliquots ready for suspension, or in prepared doses. Barium sulfate has a long history of use in diagnostic"
    },
    {
      "type": "paragraph",
      "text": "imaging, having been first described as a gastrointestinal contrast medium in 1910. Barium was the default enteric contrast"
    },
    {
      "type": "paragraph",
      "text": "medium for the evaluation of the GI tract for almost a century, and it retains value with both fluoroscopy and cross-sectional"
    },
    {
      "type": "paragraph",
      "text": "imaging."
    },
    {
      "type": "paragraph",
      "text": "Barium Sulfate in Fluoroscopy"
    },
    {
      "type": "paragraph",
      "text": "Barium sulfate preparations remain the contrast media of choice for fluoroscopic imaging due to the delineation of mucosal detail"
    },
    {
      "type": "paragraph",
      "text": "and resistance to dilution. This is particularly helpful when performing double contrast studies and studies of swallowing"
    },
    {
      "type": "paragraph",
      "text": "mechanics using differing consistencies."
    },
    {
      "type": "paragraph",
      "text": "During a single contrast fluoroscopic examination, the optimal mixture for stability in suspension and bowel wall coating is 60%"
    },
    {
      "type": "paragraph",
      "text": "weight/volume (w/v) [1]. The volume of barium required varies by procedure and individual patient anatomy. For double contrast"
    },
    {
      "type": "paragraph",
      "text": "GI studies, high density barium (up to 250% w/v) is used in conjunction with air or effervescent material with a suspension of 85-"
    },
    {
      "type": "paragraph",
      "text": "100% weight/volume recommended for optimal double contrast imaging in the colon [2]."
    },
    {
      "type": "paragraph",
      "text": "The composition of barium mixtures is altered in different areas of the gastrointestinal tract by local conditions including the"
    },
    {
      "type": "paragraph",
      "text": "presence of fluid and luminal acidity, which affects flocculation (clumping out of suspension) and coating. Also, local differences"
    },
    {
      "type": "paragraph",
      "text": "in tap water composition obtained from municipal sources alter the qualities of barium, so that trial and error may be needed to"
    },
    {
      "type": "paragraph",
      "text": "obtain the optimal constitution [3]."
    },
    {
      "type": "paragraph",
      "text": "Water-soluble contrast media (discussed below) are generally preferred as oral contrast agents when a bowel perforation is"
    },
    {
      "type": "paragraph",
      "text": "suspected or known to exist. If an initial study with an iodinated contrast medium fails to demonstrate a suspected perforation,"
    },
    {
      "type": "paragraph",
      "text": "barium sulfate can then be administered. Such follow-up studies may be important as some small leaks may be undetectable with"
    },
    {
      "type": "paragraph",
      "text": "water-soluble media but subsequently seen when using barium-based media [4,5]."
    },
    {
      "type": "paragraph",
      "text": "Barium Sulfate in Cross Sectional Imaging"
    },
    {
      "type": "paragraph",
      "text": "Extremely dilute barium sulfate solutions are commonly used for opacification of the GI tract with CT, and less commonly with"
    },
    {
      "type": "paragraph",
      "text": "PET/CT. Its use varies among radiology departments, with some opacifying the GI tract routinely and others seldom or for specific"
    },
    {
      "type": "paragraph",
      "text": "indications only. The principal disadvantage is the time taken to opacify the GI tract which becomes relevant in emergency care"
    },
    {
      "type": "paragraph",
      "text": "[6,7]. Many feel that its routine use cannot be justified as it is seldom necessary to repeat a study with oral contrast following a"
    },
    {
      "type": "paragraph",
      "text": "study without it [7,8]. Targeted utilization (for example, for postoperative evaluation or in, patients who cannot receive"
    },
    {
      "type": "paragraph",
      "text": "intravenous (IV) contrast) is often suggested. Barium sulfate is avoided in patients with suspected perforation and known barium"
    },
    {
      "type": "paragraph",
      "text": "allergy in favor of water-soluble contrast (see below). There is no difference in opacification of the bowel on CT with barium"
    },
    {
      "type": "paragraph",
      "text": "sulfate or water-soluble alternatives [9]."
    },
    {
      "type": "image",
      "assetId": "asset_63b9ef7279",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "GASTROINTESTINAL (GI) CONTRAST MEDIA IN ADULTS: INDICATIONS AND GUIDELINES"
    },
    {
      "type": "paragraph",
      "text": "62"
    },
    {
      "type": "paragraph",
      "text": "For evaluation of the small bowel with CT or MR enterography, routine oral preparations of dilute barium should not be used as"
    },
    {
      "type": "paragraph",
      "text": "they may obscure mural or mucosal abnormalities due to the density. Instead, negative contrast agents are often used (discussed"
    },
    {
      "type": "paragraph",
      "text": "below)."
    },
    {
      "type": "paragraph",
      "text": "Non-Allergic Complications of Barium Sulfate"
    },
    {
      "type": "paragraph",
      "text": "The most serious complication from the use of barium in the GI tract is leakage into the mediastinum or peritoneal cavity [10]."
    },
    {
      "type": "paragraph",
      "text": "The potential complications of a barium leak depend on the site from which the spill occurs. Esophageal leakage may cause"
    },
    {
      "type": "paragraph",
      "text": "mediastinitis. Gastric, duodenal, and small intestinal leakage may result in peritonitis. Escape of barium from the colon, where"
    },
    {
      "type": "paragraph",
      "text": "the bacterial count is highest, carries the highest mortality (likely primarily related to leakage of stool). Water-soluble contrast"
    },
    {
      "type": "paragraph",
      "text": "media (discussed below) are generally preferred as oral contrast agents when a bowel perforation is suspected or known to exist."
    },
    {
      "type": "paragraph",
      "text": "If an initial study with an iodinated contrast medium fails to demonstrate a suspected perforation, barium sulfate can then be"
    },
    {
      "type": "paragraph",
      "text": "administered. Such follow-up studies may be important as some small leaks may be undetectable with water-soluble media but"
    },
    {
      "type": "paragraph",
      "text": "subsequently seen when using barium-based media [4,5]."
    },
    {
      "type": "paragraph",
      "text": "Although barium sulfate is inert, it can occasionally produce symptoms if aspirated, particularly in patients who have underlying"
    },
    {
      "type": "paragraph",
      "text": "lung disease. While barium is usually mobilized proximally by ciliary action of normal bronchial epithelium, damaged epithelium"
    },
    {
      "type": "paragraph",
      "text": "from bronchial disease delays the normal elimination of barium [1]. If not completely expectorated, retained barium in the lungs"
    },
    {
      "type": "paragraph",
      "text": "can remain indefinitely and may cause inflammation [11]. High volume aspiration can lead to acute respiratory distress or"
    },
    {
      "type": "paragraph",
      "text": "pneumonia [12]."
    },
    {
      "type": "paragraph",
      "text": "Other reactions to GI tract barium"
    },
    {
      "type": "paragraph",
      "text": "Adverse reactions to oral and rectal barium contrast media are almost always mild, with the most common symptoms including"
    },
    {
      "type": "paragraph",
      "text": "nausea, vomiting, and abdominal cramping or discomfort during and/or after the examination. These symptoms are likely not"
    },
    {
      "type": "paragraph",
      "text": "hypersensitivity reactions but are part of a physiologic response resulting from distention of a viscus. Vasovagal reactions can"
    },
    {
      "type": "paragraph",
      "text": "also be encountered, when the colon is distended during a double contrast barium enema."
    },
    {
      "type": "paragraph",
      "text": "Direct barium toxicity"
    },
    {
      "type": "paragraph",
      "text": "Direct toxicity of orally or rectally administered barium has been reported on very rare occasions [13,14]. Any barium that"
    },
    {
      "type": "paragraph",
      "text": "dissociates from the stable barium sulfate compound may form other chemical compounds that become soluble and are absorbed"
    },
    {
      "type": "paragraph",
      "text": "into the blood stream resulting in toxicity"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "for example, barium chloride, barium sulfide, or barium carbonate [15]. This is more"
    },
    {
      "type": "paragraph",
      "text": "likely to occur if industrial grade barium contaminates pharmaceutical grade barium distributed for diagnostic use [16]. Case"
    },
    {
      "type": "paragraph",
      "text": "reports of toxicity with pharmaceutical grade barium also exist [14,17]."
    },
    {
      "type": "paragraph",
      "text": "Acute symptoms of barium toxicity are usually rapid in onset and include nausea, vomiting, and watery diarrhea. Absorption of"
    },
    {
      "type": "paragraph",
      "text": "barium can result in changes in electrolyte balance, causing rapid and severe hypokalemia [18,19]. Untreated, this can lead to a"
    },
    {
      "type": "paragraph",
      "text": "cascade of severe muscle weakness, respiratory arrest, coma, cardiac arrhythmia, and death [16,20]. Therapy consists of aggressive"
    },
    {
      "type": "paragraph",
      "text": "potassium infusion with monitoring and correction of electrolyte imbalances [16,21]."
    },
    {
      "type": "paragraph",
      "text": "Contraindications to administration of barium"
    },
    {
      "type": "paragraph",
      "text": "There are no absolute contraindications for the use of barium compounds, although as noted above, it is generally recommended"
    },
    {
      "type": "paragraph",
      "text": "that barium not be administered to individuals who are suspected or known to have bowel perforations or suspected allergy to"
    },
    {
      "type": "paragraph",
      "text": "barium and/or barium components."
    },
    {
      "type": "paragraph",
      "text": "Iodinated (Water-Soluble) Enteric Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Two commercial iodinated contrast agents are commonly used for enteric opacification: Gastrografin(R) (Bracco Diagnostics, Inc.;"
    },
    {
      "type": "paragraph",
      "text": "Princeton, NJ) and Gastroview(R) (Covidien; Hazelwood, MO) are solutions comprising 660 mg/ml diatrizoate meglumine and"
    },
    {
      "type": "paragraph",
      "text": "100 mg/ml diatrizoate sodium. The result is a solution that has 367 mg (37%) of iodine per ml [22,23]. Gastrografin(R) and"
    },
    {
      "type": "paragraph",
      "text": "Gastroview(R) are hypertonic solutions and are considered High Osmolar Contrast Media (HOCM)."
    },
    {
      "type": "paragraph",
      "text": "Low osmolar iohexol (Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "GE Healthcare; Princeton, NJ) has an FDA-approved indication for oral use in select"
    },
    {
      "type": "paragraph",
      "text": "concentrations. Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "350 is approved for oral or rectal administration in adults, with lower concentrations approved for"
    },
    {
      "type": "paragraph",
      "text": "pediatric patients. Diluted and oral solutions of iohexol are approved for use in conjunction with intravenous administration of"
    },
    {
      "type": "paragraph",
      "text": "iohexol for CT imaging of the abdomen (see prescribing information for further detail) [24,25]. Dilution for CT applications aims"
    },
    {
      "type": "paragraph",
      "text": "to avoid artifacts that may occur from high attenuation of the contrast media."
    },
    {
      "type": "image",
      "assetId": "asset_e42abbe044",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "GASTROINTESTINAL (GI) CONTRAST MEDIA IN ADULTS: INDICATIONS AND GUIDELINES"
    },
    {
      "type": "paragraph",
      "text": "63"
    },
    {
      "type": "paragraph",
      "text": "Diagnostic use of water-soluble enteric contrast media for Conventional Fluoroscopic Examinations"
    },
    {
      "type": "paragraph",
      "text": "As discussed above, barium sulfate formulations are generally the preferred agents for opacification of the gastrointestinal tract"
    },
    {
      "type": "paragraph",
      "text": "for conventional fluoroscopic examinations [1,2]. The use of water-soluble contrast media during fluoroscopy is typically reserved"
    },
    {
      "type": "paragraph",
      "text": "for selected situations, including:"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Possible bowel perforation, postoperative leak, enteric fistula/sinus tract, or abscess"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Confirmation of feeding tube positioning"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Prior to planned endoscopic procedures"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "In small bowel obstruction when surgery may be planned"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "In patients with prior allergic-like reactions to barium"
    },
    {
      "type": "paragraph",
      "text": "Diagnostic use of water-soluble enteric contrast media for CT"
    },
    {
      "type": "paragraph",
      "text": "Common indications for the use of enterically administered water soluble contrast in Abdominopelvic CT include [26]:"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Oncologic imaging"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Suspected bowel leak, fistula, abscess, or fluid collection"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Abdominal pain"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "CT colonography"
    },
    {
      "type": "paragraph",
      "text": "Water-soluble contrast media are the preferred agents when evaluating for hollow viscus/bowel perforation because it is rapidly"
    },
    {
      "type": "paragraph",
      "text": "absorbed in the peritoneum and interstitial spaces. No deleterious effects from the presence of water-soluble contrast media in the"
    },
    {
      "type": "paragraph",
      "text": "mediastinum, pleural cavity, or peritoneal cavity have been demonstrated [11]. If an initial exam performed with water soluble"
    },
    {
      "type": "paragraph",
      "text": "contrast in a patient with suspected bowel perforation fails to demonstrate a leak, one can then consider barium sulfate."
    },
    {
      "type": "paragraph",
      "text": "Therapeutic use of water-soluble enteric contrast media"
    },
    {
      "type": "paragraph",
      "text": "Oral iodinated high-osmolality contrast media (HOCM) have been used successfully for the treatment of postoperative adynamic"
    },
    {
      "type": "paragraph",
      "text": "(or paralytic) ileus and adhesive small-bowel obstruction [27-30]. Given as an enema, HOCM has proved useful in some adults"
    },
    {
      "type": "paragraph",
      "text": "with barium impaction [31] as well as in patients with cystic fibrosis who have distal intestinal obstruction syndrome (DIOS)"
    },
    {
      "type": "paragraph",
      "text": "(obstipation) [32]. This is because HOCMs are hypertonic and draw fluid into the bowel lumen."
    },
    {
      "type": "paragraph",
      "text": "Non-allergic Complications of water-soluble contrast agents"
    },
    {
      "type": "paragraph",
      "text": "Diarrhea, nausea, and vomiting may occur following enteric administration of diatrizoate meglumine/diatrizoate sodium solutions"
    },
    {
      "type": "paragraph",
      "text": "as well as iohexol solutions. Mucosal irritation has also been reported [22,24,25,33]. Mucosal inflammation, mucosal infection,"
    },
    {
      "type": "paragraph",
      "text": "or bowel obstruction can increase the amount absorbed by several fold [34-36]. As a result, it is not rare to see opacification of"
    },
    {
      "type": "paragraph",
      "text": "the urinary tract after enteric administration of water-soluble contrast media [37]."
    },
    {
      "type": "paragraph",
      "text": "Enteric HOCM in hypertonic concentrations may draw fluid into the lumen of the bowel. This can lead to hypovolemia and/or"
    },
    {
      "type": "paragraph",
      "text": "dehydration, so should also be avoided in patients with fluid and electrolyte imbalances [10,38]. Preparations made from nonionic"
    },
    {
      "type": "paragraph",
      "text": "LOCM may be preferable for these patients."
    },
    {
      "type": "paragraph",
      "text": "Because of the oral route of administration, aspiration is a risk for enteric contrast administration. Low osmolality and iso-osmolar"
    },
    {
      "type": "paragraph",
      "text": "contrast agents are preferred due to lower risks of life-threatening pulmonary edema if aspirated as compared to high osmolar"
    },
    {
      "type": "paragraph",
      "text": "agents [39-41]. Further, water soluble contrast agents should be avoided in patients with tracheoesophageal fistula due to risk of"
    },
    {
      "type": "paragraph",
      "text": "pulmonary complications [22,33]."
    },
    {
      "type": "paragraph",
      "text": "Thyroid function tests may be altered for variable periods of time [42], even in normal patients, following administration of"
    },
    {
      "type": "paragraph",
      "text": "iodinated water-soluble biliary contrast agents such as orally administered iopanoate (Telapaque(R); Winthrop Pharmaceuticals,"
    },
    {
      "type": "paragraph",
      "text": "New York, NY) or intravenously administered water-soluble contrast such as iodipamide (Cholografin(R); Bracco Diagnostic, Inc.,"
    },
    {
      "type": "paragraph",
      "text": "Princeton, NJ). Cases of hyperthyroidism have been reported following oral contrast [22,33]."
    },
    {
      "type": "image",
      "assetId": "asset_1bac4e82f4",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "GASTROINTESTINAL (GI) CONTRAST MEDIA IN ADULTS: INDICATIONS AND GUIDELINES"
    },
    {
      "type": "paragraph",
      "text": "64"
    },
    {
      "type": "paragraph",
      "text": "Neutral and Negative Enteric Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Neutral oral contrast agents (i.e., attenuation or signal intensity similar to water) are used to distend bowel without interfering"
    },
    {
      "type": "paragraph",
      "text": "with evaluation of mural enhancement. They are commonly used with MR and CT enterography, and to improve evaluation of"
    },
    {
      "type": "paragraph",
      "text": "the pancreaticobiliary tree."
    },
    {
      "type": "paragraph",
      "text": "Negative oral contrast agents (i.e., attenuation or signal intensity less than water) are used to suppress background luminal contents"
    },
    {
      "type": "paragraph",
      "text": "to improve visualization of the pancreaticobiliary tree."
    },
    {
      "type": "paragraph",
      "text": "Some neutral contrast agents contain nonabsorbable additives (resins, polyethylene glycol, mannitol, sorbitol, or other sugar"
    },
    {
      "type": "paragraph",
      "text": "alcohols) that help retain intraluminal water and prevent absorption. For example, NeuLumEx (formerly VoLumen, Bracco"
    },
    {
      "type": "paragraph",
      "text": "Diagnostics, Princeton, NJ) is a thin (0.1% w/v) barium sulfate solution approved that is widely used for CT and MRI enterography"
    },
    {
      "type": "paragraph",
      "text": "and contains a small amount of sorbitol. Sorbitol is hyperosmolar and retains water, improving bowel distention [43,44]. Breeza"
    },
    {
      "type": "paragraph",
      "text": "(Beekley Medical, Bristol, Conn) is a well-tolerated alternative neutral contrast agent containing sorbitol, mannitol and xantham"
    },
    {
      "type": "paragraph",
      "text": "gum. It is marketed as a flavored beverage and may be"
    },
    {
      "type": "paragraph",
      "text": "better tolerated than NeuLumEx [43,45]."
    },
    {
      "type": "paragraph",
      "text": "There have been very few reported serious adverse reactions to neutral or negative oral contrast media. Examples include nausea,"
    },
    {
      "type": "paragraph",
      "text": "cramping, GI distress, and diarrhea. Barium-based solutions are relatively contraindicated in patients with bowel leak due to the"
    },
    {
      "type": "paragraph",
      "text": "potential for barium peritonitis."
    },
    {
      "type": "paragraph",
      "text": "Neutral Enteric Contrast Media with CT"
    },
    {
      "type": "paragraph",
      "text": "Neutral oral contrast agents used with CT can include dilute barium-based media, water, milk, and dilute iodinated media."
    },
    {
      "type": "paragraph",
      "text": "Negative oral contrast agents are not generally used with CT."
    },
    {
      "type": "paragraph",
      "text": "Water is the least expensive, safest, and most accessible neutral contrast medium [46]. Water will distend the lumen of the stomach"
    },
    {
      "type": "paragraph",
      "text": "and proximal duodenum but not the distal small bowel or colon due to interval absorption."
    },
    {
      "type": "paragraph",
      "text": "Commercially available neutral contrast agents containing sorbitol and/or mannitol are commonly used for purposes like CT"
    },
    {
      "type": "paragraph",
      "text": "Enterography. These include NeuLumEx (Bracco Diagnostics, Princeton, NJ) and Breeza (Beekley Medical, Bristol, Conn)."
    },
    {
      "type": "paragraph",
      "text": "Milk has been tested as an inexpensive neutral oral contrast material for CT [47,48]. Milk contains fat, which slows intestinal"
    },
    {
      "type": "paragraph",
      "text": "peristalsis and transit. One comparison of whole milk to VoLumen (now NeuLumEX) in 215 adult patients found no significant"
    },
    {
      "type": "paragraph",
      "text": "difference with respect to bowel distention or bowel wall visualization but better patient acceptance [47]."
    },
    {
      "type": "paragraph",
      "text": "Other less common neutral oral contrast agents have been used with CT, including lactulose solution, polyethylene glycol (PEG),"
    },
    {
      "type": "paragraph",
      "text": "and methylcellulose. In general, these uncommon agents are not favored due to side effects such as diarrhea and dehydration."
    },
    {
      "type": "paragraph",
      "text": "Neutral and Negative Enteric Contrast Media with MRI"
    },
    {
      "type": "paragraph",
      "text": "Neutral and negative oral contrast agents are used during MRI to improve visualization of the pancreaticobiliary tree at MRCP"
    },
    {
      "type": "paragraph",
      "text": "(i.e., by suppressing background fluid within the stomach and small bowel) or improve visualization of the bowel during MR"
    },
    {
      "type": "paragraph",
      "text": "enterography (i.e., by distending the bowel lumen and enhancing evaluation of the bowel wall). In general, these agents function"
    },
    {
      "type": "paragraph",
      "text": "via T1 and T2/T2* effects which improve visualization of mucosal enhancement."
    },
    {
      "type": "paragraph",
      "text": "Neutral oral contrast agents used at MRI can include paramagnetic agents containing manganese (e.g., pineapple or blueberry"
    },
    {
      "type": "paragraph",
      "text": "juice). Use of diamagnetic agents (i.e., barium or kaopectate) or superparamagnetic substances (e.g., oral iron) is rare."
    },
    {
      "type": "paragraph",
      "text": "Perfluorochemicals (i.e. molecules where protons are replaced by flourine atoms) have been studied but are not in routine clinical"
    },
    {
      "type": "paragraph",
      "text": "use [49]."
    },
    {
      "type": "paragraph",
      "text": "Contrast Agents in the Biliary and Pancreatic Ductal Systems"
    },
    {
      "type": "paragraph",
      "text": "Orally ingested barium contrast material can reflux into the biliary tree following biliary surgery, sphincteroplasty, or biliary stent"
    },
    {
      "type": "paragraph",
      "text": "placement. Normally this is of no consequence, as the barium empties back into the bowel promptly with physiological bile flow"
    },
    {
      "type": "paragraph",
      "text": "[50,51]. However, rare clinical reports of complications like suppurative cholangitis, shock, or disseminated intravascular"
    },
    {
      "type": "paragraph",
      "text": "coagulation exist, particularly when there is retention of barium beyond 24 hours [52-55]. Although some authors have theorized"
    },
    {
      "type": "paragraph",
      "text": "that barium could dehydrate and occlude the biliary system or indwelling stents, this has not been well documented [51,56]."
    },
    {
      "type": "image",
      "assetId": "asset_b8234cee58",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "GASTROINTESTINAL (GI) CONTRAST MEDIA IN ADULTS: INDICATIONS AND GUIDELINES"
    },
    {
      "type": "paragraph",
      "text": "65"
    },
    {
      "type": "paragraph",
      "text": "Water-soluble iodinated contrast media (ICM) is instilled into the biliary ductal system during endoscopic retrograde"
    },
    {
      "type": "paragraph",
      "text": "cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography, or during intraoperative cholangiography."
    },
    {
      "type": "paragraph",
      "text": "Studies have demonstrated that small amounts may be absorbed and result in systemic exposure [57-59]. However,"
    },
    {
      "type": "paragraph",
      "text": "hypersensitivity reactions to ICM instilled during ERCP are rare [60-63]. Opacification of the biliary tree can also be achieved"
    },
    {
      "type": "paragraph",
      "text": "via intravenous injection of iodipamide (Cholografin(R), Bracco Diagnostics, Milan, Italy) before fluoroscopy or CT, although this"
    },
    {
      "type": "paragraph",
      "text": "is now rarely (if ever) performed in the United States due to increased utilization of MRCP and the higher frequency of contrast"
    },
    {
      "type": "paragraph",
      "text": "reactions with this agent [64-67]."
    },
    {
      "type": "paragraph",
      "text": "Two commonly used gadolinium-based contrast agents (GBCA)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "gadobenate dimegumine (MultiHance(R) Bracco Diagnostics,"
    },
    {
      "type": "paragraph",
      "text": "Inc., Location) and gadoxetate disodium (Eovist(R); Bayer Healthcare Pharmaceuticals, Wayne, NJ)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "also have properties that"
    },
    {
      "type": "paragraph",
      "text": "result in transportation into hepatocytes and subsequent excretion into the biliary tree [68-70]. There are also small case series"
    },
    {
      "type": "paragraph",
      "text": "describing retrograde injection of GBCA into the pancreaticobiliary tree during ERCP, although there is limited research on"
    },
    {
      "type": "paragraph",
      "text": "resulting adverse events and the potential for absorption and systemic exposure [62,71]."
    },
    {
      "type": "paragraph",
      "text": "Ancillary drugs"
    },
    {
      "type": "paragraph",
      "text": "Glucagon and Anticholinergic Agents"
    },
    {
      "type": "paragraph",
      "text": "Glucagon is FDA-approved to temporarily inhibit movement of the gastrointestinal tract in adults undergoing radiologic"
    },
    {
      "type": "paragraph",
      "text": "examinations [72-74]. Most often, glucagon is used to relax the bowel during double contrast studies of the upper GI tract or"
    },
    {
      "type": "paragraph",
      "text": "colon, or during MR enterography, although it can also be advantageous during intravascular or image-guided percutaneous"
    },
    {
      "type": "paragraph",
      "text": "procedures [75-79]. The dose in adults can depend on which portion of the GI tract is targeted for relaxation; beneficial effects"
    },
    {
      "type": "paragraph",
      "text": "are seen in the stomach with doses of 0.5 mg IV (or 2 mg IM), in small bowel with doses of 0.1 to 0.25 mg IV (or 1 mg IM), and"
    },
    {
      "type": "paragraph",
      "text": "in colon with doses of 1 mg IV (or 2 mg IM given 10 minutes in advance) [76,80]. A standard dose of 0.5-1 mg IV glucagon is"
    },
    {
      "type": "paragraph",
      "text": "commonly used for MR enterography in order to minimize motion artifacts from bowel peristalsis. Onset occurs within 1 minute"
    },
    {
      "type": "paragraph",
      "text": "when given IV or within 10 minutes when given IM and lasts at least 30 minutes [81-83]. Side effects of IV glucagon include"
    },
    {
      "type": "paragraph",
      "text": "nausea and vomiting which can be reduced by slow administration over 1 to 5 minutes [78], as well as vasovagal reactions [73]."
    },
    {
      "type": "paragraph",
      "text": "Delayed hypoglycemia has been documented in some patients [78], although this is usually not clinically significant. Notably,"
    },
    {
      "type": "paragraph",
      "text": "some package inserts for glucagon (for example, GlucaGen; Bedford Laboratories; Bedford, OH) recommend oral carbohydrates"
    },
    {
      "type": "paragraph",
      "text": "after administration of glucagon to rebuild body glycogen stores and avoid hypoglycemia. The package insert for the specific drug"
    },
    {
      "type": "paragraph",
      "text": "used at each practice should be consulted."
    },
    {
      "type": "paragraph",
      "text": "Other anticholinergic agents like hyoscyamine sulfate and hyoscine butylbromide (scopolamine) have been explored as alternative"
    },
    {
      "type": "paragraph",
      "text": "options to IV glucagon due to cost and side effect profiles. One study found that using sublingual hyoscyamine tablets resulted in"
    },
    {
      "type": "paragraph",
      "text": "subjectively equivalent quality of upper GI examinations when compared to IV glucagon [84]. Another study found no significant"
    },
    {
      "type": "paragraph",
      "text": "difference in colonic distension or abdominal discomfort when using sublingual hyoscyamine, although less nausea was reported"
    },
    {
      "type": "paragraph",
      "text": "by patients [73]. However, other studies have shown lower effectiveness and overall reduced the use of hyoscyamine [73,85-88]."
    },
    {
      "type": "paragraph",
      "text": "Metoclopramide"
    },
    {
      "type": "paragraph",
      "text": "Metoclopramide (Reglan(R); Pfizer, New York, NY) can be administered to stimulate motility of the upper GI tract and relax the"
    },
    {
      "type": "paragraph",
      "text": "pyloric sphincter without stimulating gastric, biliary, or pancreatic secretions. This can be helpful to hasten gastric emptying and"
    },
    {
      "type": "paragraph",
      "text": "small bowel transit or ease the placement of post-pyloric feeding tubes. Metoclopramide can be given at doses of 10 mg IV"
    },
    {
      "type": "paragraph",
      "text": "(slowly, over 1-2 minutes), 10 mg IM, or 20 mg PO. The onset of action is 1 to 3 minutes with IV dosing, 10 to 15 minutes with"
    },
    {
      "type": "paragraph",
      "text": "IM dosing, and 20 to 60 minutes following an oral dose. Pharmacological effects persist for 1 to 2 hours [89,90]."
    },
    {
      "type": "paragraph",
      "text": "Contraindications to metoclopramide include pheochromocytoma, as it may stimulate release of catecholamines from the tumor."
    },
    {
      "type": "paragraph",
      "text": "Epileptics may also be sensitive to its extrapyramidal effects [91]. Other adverse reactions from single doses as given in a radiology"
    },
    {
      "type": "paragraph",
      "text": "department are exceedingly rare. While adverse reactions from larger or regular dosing exist (e.g., tardive dyskinesia), this is"
    },
    {
      "type": "paragraph",
      "text": "outside of the scope of this document."
    },
    {
      "type": "paragraph",
      "text": "Secretin"
    },
    {
      "type": "paragraph",
      "text": "A synthetic version of secretin (ChiRhoClin(R), Inc., Silver Springs, MD) can be administered to stimulate pancreatic secretion"
    },
    {
      "type": "paragraph",
      "text": "and improve delineation of the main pancreatic duct or assess for leak during MRCP [92-94]. The manufacturer recommends an"
    },
    {
      "type": "paragraph",
      "text": "intravenous dose of 0.2 mcg/kg (slowly, over 1 minute) [95]."
    },
    {
      "type": "image",
      "assetId": "asset_3ed07eb616",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "GASTROINTESTINAL (GI) CONTRAST MEDIA IN ADULTS: INDICATIONS AND GUIDELINES"
    },
    {
      "type": "paragraph",
      "text": "66"
    },
    {
      "type": "paragraph",
      "text": "A relative contraindication to secretin administration is acute pancreatitis, as symptoms can be exacerbated [96]. Other side effects"
    },
    {
      "type": "paragraph",
      "text": "include nausea, flushing, abdominal pain, and vomiting [95]. Allergic-like reactions are rare, with few (if any) reported [97]."
    },
    {
      "type": "paragraph",
      "text": "Nonetheless, the manufacturer recommends giving a test dose of 0.2 mcg to assess for reactions for 1 minute before giving the"
    },
    {
      "type": "paragraph",
      "text": "remainder of the dose [95]."
    },
    {
      "type": "paragraph",
      "text": "Immediate hypersensitivity reactions to enteric contrast media"
    },
    {
      "type": "paragraph",
      "text": "Nonvascular (enteric or nonenteric) administration of contrast agents results in some systemic absorption of the agent [98]. Studies"
    },
    {
      "type": "paragraph",
      "text": "suggest that approximately 1% to 2% of enteric iodinated contrast media are normally absorbed and subsequently excreted into"
    },
    {
      "type": "paragraph",
      "text": "the urinary tract after oral or rectal administration [99,100]. As allergic-like reactions are not considered to be dose related and"
    },
    {
      "type": "paragraph",
      "text": "can occur with less than 1 ml of IV contrast media, it is generally accepted that allergic-like reactions can occur even from the"
    },
    {
      "type": "paragraph",
      "text": "small amounts of contrast medium absorbed from the gastrointestinal tract. However, these reactions allergic-like reactions after"
    },
    {
      "type": "paragraph",
      "text": "nonvascular administration of contrast remain infrequent compared to reactions after intravenous administration [101-103], with"
    },
    {
      "type": "paragraph",
      "text": "only very rare reports of moderate or severe allergic-like reactions to orally or rectally administered iodinated contrast media [36]."
    },
    {
      "type": "paragraph",
      "text": "Use of Gastrografin(R) and Gastroview(R) is contraindicated in patients with allergy to salts of diatrizoic acid or other ingredients"
    },
    {
      "type": "paragraph",
      "text": "of the solution [22,23]."
    },
    {
      "type": "paragraph",
      "text": "Strategies for Premedication or Agent-Switching"
    },
    {
      "type": "paragraph",
      "text": "There is variability in the approach to premedication for patients with a history of contrast allergies who are scheduled for exams"
    },
    {
      "type": "paragraph",
      "text": "involving nonvascular administration of contrast. Some favor following the same guidelines as for vascular administration of contrast"
    },
    {
      "type": "paragraph",
      "text": "(see"
    },
    {
      "type": "paragraph",
      "text": "Indications for Premedication"
    },
    {
      "type": "paragraph",
      "text": "in Chapter 4). Others do not recommend premedication for these patients given the rarity of"
    },
    {
      "type": "paragraph",
      "text": "immediate hypersensitivity reactions after nonvascular administration [98]. This latter approach has also been adopted by some"
    },
    {
      "type": "paragraph",
      "text": "outside of radiology, with a study showing that most urologists do not prescribe prophylaxis for contrast allergies prior to"
    },
    {
      "type": "paragraph",
      "text": "endourologic procedures [104]. Yet another approach is to only premedicate patients with a history of a severe immediate"
    },
    {
      "type": "paragraph",
      "text": "hypersensitivity reaction to the same class of contrast agent being administered extravascularly (see"
    },
    {
      "type": "paragraph",
      "text": "Table 1"
    },
    {
      "type": "paragraph",
      "text": "for description of"
    },
    {
      "type": "paragraph",
      "text": "categories of acute reactions) [105]."
    },
    {
      "type": "paragraph",
      "text": "It is known that premedication does not prevent all repeat reactions. Another mitigation strategy is to change contrast agents, whether"
    },
    {
      "type": "paragraph",
      "text": "choosing a different agent in the same class or selecting a different class of agent (iodinated contrast media vs. barium vs. gadolinium-"
    },
    {
      "type": "paragraph",
      "text": "based agent). Changing contrast media, even within the same class, may be more effective than premedication in preventing repeat"
    },
    {
      "type": "paragraph",
      "text": "reaction [98,106-"
    },
    {
      "type": "paragraph",
      "text": "109]. This is also discussed in Chapter 4 of the manual (link to"
    },
    {
      "type": "paragraph",
      "text": "Changing Contrast Media Within the Same Class"
    },
    {
      "type": "paragraph",
      "text": ")."
    },
    {
      "type": "paragraph",
      "text": "Treatment of adverse reactions to GI contrast agents and ancillary drugs"
    },
    {
      "type": "paragraph",
      "text": "Facilities should be equipped with basic supplies and medications to evaluate and treat adverse reactions to oral contrast agents and"
    },
    {
      "type": "paragraph",
      "text": "ancillary drugs. Treatment of allergic-like reactions to oral contrast agents can follow the same algorithmic approach as treatment of"
    },
    {
      "type": "paragraph",
      "text": "reactions to intravenous contrast agents. Algorithms, scenarios, and potential supplies for contrast reaction kits are provided in"
    },
    {
      "type": "paragraph",
      "text": "Table"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": ","
    },
    {
      "type": "paragraph",
      "text": "Table 3"
    },
    {
      "type": "paragraph",
      "text": ", and"
    },
    {
      "type": "paragraph",
      "text": "Table 4"
    },
    {
      "type": "paragraph",
      "text": ". Treatment of other non-allergic adverse reactions can vary and should be based on patient symptoms."
    },
    {
      "type": "paragraph",
      "text": "References"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Gelfand DW, Ott DJ. Barium sulfate suspensions: an evaluation of available products. AJR Am J Roentgenol 1982;138:935-41."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Laufer I. LM. Double Contrast Gastrointestinal Radiology. 2nd ed. Philadelphia, PA: WB Saunders; 1992."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Miller RE SJ. Radiographic Contrast Agents. Baltimore, MD: University Park Press; 1977."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Foley MJ, Ghahremani GG, Rogers LF. Reappraisal of contrast media used to detect upper gastrointestinal perforations: comparison of ionic water-"
    },
    {
      "type": "paragraph",
      "text": "soluble media with barium sulfate. Radiology 1982;144:231-7."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Swanson JO, Levine MS, Redfern RO, Rubesin SE. Usefulness of high-density barium for detection of leaks after esophagogastrectomy, total"
    },
    {
      "type": "paragraph",
      "text": "gastrectomy, and total laryngectomy. AJR Am J Roentgenol 2003;181:415-20."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Schuur JD, Chu G, Sucov A. Effect of oral contrast for abdominal computed tomography on emergency department length of stay. Emerg Radiol"
    },
    {
      "type": "paragraph",
      "text": "2010;17:267-73."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Kielar AZ, Patlas MN, Katz DS. Oral contrast for CT in patients with acute non-traumatic abdominal and pelvic pain: what should be its current role?"
    },
    {
      "type": "paragraph",
      "text": "Emerg Radiol 2016;23:477-81."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "Levenson RB, Camacho MA, Horn E, Saghir A, McGillicuddy D, Sanchez LD. Eliminating routine oral contrast use for CT in the emergency"
    },
    {
      "type": "paragraph",
      "text": "department: impact on patient throughput and diagnosis. Emerg Radiol 2012;19:513-7."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Garrett PR, Meshkov SL, Perlmutter GS. Oral contrast agents in CT of the abdomen. Radiology 1984;153:545-6."
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Ott DJ, Gelfand DW. Gastrointestinal contrast agents. Indications, uses, and risks. Jama 1983;249:2380-4."
    },
    {
      "type": "paragraph",
      "text": "11."
    },
    {
      "type": "paragraph",
      "text": "Vessal K, Montali RJ, Larson SM, Chaffee V, James AE, Jr. Evaluation of barium and gastrografin as contrast media for the diagnosis of esophageal"
    },
    {
      "type": "paragraph",
      "text": "ruptures or perforations. Am J Roentgenol Radium Ther Nucl Med 1975;123:307-19."
    },
    {
      "type": "paragraph",
      "text": "12."
    },
    {
      "type": "paragraph",
      "text": "Buschmann C, Schulz F, Tsokos M. Fatal aspiration of barium sulfate. Forensic Sci Med Pathol 2011;7:63-4."
    },
    {
      "type": "paragraph",
      "text": "13."
    },
    {
      "type": "paragraph",
      "text": "Boyd EM, Abel M. The acute toxicity of barium sulfate administered intragastrically. Can Med Assoc J 1966;94:849-53."
    },
    {
      "type": "image",
      "assetId": "asset_07ae325a81",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "GASTROINTESTINAL (GI) CONTRAST MEDIA IN ADULTS: INDICATIONS AND GUIDELINES"
    },
    {
      "type": "paragraph",
      "text": "67"
    },
    {
      "type": "paragraph",
      "text": "14."
    },
    {
      "type": "paragraph",
      "text": "Savry C, Bouche O, Lefrant JY, Saissy G, Allain P. [Barium sulfate poisoning?]. Ann Fr Anesth Reanim 1999;18:454-7."
    },
    {
      "type": "paragraph",
      "text": "15."
    },
    {
      "type": "paragraph",
      "text": "Bowen LN, Subramony SH, Cheng J, Wu SS, Okun MS. Elementary, my dear Dr. Allen: the case of barium toxicity and Pa Ping. Neurology"
    },
    {
      "type": "paragraph",
      "text": "2010;74:1546-9."
    },
    {
      "type": "paragraph",
      "text": "16."
    },
    {
      "type": "paragraph",
      "text": "Barium toxicity after exposure to contaminated contrast solution--Goias State, Brazil, 2003. MMWR Morb Mortal Wkly Rep 2003;52:1047-8."
    },
    {
      "type": "paragraph",
      "text": "17."
    },
    {
      "type": "paragraph",
      "text": "Plissier-Alicot AL, Lonetti G, Champsaur P, Allain P, Mauras Y, Botta A. Fatal poisoning due to intravasation after oral administration of barium"
    },
    {
      "type": "paragraph",
      "text": "sulfate for contrast radiography. Forensic Sci Int 1999;106:109-13."
    },
    {
      "type": "paragraph",
      "text": "18."
    },
    {
      "type": "paragraph",
      "text": "Roza O, Berman LB. The pathophysiology of barium: hypokalemic and cardiovascular effects. J Pharmacol Exp Ther 1971;177:433-9."
    },
    {
      "type": "paragraph",
      "text": "19."
    },
    {
      "type": "paragraph",
      "text": "Ahlawat SK, Sachdev A. Hypokalaemic paralysis. Postgrad Med J 1999;75:193-7."
    },
    {
      "type": "paragraph",
      "text": "20."
    },
    {
      "type": "paragraph",
      "text": "Ghose A, Sayeed AA, Hossain A, Rahman R, Faiz A, Haque G. Mass barium carbonate poisoning with fatal outcome, lessons learned: a case series."
    },
    {
      "type": "paragraph",
      "text": "Cases J 2009;2:9327."
    },
    {
      "type": "paragraph",
      "text": "21."
    },
    {
      "type": "paragraph",
      "text": "Payen C, Dellinger A, Pulce C, et al. Intoxication by large amounts of barium nitrate overcome by early massive K supplementation and oral"
    },
    {
      "type": "paragraph",
      "text": "administration of magnesium sulphate. Hum Exp Toxicol 2011;30:34-7."
    },
    {
      "type": "paragraph",
      "text": "22."
    },
    {
      "type": "paragraph",
      "text": "GUERBET. MD-Gastroview(R). Available at: https://www.guerbet.com/en-us/products-solutions/contrast-agents/md-gastroview-diatrizoate-"
    },
    {
      "type": "paragraph",
      "text": "meglumine-and-diatrizoate-sodium-solution-usp. Accessed September 19, 2023."
    },
    {
      "type": "paragraph",
      "text": "23."
    },
    {
      "type": "paragraph",
      "text": "BRACCO. Gastrografin(R). Available at: https://www.bracco.com/en-ca/product/gastrografin. Accessed September 19, 2023."
    },
    {
      "type": "paragraph",
      "text": "24."
    },
    {
      "type": "paragraph",
      "text": "GE HEALTHCARE. Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "(iohexol) injection. Available at: https://www.gehealthcare.com/products/contrast-media/omnipaque. Accessed"
    },
    {
      "type": "paragraph",
      "text": "September 19, 2023."
    },
    {
      "type": "paragraph",
      "text": "25."
    },
    {
      "type": "paragraph",
      "text": "GE HEALTHCARE. OMNIPAQUE. Available at: https://www.gehealthcare.com/-/jssmedia/GEHC/US/Files/Products/Contrast-"
    },
    {
      "type": "paragraph",
      "text": "Media/Omnipaque/omnipaque-uspi.pdf. Accessed September 19, 2023."
    },
    {
      "type": "paragraph",
      "text": "26."
    },
    {
      "type": "paragraph",
      "text": "Pickhardt PJ. Positive Oral Contrast Material for Abdominal CT: Current Clinical Indications and Areas of Controversy. American Journal of"
    },
    {
      "type": "paragraph",
      "text": "Roentgenology 2020;215:69-78."
    },
    {
      "type": "paragraph",
      "text": "27."
    },
    {
      "type": "paragraph",
      "text": "Biondo S, Pars D, Mora L, Mart Ragu J, Kreisler E, Jaurrieta E. Randomized clinical study of Gastrografin administration in patients with"
    },
    {
      "type": "paragraph",
      "text": "adhesive small bowel obstruction. Br J Surg 2003;90:542-6."
    },
    {
      "type": "paragraph",
      "text": "28."
    },
    {
      "type": "paragraph",
      "text": "Burge J, Abbas SM, Roadley G, et al. Randomized controlled trial of Gastrografin in adhesive small bowel obstruction. ANZ J Surg 2005;75:672-4."
    },
    {
      "type": "paragraph",
      "text": "29."
    },
    {
      "type": "paragraph",
      "text": "Kapoor S, Jain G, Sewkani A, Sharma S, Patel K, Varshney S. Prospective evaluation of oral gastrografin in postoperative small bowel obstruction. J"
    },
    {
      "type": "paragraph",
      "text": "Surg Res 2006;131:256-60."
    },
    {
      "type": "paragraph",
      "text": "30."
    },
    {
      "type": "paragraph",
      "text": "Choi HK, Chu KW, Law WL. Therapeutic value of gastrografin in adhesive small bowel obstruction after unsuccessful conservative treatment: a"
    },
    {
      "type": "paragraph",
      "text": "prospective randomized trial. Ann Surg 2002;236:1-6."
    },
    {
      "type": "paragraph",
      "text": "31."
    },
    {
      "type": "paragraph",
      "text": "Zer M, Rubin M, Dintsman M. Dissolution of Barium-impaction ileus by Gastrografin. Dis Colon Rectum 1978;21:430-4."
    },
    {
      "type": "paragraph",
      "text": "32."
    },
    {
      "type": "paragraph",
      "text": "Agrons GA, Corse WR, Markowitz RI, Suarez ES, Perry DR. Gastrointestinal manifestations of cystic fibrosis: radiologic-pathologic correlation."
    },
    {
      "type": "paragraph",
      "text": "Radiographics 1996;16:871-93."
    },
    {
      "type": "paragraph",
      "text": "33."
    },
    {
      "type": "paragraph",
      "text": "Bracco Imaging Canada. GASTROGRAFIN(R) - PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION. Available"
    },
    {
      "type": "paragraph",
      "text": "at: https://pdf.hres.ca/dpd_pm/00065640.PDF. Accessed September 19, 2023."
    },
    {
      "type": "paragraph",
      "text": "34."
    },
    {
      "type": "paragraph",
      "text": "Halme L, Edgren J, von Smitten K, Linden H. Increased urinary excretion of iohexol after enteral administration in patients with ileal Crohn's disease."
    },
    {
      "type": "paragraph",
      "text": "A new test for disease activity. Acta Radiol 1993;34:237-41."
    },
    {
      "type": "paragraph",
      "text": "35."
    },
    {
      "type": "paragraph",
      "text": "Marinelli DL, Mintz MC. Absorption and excretion of dilute gastrografin during computed tomography in pseudomembranous colitis. J Comput"
    },
    {
      "type": "paragraph",
      "text": "Tomogr 1987;11:236-8."
    },
    {
      "type": "paragraph",
      "text": "36."
    },
    {
      "type": "paragraph",
      "text": "Miller SH. Anaphylactoid reaction after oral administration of diatrizoate meglumine and diatrizoate sodium solution. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "1997;168:959-61."
    },
    {
      "type": "paragraph",
      "text": "37."
    },
    {
      "type": "paragraph",
      "text": "Gmeinwieser J, Erhardt W, Reimann HJ, Babic R, Speck U, Wenzel-Hora B. Side effects of water-soluble contrast agents in upper gastrointestinal"
    },
    {
      "type": "paragraph",
      "text": "tract. Invest Radiol 1990;25 Suppl 1:S27-8."
    },
    {
      "type": "paragraph",
      "text": "38."
    },
    {
      "type": "paragraph",
      "text": "Horton KM, Fishman EK, Gayler B. The use of iohexol as oral contrast for computed tomography of the abdomen and pelvis. J Comput Assist"
    },
    {
      "type": "paragraph",
      "text": "Tomogr 2008;32:207-9."
    },
    {
      "type": "paragraph",
      "text": "39."
    },
    {
      "type": "paragraph",
      "text": "Seltzer SE, Jones B, McLaughlin GC. Proper choice of contrast agents in emergency gastrointestinal radiology. CRC Crit Rev Diagn Imaging"
    },
    {
      "type": "paragraph",
      "text": "1979;12:79-99."
    },
    {
      "type": "paragraph",
      "text": "40."
    },
    {
      "type": "paragraph",
      "text": "Gelfand DW. Complications of gastrointestinal radiologic procedures: I. Complications of routine fluoroscopic studies. Gastrointest Radiol"
    },
    {
      "type": "paragraph",
      "text": "1980;5:293-315."
    },
    {
      "type": "paragraph",
      "text": "41."
    },
    {
      "type": "paragraph",
      "text": "Reich SB. Production of pulmonary edema by aspiration of water-soluble nonabsorbable contrast media. Radiology 1969;92:367-70."
    },
    {
      "type": "paragraph",
      "text": "42."
    },
    {
      "type": "paragraph",
      "text": "Beng CG, Wellby ML, Symons RG, Stuart S, Marshall J. The effects of iopodate on the serum iodothyronine pattern in normal subjects. Acta"
    },
    {
      "type": "paragraph",
      "text": "Endocrinol (Copenh) 1980;93:175-8."
    },
    {
      "type": "paragraph",
      "text": "43."
    },
    {
      "type": "paragraph",
      "text": "Kolbe AB, Fletcher JG, Froemming AT, et al. Evaluation of Patient Tolerance and Small-Bowel Distention With a New Small-Bowel Distending"
    },
    {
      "type": "paragraph",
      "text": "Agent for Enterography. American Journal of Roentgenology 2016;206:994-1002."
    },
    {
      "type": "paragraph",
      "text": "44."
    },
    {
      "type": "paragraph",
      "text": "Ajaj W, Goehde SC, Schneemann H, Ruehm SG, Debatin JF, Lauenstein TC. Oral contrast agents for small bowel MRI: comparison of different"
    },
    {
      "type": "paragraph",
      "text": "additives to optimize bowel distension. Eur Radiol 2004;14:458-64."
    },
    {
      "type": "paragraph",
      "text": "45."
    },
    {
      "type": "paragraph",
      "text": "Dillman JR, Towbin AJ, Imbus R, Young J, Gates E, Trout AT. Comparison of Two Neutral Oral Contrast Agents in Pediatric Patients: A"
    },
    {
      "type": "paragraph",
      "text": "Prospective Randomized Study. Radiology 2018;288:245-51."
    },
    {
      "type": "paragraph",
      "text": "46."
    },
    {
      "type": "paragraph",
      "text": "Winter TC, Ager JD, Nghiem HV, Hill RS, Harrison SD, Freeny PC. Upper gastrointestinal tract and abdomen: water as an orally administered"
    },
    {
      "type": "paragraph",
      "text": "contrast agent for helical CT. Radiology 1996;201:365-70."
    },
    {
      "type": "paragraph",
      "text": "47."
    },
    {
      "type": "paragraph",
      "text": "Koo CW, Shah-Patel LR, Baer JW, Frager DH. Cost-effectiveness and patient tolerance of low-attenuation oral contrast material: milk versus"
    },
    {
      "type": "paragraph",
      "text": "VoLumen. AJR Am J Roentgenol 2008;190:1307-13."
    },
    {
      "type": "paragraph",
      "text": "48."
    },
    {
      "type": "paragraph",
      "text": "Thompson SE, Raptopoulos V, Sheiman RL, McNicholas MM, Prassopoulos P. Abdominal helical CT: milk as a low-attenuation oral contrast agent."
    },
    {
      "type": "paragraph",
      "text": "Radiology 1999;211:870-5."
    },
    {
      "type": "paragraph",
      "text": "49."
    },
    {
      "type": "paragraph",
      "text": "Mattrey RF, Hajek PC, Gylys-Morin VM, et al. Perfluorochemicals as gastrointestinal contrast agents for MR imaging: preliminary studies in rats and"
    },
    {
      "type": "paragraph",
      "text": "humans. AJR Am J Roentgenol 1987;148:1259-63."
    },
    {
      "type": "paragraph",
      "text": "50."
    },
    {
      "type": "paragraph",
      "text": "Arpurt JP, Caroli-Bosc FX, Harris A, Delmont J. Reflux of air or barium into the biliary ducts. Gastroenterology 1992;103:1989-90."
    },
    {
      "type": "paragraph",
      "text": "51."
    },
    {
      "type": "paragraph",
      "text": "Walsham A, Larsen J. Adverse effects of barium sulfate in the biliary tract. Diagn Interv Radiol 2008;14:94-6."
    },
    {
      "type": "paragraph",
      "text": "52."
    },
    {
      "type": "paragraph",
      "text": "Zeman RK, Burrell MI. Gallbladder and Bile Duct Imaging: A Clinical Radiologic Approach: Churchill Livingstone; 1987."
    },
    {
      "type": "paragraph",
      "text": "53."
    },
    {
      "type": "paragraph",
      "text": "Hanson JA, Borre C, Rivers G. What is your diagnosis? Foreign body obstruction of the duodenum with reflux of barium sulfate into the gallbladder"
    },
    {
      "type": "image",
      "assetId": "asset_9269523187",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "GASTROINTESTINAL (GI) CONTRAST MEDIA IN ADULTS: INDICATIONS AND GUIDELINES"
    },
    {
      "type": "paragraph",
      "text": "68"
    },
    {
      "type": "paragraph",
      "text": "and intrahepatic bile ducts. J Am Vet Med Assoc 1998;213:1257-8."
    },
    {
      "type": "paragraph",
      "text": "54."
    },
    {
      "type": "paragraph",
      "text": "Gibney RG BH. Cholangiography and pancreatography. 2nd ed. Rockville, MD: Aspen Publishers; 1989."
    },
    {
      "type": "paragraph",
      "text": "55."
    },
    {
      "type": "paragraph",
      "text": "J. S. Barium sulfate: toxicity and complications. 2nd ed. Rockville, MD: Aspen Publishers; 1989."
    },
    {
      "type": "paragraph",
      "text": "56."
    },
    {
      "type": "paragraph",
      "text": "Hunter TB FL. Outline of radiographic contrast agents. Appl Radiol 1987:16:137-58."
    },
    {
      "type": "paragraph",
      "text": "57."
    },
    {
      "type": "paragraph",
      "text": "Sable RA, Rosenthal WS, Siegel J, Ho R, Jankowski RH. Absorption of contrast medium during ERCP. Dig Dis Sci 1983;28:801-6."
    },
    {
      "type": "paragraph",
      "text": "58."
    },
    {
      "type": "paragraph",
      "text": "Mann K, Rendl J, Busley R, et al. Systemic iodine absorption during endoscopic application of radiographic contrast agents for endoscopic retrograde"
    },
    {
      "type": "paragraph",
      "text": "cholangiopancreaticography. Eur J Endocrinol 1994;130:498-501."
    },
    {
      "type": "paragraph",
      "text": "59."
    },
    {
      "type": "paragraph",
      "text": "Hopper KD, Wegert SJ, Hallgren SE. Renal excretion of endoscopic retrograde cholangiopancreatography injected contrast. A common phenomenon."
    },
    {
      "type": "paragraph",
      "text": "Invest Radiol 1989;24:394-6."
    },
    {
      "type": "paragraph",
      "text": "60."
    },
    {
      "type": "paragraph",
      "text": "Draganov P, Cotton PB. Iodinated contrast sensitivity in ERCP. Am J Gastroenterol 2000;95:1398-401."
    },
    {
      "type": "paragraph",
      "text": "61."
    },
    {
      "type": "paragraph",
      "text": "Draganov PV, Forsmark CE. Prospective evaluation of adverse reactions to iodine-containing contrast media after ERCP. Gastrointest Endosc"
    },
    {
      "type": "paragraph",
      "text": "2008;68:1098-101."
    },
    {
      "type": "paragraph",
      "text": "62."
    },
    {
      "type": "paragraph",
      "text": "Lawrence C, Cotton PB. Gadolinium as an alternative contrast agent for therapeutic ERCP in the iodine-allergic patient. Endoscopy 2009;41:564-7."
    },
    {
      "type": "paragraph",
      "text": "63."
    },
    {
      "type": "paragraph",
      "text": "Trottier-Tellier F, Harvey L, Bernard H, Baillargeon J. A325 RISK EVALUATION OF ENDOSCOPIC RETROGRADE"
    },
    {
      "type": "paragraph",
      "text": "CHOLANGIOPANCREATOGRAPHY (ERCP)-RELATED CONTRAST MEDIA (CM) ALLERGIC REACTION AMONG PATIENTS KNOWN"
    },
    {
      "type": "paragraph",
      "text": "FOR ADVERSE REACTION TO IODINE CONTAINING PRODUCT. Journal of the Canadian Association of Gastroenterology 2018;1:565-66."
    },
    {
      "type": "paragraph",
      "text": "64."
    },
    {
      "type": "paragraph",
      "text": "Nilsson U. Adverse reactions to iotroxate at intravenous cholangiography. A prospective clinical investigation and review of the literature. Acta"
    },
    {
      "type": "paragraph",
      "text": "Radiol 1987;28:571-5."
    },
    {
      "type": "paragraph",
      "text": "65."
    },
    {
      "type": "paragraph",
      "text": "Persson A, Dahlstrm N, Smedby O, Brismar TB. Three-dimensional drip infusion CT cholangiography in patients with suspected obstructive biliary"
    },
    {
      "type": "paragraph",
      "text": "disease: a retrospective analysis of feasibility and adverse reaction to contrast material. BMC Med Imaging 2006;6:1."
    },
    {
      "type": "paragraph",
      "text": "66."
    },
    {
      "type": "paragraph",
      "text": "Schroeder T, Radtke A, Debatin JF, et al. Contrast-enhanced multidetector-CT cholangiography after living donor liver transplantation."
    },
    {
      "type": "paragraph",
      "text": "Hepatogastroenterology 2007;54:1176-80."
    },
    {
      "type": "paragraph",
      "text": "67."
    },
    {
      "type": "paragraph",
      "text": "Schroeder T, Radtke A, Kuehl H, Debatin JF, Malag M, Ruehm SG. Evaluation of living liver donors with an all-inclusive 3D multi-detector row"
    },
    {
      "type": "paragraph",
      "text": "CT protocol. Radiology 2006;238:900-10."
    },
    {
      "type": "paragraph",
      "text": "68."
    },
    {
      "type": "paragraph",
      "text": "Frydrychowicz A, Lubner MG, Brown JJ, et al. Hepatobiliary MR imaging with gadolinium-based contrast agents. J Magn Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": "2012;35:492-511."
    },
    {
      "type": "paragraph",
      "text": "69."
    },
    {
      "type": "paragraph",
      "text": "FDA. MultiHance (gadobenate dimeglumine) Injection. Available at:"
    },
    {
      "type": "paragraph",
      "text": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021357s009lbl.pdf. Accessed September 19, 2023."
    },
    {
      "type": "paragraph",
      "text": "70."
    },
    {
      "type": "paragraph",
      "text": "FDA. EOVIST (Gadoxetate Disodium) Injection for intravenous use Available at:"
    },
    {
      "type": "paragraph",
      "text": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022090s004lbl.pdf. Accessed September 19, 2023."
    },
    {
      "type": "paragraph",
      "text": "71."
    },
    {
      "type": "paragraph",
      "text": "Dorta G, Uske A, Blum AL. Meglumine gadoterate: a new safe radiocontrast medium for endoscopic retrograde cholangiopancreatography?"
    },
    {
      "type": "paragraph",
      "text": "Digestion 1997;58:289-92."
    },
    {
      "type": "paragraph",
      "text": "72."
    },
    {
      "type": "paragraph",
      "text": "FDA. GLUCAGON for injection, for subcutaneous, intramuscular or intravenous use Available at:"
    },
    {
      "type": "paragraph",
      "text": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201849s005lbl.pdf. Accessed September 19, 2023."
    },
    {
      "type": "paragraph",
      "text": "73."
    },
    {
      "type": "paragraph",
      "text": "Bova JG, Jurdi RA, Bennett WF. Antispasmodic drugs to reduce discomfort and colonic spasm during barium enemas: comparison of oral"
    },
    {
      "type": "paragraph",
      "text": "hyoscyamine, i.v. glucagon, and no drug. AJR Am J Roentgenol 1993;161:965-8."
    },
    {
      "type": "paragraph",
      "text": "74."
    },
    {
      "type": "paragraph",
      "text": "Thoeni RF, Margulis AR. The state of radiographic technique in the examination of the colon: a survey in 1987. Radiology 1988;167:7-12."
    },
    {
      "type": "paragraph",
      "text": "75."
    },
    {
      "type": "paragraph",
      "text": "Miller RE, Chernish SM, Brunelle RL. Gastrointestinal radiography with glucagon. Gastrointest Radiol 1979;4:1-10."
    },
    {
      "type": "paragraph",
      "text": "76."
    },
    {
      "type": "paragraph",
      "text": "Oppenheimer J, Ray CE, Jr., Kondo KL. Miscellaneous pharmaceutical agents in interventional radiology. Semin Intervent Radiol 2010;27:422-30."
    },
    {
      "type": "paragraph",
      "text": "77."
    },
    {
      "type": "paragraph",
      "text": "Skucas J. The use of antispasmodic drugs during barium enemas. AJR Am J Roentgenol 1994;162:1323-5."
    },
    {
      "type": "paragraph",
      "text": "78."
    },
    {
      "type": "paragraph",
      "text": "Chernish SM, Maglinte DD. Glucagon: common untoward reactions--review and recommendations. Radiology 1990;177:145-6."
    },
    {
      "type": "paragraph",
      "text": "79."
    },
    {
      "type": "paragraph",
      "text": "Feczko PJ, Simms SM, Iorio J, Halpert R. Gastroduodenal response to low-dose glucagon. AJR Am J Roentgenol 1983;140:935-40."
    },
    {
      "type": "paragraph",
      "text": "80."
    },
    {
      "type": "paragraph",
      "text": "Skucas J. Optimal dose of glucagon. Radiology 1992;183:325."
    },
    {
      "type": "paragraph",
      "text": "81."
    },
    {
      "type": "paragraph",
      "text": "Chernish SM, Maglinte DD, Brunelle RL. The laboratory response to glucagon dosages used in gastrointestinal examinations. Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": "1988;23:847-52."
    },
    {
      "type": "paragraph",
      "text": "82."
    },
    {
      "type": "paragraph",
      "text": "Gutzeit A, Binkert CA, Koh DM, et al. Evaluation of the anti-peristaltic effect of glucagon and hyoscine on the small bowel: comparison of"
    },
    {
      "type": "paragraph",
      "text": "intravenous and intramuscular drug administration. Eur Radiol 2012;22:1186-94."
    },
    {
      "type": "paragraph",
      "text": "83."
    },
    {
      "type": "paragraph",
      "text": "Morris CH, Baker J. Glucagon. StatPearls. Treasure Island (FL): StatPearls Publishing"
    },
    {
      "type": "paragraph",
      "text": "Copyright 2023, StatPearls Publishing LLC.; 2023."
    },
    {
      "type": "paragraph",
      "text": "84."
    },
    {
      "type": "paragraph",
      "text": "Moeller G, Hughes JJ, Mangano FA, Gelormini R, Tomlinson TL, DiPalma JA. Comparison of L-hyoscyamine, glucagon, and placebo for air-"
    },
    {
      "type": "paragraph",
      "text": "contrast upper gastrointestinal series. Gastrointest Radiol 1992;17:195-8."
    },
    {
      "type": "paragraph",
      "text": "85."
    },
    {
      "type": "paragraph",
      "text": "Bova JG, Bhattacharjee N, Jurdi R, Bennett WF. Comparison of no medication, placebo, and hyoscyamine for reducing pain during a barium enema."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgenol 1999;172:1285-7."
    },
    {
      "type": "paragraph",
      "text": "86."
    },
    {
      "type": "paragraph",
      "text": "Wagner M, Klessen C, Rief M, et al. High-resolution T2-weighted abdominal magnetic resonance imaging using respiratory triggering: impact of"
    },
    {
      "type": "paragraph",
      "text": "butylscopolamine on image quality. Acta Radiol 2008;49:376-82."
    },
    {
      "type": "paragraph",
      "text": "87."
    },
    {
      "type": "paragraph",
      "text": "Froehlich JM, Daenzer M, von Weymarn C, Erturk SM, Zollikofer CL, Patak MA. Aperistaltic effect of hyoscine N-butylbromide versus glucagon on"
    },
    {
      "type": "paragraph",
      "text": "the small bowel assessed by magnetic resonance imaging. Eur Radiol 2009;19:1387-93."
    },
    {
      "type": "paragraph",
      "text": "88."
    },
    {
      "type": "paragraph",
      "text": "Ghobrial PM, Neuberger I, Guglielmo FF, et al. Cine MR enterography grading of small bowel peristalsis: evaluation of the antiperistaltic"
    },
    {
      "type": "paragraph",
      "text": "effectiveness of sublingual hyoscyamine sulfate. Acad Radiol 2014;21:86-91."
    },
    {
      "type": "paragraph",
      "text": "89."
    },
    {
      "type": "paragraph",
      "text": "Young BM, Fletcher JG, Booya F, et al. Head-to-head comparison of oral contrast agents for cross-sectional enterography: small bowel distention,"
    },
    {
      "type": "paragraph",
      "text": "timing, and side effects. J Comput Assist Tomogr 2008;32:32-8."
    },
    {
      "type": "paragraph",
      "text": "90."
    },
    {
      "type": "paragraph",
      "text": "Garra G, Singer AJ, Bamber D, Chohan J, Troxell R, Thode HC, Jr. Pretreatment of patients requiring oral contrast abdominal computed tomography"
    },
    {
      "type": "paragraph",
      "text": "with antiemetics: a randomized controlled trial of efficacy. Ann Emerg Med 2009;53:528-33."
    },
    {
      "type": "paragraph",
      "text": "91."
    },
    {
      "type": "paragraph",
      "text": "Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV. Metoclopramide and tardive dyskinesia. Biol Psychiatry 1994;36:630-2."
    },
    {
      "type": "paragraph",
      "text": "92."
    },
    {
      "type": "paragraph",
      "text": "Matos C, Winant C, Devire J. Magnetic resonance pancreatography. Abdom Imaging 2001;26:243-53."
    },
    {
      "type": "paragraph",
      "text": "93."
    },
    {
      "type": "paragraph",
      "text": "Dreiling DA, Messer J. The secretin story: a saga in clinical medicine and gastrointestinal physiology. Am J Gastroenterol 1978;70:455-79."
    },
    {
      "type": "paragraph",
      "text": "94."
    },
    {
      "type": "paragraph",
      "text": "Laugier R. Dynamic endoscopic manometry of the response to secretin in patients with chronic pancreatitis. Endoscopy 1994;26:222-7."
    },
    {
      "type": "paragraph",
      "text": "95."
    },
    {
      "type": "paragraph",
      "text": "FDA. ChiRhoStim(R) (Human Secretin) Injection, lyophilized powder for intravenous use, 16 mcg and 40 mcg vials Available at:"
    },
    {
      "type": "image",
      "assetId": "asset_dcba09a4ac",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "GASTROINTESTINAL (GI) CONTRAST MEDIA IN ADULTS: INDICATIONS AND GUIDELINES"
    },
    {
      "type": "paragraph",
      "text": "69"
    },
    {
      "type": "paragraph",
      "text": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021256s002lbl.pdf. Accessed September 19, 2023."
    },
    {
      "type": "paragraph",
      "text": "96."
    },
    {
      "type": "paragraph",
      "text": "Boraschi P, Donati F, Gigoni R, et al. Pancreatic transplants: secretin-stimulated MR pancreatography. Abdom Imaging 2007;32:207-14."
    },
    {
      "type": "paragraph",
      "text": "97."
    },
    {
      "type": "paragraph",
      "text": "Wu B, Conwell DL. The endoscopic pancreatic function test. Am J Gastroenterol 2009;104:2381-3."
    },
    {
      "type": "paragraph",
      "text": "98."
    },
    {
      "type": "paragraph",
      "text": "Davis PL. Anaphylactoid reactions to the nonvascular administration of water-soluble iodinated contrast media. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2015;204:1140-5."
    },
    {
      "type": "paragraph",
      "text": "99."
    },
    {
      "type": "paragraph",
      "text": "Eisenberg RL, Hedgcock MW, Shanser JD, Brenner RJ, Gedgaudas RK, Marks WM. Iodine absorption from the gastrointestinal tract during"
    },
    {
      "type": "paragraph",
      "text": "hypaque-enema examination. Radiology 1979;133:597-9."
    },
    {
      "type": "paragraph",
      "text": "100. Rosen RS, Jacobson G. VISIBLE URINARY TRACT EXCRETION FOLLOWING ORAL ADMINISTRATION OF WATER-SOLUBLE"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA. Radiology 1965;84:1031-2."
    },
    {
      "type": "paragraph",
      "text": "101. Kim YS, Choi YH, Cho YJ, et al. Incidence of Breakthrough Reaction in Patients with Prior Acute Allergic-Like Reactions to Iodinated Contrast"
    },
    {
      "type": "paragraph",
      "text": "Media according to the Administration Route. Korean J Radiol 2018;19:352-57."
    },
    {
      "type": "paragraph",
      "text": "102. Joseph JP, Domino P, Bird VG, Sharma N, Ford S, Caruso LJ. Outcomes in Patients with Known Contrast Allergy Undergoing Contrast-Enhanced"
    },
    {
      "type": "paragraph",
      "text": "Endourologic Procedures: A Retrospective Cohort Study. J Endourol 2021;35:1857-62."
    },
    {
      "type": "paragraph",
      "text": "103. Widmark JM. Imaging-related medications: a class overview. Proc (Bayl Univ Med Cent) 2007;20:408-17."
    },
    {
      "type": "paragraph",
      "text": "104. Mohapatra A, Hyun G, Semins MJ. Trends in the Usage of Contrast Allergy Prophylaxis for Endourologic Procedures. Urology 2019;131:53-56."
    },
    {
      "type": "paragraph",
      "text": "105. Yale School of Medicine. Premedication Policy for Non-Vascular Administration of Contrast in Patients with Contrast Allergy."
    },
    {
      "type": "paragraph",
      "text": "Availableat:https://medicine.yale.edu/diagnosticradiology/qualitysafety/nonvascular%20contrast%20v4_442936_51324_v1_456180_51324_v1.pdf."
    },
    {
      "type": "paragraph",
      "text": "Accessed September 19, 2023."
    },
    {
      "type": "paragraph",
      "text": "106. Umakoshi H, Nihashi T, Takada A, et al. Iodinated Contrast Media Substitution to Prevent Recurrent Hypersensitivity Reactions: A Systematic"
    },
    {
      "type": "paragraph",
      "text": "Review and Meta-Analysis. Radiology 2022;305:341-49."
    },
    {
      "type": "paragraph",
      "text": "107. McDonald JS, Larson NB, Kolbe AB, et al. Prevention of Allergic-like Reactions at Repeat CT: Steroid Pretreatment versus Contrast Material"
    },
    {
      "type": "paragraph",
      "text": "Substitution. Radiology 2021;301:133-40."
    },
    {
      "type": "paragraph",
      "text": "108. Abe S, Fukuda H, Tobe K, Ibukuro K. Protective effect against repeat adverse reactions to iodinated contrast medium: Premedication vs. changing the"
    },
    {
      "type": "paragraph",
      "text": "contrast medium. Eur Radiol 2016;26:2148-54."
    },
    {
      "type": "paragraph",
      "text": "109. Park SJ, Kang DY, Sohn KH, et al. Immediate Mild Reactions to CT with Iodinated Contrast Media: Strategy of Contrast Media Readministration"
    },
    {
      "type": "paragraph",
      "text": "without Corticosteroids. Radiology 2018;288:710-16."
    },
    {
      "type": "paragraph",
      "text": "Revision History"
    },
    {
      "type": "paragraph",
      "text": "2013: Revision"
    },
    {
      "type": "paragraph",
      "text": "2024: Major Revision"
    },
    {
      "type": "image",
      "assetId": "asset_01671a0996",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ACR"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "ASNR POSITION STATEMENT ON THE USE OF GADOLINIUM CONTRAST AGENTS"
    },
    {
      "type": "paragraph",
      "text": "70"
    },
    {
      "type": "paragraph",
      "text": "ACR"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "ASNR POSITION STATEMENT ON THE USE OF"
    },
    {
      "type": "paragraph",
      "text": "GADOLINIUM CONTRAST AGENTS"
    },
    {
      "type": "paragraph",
      "text": "Following U.S. Food and Drug Administration (FDA) approval in 1988, gadolinium-based contrast agents (GBCAs) have been"
    },
    {
      "type": "paragraph",
      "text": "used for diagnosis and treatment guidance in more than 300 million patients worldwide. GBCAs increase the conspicuity of"
    },
    {
      "type": "paragraph",
      "text": "diseased tissues. All GBCAs share a common structure of an organic ligand that tightly binds to and improves the stability,"
    },
    {
      "type": "paragraph",
      "text": "solubility, and safety of the central gadolinium heavy metal ion. In typical patients, the chelate is mostly eliminated via the"
    },
    {
      "type": "paragraph",
      "text": "kidneys, with some amount of liver excretion demonstrated for a few of the agents."
    },
    {
      "type": "paragraph",
      "text": "Since 2006, radiologists have withheld some GBCAs from patients with acute kidney injury and/or severe chronic kidney"
    },
    {
      "type": "paragraph",
      "text": "disease, if the estimated glomerular filtration rate (GFR) is <30 mL/min/1.73 m"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": ", because of the increased risk of nephrogenic"
    },
    {
      "type": "paragraph",
      "text": "systemic fibrosis (NSF). NSF is a rare but serious systemic disease characterized by fibrosis of the skin and other tissues"
    },
    {
      "type": "paragraph",
      "text": "throughout the body in renally impaired individuals. As a result of judicious use of GBCAs among patients with compromised"
    },
    {
      "type": "paragraph",
      "text": "renal function and a decrease in utilization of those GBCAs that are more highly associated with NSF, there has been a drastic"
    },
    {
      "type": "paragraph",
      "text": "reduction in the number of cases encountered since restrictive guidelines were put into place after the association of NSF with"
    },
    {
      "type": "paragraph",
      "text": "GBCAs was identified in 2006."
    },
    {
      "type": "paragraph",
      "text": "Recently, residual gadolinium has been found within the brain tissue of patients who received multiple doses of GBCAs over"
    },
    {
      "type": "paragraph",
      "text": "their lifetimes. For reasons that remain unclear, gadolinium deposition appears to occur preferentially in certain specific areas"
    },
    {
      "type": "paragraph",
      "text": "of the brain, even in the absence of clinically evident disease and in the setting of an intact blood brain barrier. Such deposition"
    },
    {
      "type": "paragraph",
      "text": "is not expected, and led the FDA to publish a Safety Alert in July of 2015 indicating that they were actively investigating the"
    },
    {
      "type": "paragraph",
      "text": "risk and clinical significance of these gadolinium deposits. To date, no adverse health effects have been uncovered, but the"
    },
    {
      "type": "paragraph",
      "text": "radiology community has initiated a rigorous investigation."
    },
    {
      "type": "paragraph",
      "text": "Gadolinium deposition in the brain may be dose dependent and can occur in patients with no clinical evidence of kidney or"
    },
    {
      "type": "paragraph",
      "text": "liver disease. Fortunately, there have been no reports to date to suggest these deposits are associated with histologic changes"
    },
    {
      "type": "paragraph",
      "text": "that would suggest neurotoxicity, even among GBCAs with the highest rates of deposition. Although there are no known adverse"
    },
    {
      "type": "paragraph",
      "text": "clinical consequences associated with gadolinium deposition in the brain, additional research is warranted to elucidate the"
    },
    {
      "type": "paragraph",
      "text": "mechanisms of deposition, the chelation state of these deposits, the relationship to GBCA stability and binding affinity, and"
    },
    {
      "type": "paragraph",
      "text": "theoretical toxic potential, which may be different for different GBCAs. Until we fully understand the mechanisms involved"
    },
    {
      "type": "paragraph",
      "text": "and their clinical consequences, the safety and tissue deposition potential of all GBCAs must be carefully evaluated."
    },
    {
      "type": "paragraph",
      "text": "GBCAs provide crucial, life-saving medical information. Each time a gadolinium-enhanced MRI study is considered, it would"
    },
    {
      "type": "paragraph",
      "text": "be prudent to consider the clinical benefit of the diagnostic information or treatment result that MRI or MRA may provide"
    },
    {
      "type": "paragraph",
      "text": "against the unknown potential risk of gadolinium deposition in the brain for each individual patient. Particular attention should"
    },
    {
      "type": "paragraph",
      "text": "be paid to pediatric and other patients who may receive many GBCA-enhanced MRI studies over the course of their lifetimes."
    },
    {
      "type": "paragraph",
      "text": "If the decision for an individual patient is made to use a GBCA for an MRI study, multiple factors need to be considered when"
    },
    {
      "type": "paragraph",
      "text": "selecting a GBCA, including diagnostic efficacy, relaxivity, rate of adverse reactions, dosing/concentration, and propensity to"
    },
    {
      "type": "paragraph",
      "text": "deposit in more sensitive organs such as the brain. As this gadolinium deposition phenomenon remains a relatively undefined"
    },
    {
      "type": "paragraph",
      "text": "clinical phenomenon, and accurate and complete data may be useful as investigations proceed, the identity and dose of GBCA"
    },
    {
      "type": "paragraph",
      "text": "used should be recorded after each intravenous administration."
    },
    {
      "type": "paragraph",
      "text": "The radiology community will continue to assess the safety of GBCAs and modify clinical practice recommendations"
    },
    {
      "type": "paragraph",
      "text": "accordingly as new data becomes available."
    },
    {
      "type": "image",
      "assetId": "asset_5806f36e75",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ADVERSE REACTIONS TO GADOLINIUM-BASED CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "71"
    },
    {
      "type": "paragraph",
      "text": "ADVERSE REACTIONS TO GADOLINIUM-BASED CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "Gadolinium-based contrast media (GBCM) have been approved for parenteral use since the late 1980s. These agents can be"
    },
    {
      "type": "paragraph",
      "text": "differentiated on the basis of chelate chemistry, stability, viscosity, osmolality, and, in some cases, effectiveness for specific"
    },
    {
      "type": "paragraph",
      "text": "applications. GBCM are extremely well tolerated by the vast majority of patients in whom they are injected. Acute adverse reactions"
    },
    {
      "type": "paragraph",
      "text": "are encountered with a lower frequency than is observed after administration of iodinated contrast media."
    },
    {
      "type": "paragraph",
      "text": "Adverse Reactions"
    },
    {
      "type": "paragraph",
      "text": "The adverse event rate for GBCM administered at clinical doses (0.1"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "0.2 mmol/kg for most GBCM) ranges from 0.07% to 2.4%."
    },
    {
      "type": "paragraph",
      "text": "Most reactions are mild and physiologic, including coldness, warmth, or pain at the injection site; nausea with or without vomiting;"
    },
    {
      "type": "paragraph",
      "text": "headache; paresthesias; and dizziness. Allergic- like reactions are uncommon and vary in frequency from 0.004% to"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "0.7%. The"
    },
    {
      "type": "paragraph",
      "text": "manifestations of an allergic- like reaction to a GBCM are similar to those of an allergic-like reaction to an iodinated contrast"
    },
    {
      "type": "paragraph",
      "text": "medium. Severe life-threatening anaphylactic reactions occur [1-6] but are exceedingly rare (0.001% to 0.01%) [7-9] In an"
    },
    {
      "type": "paragraph",
      "text": "accumulated series of 687,000 doses there were only five severe reactions [10]. In a survey of 20 million administered doses, there"
    },
    {
      "type": "paragraph",
      "text": "were 55 severe reactions. A large single-institution study that included more than 100,000 GBCM injections demonstrated an"
    },
    {
      "type": "paragraph",
      "text": "allergic-like reaction frequency of 0.15%, with 0.13% mild reactions and 0.006% severe reactions (six reactions) [11]. Fatal"
    },
    {
      "type": "paragraph",
      "text": "reactions to gadolinium chelate agents occur but are extremely rare [12]."
    },
    {
      "type": "paragraph",
      "text": "GBCM administered to patients with acute kidney injury or severe chronic kidney disease can result in a syndrome of nephrogenic"
    },
    {
      "type": "paragraph",
      "text": "systemic fibrosis (NSF) [13,14]. For more information, see the chapter on"
    },
    {
      "type": "paragraph",
      "text": "Nephrogenic Systemic Fibrosis"
    },
    {
      "type": "paragraph",
      "text": ". GBCM are not considered"
    },
    {
      "type": "paragraph",
      "text": "nephrotoxic at dosages approved for MR imaging."
    },
    {
      "type": "paragraph",
      "text": "Risk Factors"
    },
    {
      "type": "paragraph",
      "text": "The frequency of acute adverse reactions to GBCM is about eight times higher in patients with a previous reaction to GBCM. At"
    },
    {
      "type": "paragraph",
      "text": "many institutions, a prior allergic-like reaction to GBCM is often an indication for corticosteroid prophylaxis prior to subsequent"
    },
    {
      "type": "paragraph",
      "text": "exposures. One GBCM, gadobenate dimeglumine, has FDA labeling contraindicating use in patients who have a history of an"
    },
    {
      "type": "paragraph",
      "text": "allergic-like reaction to GBCM. Some reports have suggested that GBCM that have been most commonly associated with NSF are"
    },
    {
      "type": "paragraph",
      "text": "less likely to be associated with allergic-like reactions and vice versa [15]."
    },
    {
      "type": "paragraph",
      "text": "Patients with asthma and various other allergies may have a mild increased risk for an allergic-like reaction to GBCM compared to"
    },
    {
      "type": "paragraph",
      "text": "the general population, but many institutions do not have special procedures for these patients given the extremely low overall"
    },
    {
      "type": "paragraph",
      "text": "reaction rate for GBCM. There is no cross-reactivity between GBCM and iodinated contrast media."
    },
    {
      "type": "paragraph",
      "text": "In a patient with previous moderate or severe allergic-like reactions to a specific GBCM, it may be prudent to use a different GBCM"
    },
    {
      "type": "paragraph",
      "text": "and premedicate for subsequent MR examinations, although there are no published studies to confirm that this approach is"
    },
    {
      "type": "paragraph",
      "text": "efficacious in reducing the likelihood of a repeat contrast reaction."
    },
    {
      "type": "paragraph",
      "text": "The Safety of Gadolinium-Based Contrast Media in Patients with Sickle Cell Disease"
    },
    {
      "type": "paragraph",
      "text": "Early in vitro research investigating the effects of a strong external magnetic field (e.g., MR magnet) on red blood cells (erythrocytes)"
    },
    {
      "type": "paragraph",
      "text": "suggested that fully deoxygenated sickle erythrocytes align perpendicularly to a magnetic field. It was hypothesized that this"
    },
    {
      "type": "paragraph",
      "text": "alignment could further restrict sickle erythrocyte flow through small vessels and promote vaso-occlusive complications in sickle"
    },
    {
      "type": "paragraph",
      "text": "cell patients [16]. Based on this supposition, FDA package inserts suggested caution in patients with sickle cell disease for two"
    },
    {
      "type": "paragraph",
      "text": "GBCM approved for use in the United States (gadoversetamide [OptiMARK, Guerbet] and gadoteridol [Prohance, Bracco"
    },
    {
      "type": "paragraph",
      "text": "Diagnostics])."
    },
    {
      "type": "paragraph",
      "text": "To the best of our knowledge and noted in a review of the literature [17], there has been no documented in vivo vaso-occlusive or"
    },
    {
      "type": "paragraph",
      "text": "hemolytic complication directly related to the IV administration of GBCM in a sickle cell disease patient. A small retrospective"
    },
    {
      "type": "paragraph",
      "text": "study with a control group showed no significantly increased risk of vaso- occlusive or hemolytic adverse events when administering"
    },
    {
      "type": "paragraph",
      "text": "GBCM to sickle cell disease patients [18]. Additionally, several small scientific studies [19-21] of patients with sickle cell disease"
    },
    {
      "type": "paragraph",
      "text": "have employed MR imaging with GBCM without reported adverse effects."
    },
    {
      "type": "paragraph",
      "text": "Therefore, the risk to patients with sickle cell disease from IV-administered GBCM at approved dosages is very low or nonexistent,"
    },
    {
      "type": "paragraph",
      "text": "and there is no reason to withhold these agents from these patients when their use is otherwise indicated."
    },
    {
      "type": "image",
      "assetId": "asset_7b299d3976",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ADVERSE REACTIONS TO GADOLINIUM-BASED CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "72"
    },
    {
      "type": "paragraph",
      "text": "Breath-holding Difficulty with Gadoxetate Disodium"
    },
    {
      "type": "paragraph",
      "text": "Several studies have noted that gadoxetate disodium may be associated with transient severe respiratory motion- related artifact that"
    },
    {
      "type": "paragraph",
      "text": "manifests in the arterial phase of dynamic T1-weighted gradient echo imaging and resolves shortly thereafter [22-26]. This"
    },
    {
      "type": "paragraph",
      "text": "manifestation has been described as transient dyspnea. At one institution, patient surveys showed that significantly more p"
    },
    {
      "type": "paragraph",
      "text": "atients"
    },
    {
      "type": "paragraph",
      "text": "complained of subjective shortness of breath following gadoxetate disodium compared to gadobenate dimeglumine exposure [22]."
    },
    {
      "type": "paragraph",
      "text": "The reported rate of occurrence of transient dyspnea has varied by site, imaging acquisition parameters, and administered v"
    },
    {
      "type": "paragraph",
      "text": "olume,"
    },
    {
      "type": "paragraph",
      "text": "ranging from 4% to 14% [22-26]."
    },
    {
      "type": "paragraph",
      "text": "Based on the volume-effect relationship and the lack of identifiable atopic covariates, this appears to be a physiologic reaction,"
    },
    {
      "type": "paragraph",
      "text": "manifesting as dyspnea or breath-holding difficulty that is unique to this agent [25]. The event is self-limited and does not appear to"
    },
    {
      "type": "paragraph",
      "text": "relate to allergic-like bronchospasm [22,24,25]. Therefore, corticosteroid prophylaxis is unlikely to be beneficial and is not felt to"
    },
    {
      "type": "paragraph",
      "text": "be indicated. Strong risk factors include a larger administered volume irrespective of patient weight (20 mL doses are twice as likely"
    },
    {
      "type": "paragraph",
      "text": "to cause the artifact as 10 mL doses) [25], chronic obstructive pulmonary disease (patients with COPD have a 35"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "40% event rate)"
    },
    {
      "type": "paragraph",
      "text": "[25], and re-administering the agent to patients who have previously had a similar reaction (previously affected patients have a 60%"
    },
    {
      "type": "paragraph",
      "text": "event rate on subsequent studies compared to a 5% event rate in the unaffected population) [26]. Imaging strategies to avoid the"
    },
    {
      "type": "paragraph",
      "text": "artifact include minimizing the injected volume (<=10 mL), avoiding the agent in patients who have experienced it before, and"
    },
    {
      "type": "paragraph",
      "text": "acquiring more than one arterial phase with a short temporal footprint [22-26]"
    },
    {
      "type": "paragraph",
      "text": "Treatment of Acute Adverse Reactions"
    },
    {
      "type": "paragraph",
      "text": "Treatment of acute adverse reactions to GBCM is similar to that for acute reactions to iodinated contrast media (see"
    },
    {
      "type": "paragraph",
      "text": "Tables 2"
    },
    {
      "type": "paragraph",
      "text": "and"
    },
    {
      "type": "paragraph",
      "text": "3"
    },
    {
      "type": "paragraph",
      "text": "). In any facility where contrast media are injected, it is imperative that personnel trained in recognizing and handling reactions"
    },
    {
      "type": "paragraph",
      "text": "and the equipment and medications to do so be on site or immediately available. Most MR facilities take the position that patients"
    },
    {
      "type": "paragraph",
      "text": "requiring treatment should be taken out of the imaging room immediately and away from the magnet so that none of the resuscitative"
    },
    {
      "type": "paragraph",
      "text": "equipment becomes a magnetic hazard."
    },
    {
      "type": "paragraph",
      "text": "Extravasation"
    },
    {
      "type": "paragraph",
      "text": "Extravasation events to GBCM are rare, with one series demonstrating a rate of 0.05% (28,000 doses). Laboratory studies in animals"
    },
    {
      "type": "paragraph",
      "text": "have demonstrated that both gadopentetate dimeglumine and gadoteridol are less toxic to the skin and subcutaneous tissues than are"
    },
    {
      "type": "paragraph",
      "text": "equal volumes of iodinated contrast media [27,28]. The small volumes typically injected for MR studies limit the chances of"
    },
    {
      "type": "paragraph",
      "text": "developing compartment syndrome. For these reasons the likelihood of a significant injury resulting from extravasated MR contrast"
    },
    {
      "type": "paragraph",
      "text": "media is extremely low."
    },
    {
      "type": "paragraph",
      "text": "Serum Calcium Determinations"
    },
    {
      "type": "paragraph",
      "text": "Some linear nonionic GBCM (e.g., gadoversetamide, gadodiamide) may interfere with total serum calcium values as determined"
    },
    {
      "type": "paragraph",
      "text": "with some calcium assay methods [29,30]. These GBCM do not cause actual reductions in serum calcium. Rather, they interfere"
    },
    {
      "type": "paragraph",
      "text": "with the test, leading to falsely low serum calcium laboratory values. In one report by Brown and associates [30], calcium levels"
    },
    {
      "type": "paragraph",
      "text": "measured by only one of three different assays (the orthocresolphthalein assay) showed a temporary decrease for just two of four"
    },
    {
      "type": "paragraph",
      "text": "studied GBCM (gadopentetate and gadoteridol had no effect), the length and severity of which closely mirrored the concentration"
    },
    {
      "type": "paragraph",
      "text": "of the measured GBCM in blood."
    },
    {
      "type": "paragraph",
      "text": "Off-Label Use of MRI Contrast Agents"
    },
    {
      "type": "paragraph",
      "text": "In the past, radiologists often used GBCM in an off-label fashion (e.g., off-label higher doses or off-label indications). By definition,"
    },
    {
      "type": "paragraph",
      "text": "such usage is not approved by the FDA. However, physicians have some latitude in off-label GBCM use as guided by clinical"
    },
    {
      "type": "paragraph",
      "text": "circumstances as long as they can justify such usage in individual cases. Extremely high doses of GBCM much greater than FDA"
    },
    {
      "type": "paragraph",
      "text": "labeling (which were used frequently in the past) have largely been abandoned, especially in patients with severe chronic kidney"
    },
    {
      "type": "paragraph",
      "text": "disease and acute kidney injury due to concerns regarding nephrogenic systemic fibrosis."
    },
    {
      "type": "paragraph",
      "text": "References"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Weiss KL. Severe anaphylactoid reaction after iv. Gd-DTPA."
    },
    {
      "type": "paragraph",
      "text": "Magn Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": ". 1990;8(6):817-818."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Omohundro JE, Elderbrook MK, Ringer TV. Laryngospasm after administration of gadopentetate dimeglumine. J"
    },
    {
      "type": "paragraph",
      "text": "Magn Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "1992;2(6):729-730."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Tardy B, Guy C, Barral G, Page Y, Ollagnier M, Bertrand JC. Anaphylactic shock induced by intravenous gadopentetate dimeglumine."
    },
    {
      "type": "paragraph",
      "text": "Lancet"
    },
    {
      "type": "paragraph",
      "text": ". 1992;339(8791):494."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Takebayashi S, Sugiyama M, Nagase M, Matsubara S. Severe adverse reaction to iv gadopentetate dimeglumine."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "1993;160(3):659."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Witte RJ AL. Life-threatening anaphylactoid reaction after intravenous gadoteridol administration in a patient who had previously received"
    },
    {
      "type": "image",
      "assetId": "asset_f4d3a8060d",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ADVERSE REACTIONS TO GADOLINIUM-BASED CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "73"
    },
    {
      "type": "paragraph",
      "text": "gadopentetate dimeglumine."
    },
    {
      "type": "paragraph",
      "text": "AJNR Am J Neuroradiol"
    },
    {
      "type": "paragraph",
      "text": ". 1994; 15:523-524."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Murphy KJ, Brunberg JA, Cohan RH. Adverse reactions to gadolinium contrast media: a review of 36 cases."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "1996;167(4):847-849."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Murphy KJ BJ, Cohan RH. Adverse reactions to gadolinium contrast media: a review of 36 cases. 1996; 167:847-849."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "Runge VM. Safety of approved MR contrast media for intravenous injection."
    },
    {
      "type": "paragraph",
      "text": "J Magn Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": ". 2000;12(2):205-213."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Runge VM. Safety of magnetic resonance contrast media."
    },
    {
      "type": "paragraph",
      "text": "Top Magn Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": ". 2001;12(4):309-314."
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Murphy KP SK, Cohan RH, Mermillod B, Ellis JH. Occurrence of adverse reactions to gadolinium-based contrast material and management of patients"
    },
    {
      "type": "paragraph",
      "text": "at increased risk: a survey of the American Society of Neuroradiology Fellowship Directors."
    },
    {
      "type": "paragraph",
      "text": "Acad Radiol"
    },
    {
      "type": "paragraph",
      "text": ". 1999; 6:656-664."
    },
    {
      "type": "paragraph",
      "text": "11."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS DJ, Cohan RH, Hussain HK, Khalatbari S, McHugh JB, Ellis JH. Effect of abrupt substitution of gadobenate dimeglumine for"
    },
    {
      "type": "paragraph",
      "text": "gadopentetate dimeglumine on rate of allergic-like reactions."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": ". 2013; 266:773-782."
    },
    {
      "type": "paragraph",
      "text": "12."
    },
    {
      "type": "paragraph",
      "text": "Jordan RM, Mintz RD. Fatal reaction to gadopentetate dimeglumine."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": ". 1995;164(3):743-744."
    },
    {
      "type": "paragraph",
      "text": "13."
    },
    {
      "type": "paragraph",
      "text": "Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": ". 2007;188(6):1447-1474."
    },
    {
      "type": "paragraph",
      "text": "14."
    },
    {
      "type": "paragraph",
      "text": "Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007;242(3):647-"
    },
    {
      "type": "paragraph",
      "text": "649."
    },
    {
      "type": "paragraph",
      "text": "15."
    },
    {
      "type": "paragraph",
      "text": "Jung JW, Kang HR, Kim MH, et al. Immediate hypersensitivity reaction to gadolinium-based MR contrast media."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": ". 2012;264(2):414-422."
    },
    {
      "type": "paragraph",
      "text": "16."
    },
    {
      "type": "paragraph",
      "text": "Brody AS, Sorette MP, Gooding CA, et al. AUR memorial Award. Induced alignment of flowing sickle erythrocytes in a magnetic field. A preliminary"
    },
    {
      "type": "paragraph",
      "text": "report."
    },
    {
      "type": "paragraph",
      "text": "Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": ". 1985;20(6):560-566."
    },
    {
      "type": "paragraph",
      "text": "17."
    },
    {
      "type": "paragraph",
      "text": "Kanal E, Shellock FG, Talagala L. Safety considerations in MR imaging."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": ". 1990;176(3):593-606."
    },
    {
      "type": "paragraph",
      "text": "18."
    },
    {
      "type": "paragraph",
      "text": "Dillman JR, Ellis JH, Cohan RH, et al. Safety of gadolinium-based contrast material in sickle cell disease."
    },
    {
      "type": "paragraph",
      "text": "J Magn Reson Imaging."
    },
    {
      "type": "paragraph",
      "text": "2011;34(4):917-"
    },
    {
      "type": "paragraph",
      "text": "920."
    },
    {
      "type": "paragraph",
      "text": "19."
    },
    {
      "type": "paragraph",
      "text": "Umans H, Haramati N, Flusser G. The diagnostic role of gadolinium enhanced MRI in distinguishing between acute medullary bone infarct and"
    },
    {
      "type": "paragraph",
      "text": "osteomyelitis."
    },
    {
      "type": "paragraph",
      "text": "Magn Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": ". 2000;18(3):255-262."
    },
    {
      "type": "paragraph",
      "text": "20."
    },
    {
      "type": "paragraph",
      "text": "Westwood MA, Shah F, Anderson LJ, et al. Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy."
    },
    {
      "type": "paragraph",
      "text": "J Magn"
    },
    {
      "type": "paragraph",
      "text": "Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": ". 2007;26(3):564-568."
    },
    {
      "type": "paragraph",
      "text": "21."
    },
    {
      "type": "paragraph",
      "text": "Zimmerman RA. MRI/MRA evaluation of sickle cell disease of the brain."
    },
    {
      "type": "paragraph",
      "text": "Pediatr Radiol"
    },
    {
      "type": "paragraph",
      "text": ". 2005;35(3):249-257."
    },
    {
      "type": "paragraph",
      "text": "22."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS, Viglianti BL, Al-Hawary MM, et al. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium"
    },
    {
      "type": "paragraph",
      "text": "and gadobenate dimeglumine: effect on arterial phase image quality."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": ". 2013;266(2):452- 461."
    },
    {
      "type": "paragraph",
      "text": "23."
    },
    {
      "type": "paragraph",
      "text": "Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR. Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium:"
    },
    {
      "type": "paragraph",
      "text": "examination recovery with a multiple arterial phase acquisition."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": ". 2014;271(2):426-434."
    },
    {
      "type": "paragraph",
      "text": "24."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS CE, Kaza RK, et al. Matched within-patient cohort study of transient arterial-phase respiratory motion related artifact in MRI of the"
    },
    {
      "type": "paragraph",
      "text": "liver: Gd-EOB-DTPA vs. Gd-BOPTA."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": ". 2014; 272:123-131."
    },
    {
      "type": "paragraph",
      "text": "25."
    },
    {
      "type": "paragraph",
      "text": "Davenport MS BM, Pietryga JA, et al. Dose-toxicity relationship of gadoxetate disodium and transient post-injection dyspnea."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": ". 2014; In press."
    },
    {
      "type": "paragraph",
      "text": "26."
    },
    {
      "type": "paragraph",
      "text": "Bashir MR CP, Davenport MS, et al. Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium is more common"
    },
    {
      "type": "paragraph",
      "text": "in patients with a prior episode of arterial phase motion associated with gadoxetate disodium."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": ". 2015;274: 141-148."
    },
    {
      "type": "paragraph",
      "text": "27."
    },
    {
      "type": "paragraph",
      "text": "McAlister WH, McAlister VI, Kissane JM. The effect of Gd-dimeglumine on subcutaneous tissues: a study with rats."
    },
    {
      "type": "paragraph",
      "text": "AJNR Am J Neuroradiol"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "1990;11(2):325-327."
    },
    {
      "type": "paragraph",
      "text": "28."
    },
    {
      "type": "paragraph",
      "text": "Cohan RH, Leder RA, Herzberg AJ, et al. Extravascular toxicity of two magnetic resonance contrast agents. Preliminary experience in the rat."
    },
    {
      "type": "paragraph",
      "text": "Invest"
    },
    {
      "type": "paragraph",
      "text": "Radiol"
    },
    {
      "type": "paragraph",
      "text": ". 1991;26(3):224-226."
    },
    {
      "type": "paragraph",
      "text": "29."
    },
    {
      "type": "paragraph",
      "text": "Lin J IJ, Port M, et al. Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric"
    },
    {
      "type": "paragraph",
      "text": "reagents."
    },
    {
      "type": "paragraph",
      "text": "J Pharm Biomed Anal"
    },
    {
      "type": "paragraph",
      "text": ". 1999; 21:931-943."
    },
    {
      "type": "paragraph",
      "text": "30."
    },
    {
      "type": "paragraph",
      "text": "Brown JJ, Hynes MR, Wible JH, Jr. Measurement of serum calcium concentration after administration of four gadolinium- based contrast agents to"
    },
    {
      "type": "paragraph",
      "text": "human volunteers."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": ". 2007;189(6):1539-1544."
    },
    {
      "type": "paragraph",
      "text": "Revision History"
    },
    {
      "type": "paragraph",
      "text": "2 June 2014: Major revisions"
    },
    {
      "type": "paragraph",
      "text": "15 April 2013: Minor revisions"
    },
    {
      "type": "paragraph",
      "text": "26 June 2012: Minor revisions May"
    },
    {
      "type": "paragraph",
      "text": "2008: First version"
    },
    {
      "type": "image",
      "assetId": "asset_e1c318396e",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ADVERSE REACTIONS TO GADOLINIUM-BASED CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "74"
    },
    {
      "type": "paragraph",
      "text": "Gadolinium Pregnancy Screening Statement"
    },
    {
      "type": "paragraph",
      "text": "It has been shown that some gadolinium-based contrast agents (GBCAs) pass the placental barrier into the fetal circulation of"
    },
    {
      "type": "paragraph",
      "text": "nonhuman primates [1]. While multiple small sample size studies have not shown convincing evidence of adverse effects from fetal"
    },
    {
      "type": "paragraph",
      "text": "exposure to GBCAs [2,3], a 2016 retrospective study cited an increased risk of stillbirth/neonatal death as well as increased risk of"
    },
    {
      "type": "paragraph",
      "text": "rheumatologic, inflammatory, or infiltrative skin conditions in the offspring after GBCA exposure during pregnancy [4]. While,"
    },
    {
      "type": "paragraph",
      "text": "questions have been raised regarding study methodology, and these results have not been independently confirmed, both uncertainty"
    },
    {
      "type": "paragraph",
      "text": "and an abundance of caution in general about the effect of GBCA exposure and retention on the developing fetus has led to statements"
    },
    {
      "type": "paragraph",
      "text": "in the"
    },
    {
      "type": "paragraph",
      "text": "ACR Manual on Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "[5] and the"
    },
    {
      "type": "paragraph",
      "text": "ACR Manual on MR Safety"
    },
    {
      "type": "paragraph",
      "text": "[6] recommending avoidance of routine administration"
    },
    {
      "type": "paragraph",
      "text": "of GBCAs to pregnant patients. A decision to administer GBCAs to a pregnant woman should only be made when there is the potential"
    },
    {
      "type": "paragraph",
      "text": "for significant clinical benefit that outweighs the unknown risk of fetal exposure and should be the product of discussion that involves"
    },
    {
      "type": "paragraph",
      "text": "the referring provider and patient."
    },
    {
      "type": "paragraph",
      "text": "A 2019 study cited increased prevalence of GBCA administration during the first trimester as opposed to later in pregnancy, indicating"
    },
    {
      "type": "paragraph",
      "text": "that many exposures have occurred without pregnancy screening and/or prior to recognition of pregnancy. This suggests a potential"
    },
    {
      "type": "paragraph",
      "text": "need for more vigilant pregnancy screening protocols [7]. The current standard of practice is to avoid routine GBCA administration"
    },
    {
      "type": "paragraph",
      "text": "during pregnancy due to the unknown risk of fetal exposure [5,6,8]; and we recommend that imaging facilities have an established"
    },
    {
      "type": "paragraph",
      "text": "standardized system of screening in place that includes screening for unsuspected pregnancy prior to GBCA administration within"
    },
    {
      "type": "paragraph",
      "text": "existing institutional protocols that similarly screen patients prior to exposure to ionizing radiation and/or anesthesia. Protocols"
    },
    {
      "type": "paragraph",
      "text": "regarding pregnancy testing and reporting of results for pediatric patients and patients with legal guardians must be in accordance"
    },
    {
      "type": "paragraph",
      "text": "with local and state regulatory statutes."
    },
    {
      "type": "paragraph",
      "text": "There is variability in the accuracy of pregnancy tests early in gestation, and at a minimum, testing will be falsely negative in the first"
    },
    {
      "type": "paragraph",
      "text": "two weeks of pregnancy. As such, there is no screening method that will be 100% effective in detection of unsuspected pregnancy."
    },
    {
      "type": "paragraph",
      "text": "Regardless of which screening option is chosen, women of child-bearing age should be informed of the lack of certainty regarding"
    },
    {
      "type": "paragraph",
      "text": "risk of fetal GBCA exposure. An increased awareness of the issue by the patient may facilitate information sharing between patient"
    },
    {
      "type": "paragraph",
      "text": "and MRI staff regarding potential for pregnancy that would improve accuracy of screening. Any discussion with referring providers"
    },
    {
      "type": "paragraph",
      "text": "or patients acknowledging uncertain risks of GBCAs should always be coupled with an assessment of the known diagnostic benefits"
    },
    {
      "type": "paragraph",
      "text": "accrued from contrast-enhanced examinations on a per patient basis."
    },
    {
      "type": "paragraph",
      "text": "References"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Oh KY, Roberts VH, Schabel MC, Grove KL, Woods M, Frias AE. Gadolinium Chelate Contrast Material in Pregnancy: Fetal Biodistribution in the"
    },
    {
      "type": "paragraph",
      "text": "Nonhuman Primate. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2015;276:110-8."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "De Santis M, Straface G, Cavaliere AF, Carducci B, Caruso A. Gadolinium periconceptional exposure: pregnancy and neonatal outcome. Acta"
    },
    {
      "type": "paragraph",
      "text": "obstetricia et gynecologica Scandinavica"
    },
    {
      "type": "paragraph",
      "text": "2007;86:99-101."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Spencer JA, Tomlinson AJ, Weston MJ, Lloyd SN. Early report: comparison of breath-hold MR excretory urography, Doppler ultrasound and isotope"
    },
    {
      "type": "paragraph",
      "text": "renography in evaluation of symptomatic hydronephrosis in pregnancy. Clinical radiology"
    },
    {
      "type": "paragraph",
      "text": "2000;55:446-53."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association Between MRI Exposure During Pregnancy and Fetal and Childhood"
    },
    {
      "type": "paragraph",
      "text": "Outcomes. Jama"
    },
    {
      "type": "paragraph",
      "text": "2016;316:952-61."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "American College of Radiology. ACR Manual on Contrast Media. Available at:"
    },
    {
      "type": "paragraph",
      "text": "https://www.acr.org/-/media/ACR/Files/Clinical-"
    },
    {
      "type": "paragraph",
      "text": "Resources/Contrast_Media.pdf"
    },
    {
      "type": "paragraph",
      "text": ". Accessed January 31, 2022."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "American College of Radiology; ACR Committee on MR Safety. ACR Manual on MR Safety. Available at:"
    },
    {
      "type": "paragraph",
      "text": "https://www.acr.org/-"
    },
    {
      "type": "paragraph",
      "text": "/media/ACR/Files/Radiology-Safety/MR-Safety/Manual-on-MR-Safety.pdf"
    },
    {
      "type": "paragraph",
      "text": ". Accessed September 7, 2021."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Bird ST, Gelperin K, Sahin L, et al. First-Trimester Exposure to Gadolinium-based Contrast Agents: A Utilization Study of 4.6 Million U.S."
    },
    {
      "type": "paragraph",
      "text": "Pregnancies. Radiology"
    },
    {
      "type": "paragraph",
      "text": "2019;293:193-200."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "Committee on Obstetric Practice. Committee Opinion No. 723: Guidelines for Diagnostic Imaging During Pregnancy and Lactation. Obstetrics and"
    },
    {
      "type": "paragraph",
      "text": "gynecology"
    },
    {
      "type": "paragraph",
      "text": "2017;130:e210-e16."
    },
    {
      "type": "image",
      "assetId": "asset_954043a558",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "NEPHROGENIC SYSTEMIC FIBROSIS"
    },
    {
      "type": "paragraph",
      "text": "75"
    },
    {
      "type": "paragraph",
      "text": "NEPHROGENIC SYSTEMIC FIBROSIS"
    },
    {
      "type": "paragraph",
      "text": "Definition"
    },
    {
      "type": "paragraph",
      "text": "Nephrogenic systemic fibrosis (NSF) is a disease, primarily involving the skin and subcutaneous tissues but also known to involve"
    },
    {
      "type": "paragraph",
      "text": "other organs, such as the lungs, esophagus, heart, and skeletal muscles. Initial symptoms typically include skin thickening and/or"
    },
    {
      "type": "paragraph",
      "text": "pruritus. Symptoms and signs may develop and progress rapidly, with some affected patients developing contractures and joint"
    },
    {
      "type": "paragraph",
      "text": "immobility. In some patients, the disease may be fatal."
    },
    {
      "type": "paragraph",
      "text": "Associations"
    },
    {
      "type": "paragraph",
      "text": "Gadolinium-based contrast agent (GBCA) administration"
    },
    {
      "type": "paragraph",
      "text": "When first described in 2000, NSF was noted to occur predominantly in patients with end-stage chronic kidney disease (CKD),"
    },
    {
      "type": "paragraph",
      "text": "particularly in patients on dialysis. In 2006, several groups noted a strong association between gadolinium-based contrast agent"
    },
    {
      "type": "paragraph",
      "text": "(GBCA) administration in patients with advanced renal disease and the development of NSF [1,2], and it is now generally accepted"
    },
    {
      "type": "paragraph",
      "text": "that GBCA exposure is a necessary factor in the development of NSF, although in rare instances NSF can be diagnosed without"
    },
    {
      "type": "paragraph",
      "text": "known GBCA exposure. The time between injection of GBCA and the onset of NSF symptoms occurs within days to months in the"
    },
    {
      "type": "paragraph",
      "text": "vast majority of patients [1-6]; however, in rare cases, symptoms have appeared years after the last reported exposure [5]."
    },
    {
      "type": "paragraph",
      "text": "The association between NSF development and exposure to GBCAs is widely accepted. It is now known that there are differences in"
    },
    {
      "type": "paragraph",
      "text": "the likelihood of a patient developing NSF after exposure to different formulations of GBCAs. Almost all unconfounded cases have"
    },
    {
      "type": "paragraph",
      "text": "been reported after exposure to gadodiamide, gadopentetate dimeglumine, and/or gadoversetamide, while some GBCAs have been"
    },
    {
      "type": "paragraph",
      "text": "associated with few, if any, confirmed unconfounded cases of NSF. If the prevailing hypothesis is true"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "that the development of NSF"
    },
    {
      "type": "paragraph",
      "text": "is related to the release of gadolinium from the chelates that constitute GBCAs"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "the differences in number of reported cases may, in"
    },
    {
      "type": "paragraph",
      "text": "part, be explained by differences in the chemical properties of different GBCAs. However, it remains possible that a combination of"
    },
    {
      "type": "paragraph",
      "text": "other factors, including market share, number of years that the agent has been in use, patient populations, and possible reporting bias,"
    },
    {
      "type": "paragraph",
      "text": "may have contributed, in part, to some of the differences in the number of reported cases associated with the various GBCAs."
    },
    {
      "type": "paragraph",
      "text": "Utilizing both empirical data and theoretical lines of reasoning, the ACR Committee on Drugs and Contrast Media, the European"
    },
    {
      "type": "paragraph",
      "text": "Medicines Agency (EMA), and the U.S. Food and Drug Administration (FDA) all have classified GBCAs into different groups based"
    },
    {
      "type": "paragraph",
      "text": "on reported associations with NSF in vulnerable patients, although the scheme used by each is not identical [7,8]. The ACR"
    },
    {
      "type": "paragraph",
      "text": "classification is given in"
    },
    {
      "type": "paragraph",
      "text": "Table 1"
    },
    {
      "type": "paragraph",
      "text": "in this chapter."
    },
    {
      "type": "paragraph",
      "text": "Chronic kidney disease"
    },
    {
      "type": "paragraph",
      "text": "Based on current knowledge, it is estimated that patients with end-stage CKD (CKD5, eGFR <15 ml/ min/1.73 m2) and severe CKD"
    },
    {
      "type": "paragraph",
      "text": "(CKD4, eGFR 15-29 ml/min/1.73 m2) have a 1% to 7% chance of developing NSF after one or more exposures to group 1 GBCAs"
    },
    {
      "type": "paragraph",
      "text": "with the strongest association with NSF [1-6,9]."
    },
    {
      "type": "paragraph",
      "text": "However, most patients who developed NSF had end-stage kidney disease and were on dialysis at the time of exposure. Moreover,"
    },
    {
      "type": "paragraph",
      "text": "among patients with severe CKD (CKD4) that developed NSF (approximately 3% of all reported NSF cases), most had an eGFR"
    },
    {
      "type": "paragraph",
      "text": "closer to 15 ml/min/1.73 m2 than to 30 ml/min/1.73 m2. There have been rare, published case reports of patients with eGFR values"
    },
    {
      "type": "paragraph",
      "text": "above 30 ml/min/1.73 m2 [10-12]."
    },
    {
      "type": "paragraph",
      "text": "Acute kidney injury (AKI)"
    },
    {
      "type": "paragraph",
      "text": "Between 12% and 20% of confirmed cases of NSF have occurred in patients with AKI, often superimposed upon CKD [13,14]."
    },
    {
      "type": "paragraph",
      "text": "Some cases of NSF have developed in patients with AKI without underlying CKD [15]. Hence, AKI alone is also a risk factor for"
    },
    {
      "type": "paragraph",
      "text": "NSF."
    },
    {
      "type": "paragraph",
      "text": "High-dose and multiple exposures"
    },
    {
      "type": "paragraph",
      "text": "Cases of NSF have occurred following a single exposure to a GBCA, including a single exposure to a standard (0.1 mmol/kg) single"
    },
    {
      "type": "paragraph",
      "text": "dose [5,16]. Nevertheless, NSF occurs most commonly in patients who have received high doses of GBCA, either as a single"
    },
    {
      "type": "paragraph",
      "text": "administration or cumulatively, in multiple administrations over months to years [6,17]."
    },
    {
      "type": "paragraph",
      "text": "Most patients with severe CKD exposed to high doses and/or many doses of GBCAs have not developed NSF [5]. One study [18]"
    },
    {
      "type": "paragraph",
      "text": "described 30 patients who had an eGFR of under 30 ml/min/1.73 m2 and who were exposed to high doses of gadodiamide (median"
    },
    {
      "type": "paragraph",
      "text": "dose of 90 ml and range of 40 to 200 ml). Only one of the 30 patients subsequently developed NSF, an observed incidence of about"
    },
    {
      "type": "image",
      "assetId": "asset_a31c0b8f75",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "NEPHROGENIC SYSTEMIC FIBROSIS"
    },
    {
      "type": "paragraph",
      "text": "76"
    },
    {
      "type": "paragraph",
      "text": "3%."
    },
    {
      "type": "paragraph",
      "text": "A few cases of NSF also have been reported in patients with no known GBCA exposure [19]. In some of these cases, subsequent"
    },
    {
      "type": "paragraph",
      "text": "tissue biopsy evaluation revealed elevated gadolinium levels in the tissues of these patients, suggesting that at least some of these"
    },
    {
      "type": "paragraph",
      "text": "patients had prior unknown GBCA exposure [20, 21]."
    },
    {
      "type": "paragraph",
      "text": "Other possible risk factors"
    },
    {
      "type": "paragraph",
      "text": "It is not understood why some patients with severe CKD or AKI develop NSF following exposure to GBCAs and others do not, but"
    },
    {
      "type": "paragraph",
      "text": "a number of possible co-factors have been postulated to play a role. These include metabolic acidosis or medications that predispose"
    },
    {
      "type": "paragraph",
      "text": "patients to acidosis [1,21]; elevated iron, calcium, and/or phosphate levels [21,22]; high-dose erythropoietin therapy [13];"
    },
    {
      "type": "paragraph",
      "text": "immunosuppression [6]; vasculopathy [23]; and infection [24] or other acute proinflammatory events [4,25]. However, none of these"
    },
    {
      "type": "paragraph",
      "text": "have been consistently confirmed as true cofactors. As a result, routine screening for these factors prior to GBCA administration is"
    },
    {
      "type": "paragraph",
      "text": "not recommended."
    },
    {
      "type": "paragraph",
      "text": "Hepatic insufficiency/hepatorenal syndrome"
    },
    {
      "type": "paragraph",
      "text": "Initially, a number of researchers observed that a disproportionate number of affected patients had concomitant severe liver and renal"
    },
    {
      "type": "paragraph",
      "text": "dysfunction [4,5],"
    },
    {
      "type": "paragraph",
      "text": "prompting the FDA to warn against the use of GBCAs in patients with acute renal insufficiency of any severity"
    },
    {
      "type": "paragraph",
      "text": "due to the hepatorenal syndrome or in the perioperative liver transplantation period"
    },
    {
      "type": "paragraph",
      "text": "[26]. However, most data do not support this"
    },
    {
      "type": "paragraph",
      "text": "conclusion. For example, in one study, a review of the literature found that of 335 patients with NSF, 35 (10%) had concomitant liver"
    },
    {
      "type": "paragraph",
      "text": "disease [27]; however, all but one of these patients also had known severe renal insufficiency (eGFR of <30 ml/min/1.73 m2) prior"
    },
    {
      "type": "paragraph",
      "text": "to GBCA administration. Thus, hepatic disease in and of itself, in the absence of AKI or severe CKD, is no longer considered an"
    },
    {
      "type": "paragraph",
      "text": "independent risk factor for NSF."
    },
    {
      "type": "paragraph",
      "text": "Postulated Mechanism"
    },
    {
      "type": "paragraph",
      "text": "The exact mechanism of NSF causation is unknown. The most widely held hypothesis is that gadolinium ions dissociate from the"
    },
    {
      "type": "paragraph",
      "text": "chelates in GBCAs in patients with significantly degraded renal function due to the prolonged clearance times of the GBCAs, as well"
    },
    {
      "type": "paragraph",
      "text": "as to other metabolic factors associated with this level of renal disease. The free gadolinium then binds with an anion such as"
    },
    {
      "type": "paragraph",
      "text": "phosphate, and the resulting insoluble precipitate is deposited in various tissues [9,28]. A fibrotic reaction ensues, involving the"
    },
    {
      "type": "paragraph",
      "text": "activation of circulating fibrocytes [28,29]. This hypothesis is supported by the greater presence of gadolinium in affected tissues of"
    },
    {
      "type": "paragraph",
      "text": "NSF patients relative to unaffected tissues [30]. Nevertheless, the detection of gadolinium in tissues is complicated and is not"
    },
    {
      "type": "paragraph",
      "text": "considered a requirement for the diagnosis of NSF."
    },
    {
      "type": "paragraph",
      "text": "If the propensity for gadolinium to dissociate from various chelates is eventually proved to contribute to, or be primarily responsible"
    },
    {
      "type": "paragraph",
      "text": "for, the development of NSF, this may help explain, at least in part, why the various GBCAs differ in their apparent NSF safety"
    },
    {
      "type": "paragraph",
      "text": "profile in at-risk patients, since these agents have varying degrees of stability in vitro and in vivo [31]."
    },
    {
      "type": "paragraph",
      "text": "Assessment of Risk (See"
    },
    {
      "type": "paragraph",
      "text": "Table 1"
    },
    {
      "type": "paragraph",
      "text": "for the classification of GBCAs)"
    },
    {
      "type": "paragraph",
      "text": "Group II agents"
    },
    {
      "type": "paragraph",
      "text": "Based on the most recent scientific and clinical evidence [32-43] the ACR Committee on Drugs and Contrast Media considers the"
    },
    {
      "type": "paragraph",
      "text": "risk of NSF among patients exposed to standard or lower than standard doses of group II GBCAs is sufficiently low or possibly"
    },
    {
      "type": "paragraph",
      "text": "nonexistent such that assessment of renal function with a questionnaire or laboratory testing is optional prior to intravenous"
    },
    {
      "type": "paragraph",
      "text": "administration. As in all instances, group II GBCAs should only be administered if they are deemed necessary by the supervising"
    },
    {
      "type": "paragraph",
      "text": "radiologist, and the lowest dose needed for diagnosis should be used as deemed necessary by the supervising radiologist."
    },
    {
      "type": "paragraph",
      "text": "1"
    },
    {
      "type": "paragraph",
      "text": "Certain newer FDA-approved agents may be designated as a group II * provisional status based on favorable biochemical profile and"
    },
    {
      "type": "paragraph",
      "text": "available laboratory data. These agents are considered provisional due to a relative lack of in-use clinical performance data and/or"
    },
    {
      "type": "paragraph",
      "text": "incomplete clinical data related to use in higher risk populations. Agents in this category can be treated similar to a group II agent or"
    },
    {
      "type": "paragraph",
      "text": "a group III agent per local practice preference."
    },
    {
      "type": "paragraph",
      "text": "1"
    },
    {
      "type": "paragraph",
      "text": "The ACR Committee on Drugs and Contrast Media recognizes that as of this writing (4-6-2017), U.S. Food and Drug Administration (FDA) guidelines and drug"
    },
    {
      "type": "paragraph",
      "text": "labeling for GBCA have the same recommendations for each GBCA with respect to assessing renal function prior to GBCA administration. Nevertheless, the"
    },
    {
      "type": "paragraph",
      "text": "committee authoring this Manual has reviewed the evidence and believes that the prevailing weight of clinical evidence on this matter allows less stringent yet"
    },
    {
      "type": "paragraph",
      "text": "safe patient management which should reduce patient cost and inconvenience. This footnote is designed to alert readers that the ACR recommendations differ in"
    },
    {
      "type": "paragraph",
      "text": "case their personal philosophy or institutional policies necessitate adherence to the more restrictive FDA guidelines."
    },
    {
      "type": "image",
      "assetId": "asset_f448f1b3d3",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "NEPHROGENIC SYSTEMIC FIBROSIS"
    },
    {
      "type": "paragraph",
      "text": "77"
    },
    {
      "type": "paragraph",
      "text": "Group I and III agents"
    },
    {
      "type": "paragraph",
      "text": "The ACR Committee on Drugs and Contrast Media concludes that patients receiving group I GBCAs should be considered at risk of"
    },
    {
      "type": "paragraph",
      "text": "developing NSF if any of the following conditions apply to the patient:"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "On dialysis (of any form)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Severe or end-stage CKD (CKD 4 or 5, eGFR < 30 mL / min/1.73 m2) without dialysis"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "AKI [44,45]"
    },
    {
      "type": "paragraph",
      "text": "There is insufficient real-life data to determine the risk of NSF from administration of group III agents. Thus, it is important to identify"
    },
    {
      "type": "paragraph",
      "text": "patients at risk of developing NSF, as defined above, prior to injection of group I and III GBCAs. The method used to identify such"
    },
    {
      "type": "paragraph",
      "text": "patients may differ for outpatients versus inpatients."
    },
    {
      "type": "paragraph",
      "text": "Identifying at-risk outpatients"
    },
    {
      "type": "paragraph",
      "text": "Outpatients who may be receiving group I or group III agents should be screened for conditions and other factors that may be"
    },
    {
      "type": "paragraph",
      "text": "associated with renal function impairment."
    },
    {
      "type": "paragraph",
      "text": "Simply asking patients if they have a problem with their kidneys is not considered an effective screening tool, as this has been shown"
    },
    {
      "type": "paragraph",
      "text": "to fail to detect the majority of patients with chronic kidney disease, even those with eGFR<30 ml/min/1.73 m2 [46]."
    },
    {
      "type": "paragraph",
      "text": "A more reliable method to identify outpatients who may have renal function impairment is to utilize a panel of questions that includes"
    },
    {
      "type": "paragraph",
      "text": "risk factors for compromised renal function. The following list of risk factors can be used to identify patients who have impaired"
    },
    {
      "type": "paragraph",
      "text": "renal function. This list represents a blend of published data [47,48] and expert opinion; alternative lists may be as or more effective"
    },
    {
      "type": "paragraph",
      "text": "depending on practice patterns:"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "History of renal disease, including:"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Dialysis"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Kidney transplant"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Single kidney"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Kidney surgery"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "History of known cancer involving the kidney(s)"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "History of CKD or prior history of AKI"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "History of diabetes mellitus (optional)"
    },
    {
      "type": "paragraph",
      "text": "Many additional factors may have deleterious effects on renal function, including multiple myeloma, systemic lupus erythematosus,"
    },
    {
      "type": "paragraph",
      "text": "urinary tract infection, and use of some medications (e.g., nonsteroidal anti-inflammatory drugs, diuretics, aminoglycosides,"
    },
    {
      "type": "paragraph",
      "text": "cyclosporine A, amphotericin, and others); however, the ACR Committee on Drugs and Contrast Media currently does not"
    },
    {
      "type": "paragraph",
      "text": "recommend routinely screening for these additional possible risk factors, since the incremental benefit in patient safety from such"
    },
    {
      "type": "paragraph",
      "text": "screening has not been established and is considered to be low by the committee."
    },
    {
      "type": "paragraph",
      "text": "Once an outpatient is identified as being at risk for having reduced renal function based on screening, and group I or group III GBCA"
    },
    {
      "type": "paragraph",
      "text": "administration is contemplated, renal function should be assessed by laboratory testing (checking results of prior laboratory tests"
    },
    {
      "type": "paragraph",
      "text": "performed within an acceptable time window, and ordering new laboratory tests only if necessary) and calculation of eGFR. However,"
    },
    {
      "type": "paragraph",
      "text": "if the patient is on dialysis or has known AKI, laboratory testing and calculation of eGFR is not useful or necessary (i.e., eGFR is not"
    },
    {
      "type": "paragraph",
      "text": "accurate in this setting, and these patients would be considered at risk for NSF prior to group I or group III administration regardless"
    },
    {
      "type": "paragraph",
      "text": "of calculated eGFR)."
    },
    {
      "type": "paragraph",
      "text": "Calculating eGFR"
    },
    {
      "type": "paragraph",
      "text": "For adults, eGFR calculation is commonly performed using the Modification of Diet in Renal Disease (MDRD) equation or the"
    },
    {
      "type": "paragraph",
      "text": "Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. The four-variable MDRD equation takes into account"
    },
    {
      "type": "paragraph",
      "text": "age, gender, and serum creatinine level. The updated Schwartz equation should be used for children (also see Chapter on"
    },
    {
      "type": "paragraph",
      "text": "Contrast"
    },
    {
      "type": "paragraph",
      "text": "Media in Children"
    },
    {
      "type": "paragraph",
      "text": ")."
    },
    {
      "type": "paragraph",
      "text": "A number of websites and point-of-service tools are available that can calculate eGFR values in adults and children. For consistency,"
    },
    {
      "type": "paragraph",
      "text": "radiologists may wish to identify which equation(s) are in use in their laboratory facilities."
    },
    {
      "type": "image",
      "assetId": "asset_5362ae0941",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "NEPHROGENIC SYSTEMIC FIBROSIS"
    },
    {
      "type": "paragraph",
      "text": "78"
    },
    {
      "type": "paragraph",
      "text": "When eGFR is recommended in outpatients with risk factor(s) for compromised renal function"
    },
    {
      "type": "paragraph",
      "text": "For those patients identified by screening to have one or more risk factors for compromised renal function and in whom administration"
    },
    {
      "type": "paragraph",
      "text": "of a group I or group III agent is planned, there is no high-level scientific evidence to guide the optimal time interval between eGFR"
    },
    {
      "type": "paragraph",
      "text": "determination and GBCA injection. Nevertheless, the ACR Committee on Drugs and Contrast Media has made recommendations"
    },
    {
      "type": "paragraph",
      "text": "(see"
    },
    {
      "type": "paragraph",
      "text": "Table 2"
    },
    {
      "type": "paragraph",
      "text": "in this chapter) that take into consideration the need to maintain patient safety while minimizing the burden associated"
    },
    {
      "type": "paragraph",
      "text": "with excessive laboratory testing."
    },
    {
      "type": "paragraph",
      "text": "Identifying at-risk inpatients"
    },
    {
      "type": "paragraph",
      "text": "For all inpatients, an eGFR level should be obtained within 2 days prior to planned administration of a group I or group III GBCA."
    },
    {
      "type": "paragraph",
      "text": "In addition, ordering health professionals should assess inpatients for the possibility of AKI, as eGFR calculation alone has limited"
    },
    {
      "type": "paragraph",
      "text": "accuracy for the detection of AKI."
    },
    {
      "type": "paragraph",
      "text": "General Recommendations for Imaging Patients at Risk for NSF"
    },
    {
      "type": "paragraph",
      "text": "Group II agents are strongly preferred in patients at risk for NSF. Given the very low, if any, risk of NSF development with group II"
    },
    {
      "type": "paragraph",
      "text": "agents, regardless of renal function or dialysis status, informed consent is not recommended prior to GBCA group II injection, but"
    },
    {
      "type": "paragraph",
      "text": "deference is made to local practice preferences."
    },
    {
      "type": "paragraph",
      "text": "If use of a group I or group III agent is being considered in a patient with a risk of NSF, the potential benefit of a GBCA-enhanced"
    },
    {
      "type": "paragraph",
      "text": "MRI exam is felt to outweigh the risk of NSF in an individual patient, and there is no suitable alternative, the referring physician and"
    },
    {
      "type": "paragraph",
      "text": "patient should be informed of the risks of GBCA administration, and both should agree with the decision to proceed with GBCA"
    },
    {
      "type": "paragraph",
      "text": "injection. Group I agents (see"
    },
    {
      "type": "paragraph",
      "text": "Table 1"
    },
    {
      "type": "paragraph",
      "text": "), the GBCAs that have been most often associated with NSF, have been contraindicated by the"
    },
    {
      "type": "paragraph",
      "text": "FDA for use in these patients [26]."
    },
    {
      "type": "paragraph",
      "text": "The lowest dose of GBCA required to obtain the needed clinical information should be used in at-risk patients, and it should generally"
    },
    {
      "type": "paragraph",
      "text": "not exceed the recommended single dose. (Note: the lowest diagnostic dose has not been thoroughly investigated for many"
    },
    {
      "type": "paragraph",
      "text": "indications; be careful not to minimize dose below diagnostic quality)."
    },
    {
      "type": "paragraph",
      "text": "Exceptions to the above recommendations may be made at the discretion of the supervising radiologist, such as in the rare instance"
    },
    {
      "type": "paragraph",
      "text": "of an acute, life-threatening condition, and after consultation with the referring health care professional. Documentation of the"
    },
    {
      "type": "paragraph",
      "text": "rationale for the exception is recommended."
    },
    {
      "type": "paragraph",
      "text": "Limiting use of GBCAs in at-risk patients has already had a dramatic effect in reducing or even eliminating the number of new cases"
    },
    {
      "type": "paragraph",
      "text": "of NSF [49]. It must be remembered that the risks of administering a GBCA to a high-risk patient must always be balanced against"
    },
    {
      "type": "paragraph",
      "text": "the often substantial risks of not performing a needed contrast-enhanced imaging procedure."
    },
    {
      "type": "paragraph",
      "text": "Multiple doses of GBCA"
    },
    {
      "type": "paragraph",
      "text": "In unusual circumstances, it may be necessary to administer multiple doses of a GBCA within a relatively short time frame. Examples"
    },
    {
      "type": "paragraph",
      "text": "include a rapid change in patient condition for which an additional enhanced MR exam may be of benefit or when the initial MR"
    },
    {
      "type": "paragraph",
      "text": "exam indicates an acute need for a more sophisticated enhanced MR exam. In patients not at risk of NSF, there is no contraindication"
    },
    {
      "type": "paragraph",
      "text": "if the examination(s) are determined to be necessary. In patients at risk of NSF, the committee recommends the use of group II"
    },
    {
      "type": "paragraph",
      "text": "agent(s)."
    },
    {
      "type": "paragraph",
      "text": "Additional Specific Recommendations for Specific Groups of Patients"
    },
    {
      "type": "paragraph",
      "text": "Patients with end-stage renal disease on chronic dialysis"
    },
    {
      "type": "paragraph",
      "text": "If a contrast-enhanced cross-sectional imaging study is required in an anuric patient with no residual renal function, it would be"
    },
    {
      "type": "paragraph",
      "text": "reasonable to consider administering iodinated contrast media and performing a CT rather than an MRI, assuming the anticipated"
    },
    {
      "type": "paragraph",
      "text": "diagnostic yield is similar."
    },
    {
      "type": "paragraph",
      "text": "If a contrast-enhanced MR examination is to be performed in a patient with end-stage renal disease on chronic dialysis, injection of"
    },
    {
      "type": "paragraph",
      "text": "group I agents (see Table 1) is contraindicated, and the committee recommends the use of a group II agent. When using a group II"
    },
    {
      "type": "paragraph",
      "text": "agent, the risk of NSF is extremely low. The ACR Committee on Drugs and Contrast Media and National Kidney Foundation also"
    },
    {
      "type": "paragraph",
      "text": "recommend that elective GBCA-enhanced MRI examinations be performed as closely before a regularly scheduled hemodialysis as"
    },
    {
      "type": "paragraph",
      "text": "is possible, as dialysis can improve GBCM clearance. However, due to associated increased risk of catheter placement and infection,"
    },
    {
      "type": "image",
      "assetId": "asset_e088255f45",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "NEPHROGENIC SYSTEMIC FIBROSIS"
    },
    {
      "type": "paragraph",
      "text": "79"
    },
    {
      "type": "paragraph",
      "text": "the possibility of worsening kidney function in patients with AKI and CKD, the perceived very low risk of NSF from group II and"
    },
    {
      "type": "paragraph",
      "text": "probably III GBCM agents, dialysis should not be initiated or altered (i.e. daily dialysis or multiple per-day dialysis sessions) [42,"
    },
    {
      "type": "paragraph",
      "text": "50]."
    },
    {
      "type": "paragraph",
      "text": "Peritoneal dialysis may provide less NSF risk reduction compared to hemodialysis, but this has not been adequately studied."
    },
    {
      "type": "paragraph",
      "text": "Patients with CKD 4or5 (eGFR<30mL/min/1.73m2) not on chronic dialysis"
    },
    {
      "type": "paragraph",
      "text": "Group I agents are contraindicated in this setting. If a GBCA-enhanced MRI study is to be performed, a group II agent should be"
    },
    {
      "type": "paragraph",
      "text": "used."
    },
    {
      "type": "paragraph",
      "text": "Patients with CKD 3 (eGFR 30 to 59 mL / min/1.73 m2)"
    },
    {
      "type": "paragraph",
      "text": "NSF developing after GBCA administration to patients with stable eGFR 30-59 ml/min/1.73 m2 is exceedingly rare. No special"
    },
    {
      "type": "paragraph",
      "text": "precautions are necessary in this group."
    },
    {
      "type": "paragraph",
      "text": "Patients with CKD 1or2 (eGFR60to119mlmin/1.73m2)"
    },
    {
      "type": "paragraph",
      "text": "There is no evidence that patients in these groups are at increased risk of developing NSF. Any GBCA can be administered safely to"
    },
    {
      "type": "paragraph",
      "text": "these patients."
    },
    {
      "type": "paragraph",
      "text": "Patients with acute kidney injury (AKI)"
    },
    {
      "type": "paragraph",
      "text": "Patients with AKI who have been exposed to GBCA are at risk for developing NSF. Due to the temporal lag between eGFR (which"
    },
    {
      "type": "paragraph",
      "text": "is calculated using serum creatinine values) and actual glomerular filtration rates, it is not possible to determine whether a given"
    },
    {
      "type": "paragraph",
      "text": "patient has AKI based on a single eGFR determination. Accordingly, group I agents should be avoided in patients with known or"
    },
    {
      "type": "paragraph",
      "text": "suspected AKI. If GBCA is to be administered in this setting, a group II agent is preferred."
    },
    {
      "type": "paragraph",
      "text": "Children"
    },
    {
      "type": "paragraph",
      "text": "A systematic search of databases published in 2014 [51] found only 23 reported pediatric cases of NSF, and no cases in children"
    },
    {
      "type": "paragraph",
      "text": "under the age of 6 years. Nevertheless, there is not enough data to demonstrate that NSF is less likely to occur in children than in"
    },
    {
      "type": "paragraph",
      "text": "adults with similarly significant renal disease. Therefore, it is prudent to follow the same guidelines for adult and pediatric patients"
    },
    {
      "type": "paragraph",
      "text": "as described in the remainder of this document. However, eGFR values in certain premature infants and neonates may be <30"
    },
    {
      "type": "paragraph",
      "text": "ml/min/1.73 m2 simply due to immature renal function (and not due to pathologic renal impairment). In these individuals, the ACR"
    },
    {
      "type": "paragraph",
      "text": "Committee on Drugs and Contrast Media believes that caution should still be used when administering GBCAs, and group II agents"
    },
    {
      "type": "paragraph",
      "text": "should be used in this setting if feasible."
    },
    {
      "type": "paragraph",
      "text": "Caveat"
    },
    {
      "type": "paragraph",
      "text": "Information on NSF and its relationship to GBCA administration continues to evolve, and the summary included here represents only"
    },
    {
      "type": "paragraph",
      "text": "the most recent opinions of the ACR Committee on Drugs and Contrast Media. If additional information becomes available, our"
    },
    {
      "type": "paragraph",
      "text": "understanding of causative events leading to NSF and recommendations for preventing it may change, leading to further revisions of"
    },
    {
      "type": "paragraph",
      "text": "this document."
    },
    {
      "type": "image",
      "assetId": "asset_93154d6dbe",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "NEPHROGENIC SYSTEMIC FIBROSIS"
    },
    {
      "type": "paragraph",
      "text": "80"
    },
    {
      "type": "paragraph",
      "text": "TABLE 1. ACR Manual Classification of Gadolinium-Based Agents Relative to Nephrogenic Systemic Fibrosis"
    },
    {
      "type": "paragraph",
      "text": "Group I: Agents associated with the greatest number of NSF cases:"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Gadodiamide (Omniscan(R)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Gadopentetate dimeglumine (Magnevist(R)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Bayer HealthCare Pharmaceuticals)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Gadoversetamide (OptiMARK(R)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "Group II: Agents associated with few, if any, unconfounded cases of NSF:"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Gadobenate dimeglumine (MultiHance(R)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Bracco Diagnostics)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Gadobutrol (Gadavist(R)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Bayer HealthCare Pharmaceuticals; Gadovist in many countries)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Gadoteric acid (Dotarem(R)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Guerbet, Clariscan"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Gadoteridol (ProHance(R)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Bracco Diagnostics)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Gadopiclenol"
    },
    {
      "type": "paragraph",
      "text": "*"
    },
    {
      "type": "paragraph",
      "text": "(Elucirem(R)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Guerbet, Vueway(R)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Bracco Diagnostics)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Gadoxetate disodium (Eovist"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Bayer HealthCare Pharmaceuticals; Primovist in many countries)"
    },
    {
      "type": "paragraph",
      "text": "Group III: Agents for which data remains limited regarding NSF risk, but for which few, if any unconfounded cases of NSF have been"
    },
    {
      "type": "paragraph",
      "text": "reported:"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "No agents currently in this category (as of April 2024)"
    },
    {
      "type": "paragraph",
      "text": "* Gadopiclenol demonstrates kinetic stability and long dissociation half-life that are comparable to other Group II macrocyclic agents. Based on the available evidence [52-55], the ACR"
    },
    {
      "type": "paragraph",
      "text": "Committee on Drugs and Contrast Media considers the risk of NSF among patients exposed to a standard or lower than standard dose of gadopiclenol to theoretically be sufficiently low or"
    },
    {
      "type": "paragraph",
      "text": "possibly non-existent such that it has been classified as a Group II* agent (provisional status)."
    },
    {
      "type": "paragraph",
      "text": "However, in vivo long-term human data for potential NSF risk associated with gadopiclenol in patients with severe or end-stage kidney disease (eGFR < 30mL/min/1.73m^2) is not currently"
    },
    {
      "type": "paragraph",
      "text": "(January, 2025) as well-established as other group II agents. It is at the discretion of local practices whether to treat this as a group II or group III agent."
    },
    {
      "type": "paragraph",
      "text": "TABLE 2. eGFR Evaluation of Renal Function to Group I or Group III GBCA Administration"
    },
    {
      "type": "paragraph",
      "text": "Patient Condition"
    },
    {
      "type": "paragraph",
      "text": "eGFR Requirement"
    },
    {
      "type": "paragraph",
      "text": "Patient on dialysis (any type)"
    },
    {
      "type": "paragraph",
      "text": "No eGFR required"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "eGFR is not helpful in this situation."
    },
    {
      "type": "paragraph",
      "text": "Patient with AKI"
    },
    {
      "type": "paragraph",
      "text": "No eGFR required"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "eGFR is not helpful in this situation."
    },
    {
      "type": "paragraph",
      "text": "Inpatient"
    },
    {
      "type": "paragraph",
      "text": "Obtain eGFR within 2 days of the MRI study."
    },
    {
      "type": "paragraph",
      "text": "Outpatient/ED with no prior eGFR at the time the MR exam is"
    },
    {
      "type": "paragraph",
      "text": "scheduled"
    },
    {
      "type": "paragraph",
      "text": "If NO risk factors [1], no eGFR required."
    },
    {
      "type": "paragraph",
      "text": "WITH risk factors [1], obtain eGFR.*"
    },
    {
      "type": "paragraph",
      "text": "Outpatient/ED with most recent prior eGFR of 45 or above"
    },
    {
      "type": "paragraph",
      "text": "If NO risk factor [1] and eGFR of 60 or above, no new eGFR is required."
    },
    {
      "type": "paragraph",
      "text": "WITH risk factors [1] and/or eGFR 45-59, if most recent prior eGFR is within 6 weeks of"
    },
    {
      "type": "paragraph",
      "text": "the MRI, no new eGFR is needed; otherwise obtain a new eGFR.**"
    },
    {
      "type": "paragraph",
      "text": "Outpatient/ED with most recent prior eGFR of 44 or below"
    },
    {
      "type": "paragraph",
      "text": "Obtain eGFR within 2 days of the MRI study"
    },
    {
      "type": "paragraph",
      "text": "** If the new eGFR is to be obtained expressly for evaluation of suitability for administration of GBCA, obtaining the eGFR within 2 days of the MRI exam would avoid the"
    },
    {
      "type": "paragraph",
      "text": "situation where the new eGFR might be less than 45 and require another eGFR within two days of the MRI exam, as per the last line in the table."
    },
    {
      "type": "paragraph",
      "text": "[1]"
    },
    {
      "type": "paragraph",
      "text": "Risk Factors:"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "History of renal disease, including:"
    },
    {
      "type": "paragraph",
      "text": "a."
    },
    {
      "type": "paragraph",
      "text": "Prior dialysis"
    },
    {
      "type": "paragraph",
      "text": "b."
    },
    {
      "type": "paragraph",
      "text": "Renal transplant"
    },
    {
      "type": "paragraph",
      "text": "c."
    },
    {
      "type": "paragraph",
      "text": "Single kidney"
    },
    {
      "type": "paragraph",
      "text": "d."
    },
    {
      "type": "paragraph",
      "text": "Kidney surgery"
    },
    {
      "type": "paragraph",
      "text": "e."
    },
    {
      "type": "paragraph",
      "text": "Renal cancer"
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Diabetes mellitus"
    },
    {
      "type": "paragraph",
      "text": "(optional)"
    },
    {
      "type": "image",
      "assetId": "asset_4f5d4d0d72",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "NEPHROGENIC SYSTEMIC FIBROSIS"
    },
    {
      "type": "paragraph",
      "text": "81"
    },
    {
      "type": "paragraph",
      "text": "REFERENCES"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Grobner T. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrology,"
    },
    {
      "type": "paragraph",
      "text": "dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2006;21:1104-8."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic"
    },
    {
      "type": "paragraph",
      "text": "resonance imaging. Journal of the American Society of Nephrology : JASN 2006;17:2359-62."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be"
    },
    {
      "type": "paragraph",
      "text": "concerned. AJR. American journal of roentgenology 2007;188:586-92."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148-57."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR. American journal of roentgenology 2008;190:736-41."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American"
    },
    {
      "type": "paragraph",
      "text": "universities. Radiology 2008;248:799-806."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Agency EM. Questions and answers on the review of gadolinium-containing contrast agents. Available at:"
    },
    {
      "type": "paragraph",
      "text": "https://www.ema.europa.eu/en/documents/referral/questions-answers-review-gadolinium-containing-contrast-agents_en.pdf. Accessed April 29, 2021."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "Gadolinium-Based Contrast Agents & Nephrogenic Systemic Fibrosis FDA Briefing Document. Joint Meeting of the Cardiovascular and Renal Drugs and"
    },
    {
      "type": "paragraph",
      "text": "Drug Safety and Risk Management Advisory Committee."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal"
    },
    {
      "type": "paragraph",
      "text": "replacement therapy cohort. Radiology 2007;245:168-75."
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Shibui K K, Sato N, Watanabe Y, Kohara M, Mochizuki T. A case of NSF attributable to contrast MRI repeated in a patient with Stage 3 CKD at a renal"
    },
    {
      "type": "paragraph",
      "text": "function of eGFR > 30 mL / min/1.73 m2. Japanese Journal of Nephrology 2009;51."
    },
    {
      "type": "paragraph",
      "text": "11."
    },
    {
      "type": "paragraph",
      "text": "Lohani S, Golenbiewski J, Swami A, Halalau A. A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with a normal"
    },
    {
      "type": "paragraph",
      "text": "eGFR. BMJ Case Reports 2017;2017:bcr-2017-221016."
    },
    {
      "type": "paragraph",
      "text": "12."
    },
    {
      "type": "paragraph",
      "text": "Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. Journal of the American Society of Nephrology: JASN 2007; 18:2636-43."
    },
    {
      "type": "paragraph",
      "text": "13."
    },
    {
      "type": "paragraph",
      "text": "Abu-Alfa AK. Nephrogenic systemic fibrosis and gadolinium-based contrast agents. Advances in chronic kidney disease 2011;18:188-98."
    },
    {
      "type": "paragraph",
      "text": "14."
    },
    {
      "type": "paragraph",
      "text": "Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008;248:807-16."
    },
    {
      "type": "paragraph",
      "text": "15."
    },
    {
      "type": "paragraph",
      "text": "Kalb RE, Helm TN, Sperry H, Thakral C, Abraham JL, Kanal E. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient"
    },
    {
      "type": "paragraph",
      "text": "kidney injury. British Journal of Dermatology 2008;158:607-10."
    },
    {
      "type": "paragraph",
      "text": "16."
    },
    {
      "type": "paragraph",
      "text": "Pryor JG, Poggioli G, Galaria N, et al. Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. Journal of the American Academy of"
    },
    {
      "type": "paragraph",
      "text": "Dermatology 2007;57:105-11."
    },
    {
      "type": "paragraph",
      "text": "17."
    },
    {
      "type": "paragraph",
      "text": "Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent"
    },
    {
      "type": "paragraph",
      "text": "literature. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant"
    },
    {
      "type": "paragraph",
      "text": "Surgeons 2007;7:2425-32."
    },
    {
      "type": "paragraph",
      "text": "18."
    },
    {
      "type": "paragraph",
      "text": "Bridges MD, St Amant BS, McNeil RB, Cernigliaro JG, Dwyer JP, Fitzpatrick PM. High-dose gadodiamide for catheter angiography and CT in patients"
    },
    {
      "type": "paragraph",
      "text": "with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function. AJR. American journal"
    },
    {
      "type": "paragraph",
      "text": "of roentgenology 2009;192:1538-43."
    },
    {
      "type": "paragraph",
      "text": "19."
    },
    {
      "type": "paragraph",
      "text": "Weiss AS, Lucia MS, Teitelbaum I. A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nature clinical practice. Nephrology"
    },
    {
      "type": "paragraph",
      "text": "2007;3:111-5."
    },
    {
      "type": "paragraph",
      "text": "20."
    },
    {
      "type": "paragraph",
      "text": "Kallen AJ, Jhung MA, Cheng S, et al. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study."
    },
    {
      "type": "paragraph",
      "text": "American journal of kidney diseases : the official journal of the National Kidney Foundation 2008;51:966-75."
    },
    {
      "type": "paragraph",
      "text": "21."
    },
    {
      "type": "paragraph",
      "text": "High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. Journal of"
    },
    {
      "type": "paragraph",
      "text": "the American Academy of Dermatology 2007;56:21-6."
    },
    {
      "type": "paragraph",
      "text": "22."
    },
    {
      "type": "paragraph",
      "text": "Peak AS, Sheller A. Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis. The Annals of pharmacotherapy 2007;41:1481-5."
    },
    {
      "type": "paragraph",
      "text": "23."
    },
    {
      "type": "paragraph",
      "text": "Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure."
    },
    {
      "type": "paragraph",
      "text": "The American journal of medicine 2003;114:563-72."
    },
    {
      "type": "paragraph",
      "text": "24."
    },
    {
      "type": "paragraph",
      "text": "Golding LP, Provenzale JM. Nephrogenic systemic fibrosis: possible association with a predisposing infection. AJR. American journal of roentgenology"
    },
    {
      "type": "paragraph",
      "text": "2008;190:1069-75."
    },
    {
      "type": "paragraph",
      "text": "25."
    },
    {
      "type": "paragraph",
      "text": "Wiginton CD, Kelly B, Oto A, et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR."
    },
    {
      "type": "paragraph",
      "text": "American journal of roentgenology 2008;190:1060-8."
    },
    {
      "type": "paragraph",
      "text": "26."
    },
    {
      "type": "paragraph",
      "text": "FDA. Information for healthcare professionals: Gadolinium-based contrast agents for magnetic resonance imaging (marketed as Magnevist, MultiHance,"
    },
    {
      "type": "paragraph",
      "text": "Omniscan, OptiMARK, ProHance)."
    },
    {
      "type": "paragraph",
      "text": "27."
    },
    {
      "type": "paragraph",
      "text": "Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson"
    },
    {
      "type": "paragraph",
      "text": "Imaging 2009;30:1313-22."
    },
    {
      "type": "paragraph",
      "text": "28."
    },
    {
      "type": "paragraph",
      "text": "Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-"
    },
    {
      "type": "paragraph",
      "text": "term persistence in nephrogenic systemic fibrosis. The British journal of dermatology 2008;158:273-80."
    },
    {
      "type": "paragraph",
      "text": "29."
    },
    {
      "type": "paragraph",
      "text": "Rosenkranz AR, Grobner T, Mayer GJ. Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic"
    },
    {
      "type": "paragraph",
      "text": "Systemic Fibrosis? Wiener klinische Wochenschrift 2007;119:271-5."
    },
    {
      "type": "paragraph",
      "text": "30"
    },
    {
      "type": "paragraph",
      "text": "Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR. Quantification of gadolinium in fresh skin and serum samples from patients"
    },
    {
      "type": "paragraph",
      "text": "with nephrogenic systemic fibrosis. Journal of the American Academy of Dermatology 2011;64:91-6."
    },
    {
      "type": "paragraph",
      "text": "31."
    },
    {
      "type": "paragraph",
      "text": "Rofsky NM, Sherry AD, Lenkinski RE. Nephrogenic systemic fibrosis: a chemical perspective. Radiology 2008;247:608-12."
    },
    {
      "type": "paragraph",
      "text": "32."
    },
    {
      "type": "paragraph",
      "text": "Amet S, Launay-Vacher V, Clment O, et al. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic"
    },
    {
      "type": "paragraph",
      "text": "resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrognique Systmique study. Investigative radiology 2014;49:109-"
    },
    {
      "type": "paragraph",
      "text": "15."
    },
    {
      "type": "paragraph",
      "text": "33."
    },
    {
      "type": "paragraph",
      "text": "Bruce R, Wentland AL, Haemel AK, et al. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal"
    },
    {
      "type": "paragraph",
      "text": "Insufficiency Compared With Gadodiamide. Investigative radiology 2016;51:701-05."
    },
    {
      "type": "paragraph",
      "text": "34."
    },
    {
      "type": "paragraph",
      "text": "Martin DR, Krishnamoorthy SK, Kalb B, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI"
    },
    {
      "type": "paragraph",
      "text": "protocols. J Magn Reson Imaging 2010;31:440-6."
    },
    {
      "type": "paragraph",
      "text": "35."
    },
    {
      "type": "paragraph",
      "text": "Michaely HJ, Aschauer M, Deutschmann H, et al. Gadobutrol in Renally Impaired Patients: Results of the GRIP Study. Investigative radiology 2017;52:55-"
    },
    {
      "type": "paragraph",
      "text": "60."
    },
    {
      "type": "paragraph",
      "text": "36."
    },
    {
      "type": "paragraph",
      "text": "Nandwana SB, Moreno CC, Osipow MT, Sekhar A, Cox KL. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a"
    },
    {
      "type": "paragraph",
      "text": "Real Risk in Patients with Impaired Renal Function? Radiology 2015;276:741-7."
    },
    {
      "type": "paragraph",
      "text": "37."
    },
    {
      "type": "paragraph",
      "text": "Reilly RF. Risk for Nephrogenic Systemic Fibrosis with Gadoteridol (ProHance) in Patients Who Are on Long-Term Hemodialysis. Clinical Journal of the"
    },
    {
      "type": "paragraph",
      "text": "American Society of Nephrology 2008;3:747-51."
    },
    {
      "type": "paragraph",
      "text": "38."
    },
    {
      "type": "paragraph",
      "text": "Soulez G, Bloomgarden DC, Rofsky NM, et al. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney"
    },
    {
      "type": "paragraph",
      "text": "Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol. AJR. American journal of roentgenology 2015;205:469-78."
    },
    {
      "type": "paragraph",
      "text": "39."
    },
    {
      "type": "paragraph",
      "text": "Wang Y, Alkasab TK, Narin O, et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines."
    },
    {
      "type": "paragraph",
      "text": "Radiology 2011;260:105-11."
    },
    {
      "type": "image",
      "assetId": "asset_b82f98286f",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "NEPHROGENIC SYSTEMIC FIBROSIS"
    },
    {
      "type": "paragraph",
      "text": "82"
    },
    {
      "type": "paragraph",
      "text": "40."
    },
    {
      "type": "paragraph",
      "text": "Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5"
    },
    {
      "type": "paragraph",
      "text": "Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis. JAMA Intern Med"
    },
    {
      "type": "paragraph",
      "text": "2020;180:223-30."
    },
    {
      "type": "paragraph",
      "text": "41."
    },
    {
      "type": "paragraph",
      "text": "Shankar PR, Davenport MS. Risk of Nephrogenic Systemic Fibrosis in Stage 4 and 5 Chronic Kidney Disease Following Group II Gadolinium-based"
    },
    {
      "type": "paragraph",
      "text": "Contrast Agent Administration: Subanalysis by Chronic Kidney Disease Stage. Radiology 2020;297:447-48."
    },
    {
      "type": "paragraph",
      "text": "42."
    },
    {
      "type": "paragraph",
      "text": "Weinreb JC, Rodby RA, Yee J, et al. Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from"
    },
    {
      "type": "paragraph",
      "text": "the American College of Radiology and the National Kidney Foundation. Kidney Med 2021;3:142-50."
    },
    {
      "type": "paragraph",
      "text": "43."
    },
    {
      "type": "paragraph",
      "text": "Starekova J, Pirasteh A, Reeder SB. Update on Gadolinium-Based Contrast Agent Safety, From the AJR Special Series on Contrast Media. AJR. American"
    },
    {
      "type": "paragraph",
      "text": "journal of roentgenology 2024;223:e2330036."
    },
    {
      "type": "paragraph",
      "text": "44."
    },
    {
      "type": "paragraph",
      "text": "Kanal E, Barkovich AJ, Bell C, et al. ACR Guidance Document for Safe MR Practices: 2007. American Journal of Roentgenology 2007;188:1447-74."
    },
    {
      "type": "paragraph",
      "text": "45."
    },
    {
      "type": "paragraph",
      "text": "Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007;242:647-9."
    },
    {
      "type": "paragraph",
      "text": "46."
    },
    {
      "type": "paragraph",
      "text": "Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. Journal of the"
    },
    {
      "type": "paragraph",
      "text": "American Society of Nephrology : JASN 2005;16:180-8."
    },
    {
      "type": "paragraph",
      "text": "47."
    },
    {
      "type": "paragraph",
      "text": "Choyke PL, Cady J, DePollar SL, Austin H. Determination of serum creatinine prior to iodinated contrast media: is it necessary in all patients? Techniques"
    },
    {
      "type": "paragraph",
      "text": "in urology 1998;4:65-9."
    },
    {
      "type": "paragraph",
      "text": "48."
    },
    {
      "type": "paragraph",
      "text": "Tippins RB, Torres WE, Baumgartner BR, Baumgarten DA. Are screening serum creatinine levels necessary prior to outpatient CT examinations?"
    },
    {
      "type": "paragraph",
      "text": "Radiology 2000;216:481-4."
    },
    {
      "type": "paragraph",
      "text": "49."
    },
    {
      "type": "paragraph",
      "text": "Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER, 3rd, Semelka RC. Nephrogenic systemic fibrosis: change in incidence following a switch"
    },
    {
      "type": "paragraph",
      "text": "in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities. Radiology 2009;253:689-96."
    },
    {
      "type": "paragraph",
      "text": "50."
    },
    {
      "type": "paragraph",
      "text": "Yee J. Prophylactic Hemodialysis for Protection Against Gadolinium-Induced Nephrogenic Systemic Fibrosis: A doll's House. Advances in chronic kidney"
    },
    {
      "type": "paragraph",
      "text": "disease 2017;24:133-35."
    },
    {
      "type": "paragraph",
      "text": "51."
    },
    {
      "type": "paragraph",
      "text": "Nardone B, Saddleton E, Laumann AE, et al. Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatric radiology 2014;44:173-"
    },
    {
      "type": "paragraph",
      "text": "80."
    },
    {
      "type": "paragraph",
      "text": "52."
    },
    {
      "type": "paragraph",
      "text": "Robic C, Port M, Rousseaux O, et al. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High"
    },
    {
      "type": "paragraph",
      "text": "T1 Relaxivity. Investigative radiology 2019;54:475-84."
    },
    {
      "type": "paragraph",
      "text": "53."
    },
    {
      "type": "paragraph",
      "text": "Fretellier N, Rasschaert M, Bocanegra J, et al. Safety and Gadolinium Distribution of the New High-Relaxivity Gadolinium Chelate Gadopiclenol in a Rat"
    },
    {
      "type": "paragraph",
      "text": "Model of Severe Renal Failure. Investigative radiology 2021;56:826-36."
    },
    {
      "type": "paragraph",
      "text": "54."
    },
    {
      "type": "paragraph",
      "text": "Loevner LA, Kolumban B, Hutoczki G, et al. Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The"
    },
    {
      "type": "paragraph",
      "text": "PICTURE Randomized Clinical Trial. Investigative radiology 2023;58:307-13."
    },
    {
      "type": "paragraph",
      "text": "55."
    },
    {
      "type": "paragraph",
      "text": "Jurkiewicz E, Tsvetkova S, Grinberg A, Pasquiers B. Pharmacokinetics, Safety, and Efficacy of Gadopiclenol in Pediatric Patients Aged 2 to 17 Years."
    },
    {
      "type": "paragraph",
      "text": "Investigative radiology 2022;57:510-16."
    },
    {
      "type": "paragraph",
      "text": "Revision History"
    },
    {
      "type": "paragraph",
      "text": "June 2025: Minor revisions"
    },
    {
      "type": "paragraph",
      "text": "April 2023: Minor Revisions"
    },
    {
      "type": "paragraph",
      "text": "July 2021: Updated to reflect the ACR-NKF Consensus Statement"
    },
    {
      "type": "paragraph",
      "text": "15 May 2017: Major revisions"
    },
    {
      "type": "image",
      "assetId": "asset_a9d18a8f87",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "NEPHROGENIC SYSTEMIC FIBROSIS"
    },
    {
      "type": "paragraph",
      "text": "83"
    },
    {
      "type": "paragraph",
      "text": "ACR Contrast Manual Update January 2025 : Clarification on gadolinium-based contrast agent groups:"
    },
    {
      "type": "paragraph",
      "text": "In early 2024, two additional agents (gadoxetic acid and gadopiclenol) were classified as Group II gadolinium-based"
    },
    {
      "type": "paragraph",
      "text": "contrast agents in the ACR Manual on Contrast Media. Following feedback from the radiology community, the"
    },
    {
      "type": "paragraph",
      "text": "committee has revisited this decision. The committee would like to take this opportunity to share clarity on the"
    },
    {
      "type": "paragraph",
      "text": "decision-making process of gadolinium-based contrast agent classification."
    },
    {
      "type": "paragraph",
      "text": "Group II gadolinium-"
    },
    {
      "type": "paragraph",
      "text": "based contrast agents are defined as, agents associated with few, if any, unconfounded cases of"
    },
    {
      "type": "paragraph",
      "text": "nephrogenic systemic fibrosis (NSF). Restrictions and cautions concerning use of these agents have progressively"
    },
    {
      "type": "paragraph",
      "text": "been reduced over time based on favorable laboratory data, longitudinal clinical in vivo data with respect to NSF risk,"
    },
    {
      "type": "paragraph",
      "text": "and interdisciplinary practice consensus [1-3]."
    },
    {
      "type": "paragraph",
      "text": "Gadopiclenol (Elucirem (R) - Guerbet, Vueway (R)- Bracco Diagnostics) is a newer agent, initially classified as a Group"
    },
    {
      "type": "paragraph",
      "text": "II * by the committee in 2024. A common question has arisen regarding the meaning of this *, and how this might be"
    },
    {
      "type": "paragraph",
      "text": "applied to clinical practice."
    },
    {
      "type": "paragraph",
      "text": "The * designation is now described as a provisional status, reflecting the lack of in vivo clinical data related to"
    },
    {
      "type": "paragraph",
      "text": "gadopiclenol and specifically the in vivo risk associated with NSF when administered to patients with severe and end"
    },
    {
      "type": "paragraph",
      "text": "stage CKD (CKD 4 and 5 without or with dialysis [eGFR < 30mL/min/1.73m^2]). Traditional group II agents"
    },
    {
      "type": "paragraph",
      "text": "(gadobenate dimeglumine, gadobutrol, gadoteric acid, gadoteridol), have a pooled upper bound risk of NSF from"
    },
    {
      "type": "paragraph",
      "text": "group II GBCA administration in stage 4 or 5 CKD likely less than 0.07%; upper bound risk stratification by"
    },
    {
      "type": "paragraph",
      "text": "individual agents varies between 0.12%-1.59% based on differences in sample sizes available at the time of meta-"
    },
    {
      "type": "paragraph",
      "text": "analysis [1]. Currently (January 2025) the published risk for gadopiclenol in patients with CKD 4 and 5 without or"
    },
    {
      "type": "paragraph",
      "text": "with dialysis is limited [4]."
    },
    {
      "type": "paragraph",
      "text": "Additionally, traditional group II agents have been used in clinical practice for at least a decade, lending a degree of"
    },
    {
      "type": "paragraph",
      "text": "comfort based on established clinical track records. For these collective reasons, while the committee feels"
    },
    {
      "type": "paragraph",
      "text": "biochemically and theoretically gadopiclenol should behave similar to group II agents, the difference in real world"
    },
    {
      "type": "paragraph",
      "text": "data warrant a slightly different classification (Group II * - provisional status), until a time when the published"
    },
    {
      "type": "paragraph",
      "text": "literature and time-in-practice prove sufficient to classify this similarly to other Group II agents. As detailed within the"
    },
    {
      "type": "paragraph",
      "text": "2025 contrast manual update:"
    },
    {
      "type": "paragraph",
      "text": "Certain newer FDA-approved agents may be designated as a group II * provisional status based on favorable"
    },
    {
      "type": "paragraph",
      "text": "biochemical profile and available laboratory data. These agents are considered provisional due to a relative lack of"
    },
    {
      "type": "paragraph",
      "text": "in-use clinical performance data and/or incomplete clinical data related to use in higher risk populations. Agents in"
    },
    {
      "type": "paragraph",
      "text": "this category can be treated similar to a group II agent or a group III agent per local practice preference."
    },
    {
      "type": "paragraph",
      "text": "Gadoxetic acid (Eovist"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Bayer HealthCare Pharmaceuticals; Primovist in many countries) has been classified"
    },
    {
      "type": "paragraph",
      "text": "previously as a group III agent but was changed to a group II classification in 2024. This is based on a longer clinical"
    },
    {
      "type": "paragraph",
      "text": "in use period and favorable data related to risk for NSF in patients with CKD 4 and 5 without or with dialysis [4]. The"
    },
    {
      "type": "paragraph",
      "text": "data used to make this determination was based on a combination of both published data and additional clinical"
    },
    {
      "type": "paragraph",
      "text": "administrations in higher risk patients provided to the committee. Based on published and clinical data available to the"
    },
    {
      "type": "paragraph",
      "text": "committee, the risk of NSF is felt to be within a safe upper limit margin, similar to other group II agents. Since its"
    },
    {
      "type": "paragraph",
      "text": "introduction in 2010, there have been over 10 million estimated world-wide gadoxetic acid exposures now compared"
    },
    {
      "type": "paragraph",
      "text": "to the 800,000 at the time of the initial classification. Reclassification of gadoxetic acid from a group III agent to a"
    },
    {
      "type": "paragraph",
      "text": "group II agent reflects integration of new data over time."
    },
    {
      "type": "paragraph",
      "text": "Gadolinium-based contrast agent groupings are designed to be fluid and evolve with new information and time. The"
    },
    {
      "type": "paragraph",
      "text": "changes made to gadolinium-based contrast agent classifications within the past two years reflect these changes."
    },
    {
      "type": "paragraph",
      "text": "References:"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Woolen SA, Shankar PR, Gagnier JJ, MacEachern MP, Singer L, Davenport MS. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5"
    },
    {
      "type": "paragraph",
      "text": "Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis. JAMA Intern Med"
    },
    {
      "type": "paragraph",
      "text": "2020;180:223-30."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Shankar PR, Davenport MS. Risk of Nephrogenic Systemic Fibrosis in Stage 4 and 5 Chronic Kidney Disease Following Group II Gadolinium-based"
    },
    {
      "type": "paragraph",
      "text": "Contrast Agent Administration: Subanalysis by Chronic Kidney Disease Stage. Radiology 2020;297:447-48."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Weinreb JC, Rodby RA, Yee J, et al. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the"
    },
    {
      "type": "image",
      "assetId": "asset_923fdf08ed",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "NEPHROGENIC SYSTEMIC FIBROSIS"
    },
    {
      "type": "paragraph",
      "text": "84"
    },
    {
      "type": "paragraph",
      "text": "American College of Radiology and the National Kidney Foundation. Radiology 2021;298:28-35."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Starekova J, Pirasteh A, Reeder SB. Update on Gadolinium-Based Contrast Agent Safety, From the AJR Special Series on Contrast Media. AJR Am J"
    },
    {
      "type": "paragraph",
      "text": "Roentgenol 2024;223:e2330036."
    },
    {
      "type": "image",
      "assetId": "asset_e1835289c9",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ULTRASOUND CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "85"
    },
    {
      "type": "paragraph",
      "text": "ULTRASOUND CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "Contrast agents available for ultrasound, consisting of microbubbles or microspheres, allow for transient improvement in"
    },
    {
      "type": "paragraph",
      "text": "ultrasound contrast resolution, increased conspicuity of vascularity, and detection of blood flow."
    },
    {
      "type": "paragraph",
      "text": "With dedicated ultrasound software, these contrast agents, composed of an outer phospholipid or protein wall and a central inert"
    },
    {
      "type": "paragraph",
      "text": "echogenic gas, enhance the acoustic ultrasound signal from blood. Such contrast agents can be safely injected intravenously through"
    },
    {
      "type": "paragraph",
      "text": "a peripheral or central line, or instilled into hollow structures, such as the urinary bladder."
    },
    {
      "type": "paragraph",
      "text": "Approved Agents and Uses"
    },
    {
      "type": "paragraph",
      "text": "There are three ultrasound contrast agents with FDA approval available in the United States [1-3]:"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Definity"
    },
    {
      "type": "paragraph",
      "text": "(R)"
    },
    {
      "type": "paragraph",
      "text": "(perflutren lipid microspheres)"
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Lumason"
    },
    {
      "type": "paragraph",
      "text": "(R)"
    },
    {
      "type": "paragraph",
      "text": "(sulfur hexafluoride lipid-type A microspheres; also known as SonoVue"
    },
    {
      "type": "paragraph",
      "text": "(R)"
    },
    {
      "type": "paragraph",
      "text": ")"
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Optison"
    },
    {
      "type": "paragraph",
      "text": "(R)"
    },
    {
      "type": "paragraph",
      "text": "(perflutren protein-type A)"
    },
    {
      "type": "paragraph",
      "text": "At the time of this publication, Definity, Lumason, and Optison are approved for intravenous administration in adults undergoing"
    },
    {
      "type": "paragraph",
      "text": "echocardiography to improve visualization of the left ventricular cavity and its endocardial borders. Lumason is also approved"
    },
    {
      "type": "paragraph",
      "text": "for liver imaging in both children and adults, and for imaging of the pediatric urinary tract for evaluation of suspected or known"
    },
    {
      "type": "paragraph",
      "text": "vesicoureteral reflux (voiding ultrasonography) [4-7]."
    },
    {
      "type": "paragraph",
      "text": "In addition to these approved indications, ultrasound contrast agents also have been used off-label to assess for the presence and"
    },
    {
      "type": "paragraph",
      "text": "dynamics of blood flow in tumors [8], to differentiate benign cysts from solid masses in the kidney [9], to detect solid organ injury"
    },
    {
      "type": "paragraph",
      "text": "in the setting of trauma [10-12], to detect and characterize endoleaks after abdominal aortic aneurysm repair [13,14], to detect"
    },
    {
      "type": "paragraph",
      "text": "bowel wall inflammation in Crohns disease [15"
    },
    {
      "type": "paragraph",
      "text": "-18], to discriminate abscess from phlegmon [19], and to guide and monitor"
    },
    {
      "type": "paragraph",
      "text": "ultrasound- guided interventions and ablative therapies [20]. Some of these off-label indications are in clinical use, while others"
    },
    {
      "type": "paragraph",
      "text": "remain investigatory."
    },
    {
      "type": "paragraph",
      "text": "Contrast Agent Administration and Ultrasound Imaging"
    },
    {
      "type": "paragraph",
      "text": "As detailed in the package labeling, these contrast agents are approved for intravenous slow infusion and/or bolus injection. After"
    },
    {
      "type": "paragraph",
      "text": "reconstitution, they are typically hand injected through a moderate- or large- bore peripheral intravenous catheter followed by a"
    },
    {
      "type": "paragraph",
      "text": "saline flush. The maximum volume of contrast material that can be administered per injection and per imaging session differs by"
    },
    {
      "type": "paragraph",
      "text": "contrast agent."
    },
    {
      "type": "paragraph",
      "text": "Dedicated ultrasound software is available from most ultrasound vendors. Such software functions to suppress the background"
    },
    {
      "type": "paragraph",
      "text": "tissue signal and maximize the signal from the contrast agent due to a combination of soundwave reflection and microbubble"
    },
    {
      "type": "paragraph",
      "text": "resonance."
    },
    {
      "type": "paragraph",
      "text": "The likelihood of bubble rupture can and should be minimized by avoiding small intravenous catheters"
    },
    {
      "type": "paragraph",
      "text": "and using a low mechanical index during imaging. The safety of high mechanical index imaging (>0.8) has not been well studied"
    },
    {
      "type": "paragraph",
      "text": "and can cause microbubble cavitation or rupture."
    },
    {
      "type": "paragraph",
      "text": "Pharmacodynamics and Pharmacokinetics"
    },
    {
      "type": "paragraph",
      "text": "Intravascularly administered ultrasound contrast agents generally remain in the blood pool because they are too large to enter the"
    },
    {
      "type": "paragraph",
      "text": "interstitium (mean microbubble diameter: Definity [1.1-"
    },
    {
      "type": "paragraph",
      "text": "3.3 m], Lumason [1.5"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2.5 m], Optison [3.0"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4.5 m). This property"
    },
    {
      "type": "paragraph",
      "text": "differs from most CT and MRI contrast media."
    },
    {
      "type": "paragraph",
      "text": "Real-time assessment can be obtained over an approximately 10-minute period. After this time, the microbubbles spontaneously"
    },
    {
      "type": "paragraph",
      "text": "rupture and dissolve, releasing an inert gas that is mostly eliminated through the lungs."
    },
    {
      "type": "image",
      "assetId": "asset_a4476cb5f6",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ULTRASOUND CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "86"
    },
    {
      "type": "paragraph",
      "text": "Safety Profile"
    },
    {
      "type": "paragraph",
      "text": "Ultrasound contrast agents are safe, with an adverse event rate similar to or less than that of modern CT and MRI contrast agents."
    },
    {
      "type": "paragraph",
      "text": "A large retrospective investigation of more than 78,000 doses of Definity and Optison found a severe reaction rate of 0.01%"
    },
    {
      "type": "paragraph",
      "text": "(n=8); half of these reactions (4 of 8) were considered anaphylactoid and there were no deaths [21]. Another large retrospective"
    },
    {
      "type": "paragraph",
      "text": "study evaluating the use of SonoVue in 23,188 subjects documented 29 adverse events, with only two considered serious [22]."
    },
    {
      "type": "paragraph",
      "text": "The majority of adverse events are mild and likely physiologic in etiology, including symptoms such as headache, a sensation"
    },
    {
      "type": "paragraph",
      "text": "of warmth or flushing, nausea, and altered taste. The majority of severe reactions occur within 30 minutes of administration."
    },
    {
      "type": "paragraph",
      "text": "A review performed by the Society for Pediatric Radiology in conjunction with the International Contrast Ultrasound Society"
    },
    {
      "type": "paragraph",
      "text": "concluded that noncardiac applications of contrast-enhanced ultrasound"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "including intravenous and intravesical administration"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "are safe, with side effects uncommon and typically minor [23]. A study [24] showed that that the intravenous injection of"
    },
    {
      "type": "paragraph",
      "text": "microspheres is also well-tolerated in the pediatric population, with only minor side effects."
    },
    {
      "type": "paragraph",
      "text": "Ultrasound contrast agents are contraindicated for intra-arterial injection and in patients with previous hypersensitivity reaction"
    },
    {
      "type": "paragraph",
      "text": "to microspheres. Old labeling included a contraindication for patients with a known or suspected right-to-left or bidirectional"
    },
    {
      "type": "paragraph",
      "text": "shunt, but that labeling has been removed from the package inserts by the FDA, and it is no longer considered a contraindication."
    },
    {
      "type": "paragraph",
      "text": "The risk for a serious cardiopulmonary reaction may be increased in patients who also have an unstable cardiopulmonary condition"
    },
    {
      "type": "paragraph",
      "text": "(e.g., acute myocardial infarction, unstable congestive heart failure). However, a study [25] of 1513 hospitalized patients with"
    },
    {
      "type": "paragraph",
      "text": "pulmonary hypertension showed that adverse reactions to Definity were very rare (0.002%)."
    },
    {
      "type": "paragraph",
      "text": "Ultrasound contrast agents have no known renal toxicity in approved doses. There are no adequate and well- controlled studies"
    },
    {
      "type": "paragraph",
      "text": "of these agents in pregnant women. While there are no known risks, these agents should only be used when needed and the"
    },
    {
      "type": "paragraph",
      "text": "benefits outweigh any potential small risks to the fetus. As the effects of these contrast agents on human breast milk is currently"
    },
    {
      "type": "paragraph",
      "text": "unknown, temporary (~24 hours) pumping and discarding of milk may be considered. Optison contains human albumin, a"
    },
    {
      "type": "paragraph",
      "text": "derivative of human blood, and may confer a theoretical risk of viral or prion infection; additionally, it may be contraindicated in"
    },
    {
      "type": "paragraph",
      "text": "patients with religious or ethical objections to the intravascular receipt of human blood products."
    },
    {
      "type": "paragraph",
      "text": "As with all contrast agents, appropriate resuscitation equipment and trained personnel should be readily available at the time of"
    },
    {
      "type": "paragraph",
      "text": "injection in the event that an adverse reaction occurs."
    },
    {
      "type": "paragraph",
      "text": "References"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Optison"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "(perflutren protein-type A). 2017; Available at:"
    },
    {
      "type": "paragraph",
      "text": "http://www3.gehealthcare.com/en/products/categories/ contrast media/optison"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "Accessed April 10, 2017."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Lumason(R) 2017; Available at:"
    },
    {
      "type": "paragraph",
      "text": "http://imaging.bracco.com/us-en/lumason"
    },
    {
      "type": "paragraph",
      "text": ". Accessed April 10, 2017."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Definity(R) 2017; Available at:"
    },
    {
      "type": "paragraph",
      "text": "http://www.definityimaging.com/main.html"
    },
    {
      "type": "paragraph",
      "text": ". Accessed April 10, 2017."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Darge K, Troeger J. Vesicoureteral reflux grading in contrast-enhanced voiding urosonography."
    },
    {
      "type": "paragraph",
      "text": "Eur J Radiol"
    },
    {
      "type": "paragraph",
      "text": ". 2002;43(2):122-128."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Fernandez-Ibieta M, Parrondo-Muinos C, Fernandez-Masaguer LC, et al. Voiding urosonography with second-generation contrast as a main tool"
    },
    {
      "type": "paragraph",
      "text": "for examining the upper and lower urinary tract in children. Pilot Study."
    },
    {
      "type": "paragraph",
      "text": "Actas Urol Esp"
    },
    {
      "type": "paragraph",
      "text": ". 2016;40(3):183-189."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Papadopoulou F, Anthopoulou A, Siomou E, Efremidis S, Tsamboulas C, Darge K. Harmonic voiding urosonography with a second-generation"
    },
    {
      "type": "paragraph",
      "text": "contrast agent for the diagnosis of vesicoureteral reflux."
    },
    {
      "type": "paragraph",
      "text": "Pediatr Radiol"
    },
    {
      "type": "paragraph",
      "text": ". 2009;39(3):239-244."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Radmayr C, Klauser A, Pallwein L, Zurnedden D, Bartsch G, Frauscher F. Contrast enhanced reflux sonography in children: a comparison to"
    },
    {
      "type": "paragraph",
      "text": "standard radiological imaging."
    },
    {
      "type": "paragraph",
      "text": "J Urol"
    },
    {
      "type": "paragraph",
      "text": ". 2002;167(3):1428-1430."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "McCarville MB, Coleman JL, Guo J, et al. Use of Quantitative Dynamic Contrast-Enhanced Ultrasound to Assess Response to Antiangiogenic"
    },
    {
      "type": "paragraph",
      "text": "Therapy in Children and Adolescents with Solid Malignancies: A Pilot Study."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": ". 2016;206(5):933-939."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Barr RG, Peterson C, Hindi A. Evaluation of indeterminate renal masses with contrast-enhanced US: a diagnostic performance study."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": ". 2014;271(1):133-142."
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Durkin N, Deganello A, Sellars ME, Sidhu PS, Davenport M, Makin E. Post-traumatic liver and splenic pseudoaneurysms in children:"
    },
    {
      "type": "paragraph",
      "text": "Diagnosis, management, and follow-up screening using contrast enhanced ultrasound (CEUS)."
    },
    {
      "type": "paragraph",
      "text": "J Pediatr Surg"
    },
    {
      "type": "paragraph",
      "text": ". 2016;51(2):289-292."
    },
    {
      "type": "paragraph",
      "text": "11."
    },
    {
      "type": "paragraph",
      "text": "Miele V, Piccolo CL, Galluzzo M, Ianniello S, Sessa B, Trinci M. Contrast-enhanced ultrasound (CEUS) in blunt abdominal trauma."
    },
    {
      "type": "paragraph",
      "text": "Br J"
    },
    {
      "type": "paragraph",
      "text": "Radiol"
    },
    {
      "type": "paragraph",
      "text": ". 2016;89(1061):20150823."
    },
    {
      "type": "paragraph",
      "text": "12."
    },
    {
      "type": "paragraph",
      "text": "Mihalik JE, Smith RS, Toevs CC, Putnam AT, Foster JE. The use of contrast-enhanced ultrasound for the evaluation of solid abdominal organ"
    },
    {
      "type": "paragraph",
      "text": "injury in patients with blunt abdominal trauma."
    },
    {
      "type": "paragraph",
      "text": "J Trauma Acute Care Surg"
    },
    {
      "type": "paragraph",
      "text": ". 2012;73(5):1100-1105."
    },
    {
      "type": "paragraph",
      "text": "13."
    },
    {
      "type": "paragraph",
      "text": "Carrafiello G, Recaldini C, Lagana D, Piffaretti G, Fugazzola C. Endoleak detection and classification after endovascular treatment of abdominal"
    },
    {
      "type": "paragraph",
      "text": "aortic aneurysm: value of CEUS over CTA."
    },
    {
      "type": "paragraph",
      "text": "Abdom Imaging"
    },
    {
      "type": "paragraph",
      "text": ". 2008;33(3):357-362."
    },
    {
      "type": "paragraph",
      "text": "14."
    },
    {
      "type": "paragraph",
      "text": "Karthikesalingam A, Al-Jundi W, Jackson D, et al. Systematic review and meta-analysis of duplex ultrasonography, contrast-enhanced"
    },
    {
      "type": "paragraph",
      "text": "ultrasonography or computed tomography for surveillance after endovascular aneurysm repair."
    },
    {
      "type": "paragraph",
      "text": "Br J Surg"
    },
    {
      "type": "paragraph",
      "text": ". 2012;99(11):1514-1523."
    },
    {
      "type": "paragraph",
      "text": "15."
    },
    {
      "type": "paragraph",
      "text": "De Franco A, Di Veronica A, Armuzzi A, et al. Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates"
    },
    {
      "type": "paragraph",
      "text": "with disease activity. Radiology. 2012;262(2):680-688."
    },
    {
      "type": "paragraph",
      "text": "16."
    },
    {
      "type": "paragraph",
      "text": "Horjus Talabur Horje CS, Bruijnen R, Roovers L, Groenen MJ, Joosten FB, Wahab PJ. Contrast Enhanced Abdominal Ultrasound in the"
    },
    {
      "type": "image",
      "assetId": "asset_8ee0d16e07",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ULTRASOUND CONTRAST MEDIA"
    },
    {
      "type": "paragraph",
      "text": "87"
    },
    {
      "type": "paragraph",
      "text": "Assessment of Ileal Inflammation"
    },
    {
      "type": "paragraph",
      "text": "in Crohns Disease: A"
    },
    {
      "type": "paragraph",
      "text": "Comparison with MR Enterography."
    },
    {
      "type": "paragraph",
      "text": "PLoS One"
    },
    {
      "type": "paragraph",
      "text": ". 2015;10(8): e0136105."
    },
    {
      "type": "paragraph",
      "text": "17."
    },
    {
      "type": "paragraph",
      "text": "Quaia E, Cabibbo B, De Paoli L, Toscano W, Poillucci G, Cova MA. The value of time-intensity curves obtained after microbubble contrast"
    },
    {
      "type": "paragraph",
      "text": "agent injection to discriminate responders from non-responders to anti-inflammatory"
    },
    {
      "type": "paragraph",
      "text": "medication among patients with Crohns disease."
    },
    {
      "type": "paragraph",
      "text": "Eur"
    },
    {
      "type": "paragraph",
      "text": "Radiol"
    },
    {
      "type": "paragraph",
      "text": ". 2013;23(6):1650-1659."
    },
    {
      "type": "paragraph",
      "text": "18."
    },
    {
      "type": "paragraph",
      "text": "Quaia E, Migaleddu V, Baratella E, et al. The diagnostic value of small bowel wall vascularity after sulfur hexafluoride- filled microbubble"
    },
    {
      "type": "paragraph",
      "text": "injection in patients with Crohns disease. Correlation with the therapeutic effectiveness of specific anti"
    },
    {
      "type": "paragraph",
      "text": "- inflammatory treatment."
    },
    {
      "type": "paragraph",
      "text": "Eur J Radiol"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "2009;69(3):438-444."
    },
    {
      "type": "paragraph",
      "text": "19."
    },
    {
      "type": "paragraph",
      "text": "Ripolles T, Martinez-Perez MJ, Paredes JM, Vizuete J, Garcia-Martinez E, Jimenez-Restrepo DH. Contrast-enhanced ultrasound in the"
    },
    {
      "type": "paragraph",
      "text": "differentiation between phlegmon and abscess in Crohns disease and other abdominal conditions."
    },
    {
      "type": "paragraph",
      "text": "Eur J Radiol"
    },
    {
      "type": "paragraph",
      "text": ". 2013;82(10): e525-531."
    },
    {
      "type": "paragraph",
      "text": "20."
    },
    {
      "type": "paragraph",
      "text": "Meloni MF, Smolock A, Cantisani V, et al. Contrast enhanced ultrasound in the evaluation and percutaneous treatment of hepatic and renal"
    },
    {
      "type": "paragraph",
      "text": "tumors."
    },
    {
      "type": "paragraph",
      "text": "Eur J Radiol"
    },
    {
      "type": "paragraph",
      "text": ". 2015;84(9):1666-1674."
    },
    {
      "type": "paragraph",
      "text": "21."
    },
    {
      "type": "paragraph",
      "text": "Wei K, Mulvagh SL, Carson L, et al. The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383"
    },
    {
      "type": "paragraph",
      "text": "administered contrast doses."
    },
    {
      "type": "paragraph",
      "text": "J Am Soc Echocardiogr"
    },
    {
      "type": "paragraph",
      "text": ". 2008;21(11):1202-1206."
    },
    {
      "type": "paragraph",
      "text": "22."
    },
    {
      "type": "paragraph",
      "text": "Piscaglia F, Bolondi L, Italian Society for Ultrasound in M, Biology Study Group on Ultrasound Contrast A. The safety of Sonovue in"
    },
    {
      "type": "paragraph",
      "text": "abdominal applications: retrospective analysis of 23188 investigations."
    },
    {
      "type": "paragraph",
      "text": "Ultrasound Med Biol"
    },
    {
      "type": "paragraph",
      "text": ". 2006;32(9):1369-1375."
    },
    {
      "type": "paragraph",
      "text": "23."
    },
    {
      "type": "paragraph",
      "text": "Darge K, Papadopoulou F, Ntoulia A, et al. Safety of contrast-enhanced ultrasound in children for non-cardiac applications: a review by the"
    },
    {
      "type": "paragraph",
      "text": "Society for Pediatric Radiology (SPR) and the International Contrast Ultrasound Society (ICUS)."
    },
    {
      "type": "paragraph",
      "text": "Pediatr Radiol"
    },
    {
      "type": "paragraph",
      "text": ". 2013;43(9):1063-1073."
    },
    {
      "type": "paragraph",
      "text": "24."
    },
    {
      "type": "paragraph",
      "text": "Coleman JL, Navid F, Furman WL, McCarville MB. Safety of ultrasound contrast agents in the pediatric oncologic population: a single-"
    },
    {
      "type": "paragraph",
      "text": "institution experience. AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "2014;202:966-70."
    },
    {
      "type": "paragraph",
      "text": "25."
    },
    {
      "type": "paragraph",
      "text": "Wever-Pinzon O, Suma V, Ahuja A, et al. Safety of echocardiographic contrast in hospitalized patients with pulmonary hypertension: a multi-"
    },
    {
      "type": "paragraph",
      "text": "center study. Eur Heart J Cardiovasc Imaging"
    },
    {
      "type": "paragraph",
      "text": "2012;13:857-62."
    },
    {
      "type": "image",
      "assetId": "asset_a45102e383",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TREATMENT OF CONTRAST REACTIONS"
    },
    {
      "type": "paragraph",
      "text": "88"
    },
    {
      "type": "paragraph",
      "text": "TREATMENT OF CONTRAST REACTIONS"
    },
    {
      "type": "paragraph",
      "text": "Optimal treatment of contrast reactions starts with a well-designed plan and a properly trained staff. In addition to basic life"
    },
    {
      "type": "paragraph",
      "text": "support training, on-site personnel should be trained in the rapid recognition, assessment, diagnosis, and treatment of contrast"
    },
    {
      "type": "paragraph",
      "text": "reactions."
    },
    {
      "type": "paragraph",
      "text": "In evaluating a patient for a potential contrast reaction, five immediate assessments should be made if clinically feasible:"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "What is the patients general appearance?"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Can the patient speak? How does their voice sound?"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "What is the quality of the patients breathing?"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "What is the patients pulse?"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "What is the patients blood pressure?"
    },
    {
      "type": "paragraph",
      "text": "The patients level of consciousness, appearance of their skin, quality of phonation, lung auscultation, blood pressure, and"
    },
    {
      "type": "paragraph",
      "text": "heart"
    },
    {
      "type": "paragraph",
      "text": "rate assessment will allow the responding provider to quickly determine the severity of a reaction and properly diagnose it."
    },
    {
      "type": "paragraph",
      "text": "Once diagnosed, effective treatment can be rapidly and effectively administered (see"
    },
    {
      "type": "paragraph",
      "text": "Tables 1, 4,"
    },
    {
      "type": "paragraph",
      "text": "and"
    },
    {
      "type": "paragraph",
      "text": "3"
    },
    {
      "type": "paragraph",
      "text": "). Staff should be aware"
    },
    {
      "type": "paragraph",
      "text": "of how to activate the emergency response system to elevate the level of care if needed"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "for example, calling an emergency"
    },
    {
      "type": "paragraph",
      "text": "response phone number (e.g., 911 for emergency medical personnel assistance in an outpatient medical center setting)."
    },
    {
      "type": "paragraph",
      "text": "Mild immediate reactions (both allergic-like and physiologic) typically do not require medical treatment. However, a mild"
    },
    {
      "type": "paragraph",
      "text": "reaction may evolve into a moderate or severe reaction. Vital signs should be obtained to detect hypotension that may be"
    },
    {
      "type": "paragraph",
      "text": "clinically silent while the patient is supine. Any patient with a mild allergic-like reaction should be observed for a minimum"
    },
    {
      "type": "paragraph",
      "text": "of 20 to 30 minutes to ensure clinical stability or recovery. Treatment with an antihistamine may be instituted for mild"
    },
    {
      "type": "paragraph",
      "text": "symptomatic allergic-like urticarial reactions, but often is not necessary."
    },
    {
      "type": "paragraph",
      "text": "Most moderate and all severe reactions will require prompt and aggressive treatment to reduce the likelihood of an adverse"
    },
    {
      "type": "paragraph",
      "text": "outcome. Treatment algorithms for adults and children are provided in"
    },
    {
      "type": "paragraph",
      "text": "Tables 1, 2,"
    },
    {
      "type": "paragraph",
      "text": "and"
    },
    {
      "type": "paragraph",
      "text": "3"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "Ongoing quality assurance and quality improvement programs with in-service training and review sessions are helpful in"
    },
    {
      "type": "paragraph",
      "text": "ensuring that responses to contrast reactions are prompt and appropriate. This includes training of onsite health care providers"
    },
    {
      "type": "paragraph",
      "text": "in resuscitation techniques such as basic life support."
    },
    {
      "type": "paragraph",
      "text": "References"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Barach EM, Nowak RM, Lee TG, Tomlanovich MC. Epinephrine for treatment of anaphylactic shock."
    },
    {
      "type": "paragraph",
      "text": "JAMA"
    },
    {
      "type": "paragraph",
      "text": "1984; 251:2118- 2122."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Bennett MJ, Hirshman CA. Epinephrine for anaphylactic shock."
    },
    {
      "type": "paragraph",
      "text": "JAMA"
    },
    {
      "type": "paragraph",
      "text": "1985; 253:510-511."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Berg RA, et al. Part 5: adult basic life support: 2010 American Heart Association guidelines for cardio-pulmonary resuscitation and"
    },
    {
      "type": "paragraph",
      "text": "emergency cardiovascular care."
    },
    {
      "type": "paragraph",
      "text": "Circulation"
    },
    {
      "type": "paragraph",
      "text": "2010; 22:15): S685-S705."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Braddom RL, Rocco JF. Autonomic dysreflexia. A survey of current treatment."
    },
    {
      "type": "paragraph",
      "text": "Am J Phys Med Rehabil"
    },
    {
      "type": "paragraph",
      "text": "1991; 70:234-241."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Brown JH. Atropine, scopolamine, and antimuscarinic drugs. In: Gilman AG, Rall TW, Nies AS, et al, ed. The pharmaceutical basis of"
    },
    {
      "type": "paragraph",
      "text": "therapeutics. New York, NY: Pergamon; 1990:150-165."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Bush WH, Swanson DP. Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment."
    },
    {
      "type": "paragraph",
      "text": "AJR"
    },
    {
      "type": "paragraph",
      "text": "1991; 157:1153-1161."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Bush WH. Treatment of acute contrast reactions. In: Bush WH, King B, Krecke K, ed. Radiology Life Support (RAD-LS). London:"
    },
    {
      "type": "paragraph",
      "text": "Hodder Arnold Publishers; 1999."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "Chamberlain DA, Turner P, Sneddon JM. Effects of atropine on heart-rate in healthy man."
    },
    {
      "type": "paragraph",
      "text": "Lancet"
    },
    {
      "type": "paragraph",
      "text": "1967; 2:12-15."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Cohan RH, Leder RA, Ellis JH. Treatment of adverse reactions to radiographic contrast media in adults."
    },
    {
      "type": "paragraph",
      "text": "Radiol Clin North Am"
    },
    {
      "type": "paragraph",
      "text": "1996; 34:1055-1076."
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Collins MS, Hunt CH, Hartman RP. Use of IV epinephrine for treatment of patients with contrast reactions: lessons learned from a 5-year"
    },
    {
      "type": "paragraph",
      "text": "experience. AJR 2009; 192:455-461."
    },
    {
      "type": "paragraph",
      "text": "11."
    },
    {
      "type": "paragraph",
      "text": "Field JM, Hazinski MF, Sayre MR, et al. Part 1: executive summary: 2010 American Heart Association guidelines for"
    },
    {
      "type": "paragraph",
      "text": "cardiopulmonary and emergency cardiovascular care."
    },
    {
      "type": "paragraph",
      "text": "Circulation"
    },
    {
      "type": "paragraph",
      "text": "2010;122: S640-S656."
    },
    {
      "type": "paragraph",
      "text": "12."
    },
    {
      "type": "paragraph",
      "text": "Grauer K, Cavallaro D. ACLS: certification preparation and a comprehensive review. Vol I and II. St. Louis, Mo: Mosby; 1993."
    },
    {
      "type": "paragraph",
      "text": "13."
    },
    {
      "type": "paragraph",
      "text": "Guidelines for cardiopulmonary resuscitation and emergency cardiac care. Emergency Cardiac Care Committee and Subcommittees,"
    },
    {
      "type": "paragraph",
      "text": "American Heart Association. Part III. Adult advanced cardiac life support."
    },
    {
      "type": "paragraph",
      "text": "JAMA"
    },
    {
      "type": "paragraph",
      "text": "1992; 268:2199-2241."
    },
    {
      "type": "paragraph",
      "text": "14."
    },
    {
      "type": "paragraph",
      "text": "Hoffmann BB, Lefkowitz RJ. Catecholamines and sympathomimetic drugs. In: Gilman AG, Rall TW, Nies AS, et al, ed. The"
    },
    {
      "type": "paragraph",
      "text": "pharmacological basis of therapeutics. New York, NY: Pergamon; 1990:192-198."
    },
    {
      "type": "paragraph",
      "text": "15."
    },
    {
      "type": "paragraph",
      "text": "McClennan BL. Adverse reactions to iodinated contrast media. Recognition and response."
    },
    {
      "type": "paragraph",
      "text": "Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": "1994; 29 Suppl 1: S46- 50."
    },
    {
      "type": "paragraph",
      "text": "16."
    },
    {
      "type": "paragraph",
      "text": "Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association"
    },
    {
      "type": "paragraph",
      "text": "guidelines for cardio-pulmonary resuscitation and emergency cardiovascular care."
    },
    {
      "type": "paragraph",
      "text": "Circulation"
    },
    {
      "type": "paragraph",
      "text": "2010;122: S729-S767."
    },
    {
      "type": "paragraph",
      "text": "17."
    },
    {
      "type": "paragraph",
      "text": "Runge JW, Martinez JC, Caravati EM, Williamson SG, Hartsell SC. Histamine antagonists in the treatment of acute allergic reactions."
    },
    {
      "type": "image",
      "assetId": "asset_1747bbe87d",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TREATMENT OF CONTRAST REACTIONS"
    },
    {
      "type": "paragraph",
      "text": "89"
    },
    {
      "type": "paragraph",
      "text": "Ann Emerg Med"
    },
    {
      "type": "paragraph",
      "text": "1992; 21:237-242."
    },
    {
      "type": "paragraph",
      "text": "18."
    },
    {
      "type": "paragraph",
      "text": "Segal AJ, Bush WH, Jr. Avoidable errors in dealing with anaphylactoid reactions to iodinated contrast media."
    },
    {
      "type": "paragraph",
      "text": "Invest Radiol"
    },
    {
      "type": "paragraph",
      "text": "2011; 46:147-151."
    },
    {
      "type": "paragraph",
      "text": "19."
    },
    {
      "type": "paragraph",
      "text": "Swanson DP, Chilton HM, Thrall JH, ed. Pharmaceuticals in medical imaging. New York, NY: Macmillan; 1990."
    },
    {
      "type": "paragraph",
      "text": "20."
    },
    {
      "type": "paragraph",
      "text": "Travers AH, Rea TD, Bobrow BJ, et al. Part 4: CPR overview: 2010American Heart Association guidelines for cardiopulmonary"
    },
    {
      "type": "paragraph",
      "text": "resuscitation and emergency cardiovascular care."
    },
    {
      "type": "paragraph",
      "text": "Circulation"
    },
    {
      "type": "paragraph",
      "text": "2010;122: S676-S684."
    },
    {
      "type": "paragraph",
      "text": "21."
    },
    {
      "type": "paragraph",
      "text": "vanSonnenberg E, Neff CC, Pfister RC. Life-threatening hypotensive reactions to contrast media administration: comparison of"
    },
    {
      "type": "paragraph",
      "text": "pharmacologic and fluid therapy."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": "1987; 162:15-19."
    },
    {
      "type": "paragraph",
      "text": "Revision History"
    },
    {
      "type": "paragraph",
      "text": "15 January 2020: Minor revisions"
    },
    {
      "type": "image",
      "assetId": "asset_e83293fd9b",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ADMINISTRATION OF CONTRAST MEDIA TO PREGNANT OR POTENTIALLY PREGNANT PATIENTS"
    },
    {
      "type": "paragraph",
      "text": "90"
    },
    {
      "type": "paragraph",
      "text": "ADMINISTRATION OF CONTRAST MEDIA TO PREGNANT OR"
    },
    {
      "type": "paragraph",
      "text": "POTENTIALLY PREGNANT PATIENTS"
    },
    {
      "type": "paragraph",
      "text": "Studies of low-molecular weight water-soluble extracellular substances such as iodinated and gadolinium- based contrast media"
    },
    {
      "type": "paragraph",
      "text": "in pregnancy have been limited, and their effects on the human embryo or fetus are incompletely understood. Iodinated contrast"
    },
    {
      "type": "paragraph",
      "text": "media have been shown to cross the human placenta and enter the fetus in measurable quantities [1,2]. A standard gadolinium-"
    },
    {
      "type": "paragraph",
      "text": "based contrast medium has been shown to cross the placenta in primates and appear within the fetal bladder within 11 minutes"
    },
    {
      "type": "paragraph",
      "text": "after intravenous (IV) administration [3]. It is likely that all iodinated and gadolinium-based contrast media behave in a similar"
    },
    {
      "type": "paragraph",
      "text": "fashion and cross the blood-placental barrier and into the fetus."
    },
    {
      "type": "paragraph",
      "text": "After entering the fetal blood stream, these agents will be excreted via the urine into the amniotic fluid and be subsequently"
    },
    {
      "type": "paragraph",
      "text": "swallowed by the fetus [4]. It is then possible that a small amount will be absorbed from the gut of the fetus, with the additional"
    },
    {
      "type": "paragraph",
      "text": "swallowed gadolinium-based contrast agents eliminated back into the amniotic fluid."
    },
    {
      "type": "paragraph",
      "text": "In a study in primates, placental enhancement could be detected up to 2 hours following IV administration of gadopentetate"
    },
    {
      "type": "paragraph",
      "text": "dimeglumine. When gadopentetate dimeglumine was injected directly into the amniotic cavity, it was still conspicuous at 1"
    },
    {
      "type": "paragraph",
      "text": "hour after administration [3]. There are no data available to assess the rate of clearance of contrast media from the amniotic"
    },
    {
      "type": "paragraph",
      "text": "fluid."
    },
    {
      "type": "paragraph",
      "text": "Iodinated Low-Osmolality Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Mutagenic effect of low-osmolality contrast media"
    },
    {
      "type": "paragraph",
      "text": "Diagnostic iodinated contrast media have been shown to cross the human placenta and enter the fetus when given in usual"
    },
    {
      "type": "paragraph",
      "text": "clinical doses. In-vivo tests in animals have shown no evidence of either mutagenic or teratogenic effects with low-osmolality"
    },
    {
      "type": "paragraph",
      "text": "contrast media (LOCM). No well-controlled studies of the teratogenic effects of these media in pregnant women have been"
    },
    {
      "type": "paragraph",
      "text": "performed."
    },
    {
      "type": "paragraph",
      "text": "Effect of iodinated contrast media on fetal thyroid function"
    },
    {
      "type": "paragraph",
      "text": "The fetal thyroid plays an important role in the development of the central nervous system. There have been rare reports of"
    },
    {
      "type": "paragraph",
      "text": "hypothyroidism developing in the newborn infant after the administration of an iodinated contrast medium during pregnancy;"
    },
    {
      "type": "paragraph",
      "text": "however, this occurred only following amniofetography using a fat- soluble iodinated contrast medium, which was performed"
    },
    {
      "type": "paragraph",
      "text": "in the past to detect congenital malformations."
    },
    {
      "type": "paragraph",
      "text": "Intravenous administration of iodinated contrast media does not affect short-term neonatal thyroid stimulating hormone (TSH),"
    },
    {
      "type": "paragraph",
      "text": "likely because the overall amount of excess iodide in the fetal circulation is small and transient. However, the long-term effects"
    },
    {
      "type": "paragraph",
      "text": "are unknown. To date, there has been no documented case of neonatal hypothyroidism from the maternal intravascular injection"
    },
    {
      "type": "paragraph",
      "text": "of water-soluble iodinated contrast agents [5,6]. Given the current available data and routine evaluation of all newborns for"
    },
    {
      "type": "paragraph",
      "text": "congenital hypothyroidism by measurement of TSH levels at the time of their birth, no extra attention is felt to be necessary"
    },
    {
      "type": "paragraph",
      "text": "[7-9]."
    },
    {
      "type": "paragraph",
      "text": "Other adverse effects"
    },
    {
      "type": "paragraph",
      "text": "No other adverse effects have been reported in the fetus or neonate following administration of LOCM. However, information"
    },
    {
      "type": "paragraph",
      "text": "in this area is sparse."
    },
    {
      "type": "paragraph",
      "text": "Recommendations prior to performing imaging studies requiring iodinated contrast material administration"
    },
    {
      "type": "paragraph",
      "text": "Given that there are no available data to suggest any potential harm to the fetus from exposure to iodinated contrast medium"
    },
    {
      "type": "paragraph",
      "text": "via maternal IV or intra-arterial injection, we do not recommend routine screening for pregnancy prior to contrast media use."
    },
    {
      "type": "paragraph",
      "text": "This recommendation is also supported by the FDA classifying of most iodinated contrast agents as category B medications."
    },
    {
      "type": "paragraph",
      "text": "Screening for potential pregnancy in women of child-bearing age receiving radiation to the pelvis, which is discussed"
    },
    {
      "type": "paragraph",
      "text": "separately, is therefore not affected by the use of iodinated contrast agents (See the"
    },
    {
      "type": "paragraph",
      "text": "ACR"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "SPR Practice Parameter for Imaging"
    },
    {
      "type": "paragraph",
      "text": "Pregnant or Potentially Pregnant Adolescents and Women With Ionizing Radiation"
    },
    {
      "type": "paragraph",
      "text": "). We do not recommend withholding the"
    },
    {
      "type": "paragraph",
      "text": "use of iodinated contrast agents in pregnant or potentially pregnant patients when it is needed for diagnostic purposes."
    },
    {
      "type": "image",
      "assetId": "asset_9f9ee2efdc",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ADMINISTRATION OF CONTRAST MEDIA TO PREGNANT OR POTENTIALLY PREGNANT PATIENTS"
    },
    {
      "type": "paragraph",
      "text": "91"
    },
    {
      "type": "paragraph",
      "text": "Gadolinium-Based Contrast Agents"
    },
    {
      "type": "paragraph",
      "text": "Mutagenic effect of gadolinium-based contrast agents"
    },
    {
      "type": "paragraph",
      "text": "To date, there have been no known adverse effects to human fetuses reported when clinically recommended dosages of"
    },
    {
      "type": "paragraph",
      "text": "gadolinium-based contrast agents (GBCAs) have been given to pregnant women. A single cohort study of 26 women exposed"
    },
    {
      "type": "paragraph",
      "text": "to gadolinium chelates during the fi trimester of pregnancy showed no evidence of teratogenesis or mutagenesis in their progeny"
    },
    {
      "type": "paragraph",
      "text": "[10]. However, no well-controlled studies of the teratogenic effects of these media in pregnant women have been performed."
    },
    {
      "type": "paragraph",
      "text": "In a retrospective review [11] of a Canadian provincial database of births, the risk of a congenital anomaly did not differ"
    },
    {
      "type": "paragraph",
      "text": "between patients exposed to GBCAs at any time during pregnancy and those patients who did not undergo MRI."
    },
    {
      "type": "paragraph",
      "text": "Risk of nephrogenic systemic fibrosis"
    },
    {
      "type": "paragraph",
      "text": "There are no known cases of nephrogenic systemic fibrosis (NSF) linked to the use of GBCAs in pregnant patients. However,"
    },
    {
      "type": "paragraph",
      "text": "gadolinium chelates may accumulate in the amniotic fluid Therefore, there is the potential for the dissociation of the toxic free"
    },
    {
      "type": "paragraph",
      "text": "gadolinium ion, conferring a potential risk for the development of NSF in the child or mother."
    },
    {
      "type": "paragraph",
      "text": "In a retrospective review [11] of a Canadian provincial database of births, exposure to GBCAs at any time during pregnancy"
    },
    {
      "type": "paragraph",
      "text": "was associated with an increased risk in the child of a broad set of rheumatological, inflammatory, or infiltrative conditions."
    },
    {
      "type": "paragraph",
      "text": "With further analysis, only first-trimester GBCA exposure showed this association. However, the study had some substantial"
    },
    {
      "type": "paragraph",
      "text": "limitations. The control group was patients who did not undergo MRI during pregnancy, rather than patients who underwent"
    },
    {
      "type": "paragraph",
      "text": "MRI without GBCA. Also, the percentage of patients experiencing the condition was 31% in the GBCA exposed group and"
    },
    {
      "type": "paragraph",
      "text": "27% in the unexposed group (adjusted hazard ratio 1.36), which was statistically significantly different given the large numbers"
    },
    {
      "type": "paragraph",
      "text": "in the unexposed group, but is a surprisingly large baseline percentage in the unexposed group. The number of cases of a"
    },
    {
      "type": "paragraph",
      "text": "connective tissue or skin disease resembling NSF was too small for statistical analysis. Whether any of the children were"
    },
    {
      "type": "paragraph",
      "text": "exposed after birth to GBCA was not investigated."
    },
    {
      "type": "paragraph",
      "text": "Risk of still birth or neonatal death"
    },
    {
      "type": "paragraph",
      "text": "In a retrospective review [11] of a Canadian provincial database of births, exposure to GBCAs at any time during pregnancy"
    },
    {
      "type": "paragraph",
      "text": "was associated with an increased risk of stillbirth or neonatal death, although the number of deaths in the exposed group was"
    },
    {
      "type": "paragraph",
      "text": "small. In addition, the control group was patients who did not undergo MRI during pregnancy, rather than patients who"
    },
    {
      "type": "paragraph",
      "text": "underwent MRI without GBCA."
    },
    {
      "type": "paragraph",
      "text": "Recommendations for the use of GBCA-enhanced MRI examinations in pregnant patients"
    },
    {
      "type": "paragraph",
      "text": "Because it is unclear how GBCAs will affect the fetus, these agents should be administered with caution to pregnant or"
    },
    {
      "type": "paragraph",
      "text": "potentially pregnant patients. GBCAs should only be used if their usage is considered critical and the potential benefits justify"
    },
    {
      "type": "paragraph",
      "text": "the potential unknown risk to the fetus. If a GBCA is to be used in a pregnant patient, one of the agents believed to be at low"
    },
    {
      "type": "paragraph",
      "text": "risk for the development of NSF [12] should be used at the lowest possible dose to achieve diagnostic results. In pregnant"
    },
    {
      "type": "paragraph",
      "text": "patients with severely impaired renal function, the same precautions should be observed as in non-pregnant patients. The ACR"
    },
    {
      "type": "paragraph",
      "text": "Committee on Drugs and Contrast Media recommends the following concerning the performance of contrast- enhanced MRI"
    },
    {
      "type": "paragraph",
      "text": "examinations in pregnant patients:"
    },
    {
      "type": "paragraph",
      "text": "Each case should be reviewed carefully by members of the clinical and radiology service groups, and a GBCA should be"
    },
    {
      "type": "paragraph",
      "text": "administered only when there is a potential significant benefit to the patient or fetus that outweighs the possible but unknown"
    },
    {
      "type": "paragraph",
      "text": "risk of fetal exposure to free gadolinium ions."
    },
    {
      "type": "paragraph",
      "text": "A."
    },
    {
      "type": "paragraph",
      "text": "The radiologist should confer with the referring physician and document the following in the radiology report or the"
    },
    {
      "type": "paragraph",
      "text": "patients medical record:"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "That information requested from the MRI study cannot be acquired without the use of IV contrast or by using other"
    },
    {
      "type": "paragraph",
      "text": "imaging modalities."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "That the information needed affects the care of the patient and/or fetus during the pregnancy."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "That the referring physician is of the opinion that it is not prudent to wait to obtain this information until after the"
    },
    {
      "type": "paragraph",
      "text": "patient is no longer pregnant."
    },
    {
      "type": "paragraph",
      "text": "B."
    },
    {
      "type": "paragraph",
      "text": "It is recommended that informed consent be obtained from the patient after discussion with the referring physician."
    },
    {
      "type": "image",
      "assetId": "asset_13f5049183",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ADMINISTRATION OF CONTRAST MEDIA TO PREGNANT OR POTENTIALLY PREGNANT PATIENTS"
    },
    {
      "type": "paragraph",
      "text": "92"
    },
    {
      "type": "paragraph",
      "text": "Premedication of pregnant patients (with prior allergic-like reactions to iodinated or gadolinium-based contrast"
    },
    {
      "type": "paragraph",
      "text": "media)"
    },
    {
      "type": "paragraph",
      "text": "Diphenhydramine and corticosteroids (most commonly prednisone and methylprednisolone) are commonly used for prophylaxis"
    },
    {
      "type": "paragraph",
      "text": "in patients at risk for allergic-like contrast reactions to contrast media. Diphenhydramine is classified as FDA category B. (FDA"
    },
    {
      "type": "paragraph",
      "text": "category B: Animal reproductive studies have failed to demonstrate a risk to the fetus, and there are no adequate well-controlled"
    },
    {
      "type": "paragraph",
      "text": "studies in pregnant women.) Prednisone (FDA category C) and dexamethasone (FDA category C) traverse the placenta;"
    },
    {
      "type": "paragraph",
      "text": "however, most of these agents are metabolized within the placenta before reaching the fetus and therefore are not associated"
    },
    {
      "type": "paragraph",
      "text": "with teratogenicity in humans. (FDA category C: Animal reproductive studies have shown an adverse effect on fetus, and there"
    },
    {
      "type": "paragraph",
      "text": "are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women"
    },
    {
      "type": "paragraph",
      "text": "despite potential risks.) However, sporadic cases of fetal adrenal suppression have been reported. Methylprednisolone is also"
    },
    {
      "type": "paragraph",
      "text": "classified as a category C drug and carries a small risk to the fetus for the development of a cleft lip if used before 10 weeks of"
    },
    {
      "type": "paragraph",
      "text": "gestation [13,14]."
    },
    {
      "type": "paragraph",
      "text": "Recommendations for the use of corticosteroid premedication in pregnant patients"
    },
    {
      "type": "paragraph",
      "text": "Expert opinion indicates that the use of steroids in pregnancy is generally safe [15,16], although common specific regimens for"
    },
    {
      "type": "paragraph",
      "text": "premedication prior to contrast media administration have not been tested. Severe anaphylaxis in a pregnant female represents"
    },
    {
      "type": "paragraph",
      "text": "an even greater risk to the fetus than to the mother herself [17]. Given this information, we recommend that otherwise-indicated"
    },
    {
      "type": "paragraph",
      "text": "premedication to reduce the risk of contrast media reaction not be withheld because the patient is pregnant and a standard PO or"
    },
    {
      "type": "paragraph",
      "text": "IV regimen be employed (see Chapter on"
    },
    {
      "type": "paragraph",
      "text": "Patient Selection and Preparation Strategies"
    },
    {
      "type": "paragraph",
      "text": "). Both referring clinicians and their"
    },
    {
      "type": "paragraph",
      "text": "pregnant patients receiving premedication prior to contrast media administration should indicate that they understand the"
    },
    {
      "type": "paragraph",
      "text": "potential risks and benefits of the medications being used, as well as alternative diagnostic options [18]."
    },
    {
      "type": "paragraph",
      "text": "Management of contrast reactions in pregnant patients"
    },
    {
      "type": "paragraph",
      "text": "The management of contrast reactions in pregnant patients is generally the same as that of contrast reactions in non- pregnant"
    },
    {
      "type": "paragraph",
      "text": "adults [19], with minor additions."
    },
    {
      "type": "paragraph",
      "text": "For the treatment of hypotension in patients with an obviously gravid uterus, the patient may be placed in the left lateral decubitus"
    },
    {
      "type": "paragraph",
      "text": "position or positioned supine with a leftward tilt using a wedge. If cardiac compressions are required, these are usually best"
    },
    {
      "type": "paragraph",
      "text": "performed in the supine position; in this situation, manual displacement of the uterus upward and to the left is recommended (if"
    },
    {
      "type": "paragraph",
      "text": "there are sufficient personnel to perform this maneuver). These tactics reduce the compression of the inferior vena cava by the"
    },
    {
      "type": "paragraph",
      "text": "gravid uterus which may otherwise compromise venous return to the heart [19]."
    },
    {
      "type": "paragraph",
      "text": "References:"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Dean PB. Fetal uptake of an intravascular radiologic contrast medium."
    },
    {
      "type": "paragraph",
      "text": "Rofo"
    },
    {
      "type": "paragraph",
      "text": ". 1977;127(3):267-270."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Moon AJ, Katzberg RW, Sherman MP. Transplacental passage of iohexol."
    },
    {
      "type": "paragraph",
      "text": "J Pediatr"
    },
    {
      "type": "paragraph",
      "text": ". 2000;136(4):548-549."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Panigel M, Wolf G, Zeleznick A. Magnetic resonance imaging of the placenta in rhesus monkeys, Macaca mulatta. J"
    },
    {
      "type": "paragraph",
      "text": "Med Primatol"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "1988;17(1):3-18."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Kanal E, Barkovich AJ, Bell C, et al. ACR guidance document for safe MR practices: 2007."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": ". 2007;188(6):1447-"
    },
    {
      "type": "paragraph",
      "text": "1474."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Atwell TD, Lteif AN, Brown DL, McCann M, Townsend JE, Leroy AJ. Neonatal thyroid function after administration of IV iodinated"
    },
    {
      "type": "paragraph",
      "text": "contrast agent to 21 pregnant patients."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgeno"
    },
    {
      "type": "paragraph",
      "text": "l. 2008;191(1):268-271."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Bourjeily G, Chalhoub M, Phornphutkul C, Alleyne TC, Woodfield CA, Chen KK. Neonatal thyroid function: effect of a single exposure to"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast medium in utero."
    },
    {
      "type": "paragraph",
      "text": "Radiology"
    },
    {
      "type": "paragraph",
      "text": ". 2010;256(3):744-750."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Kochi MH, Kaloudis EV, Ahmed W, Moore WH. Effect of in utero exposure of iodinated intravenous contrast on neonatal thyroid"
    },
    {
      "type": "paragraph",
      "text": "function."
    },
    {
      "type": "paragraph",
      "text": "J Comput Assist Tomogr"
    },
    {
      "type": "paragraph",
      "text": ". 2012;36(2):165-169."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "McKay DB, Josephson MA. Pregnancy in recipients of solid organs--effects on mother and child."
    },
    {
      "type": "paragraph",
      "text": "N Engl J Med"
    },
    {
      "type": "paragraph",
      "text": ". 2006;354(12):1281-"
    },
    {
      "type": "paragraph",
      "text": "1293."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Rajaram S, Exley CE, Fairlie F, Matthews S. Effect of antenatal iodinated contrast agent on neonatal thyroid function."
    },
    {
      "type": "paragraph",
      "text": "Br J Radiol"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "2012;85(1015): e238-242."
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "De Santis M, Straface G, Cavaliere AF, Carducci B, Caruso A. Gadolinium periconceptional exposure: pregnancy and neonatal"
    },
    {
      "type": "paragraph",
      "text": "outcome."
    },
    {
      "type": "paragraph",
      "text": "Acta Obstet Gynecol Scand"
    },
    {
      "type": "paragraph",
      "text": ". 2007;86(1):99-101."
    },
    {
      "type": "paragraph",
      "text": "11."
    },
    {
      "type": "paragraph",
      "text": "Ray JG, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association between MRI exposure during pregnancy and fetal and"
    },
    {
      "type": "paragraph",
      "text": "childhood outcomes."
    },
    {
      "type": "paragraph",
      "text": "JAMA"
    },
    {
      "type": "paragraph",
      "text": ". 2016;316(9):952-961"
    },
    {
      "type": "paragraph",
      "text": "12."
    },
    {
      "type": "paragraph",
      "text": "Thomsen HS, Morcos SK, Almen T, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR"
    },
    {
      "type": "paragraph",
      "text": "Contrast Medium Safety Committee guidelines."
    },
    {
      "type": "paragraph",
      "text": "Eur Radiol"
    },
    {
      "type": "paragraph",
      "text": ". 2013;23(2):307-318."
    },
    {
      "type": "paragraph",
      "text": "13."
    },
    {
      "type": "paragraph",
      "text": "Niebyl JR. Clinical practice. Nausea and vomiting in pregnancy."
    },
    {
      "type": "paragraph",
      "text": "N Engl J Med"
    },
    {
      "type": "paragraph",
      "text": ". 2010;363(16):1544-1550."
    },
    {
      "type": "paragraph",
      "text": "14."
    },
    {
      "type": "paragraph",
      "text": "Wang PI, Chong ST, Kielar AZ, et al. Imaging of pregnant and lactating patients: part 1, evidence-based review and recommendations."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": ". 2012;198(4):778-784."
    },
    {
      "type": "paragraph",
      "text": "15."
    },
    {
      "type": "paragraph",
      "text": "Bonanno C, Wapner RJ. Antenatal corticosteroids in the management of preterm birth: are we back where we started?"
    },
    {
      "type": "paragraph",
      "text": "Obstet Gynecol"
    },
    {
      "type": "image",
      "assetId": "asset_1d74dd7714",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ADMINISTRATION OF CONTRAST MEDIA TO PREGNANT OR POTENTIALLY PREGNANT PATIENTS"
    },
    {
      "type": "paragraph",
      "text": "93"
    },
    {
      "type": "paragraph",
      "text": "Clin North Am"
    },
    {
      "type": "paragraph",
      "text": ". 2012;39(1):47-63."
    },
    {
      "type": "paragraph",
      "text": "16."
    },
    {
      "type": "paragraph",
      "text": "Gerosa M, Meroni PL, Cimaz R. Safety considerations when prescribing immunosuppression medication to pregnant women."
    },
    {
      "type": "paragraph",
      "text": "Expert Opin Drug Saf"
    },
    {
      "type": "paragraph",
      "text": ". 2014;13(12):1591-1599."
    },
    {
      "type": "paragraph",
      "text": "17."
    },
    {
      "type": "paragraph",
      "text": "Simons FE, Schatz M. Anaphylaxis during pregnancy."
    },
    {
      "type": "paragraph",
      "text": "J Allergy Clin Immunol"
    },
    {
      "type": "paragraph",
      "text": ". 2012;130(3):597-606."
    },
    {
      "type": "paragraph",
      "text": "18."
    },
    {
      "type": "paragraph",
      "text": "Horowitz JM, Bisla JK, Yaghmai V. Premedication of pregnant patients with history of iodinated contrast allergy."
    },
    {
      "type": "paragraph",
      "text": "Abdom Radiol (NY)"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "2016;41(12):2424-2428."
    },
    {
      "type": "paragraph",
      "text": "19."
    },
    {
      "type": "paragraph",
      "text": "Sikka A, Bisla JK, Rajan PV, et al. How to manage allergic reactions to contrast agent in pregnant patients."
    },
    {
      "type": "paragraph",
      "text": "AJR Am J Roentgenol"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "2016;206(2):247-252."
    },
    {
      "type": "paragraph",
      "text": "Revision History"
    },
    {
      "type": "paragraph",
      "text": "15 May 2017: Minor revisions"
    },
    {
      "type": "paragraph",
      "text": "28 June 2015: Major revisions"
    },
    {
      "type": "paragraph",
      "text": "23 June 2010: Minor revisions"
    },
    {
      "type": "image",
      "assetId": "asset_a6d3a4357e",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ADMINISTRATION OF CONTRAST MEDIA TO PATIENTS WHO ARE BREAST-FEEDING"
    },
    {
      "type": "paragraph",
      "text": "94"
    },
    {
      "type": "paragraph",
      "text": "Breast Feeding Recommendations with Associated Strength of Evidence"
    },
    {
      "type": "paragraph",
      "text": "Below is a summary of the recommendations related to breast feeding and the associated strength of"
    },
    {
      "type": "paragraph",
      "text": "evidence for those recommendations using the"
    },
    {
      "type": "paragraph",
      "text": "ACR Appropriateness Criteria(R) Methodology"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "Question 1. Should breast feeding be routinely ceased for 24 hours after maternal IV or IA exposure to iodinated"
    },
    {
      "type": "paragraph",
      "text": "contrast material?"
    },
    {
      "type": "paragraph",
      "text": "Recommendation: Because of the very small percentage of iodinated contrast medium that is excreted into the breast milk"
    },
    {
      "type": "paragraph",
      "text": "and absorbed by the infants gut (under 0.01%), the available data suggest that it is safe for the mother and infant to"
    },
    {
      "type": "paragraph",
      "text": "continue breast-feeding after receiving such an agent."
    },
    {
      "type": "paragraph",
      "text": "Therefore, stopping breastfeeding for 24 hours after maternal IV or"
    },
    {
      "type": "paragraph",
      "text": "IA exposure to iodinated contrast material is not required. It is recommended patients make an informed decision on"
    },
    {
      "type": "paragraph",
      "text": "managing breastmilk after exposure to iodinated contrast material."
    },
    {
      "type": "paragraph",
      "text": "Strength of Evidence: Limited"
    },
    {
      "type": "paragraph",
      "text": "Reference"
    },
    {
      "type": "paragraph",
      "text": "Name"
    },
    {
      "type": "paragraph",
      "text": "Study Quality"
    },
    {
      "type": "paragraph",
      "text": "[1]"
    },
    {
      "type": "paragraph",
      "text": "Webb 2005"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "[2]"
    },
    {
      "type": "paragraph",
      "text": "Trembley 2012"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "[3]"
    },
    {
      "type": "paragraph",
      "text": "Wang 2012"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "[4]"
    },
    {
      "type": "paragraph",
      "text": "Nielsen 1987"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "Question 2. Should breast feeding be routinely ceased for 24 hours after maternal IV or IA exposure to gadolinium-"
    },
    {
      "type": "paragraph",
      "text": "based contrast agents?"
    },
    {
      "type": "paragraph",
      "text": "Recommendation: Because of the very small percentage of gadolinium-based contrast medium that is excreted into the"
    },
    {
      "type": "paragraph",
      "text": "breast milk and absorbed by the infants gut (estimated to be under 0.0004%), the available data suggest that it is safe for"
    },
    {
      "type": "paragraph",
      "text": "the mother and infant to continue breast-feeding after receiving such an agent [5]."
    },
    {
      "type": "paragraph",
      "text": "Therefore, stopping breastfeeding for 24"
    },
    {
      "type": "paragraph",
      "text": "hours after maternal IV or IA exposure to gadolinium based contrast material is not required. It is recommended patients"
    },
    {
      "type": "paragraph",
      "text": "make an informed decision on managing breastmilk after exposure to gadolinium based contrast material."
    },
    {
      "type": "paragraph",
      "text": "Strength of Evidence: Limited"
    },
    {
      "type": "paragraph",
      "text": "Reference"
    },
    {
      "type": "paragraph",
      "text": "Name"
    },
    {
      "type": "paragraph",
      "text": "Study Quality"
    },
    {
      "type": "paragraph",
      "text": "[6]"
    },
    {
      "type": "paragraph",
      "text": "Rofsky 1993"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "[5]"
    },
    {
      "type": "paragraph",
      "text": "Kubik-Huch 2000"
    },
    {
      "type": "paragraph",
      "text": "3"
    },
    {
      "type": "paragraph",
      "text": "[7]"
    },
    {
      "type": "paragraph",
      "text": "Lin 2007"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "Question 3. Should routine thyroid function testing be performed in infants exposed to iodinated contrast material"
    },
    {
      "type": "paragraph",
      "text": "through maternal breast milk?"
    },
    {
      "type": "paragraph",
      "text": "Recommendation: No strong data exists in the literature that the amount of iodinated contrast material absorbed systemically"
    },
    {
      "type": "paragraph",
      "text": "in an infant from maternal breast milk following a conventional contrast-enhanced CT is enough to place the infant at risk"
    },
    {
      "type": "paragraph",
      "text": "for hypothyroidism. Therefore, routine thyroid function testing is not recommended in this clinical setting."
    },
    {
      "type": "paragraph",
      "text": "Strength of Evidence: Limited"
    },
    {
      "type": "paragraph",
      "text": "Reference"
    },
    {
      "type": "paragraph",
      "text": "Name"
    },
    {
      "type": "paragraph",
      "text": "Study Quality"
    },
    {
      "type": "paragraph",
      "text": "[8]"
    },
    {
      "type": "paragraph",
      "text": "Themelin 2019"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "image",
      "assetId": "asset_25ec19cdb6",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ADMINISTRATION OF CONTRAST MEDIA TO PATIENTS WHO ARE BREAST-FEEDING"
    },
    {
      "type": "paragraph",
      "text": "95"
    },
    {
      "type": "paragraph",
      "text": "ADMINISTRATION OF CONTRAST MEDIA TO PATIENTS WHO ARE"
    },
    {
      "type": "paragraph",
      "text": "BREAST-FEEDING"
    },
    {
      "type": "paragraph",
      "text": "Imaging studies requiring either iodinated or gadolinium-based contrast media are occasionally required in patients who are"
    },
    {
      "type": "paragraph",
      "text": "breast feeding. Both"
    },
    {
      "type": "paragraph",
      "text": "the patient and the patients physician may have concerns regarding potential toxicity to the infant from"
    },
    {
      "type": "paragraph",
      "text": "contrast media that is excreted into the breast milk."
    },
    {
      "type": "paragraph",
      "text": "The literature on the excretion into breast milk of iodinated and gadolinium-based contrast media and the gastrointestinal"
    },
    {
      "type": "paragraph",
      "text": "absorption of these agents from breast milk is very limited; however, several studies have shown that the expected dose of"
    },
    {
      "type": "paragraph",
      "text": "contrast medium absorbed by an infant from ingested breast milk is extremely low."
    },
    {
      "type": "paragraph",
      "text": "Iodinated X-ray Contrast Media (Ionic and Nonionic)"
    },
    {
      "type": "paragraph",
      "text": "Background"
    },
    {
      "type": "paragraph",
      "text": "The plasma half-life of intravenously administered iodinated contrast medium is approximately 2 hours, with nearly 100% of"
    },
    {
      "type": "paragraph",
      "text": "the media cleared from the bloodstream in patients with normal renal function within 24 hours. Because of its low lipid"
    },
    {
      "type": "paragraph",
      "text": "solubility, less than 1% of the administered maternal dose of iodinated contrast medium is excreted into the breast milk in the"
    },
    {
      "type": "paragraph",
      "text": "first 24 hours with one paper showing concentrations of iohexol (350 mg I/ml) of approximately 0.5% of weight-adjusted"
    },
    {
      "type": "paragraph",
      "text": "maternal dose in the first 24 hours after exposure [1,4,9]. In addition, less than 1% of the contrast medium ingested by the infant"
    },
    {
      "type": "paragraph",
      "text": "is absorbed from its gastrointestinal tract [2]. Therefore, the expected systemic dose absorbed by the infant from the breast milk"
    },
    {
      "type": "paragraph",
      "text": "is less than 0.01% of the intravascular dose given to the mother. This amount represents less than 1% of the recommended dose"
    },
    {
      "type": "paragraph",
      "text": "for an infant being prescribed iodinated contrast material intravenously related to an imaging study (usually 1.5 to 2 mL/kg)."
    },
    {
      "type": "paragraph",
      "text": "The potential risks to the infant from breast milk include allergic sensitization or reaction, which are theoretical concerns but"
    },
    {
      "type": "paragraph",
      "text": "have not been reported, and adverse effects on the infants thyroid. The likelihood of either direc"
    },
    {
      "type": "paragraph",
      "text": "t toxic or allergic-like"
    },
    {
      "type": "paragraph",
      "text": "manifestations resulting from ingested iodinated contrast material in the infant is extremely low. There is no high-quality"
    },
    {
      "type": "paragraph",
      "text": "literature on thyroid dysfunction in infants related to contrast media exposure through breast milk with a single case report"
    },
    {
      "type": "paragraph",
      "text": "inferring transient neonatal hypothyroidism induced by breast milk containing iodinated contrast media in a premature infant"
    },
    {
      "type": "paragraph",
      "text": "(despite withholding breast milk for 24 hours post exposure) [8]. As with other medications in milk, the taste of the milk may"
    },
    {
      "type": "paragraph",
      "text": "be altered if it contains contrast medium [1,2,4,9]."
    },
    {
      "type": "paragraph",
      "text": "For further information on ACR recommendations / guidelines on thyroid testing after direct iodinated contrast exposure in"
    },
    {
      "type": "paragraph",
      "text": "infants please see the ACR Statement on Use of Iodinated Contrast Material for Medical Imaging in Young Children and Need"
    },
    {
      "type": "paragraph",
      "text": "for Thyroid Monitoring and the"
    },
    {
      "type": "paragraph",
      "text": "Contrast Media in Children"
    },
    {
      "type": "paragraph",
      "text": "Chapter."
    },
    {
      "type": "paragraph",
      "text": "Recommendation"
    },
    {
      "type": "paragraph",
      "text": "Because of the very small percentage of iodinated contrast medium that is excreted into the breast milk and absorbed by the"
    },
    {
      "type": "paragraph",
      "text": "infants gut, the available data suggest that it is safe for the mother and infant to continue breast"
    },
    {
      "type": "paragraph",
      "text": "-feeding after receiving such an"
    },
    {
      "type": "paragraph",
      "text": "agent. Ultimately, however, an informed decision to temporarily stop breast-feeding should be left up to the mother after these"
    },
    {
      "type": "paragraph",
      "text": "facts are communicated. If the mother remains concerned about any potential ill effects to the infant, she may abstain from"
    },
    {
      "type": "paragraph",
      "text": "breast-feeding from the time of contrast administration for a period of 12 to 24 hours. In this situation, the mother should be"
    },
    {
      "type": "paragraph",
      "text": "told to express and discard breast milk from both breasts during that period. In anticipation of this, she may wish to use a breast"
    },
    {
      "type": "paragraph",
      "text": "pump to obtain milk before the contrast-enhanced study to feed the infant during the 24-hour period following the examination."
    },
    {
      "type": "paragraph",
      "text": "There is little value to stop breast-feeding beyond 24 hours."
    },
    {
      "type": "paragraph",
      "text": "While data remains limited, we do not recommend routine thyroid monitoring in infants (premature or term) after exposure to"
    },
    {
      "type": "paragraph",
      "text": "iodinated contrast material through ingested breast milk."
    },
    {
      "type": "paragraph",
      "text": "Gadolinium-Based Contrast Agents"
    },
    {
      "type": "paragraph",
      "text": "Background"
    },
    {
      "type": "paragraph",
      "text": "Like iodinated contrast media, gadolinium-based contrast media have a plasma half-life of approximately 2 hours and are nearly"
    },
    {
      "type": "paragraph",
      "text": "completely cleared from the bloodstream in patients with normal renal function within 24 hours. Also similar to iodinated"
    },
    {
      "type": "paragraph",
      "text": "contrast media, gadolinium-based contrast media are excreted into the breast milk. It is likely that the overwhelming bulk of"
    },
    {
      "type": "paragraph",
      "text": "gadolinium excreted in the breast milk is in a stable and chelated form [5]."
    },
    {
      "type": "image",
      "assetId": "asset_d4f405c581",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "ADMINISTRATION OF CONTRAST MEDIA TO PATIENTS WHO ARE BREAST-FEEDING"
    },
    {
      "type": "paragraph",
      "text": "96"
    },
    {
      "type": "paragraph",
      "text": "Less than 0.04% of the intravascular dose given to the mother is excreted into the breast milk in the first 24 hours [3,5,6]."
    },
    {
      "type": "paragraph",
      "text": "Because less than 1% of the contrast medium ingested by the infant is absorbed from its gastrointestinal tract [5,7], the expected"
    },
    {
      "type": "paragraph",
      "text": "systemic dose absorbed by the infant from the breast milk is less than 0.0004% of the intravascular dose given to the mother."
    },
    {
      "type": "paragraph",
      "text": "This ingested amount is far less than the permissible dose for intravenous use in neonates. The likelihood of an adverse effect"
    },
    {
      "type": "paragraph",
      "text": "from such a minute fraction of gadolinium chelate absorbed from breast milk is remote [1]). However, the potential risks to the"
    },
    {
      "type": "paragraph",
      "text": "infant include direct toxicity (including toxicity from free gadolinium, because it is unknown how much, if any, of the"
    },
    {
      "type": "paragraph",
      "text": "gadolinium in breast milk is in the unchelated form) and allergic sensitization or reaction. These are theoretical concerns but"
    },
    {
      "type": "paragraph",
      "text": "none of these complications have been reported [6]. As in the case with iodinated contrast medium, the taste of the milk may"
    },
    {
      "type": "paragraph",
      "text": "be altered if it contains a gadolinium-based contrast medium [1]."
    },
    {
      "type": "paragraph",
      "text": "Recommendation"
    },
    {
      "type": "paragraph",
      "text": "Because of the very small percentage of gadolinium-based contrast medium that is excreted into the breast milk and absorbed"
    },
    {
      "type": "paragraph",
      "text": "by the infants gut, the available data suggest that it is safe for the mother and infant to continue breast"
    },
    {
      "type": "paragraph",
      "text": "-feeding after receiving"
    },
    {
      "type": "paragraph",
      "text": "such an agent [5]."
    },
    {
      "type": "paragraph",
      "text": "Ultimately, an informed decision to temporarily stop breast-feeding should be left up to the mother after these facts are"
    },
    {
      "type": "paragraph",
      "text": "communicated as"
    },
    {
      "type": "paragraph",
      "text": "survey data suggests that patient preference and radiologists opinion may sometimes differ [10]"
    },
    {
      "type": "paragraph",
      "text": ". If the mother"
    },
    {
      "type": "paragraph",
      "text": "remains concerned about any potential ill effects to the infant, she may abstain from breast-feeding from the time of contrast"
    },
    {
      "type": "paragraph",
      "text": "administration for a period of 12 to 24 hours. In this situation, the mother should be told to express and discard breast milk from"
    },
    {
      "type": "paragraph",
      "text": "both breasts after contrast administration until breast feeding resumes. In anticipation of this, she may wish to use a breast pump"
    },
    {
      "type": "paragraph",
      "text": "to obtain milk before the contrast-enhanced study to feed the infant during the 24-hour period following the examination. There"
    },
    {
      "type": "paragraph",
      "text": "is little value to stop breast feeding beyond 24 hours, by which time the contrast media is nearly completely cleared from the"
    },
    {
      "type": "paragraph",
      "text": "mothers bloodstream."
    },
    {
      "type": "paragraph",
      "text": "References"
    },
    {
      "type": "paragraph",
      "text": "1."
    },
    {
      "type": "paragraph",
      "text": "Webb JA, Thomsen HS, Morcos SK. The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol"
    },
    {
      "type": "paragraph",
      "text": "2005;15:1234-40."
    },
    {
      "type": "paragraph",
      "text": "2."
    },
    {
      "type": "paragraph",
      "text": "Tremblay E, Thrasse E, Thomassin-Naggara I, Trop I. Quality initiatives: guidelines for use of medical imaging during pregnancy and lactation."
    },
    {
      "type": "paragraph",
      "text": "Radiographics 2012;32:897-911."
    },
    {
      "type": "paragraph",
      "text": "3."
    },
    {
      "type": "paragraph",
      "text": "Wang PI, Chong ST, Kielar AZ, et al. Imaging of pregnant and lactating patients: part 1, evidence-based review and recommendations. AJR Am"
    },
    {
      "type": "paragraph",
      "text": "J Roentgenol 2012;198:778-84."
    },
    {
      "type": "paragraph",
      "text": "4."
    },
    {
      "type": "paragraph",
      "text": "Nielsen ST, Matheson I, Rasmussen JN, Skinnemoen K, Andrew E, Hafsahl G. Excretion of iohexol and metrizoate in human breast milk. Acta"
    },
    {
      "type": "paragraph",
      "text": "Radiol 1987;28:523-6."
    },
    {
      "type": "paragraph",
      "text": "5."
    },
    {
      "type": "paragraph",
      "text": "Kubik-Huch RA, Gottstein-Aalame NM, Frenzel T, et al. Gadopentetate dimeglumine excretion into human breast milk during lactation."
    },
    {
      "type": "paragraph",
      "text": "Radiology 2000;216:555-8."
    },
    {
      "type": "paragraph",
      "text": "6."
    },
    {
      "type": "paragraph",
      "text": "Rofsky NM, Weinreb JC, Litt AW. Quantitative analysis of gadopentetate dimeglumine excreted in breast milk. J Magn Reson Imaging"
    },
    {
      "type": "paragraph",
      "text": "1993;3:131-2."
    },
    {
      "type": "paragraph",
      "text": "7."
    },
    {
      "type": "paragraph",
      "text": "Lin SP, Brown JJ. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging 2007;25:884-99."
    },
    {
      "type": "paragraph",
      "text": "8."
    },
    {
      "type": "paragraph",
      "text": "Themelin C, Pierron C, Calafat JF, de Beaufort C. Transient neonatal hypothyroidism secondary to postnatal maternal exposure to contrast"
    },
    {
      "type": "paragraph",
      "text": "medium. BMJ Case Rep 2019;12."
    },
    {
      "type": "paragraph",
      "text": "9."
    },
    {
      "type": "paragraph",
      "text": "Bettmann MA. Frequently asked questions: iodinated contrast agents. Radiographics 2004;24 Suppl 1:S3-10."
    },
    {
      "type": "paragraph",
      "text": "10."
    },
    {
      "type": "paragraph",
      "text": "Lemmenmeier S, Boehm IB. Injection of iodinated contrast media in lactating women: Shall we continue or stop breastfeeding? Eur J Radiol"
    },
    {
      "type": "paragraph",
      "text": "2024;175:111464."
    },
    {
      "type": "image",
      "assetId": "asset_1d5c3db0ca",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 1: CATEGORIES OF ACUTE REACTIONS"
    },
    {
      "type": "paragraph",
      "text": "97"
    },
    {
      "type": "paragraph",
      "text": "The following describes a classification system for acute adverse reactions to iodinated and gadolinium- containing contrast media."
    },
    {
      "type": "paragraph",
      "text": "Acute adverse reactions can be either allergic-like or physiologic. Allergic-like reactions have clinical manifestations similar to"
    },
    {
      "type": "paragraph",
      "text": "allergic reactions. They are termed allergic"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "like rather than just allergic because they are often idiosyncratic and may differ"
    },
    {
      "type": "paragraph",
      "text": "immunologically from true allergies despite their similar clinical presentations. A history of prior allergic-like reaction may be an"
    },
    {
      "type": "paragraph",
      "text": "indication for corticosteroid premedication prior to future contrast-enhanced studies that utilize a similar contrast material."
    },
    {
      "type": "paragraph",
      "text": "Physiologic reactions are not allergic-like and represent a physiologic response to the contrast material. A history of a prior"
    },
    {
      "type": "paragraph",
      "text": "physiologic reaction is not an indication for corticosteroid premedication."
    },
    {
      "type": "paragraph",
      "text": "Assessment of reaction severity is somewhat subjective, and it is difficult to succinctly describe all possible degrees of reaction"
    },
    {
      "type": "paragraph",
      "text": "severity. Sound clinical judgment should be used to determine when and how aggressively an acute reaction should be treated."
    },
    {
      "type": "paragraph",
      "text": "However, many mild reactions resolve during a period of observation without treatment."
    },
    {
      "type": "paragraph",
      "text": "Acute contrast reaction management and delayed allergic-like and non-allergic (e.g., CIN, NSF) adverse events to contrast media,"
    },
    {
      "type": "paragraph",
      "text": "are described elsewhere in this Manual."
    },
    {
      "type": "paragraph",
      "text": "Mild"
    },
    {
      "type": "paragraph",
      "text": "Signs and symptoms are self-limited without evidence of progression. Mild reactions include:"
    },
    {
      "type": "paragraph",
      "text": "Allergic-like"
    },
    {
      "type": "paragraph",
      "text": "Physiologic"
    },
    {
      "type": "paragraph",
      "text": "Limited urticaria / pruritis"
    },
    {
      "type": "paragraph",
      "text": "Limited nausea / vomiting limited"
    },
    {
      "type": "paragraph",
      "text": "Cutaneous Edema"
    },
    {
      "type": "paragraph",
      "text": "Transient flushing / warmth / chills"
    },
    {
      "type": "paragraph",
      "text": "Limited itchy/scratchy throat"
    },
    {
      "type": "paragraph",
      "text": "Headache / dizziness / anxiety / altered taste"
    },
    {
      "type": "paragraph",
      "text": "Nasal congestion"
    },
    {
      "type": "paragraph",
      "text": "Mild hypertension"
    },
    {
      "type": "paragraph",
      "text": "Sneezing / conjunctivitis / rhinorrhea"
    },
    {
      "type": "paragraph",
      "text": "Vasovagal reaction that resolves spontaneously"
    },
    {
      "type": "paragraph",
      "text": "Moderate"
    },
    {
      "type": "paragraph",
      "text": "Signs and symptoms are more pronounced and commonly require medical management. Some of these reactions have the"
    },
    {
      "type": "paragraph",
      "text": "potential to become severe if not treated. Moderate reactions include:"
    },
    {
      "type": "paragraph",
      "text": "Allergic-like"
    },
    {
      "type": "paragraph",
      "text": "Physiologic"
    },
    {
      "type": "paragraph",
      "text": "Diffuse urticaria / pruritis"
    },
    {
      "type": "paragraph",
      "text": "Protracted nausea / vomiting"
    },
    {
      "type": "paragraph",
      "text": "Diffuse erythema, stable vital signs"
    },
    {
      "type": "paragraph",
      "text": "Hypertensive urgency"
    },
    {
      "type": "paragraph",
      "text": "Facial edema without dyspnea"
    },
    {
      "type": "paragraph",
      "text": "Isolated chest pain"
    },
    {
      "type": "paragraph",
      "text": "Throat tightness or hoarseness without dyspnea"
    },
    {
      "type": "paragraph",
      "text": "Vasovagal reaction that requires and is responsive to treatment"
    },
    {
      "type": "paragraph",
      "text": "Wheezing / bronchospasm, mild or no hypoxia"
    },
    {
      "type": "paragraph",
      "text": "Severe"
    },
    {
      "type": "paragraph",
      "text": "Signs and symptoms are often life-threatening and can result in permanent morbidity or death if not managed appropriately."
    },
    {
      "type": "paragraph",
      "text": "Cardiopulmonary arrest is a nonspecific end-stage result that can be caused by a variety of the following severe reactions, both"
    },
    {
      "type": "paragraph",
      "text": "allergic-like and physiologic. If it is unclear what etiology caused the cardiopulmonary arrest, it may be judicious to assume that"
    },
    {
      "type": "paragraph",
      "text": "the reaction is/was an allergic-like one."
    },
    {
      "type": "paragraph",
      "text": "Pulmonary edema is a rare severe reaction that can occur in patients with tenuous cardiac reserve (cardiogenic pulmonary"
    },
    {
      "type": "paragraph",
      "text": "edema) or in patients with normal cardiac function (noncardiogenic pulmonary edema). Noncardiogenic pulmonary edema can"
    },
    {
      "type": "paragraph",
      "text": "be allergic-like or physiologic; if the etiology is unclear, it may be judicious to assume that the reaction is/was an allergic-like"
    },
    {
      "type": "paragraph",
      "text": "one."
    },
    {
      "type": "paragraph",
      "text": "Table 1: CATEGORIES OF ACUTE REACTIONS"
    },
    {
      "type": "image",
      "assetId": "asset_27dea98ee2",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 1: CATEGORIES OF ACUTE REACTIONS"
    },
    {
      "type": "paragraph",
      "text": "98"
    },
    {
      "type": "paragraph",
      "text": "Severe reactions include:"
    },
    {
      "type": "paragraph",
      "text": "Allergic-like"
    },
    {
      "type": "paragraph",
      "text": "Physiologic"
    },
    {
      "type": "paragraph",
      "text": "Diffuse edema, or facial edema with dyspnea"
    },
    {
      "type": "paragraph",
      "text": "Vasovagal reaction resistant to treatment"
    },
    {
      "type": "paragraph",
      "text": "Diffuse erythema with hypotension"
    },
    {
      "type": "paragraph",
      "text": "Arrhythmia"
    },
    {
      "type": "paragraph",
      "text": "Laryngeal edema with stridor and/or hypoxia"
    },
    {
      "type": "paragraph",
      "text": "Convulsions, seizures"
    },
    {
      "type": "paragraph",
      "text": "Wheezing / bronchospasm, significant hypoxia"
    },
    {
      "type": "paragraph",
      "text": "Hypertensive emergency"
    },
    {
      "type": "paragraph",
      "text": "Anaphylactic shock (hypotension + tachycardia)"
    },
    {
      "type": "image",
      "assetId": "asset_133c730c8a",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 2: TREATMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "99"
    },
    {
      "type": "paragraph",
      "text": "HIVES (Urticaria)"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "General comment: observe until hives are"
    },
    {
      "type": "paragraph",
      "text": "resolving. Further observation may be"
    },
    {
      "type": "paragraph",
      "text": "necessary if treatment is administered."
    },
    {
      "type": "paragraph",
      "text": "Mild (scattered and/or transient)"
    },
    {
      "type": "paragraph",
      "text": "No treatment often needed; however, if"
    },
    {
      "type": "paragraph",
      "text": "symptomatic, can consider"
    },
    {
      "type": "paragraph",
      "text": "Diphenhydramine (Benadryl(R))*"
    },
    {
      "type": "paragraph",
      "text": "1 mg/kg (max = 50 mg) PO, IM, or IV;"
    },
    {
      "type": "paragraph",
      "text": "administer IV dose slowly over 1"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2 min"
    },
    {
      "type": "paragraph",
      "text": "Moderate (more numerous/bothersome)"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Consider"
    },
    {
      "type": "paragraph",
      "text": "Diphenhydramine (Benadryl(R))*"
    },
    {
      "type": "paragraph",
      "text": "1 mg/kg (max = 50 mg) PO, IM, or IV;"
    },
    {
      "type": "paragraph",
      "text": "administer IV dose slowly over 1"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2 min"
    },
    {
      "type": "paragraph",
      "text": "Severe (widespread and/or progressive)"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Consider"
    },
    {
      "type": "paragraph",
      "text": "Diphenhydramine (Benadryl(R))*"
    },
    {
      "type": "paragraph",
      "text": "1 mg/kg (max = 50 mg) PO, IM, IV;"
    },
    {
      "type": "paragraph",
      "text": "administer IV dose slowly over 1"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2 min"
    },
    {
      "type": "paragraph",
      "text": "*Note: All forms can cause drowsiness; IV/IM form may cause or worsen hypotension."
    },
    {
      "type": "paragraph",
      "text": "Note: It can be difficult to dose medications accurately in neonates and infants. Also, with respect to IM delivery of epinephrine, EpiPen Jr(R)"
    },
    {
      "type": "paragraph",
      "text": "package insert does not provide dosing recommendations for children < 15 kg."
    },
    {
      "type": "image",
      "assetId": "asset_5f8a0e5582",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 2: TREATMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "100"
    },
    {
      "type": "paragraph",
      "text": "DIFFUSE ERYTHEMA"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "All forms"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "O2 by mask"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 L / min"
    },
    {
      "type": "paragraph",
      "text": "Normotensive"
    },
    {
      "type": "paragraph",
      "text": "No other treatment usually"
    },
    {
      "type": "paragraph",
      "text": "needed"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Hypotensive"
    },
    {
      "type": "paragraph",
      "text": "IV fluids: 0.9% normal saline"
    },
    {
      "type": "paragraph",
      "text": "10"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "20 mL / kg;"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Maximum of 500"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "1,000 mL"
    },
    {
      "type": "paragraph",
      "text": "Lactated Ringers"
    },
    {
      "type": "paragraph",
      "text": "If profound or unresponsive to"
    },
    {
      "type": "paragraph",
      "text": "fluids alone can also consider"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IV)*"
    },
    {
      "type": "paragraph",
      "text": "IV 0.1 mL/kg of 0.1 mg/mL (1:10,000) dilution (0.01 mg/kg);"
    },
    {
      "type": "paragraph",
      "text": "administer slowly into a running IV infusion of fluids; can repeat"
    },
    {
      "type": "paragraph",
      "text": "every 5"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "15 min, as needed; maximum single dose: 1.0 mL (0.1"
    },
    {
      "type": "paragraph",
      "text": "mg); can repeat up to 1 mg total dose"
    },
    {
      "type": "paragraph",
      "text": "or (if no IV access available)"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IM)*"
    },
    {
      "type": "paragraph",
      "text": "IM 0.01 mL/kg of 1.0 mg/mL (1:1,000) dilution (0.01 mg / kg);"
    },
    {
      "type": "paragraph",
      "text": "max 0.30 mL (0.30 mg); can repeat every 5-15 minutes up to 1 mL"
    },
    {
      "type": "paragraph",
      "text": "(1 mg) total"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine auto-injector"
    },
    {
      "type": "paragraph",
      "text": "(1.0 mg/mL (1:1,000) dilution equivalent)"
    },
    {
      "type": "paragraph",
      "text": "If < 30 kg, pediatric epinephrine auto-injector"
    },
    {
      "type": "paragraph",
      "text": "(EpiPen Jr(R) or equivalent) 0.15 mL equivalent (0.15 mg);"
    },
    {
      "type": "paragraph",
      "text": "If >= 30 kg, adult epinephrine auto"
    },
    {
      "type": "paragraph",
      "text": "-injector"
    },
    {
      "type": "paragraph",
      "text": "(EpiPen(R) or equivalent) 0.30 mL (0.30 mg)"
    },
    {
      "type": "paragraph",
      "text": "Consider calling emergency"
    },
    {
      "type": "paragraph",
      "text": "response team or 911"
    },
    {
      "type": "paragraph",
      "text": "*Note: In hypotensive patients, the preferred route of epinephrine delivery is IV, as the extremities may not be perfused sufficiently to allow for adequate"
    },
    {
      "type": "paragraph",
      "text": "absorption of IM administration. Also, with respect to IM delivery of epinephrine, the EpiPen Jr(R) package insert does not provide dosing"
    },
    {
      "type": "paragraph",
      "text": "recommendations for children < 15 kg."
    },
    {
      "type": "paragraph",
      "text": "Note: It can be difficult to dose medications accurately in neonates and infants."
    },
    {
      "type": "image",
      "assetId": "asset_e153bd86ad",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 2: TREATMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "101"
    },
    {
      "type": "paragraph",
      "text": "BRONCHOSPASM"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "All forms"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "O2 by mask"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 L / min"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Mild"
    },
    {
      "type": "paragraph",
      "text": "Beta agonist inhaler (Albuterol(R))"
    },
    {
      "type": "paragraph",
      "text": "2 puffs (90 mcg/puff) for a total of 180 mcg; can repeat up to 3"
    },
    {
      "type": "paragraph",
      "text": "times"
    },
    {
      "type": "paragraph",
      "text": "Consider calling emergency response team or 911,"
    },
    {
      "type": "paragraph",
      "text": "based upon the completeness of the response"
    },
    {
      "type": "paragraph",
      "text": "Moderate"
    },
    {
      "type": "paragraph",
      "text": "Consider adding epinephrine (IM)*"
    },
    {
      "type": "paragraph",
      "text": "IM 0.01 mL/kg of 1.0 mg/mL (1:1,000) dilution"
    },
    {
      "type": "paragraph",
      "text": "(0.01"
    },
    {
      "type": "paragraph",
      "text": "mg/kg); max 0.30 mL (0.30 mg); can repeat every 5-15"
    },
    {
      "type": "paragraph",
      "text": "minutes up to 1 mL (1 mg) total"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine auto-injector"
    },
    {
      "type": "paragraph",
      "text": "(1.0"
    },
    {
      "type": "paragraph",
      "text": "mg/mL (1:1,000) dilution equivalent)"
    },
    {
      "type": "paragraph",
      "text": "If < 30 kg, pediatric epinephrine auto-injector"
    },
    {
      "type": "paragraph",
      "text": "(EpiPen Jr(R) or equivalent) 0.15 mL equivalent (0.15 mg);"
    },
    {
      "type": "paragraph",
      "text": "If >= 30 kg, adult epinephrine auto"
    },
    {
      "type": "paragraph",
      "text": "-injector"
    },
    {
      "type": "paragraph",
      "text": "(EpiPen(R) or equivalent) 0.30 mL (0.30 mg)"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IV)*"
    },
    {
      "type": "paragraph",
      "text": "IV 0.1 mL/kg of 0.1 mg/mL (1:10,000) dilution (0.01 mg/kg);"
    },
    {
      "type": "paragraph",
      "text": "administer slowly into a running IV infusion of fluids; can"
    },
    {
      "type": "paragraph",
      "text": "repeat every 5"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "15 min, as needed; maximum single dose:1.0"
    },
    {
      "type": "paragraph",
      "text": "mL (0.1 mg); can repeat up to 1 mg total dose"
    },
    {
      "type": "paragraph",
      "text": "Consider calling emergency response team or 911 based"
    },
    {
      "type": "paragraph",
      "text": "upon the completeness of the response"
    },
    {
      "type": "paragraph",
      "text": "Severe"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IV)*"
    },
    {
      "type": "paragraph",
      "text": "IV 0.1 mL / kg of 0.1 mg/mL (1:10,000) dilution (0.01 mg / kg);"
    },
    {
      "type": "paragraph",
      "text": "administer slowly into a running IV infusion of fluids; can"
    },
    {
      "type": "paragraph",
      "text": "repeat every 5-15 min, as needed; maximum single dose: 1.0 mL"
    },
    {
      "type": "paragraph",
      "text": "(0.1 mg); can repeat up to 1 mg total dose"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IM)*"
    },
    {
      "type": "paragraph",
      "text": "IM 0.01 mL/kg of 1.0 mg/mL (1:1,000) dilution (0.01 mg/kg);"
    },
    {
      "type": "paragraph",
      "text": "max 0.30 mL (0.30 mg); can repeat every 5-15 minutes up to1"
    },
    {
      "type": "paragraph",
      "text": "mL (1 mg) total"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "image",
      "assetId": "asset_ade821e1ea",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 2: TREATMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "102"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine auto-injector"
    },
    {
      "type": "paragraph",
      "text": "(1.0 mg/mL (1:1,000) dilution equivalent)"
    },
    {
      "type": "paragraph",
      "text": "If < 30 kg, pediatric epinephrine auto-injector"
    },
    {
      "type": "paragraph",
      "text": "(EpiPen Jr(R) or equivalent) 0.15 mL equivalent (0.15 mg);"
    },
    {
      "type": "paragraph",
      "text": "If >= 30 kg, adult epinephrine auto"
    },
    {
      "type": "paragraph",
      "text": "-injector"
    },
    {
      "type": "paragraph",
      "text": "(EpiPen(R) or equivalent) 0.30 mL (0.30 mg)"
    },
    {
      "type": "paragraph",
      "text": "AND"
    },
    {
      "type": "paragraph",
      "text": "Beta agonist inhaler (Albuterol(R)) (May work"
    },
    {
      "type": "paragraph",
      "text": "synergistically)"
    },
    {
      "type": "paragraph",
      "text": "2 puffs (90 mcg/puff) for a total of 180 mcg; can repeat up to 3"
    },
    {
      "type": "paragraph",
      "text": "times"
    },
    {
      "type": "paragraph",
      "text": "Call emergency response team or 911"
    },
    {
      "type": "paragraph",
      "text": "*Note: In hypotensive patients, the preferred route of epinephrine delivery is IV, as the extremities may not be perfused sufficiently to allow for"
    },
    {
      "type": "paragraph",
      "text": "adequate absorption of IM administration. Also, with respect to IM delivery of epinephrine, the EpiPen Jr(R) package insert does not provide dosing"
    },
    {
      "type": "paragraph",
      "text": "recommendations for children < 15 kg."
    },
    {
      "type": "paragraph",
      "text": "Note: It can be difficult to dose medications accurately in neonates and infants."
    },
    {
      "type": "paragraph",
      "text": "LARYNGEAL EDEMA"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "All forms"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "O2 by mask"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 L/min"
    },
    {
      "type": "paragraph",
      "text": "IV 0.1 mL/kg of 0.1 mg/mL (1:10,000) dilution (0.01 mg/kg);"
    },
    {
      "type": "paragraph",
      "text": "administer slowly into a running IV infusion of fluids; can repeat"
    },
    {
      "type": "paragraph",
      "text": "every 5"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "15 min, as needed; maximum single dose: 1.0 mL (0.1"
    },
    {
      "type": "paragraph",
      "text": "mg); can repeat up to 1 mg total dose"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IM)*"
    },
    {
      "type": "paragraph",
      "text": "IM 0.01 mL/kg of 1.0 mg/mL (1:1,000) dilution (0.01 mg/kg);"
    },
    {
      "type": "paragraph",
      "text": "max 0.30 mL (0.30 mg); can repeat every 5-15 minutes up to 1"
    },
    {
      "type": "paragraph",
      "text": "mL (1 mg) total"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine auto-injector (1:1,000 dilution equivalent)"
    },
    {
      "type": "paragraph",
      "text": "If < 30 kg, pediatric epinephrine auto-injector"
    },
    {
      "type": "paragraph",
      "text": "(EpiPen Jr(R) or equivalent) 0.15 mL equivalent (0.15 mg);"
    },
    {
      "type": "paragraph",
      "text": "If >= 30 kg, adult epinephrine auto"
    },
    {
      "type": "paragraph",
      "text": "-injector"
    },
    {
      "type": "paragraph",
      "text": "(EpiPen(R) or equivalent) 0.30 mL (0.30 mg)"
    },
    {
      "type": "paragraph",
      "text": "Call emergency response team or 911"
    },
    {
      "type": "paragraph",
      "text": "*Note: In hypotensive patients, the preferred route of epinephrine delivery is IV, as the extremities may not be perfused sufficiently to allow for"
    },
    {
      "type": "paragraph",
      "text": "adequate absorption of IM administration. Also, with respect to IM delivery of epinephrine, the EpiPen Jr(R) package insert does not provide dosing"
    },
    {
      "type": "paragraph",
      "text": "recommendations for children < 15 kg."
    },
    {
      "type": "paragraph",
      "text": "Note: It can be difficult to dose medications accurately in neonates and infants."
    },
    {
      "type": "image",
      "assetId": "asset_025c5473ea",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 2: TREATMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "103"
    },
    {
      "type": "paragraph",
      "text": "HYPOTENSION (minimum normal blood pressure varies for children of different ages)"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "All forms"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "O2 by mask"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 L/min"
    },
    {
      "type": "paragraph",
      "text": "Elevate legs at least 60 degrees"
    },
    {
      "type": "paragraph",
      "text": "Consider IV fluids: 0.9% normal saline 10"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "20 mL/kg;"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Maximum of 500"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "1,000 mL"
    },
    {
      "type": "paragraph",
      "text": "Lactated"
    },
    {
      "type": "paragraph",
      "text": "Ringers"
    },
    {
      "type": "paragraph",
      "text": "Hypotension with bradycardia (min normal pulse varies for children of different ages) (Vasovagal reaction)"
    },
    {
      "type": "paragraph",
      "text": "If mild"
    },
    {
      "type": "paragraph",
      "text": "No other treatment usually necessary"
    },
    {
      "type": "paragraph",
      "text": "If severe (patient remains"
    },
    {
      "type": "paragraph",
      "text": "symptomatic despite above"
    },
    {
      "type": "paragraph",
      "text": "measures)"
    },
    {
      "type": "paragraph",
      "text": "In addition to above measures:"
    },
    {
      "type": "paragraph",
      "text": "Atropine (IV)"
    },
    {
      "type": "paragraph",
      "text": "IV 0.2 mL/kg of 0.1 mg/mL solution (0.02 mg/kg); Minimum"
    },
    {
      "type": "paragraph",
      "text": "single dose = 0.1 mg"
    },
    {
      "type": "paragraph",
      "text": "Maximum single dose = 0.6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "1.0 mg Maximum total dose = 1 mg"
    },
    {
      "type": "paragraph",
      "text": "for infants and children"
    },
    {
      "type": "paragraph",
      "text": "2 mg for adolescents administer into a running IV infusion of"
    },
    {
      "type": "paragraph",
      "text": "fluids"
    },
    {
      "type": "paragraph",
      "text": "Hypotension with tachycardia (max normal pulse varies for children of different ages) (Anaphylactoid reaction)"
    },
    {
      "type": "paragraph",
      "text": "If severe (hypotension persists)"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IV)*"
    },
    {
      "type": "paragraph",
      "text": "IV 0.1 mL/kg of 0.1 mg/mL (1:10,000) dilution (0.01 mg/kg);"
    },
    {
      "type": "paragraph",
      "text": "administer slowly into a running IV infusion of fluids; can repeat"
    },
    {
      "type": "paragraph",
      "text": "every 5"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "15 min, as needed; maximum single dose: 1.0 mL (0.1"
    },
    {
      "type": "paragraph",
      "text": "mg); can repeat up to 1 mg total dose"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IM)*"
    },
    {
      "type": "paragraph",
      "text": "IM 0.01 mg/kg of 1.0 mg/mL (1:1,000) dilution (0.01 mL/kg);"
    },
    {
      "type": "paragraph",
      "text": "max 0.30 mL (0.30 mg); can repeat every 5"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "15 minutes up to 1"
    },
    {
      "type": "paragraph",
      "text": "mL (1 mg) total"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine auto-injector"
    },
    {
      "type": "paragraph",
      "text": "(1.0"
    },
    {
      "type": "paragraph",
      "text": "mg/mL (1:1,000) dilution equivalent)"
    },
    {
      "type": "paragraph",
      "text": "If < 30 kg, pediatric epinephrine auto-injector"
    },
    {
      "type": "paragraph",
      "text": "(EpiPen Jr(R) or equivalent) 0.15 mL equivalent (0.15 Mg);"
    },
    {
      "type": "paragraph",
      "text": "If >= 30 kg, adult epinephrine auto"
    },
    {
      "type": "paragraph",
      "text": "-injector"
    },
    {
      "type": "paragraph",
      "text": "(EpiPen(R) or equivalent) 0.30 mL (0.30 mg)"
    },
    {
      "type": "paragraph",
      "text": "Call emergency response team or 911"
    },
    {
      "type": "paragraph",
      "text": "*Note: In hypotensive patients, the preferred route of epinephrine delivery is IV, as the extremities may not be perfused sufficiently to allow for"
    },
    {
      "type": "paragraph",
      "text": "adequate absorption of IM administration. Also, with respect to IM delivery of epinephrine, the EpiPen Jr(R) package insert does not provide"
    },
    {
      "type": "paragraph",
      "text": "dosing recommendations for children < 15 kg."
    },
    {
      "type": "paragraph",
      "text": "Note: It can be difficult to dose medications accurately in neonates and infants."
    },
    {
      "type": "image",
      "assetId": "asset_f83c069129",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 2: TREATMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "104"
    },
    {
      "type": "paragraph",
      "text": "UNRESPONSIVE AND PULSELESS"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Activate emergency response team (call 911)"
    },
    {
      "type": "paragraph",
      "text": "Start CPR"
    },
    {
      "type": "paragraph",
      "text": "Get defibrillator or automated electronic"
    },
    {
      "type": "paragraph",
      "text": "defibrillator (AED); apply as soon as"
    },
    {
      "type": "paragraph",
      "text": "available; shock as indicated"
    },
    {
      "type": "paragraph",
      "text": "Note: Please also see BLS and"
    },
    {
      "type": "paragraph",
      "text": "ACLS (PALS) booklets published by"
    },
    {
      "type": "paragraph",
      "text": "the American Heart Association"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (between 2 min cycles)"
    },
    {
      "type": "paragraph",
      "text": "0.1 mL/kg of 0.1 mg/mL (1:10,000) dilution (0.01"
    },
    {
      "type": "paragraph",
      "text": "mg/kg); administer quickly with flush or IV fluids;"
    },
    {
      "type": "paragraph",
      "text": "max dose of 10 mL (1 mg)"
    },
    {
      "type": "paragraph",
      "text": "PULMONARY EDEMA"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "O2 by mask"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 L/min"
    },
    {
      "type": "paragraph",
      "text": "Elevate head of bed"
    },
    {
      "type": "paragraph",
      "text": "Furosemide (Lasix(R)) (IV)"
    },
    {
      "type": "paragraph",
      "text": "IV 0.5"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "1.0 mg/kg; over 2 min; maximum = 40 mg"
    },
    {
      "type": "paragraph",
      "text": "Call emergency response team or 911"
    },
    {
      "type": "paragraph",
      "text": "SEIZURES/CONVULSIONS"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Observe and protect the patient"
    },
    {
      "type": "paragraph",
      "text": "Turn patient on side to avoid aspiration"
    },
    {
      "type": "paragraph",
      "text": "Suction airway, as needed"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "O2 by mask"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 L/min"
    },
    {
      "type": "paragraph",
      "text": "If unremitting"
    },
    {
      "type": "paragraph",
      "text": "Call emergency response team or 911"
    },
    {
      "type": "image",
      "assetId": "asset_d09171bfef",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 2: TREATMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN CHILDREN"
    },
    {
      "type": "paragraph",
      "text": "105"
    },
    {
      "type": "paragraph",
      "text": "HYPOGLYCEMIA"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "All forms"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "O2 by mask"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 L / min"
    },
    {
      "type": "paragraph",
      "text": "If patient is able to swallow safely"
    },
    {
      "type": "paragraph",
      "text": "Observe"
    },
    {
      "type": "paragraph",
      "text": "Administer oral glucose"
    },
    {
      "type": "paragraph",
      "text": "2 sugar packets or 15 g of glucose tablet or gel or cup (4 oz)"
    },
    {
      "type": "paragraph",
      "text": "of fruit juice"
    },
    {
      "type": "paragraph",
      "text": "If patient is unable to swallow safely"
    },
    {
      "type": "paragraph",
      "text": "And IV access is available"
    },
    {
      "type": "paragraph",
      "text": "Dextrose 50% (IV)"
    },
    {
      "type": "paragraph",
      "text": "IV D25 2 mL/ kg; IV injection over 2 min"
    },
    {
      "type": "paragraph",
      "text": "And IV access is not available"
    },
    {
      "type": "paragraph",
      "text": "Glucagon (IM/SQ)"
    },
    {
      "type": "paragraph",
      "text": "IM/SQ 0.5 mg if < 20 kg"
    },
    {
      "type": "paragraph",
      "text": "IM/SQ 1.0 mg if > 20 kg"
    },
    {
      "type": "paragraph",
      "text": "ANXIETY (PANIC ATTACK)"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Diagnosis of exclusion"
    },
    {
      "type": "paragraph",
      "text": "Assess patient for developing signs and symptoms that might indicate another type of reaction"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "Pulse oximeter"
    },
    {
      "type": "paragraph",
      "text": "If no identifiable manifestations and normal oxygenation, consider this diagnosis"
    },
    {
      "type": "paragraph",
      "text": "Reassure patient"
    },
    {
      "type": "paragraph",
      "text": "REACTION REBOUND PREVENTION"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Note: While IV corticosteroids may help prevent a short-term"
    },
    {
      "type": "paragraph",
      "text": "recurrence of an allergic-like reaction, they are not useful in"
    },
    {
      "type": "paragraph",
      "text": "the acute treatment of any reaction. However, these may be"
    },
    {
      "type": "paragraph",
      "text": "considered for patients having severe allergic-like"
    },
    {
      "type": "paragraph",
      "text": "manifestations prior to transportation to an Emergency"
    },
    {
      "type": "paragraph",
      "text": "Department of inpatient unit."
    },
    {
      "type": "paragraph",
      "text": "Hydrocortisone"
    },
    {
      "type": "paragraph",
      "text": "(Solu-Cortef(R)) (IV)"
    },
    {
      "type": "paragraph",
      "text": "IV 5 mg/kg; administer over 1-2 min;"
    },
    {
      "type": "paragraph",
      "text": "maximum: 200 mg"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Methylprednisolone"
    },
    {
      "type": "paragraph",
      "text": "(Solu-Medrol(R)) (IV)"
    },
    {
      "type": "paragraph",
      "text": "IV 1 mg/kg; administer over 1"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2 min;"
    },
    {
      "type": "paragraph",
      "text": "maximum: 40 mg"
    },
    {
      "type": "paragraph",
      "text": "Revision History"
    },
    {
      "type": "paragraph",
      "text": "14 October 2020: Minor revisions"
    },
    {
      "type": "paragraph",
      "text": "28 August 2015: Major revisions"
    },
    {
      "type": "paragraph",
      "text": "15 May 2015: Major revisions"
    },
    {
      "type": "paragraph",
      "text": "7 June 2013: Major revisions"
    },
    {
      "type": "paragraph",
      "text": "17 March 2010: Minor revisions"
    },
    {
      "type": "paragraph",
      "text": "29 October 2008: First version"
    },
    {
      "type": "image",
      "assetId": "asset_5659174ce2",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 3: MANAGEMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "106"
    },
    {
      "type": "paragraph",
      "text": "HIVES (Urticaria)"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Mild (scattered and/or transient)"
    },
    {
      "type": "paragraph",
      "text": "No treatment often needed; however, if"
    },
    {
      "type": "paragraph",
      "text": "symptomatic, can consider:"
    },
    {
      "type": "paragraph",
      "text": "Diphenhydramine (Benadryl(R))*"
    },
    {
      "type": "paragraph",
      "text": "25"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "50 mg PO"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Fexofenadine (Allegra(R))**"
    },
    {
      "type": "paragraph",
      "text": "180 mg PO"
    },
    {
      "type": "paragraph",
      "text": "Moderate (more numerous/bothersome)"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Consider diphenhydramine (Benadryl(R))*"
    },
    {
      "type": "paragraph",
      "text": "25"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "50 mg PO"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Fexofenadine (Allegra(R)}**"
    },
    {
      "type": "paragraph",
      "text": "180 mg PO"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Consider diphenhydramine (Benadryl(R))*"
    },
    {
      "type": "paragraph",
      "text": "25"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "50 mg IM or IV (administer IV dose"
    },
    {
      "type": "paragraph",
      "text": "slowly over 1"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2 min)"
    },
    {
      "type": "paragraph",
      "text": "Severe (widespread and/or progressive)"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Consider"
    },
    {
      "type": "paragraph",
      "text": "Diphenhydramine (Benadryl(R))*"
    },
    {
      "type": "paragraph",
      "text": "25"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "50 mg IM or IV (administer"
    },
    {
      "type": "paragraph",
      "text": "IV dose slowly over 1"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "2 min)"
    },
    {
      "type": "paragraph",
      "text": "* Note: all forms can cause drowsiness; IM/IV"
    },
    {
      "type": "paragraph",
      "text": "form may cause or worsen hypotension"
    },
    {
      "type": "paragraph",
      "text": "** Note: second generation antihistamines cause"
    },
    {
      "type": "paragraph",
      "text": "less drowsiness; may be beneficial for patients"
    },
    {
      "type": "paragraph",
      "text": "who need to drive themselves home"
    },
    {
      "type": "paragraph",
      "text": "Table 3: MANAGEMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "Last updated:"
    },
    {
      "type": "paragraph",
      "text": "October"
    },
    {
      "type": "paragraph",
      "text": "2020"
    },
    {
      "type": "image",
      "assetId": "asset_10a253627d",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 3: MANAGEMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "107"
    },
    {
      "type": "paragraph",
      "text": "DIFFUSE ERYTHEMA"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "All forms"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "Pulse oximeter"
    },
    {
      "type": "paragraph",
      "text": "O2 by mask"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 L/min"
    },
    {
      "type": "paragraph",
      "text": "Normotensive"
    },
    {
      "type": "paragraph",
      "text": "No other treatment usually needed"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Hypotensive"
    },
    {
      "type": "paragraph",
      "text": "IV fluids 0.9% normal saline"
    },
    {
      "type": "paragraph",
      "text": "1,000 mL rapidly"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Lactated Ringers"
    },
    {
      "type": "paragraph",
      "text": "1,000 mL rapidly"
    },
    {
      "type": "paragraph",
      "text": "If profound or unresponsive to fluids alone can"
    },
    {
      "type": "paragraph",
      "text": "also consider"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IV)*"
    },
    {
      "type": "paragraph",
      "text": "IV 1 mL of 0.1 mg/mL (1:10,000) dilution (0.1 mg);"
    },
    {
      "type": "paragraph",
      "text": "administer slowly into a running IV infusion of fluids;"
    },
    {
      "type": "paragraph",
      "text": "can repeat every few minutes as needed up to 10 mL (1"
    },
    {
      "type": "paragraph",
      "text": "mg) total"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "(if no IV access available)"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IM)*"
    },
    {
      "type": "paragraph",
      "text": "IM 0.3 mL of 1.0 mg/mL (1:1,000) dilution (0.3 mg);"
    },
    {
      "type": "paragraph",
      "text": "can repeat every 5-15 minutes up to 1 mL (1 mg) total"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine auto-injector (EpiPen(R) or equivalent)"
    },
    {
      "type": "paragraph",
      "text": "(0.3mL of 1.0 mg/mL (1:1,000) dilution, fixed [0.3mg]);"
    },
    {
      "type": "paragraph",
      "text": "can repeat every 5-15 minutes up to three times"
    },
    {
      "type": "paragraph",
      "text": "Consider calling emergency"
    },
    {
      "type": "paragraph",
      "text": "response team or 911"
    },
    {
      "type": "paragraph",
      "text": "* Note: in hypotensive patients, the preferred route"
    },
    {
      "type": "paragraph",
      "text": "of epinephrine delivery is IV, as the extremities"
    },
    {
      "type": "paragraph",
      "text": "may not be perfused sufficiently to allow for"
    },
    {
      "type": "paragraph",
      "text": "adequate absorption of IM administered drug."
    },
    {
      "type": "image",
      "assetId": "asset_31e85d5897",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 3: MANAGEMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "108"
    },
    {
      "type": "paragraph",
      "text": "BRONCHOSPASM"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "All forms"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "Pulse oximeter"
    },
    {
      "type": "paragraph",
      "text": "O2 by mask"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 L/min"
    },
    {
      "type": "paragraph",
      "text": "Mild"
    },
    {
      "type": "paragraph",
      "text": "Beta agonist inhaler (Albuterol(R))"
    },
    {
      "type": "paragraph",
      "text": "2 puffs (90 mcg/puff) for a total of 180 mcg; can repeat up to 3"
    },
    {
      "type": "paragraph",
      "text": "times"
    },
    {
      "type": "paragraph",
      "text": "Consider sending patient to the Emergency Department or"
    },
    {
      "type": "paragraph",
      "text": "calling emergency response team or 911, based upon the"
    },
    {
      "type": "paragraph",
      "text": "completeness of the response to the beta agonist inhaler"
    },
    {
      "type": "paragraph",
      "text": "Moderate"
    },
    {
      "type": "paragraph",
      "text": "Beta agonist inhaler (Albuterol(R))"
    },
    {
      "type": "paragraph",
      "text": "2 puffs (90 mcg/puff) for a total of 180 mcg; can repeat up to 3"
    },
    {
      "type": "paragraph",
      "text": "times"
    },
    {
      "type": "paragraph",
      "text": "Consider adding epinephrine (IM)*"
    },
    {
      "type": "paragraph",
      "text": "IM 0.3 mL of 1.0 mg/mL (1:1,000) dilution (0.3 mg); can repeat"
    },
    {
      "type": "paragraph",
      "text": "every 5-15 minutes up to 1 mL (1 mg) total"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine auto-injector (EpiPen(R) or equivalent) (0.3 mL of 1.0"
    },
    {
      "type": "paragraph",
      "text": "mg/mL (1:1,000) dilution, fixed [0.3mg]); can repeat every 5-15"
    },
    {
      "type": "paragraph",
      "text": "minutes up to three times"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IV)*"
    },
    {
      "type": "paragraph",
      "text": "IV 1 mL of 0.1 mg/mL(1:10,000) dilution (0.1 mg); administer"
    },
    {
      "type": "paragraph",
      "text": "slowly into a running IV infusion of fluids or use saline flush; can"
    },
    {
      "type": "paragraph",
      "text": "repeat every few minutes as needed up to 10 mL (1 mg) total"
    },
    {
      "type": "paragraph",
      "text": "Consider calling emergency response team or 911 based"
    },
    {
      "type": "paragraph",
      "text": "upon the completeness of the response"
    },
    {
      "type": "paragraph",
      "text": "Severe"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IV)*"
    },
    {
      "type": "paragraph",
      "text": "IV 1 mL of 0.1 mg/mL (1:10,000) dilution (0.1 mg); administer"
    },
    {
      "type": "paragraph",
      "text": "slowly into a running IV infusion of fluids or slow IV push"
    },
    {
      "type": "paragraph",
      "text": "followed by a slow saline flush; can repeat every few minutes as"
    },
    {
      "type": "paragraph",
      "text": "needed up to 10 mL (1 mg) total"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IM)*"
    },
    {
      "type": "paragraph",
      "text": "IM 0.3 mL of 1:1,000 dilution (0.3 mg); can repeat every 5-15"
    },
    {
      "type": "paragraph",
      "text": "minutes up to 1 mL (1 mg) total"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine auto-injector (EpiPen(R) or equivalent) (0.3 mL of 1.0"
    },
    {
      "type": "paragraph",
      "text": "mg/mL(1:1,000) dilution, Fixed [0.3mg]); can repeat every 5-15"
    },
    {
      "type": "paragraph",
      "text": "minutes up to three times"
    },
    {
      "type": "paragraph",
      "text": "AND"
    },
    {
      "type": "paragraph",
      "text": "Beta agonist inhaler (Albuterol(R)) (may work"
    },
    {
      "type": "paragraph",
      "text": "synergistically)"
    },
    {
      "type": "paragraph",
      "text": "2 puffs (90 mcg/puff) for a total of 180 mcg; can repeat up to 3"
    },
    {
      "type": "paragraph",
      "text": "times"
    },
    {
      "type": "paragraph",
      "text": "Call emergency response team or 911"
    },
    {
      "type": "paragraph",
      "text": "* Note: in hypotensive patients, the"
    },
    {
      "type": "paragraph",
      "text": "preferred route of epinephrine delivery"
    },
    {
      "type": "paragraph",
      "text": "is IV, as the extremities may not be"
    },
    {
      "type": "paragraph",
      "text": "perfused sufficiently to allow for"
    },
    {
      "type": "paragraph",
      "text": "adequate absorption of IM administered"
    },
    {
      "type": "paragraph",
      "text": "drug."
    },
    {
      "type": "image",
      "assetId": "asset_e726b553fa",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 3: MANAGEMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "109"
    },
    {
      "type": "paragraph",
      "text": "LARYNGEAL EDEMA"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "All forms"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "Pulse oximeter"
    },
    {
      "type": "paragraph",
      "text": "O2 by mask"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 L/min"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IV)*"
    },
    {
      "type": "paragraph",
      "text": "IV 1 mL of 0.1 mg/mL (1:10,000) dilution (0.1 mg);"
    },
    {
      "type": "paragraph",
      "text": "administer slowly into a running IV infusion of fluids or"
    },
    {
      "type": "paragraph",
      "text": "use saline flush; can repeat every few minutes as needed"
    },
    {
      "type": "paragraph",
      "text": "up to 10 mL (1 mg) total"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IM)"
    },
    {
      "type": "paragraph",
      "text": "IM 0.3 mL of 1.0 mg/mL (1:1,000) dilution (0.3 mg); can"
    },
    {
      "type": "paragraph",
      "text": "repeat every 5-15 minutes up to 1 mL (1 mg) total"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine auto-injector (EpiPen(R) or equivalent) (0.3"
    },
    {
      "type": "paragraph",
      "text": "mL of 1.0 mg/mL (1:1,000) dilution, fixed [0.3mg]); can"
    },
    {
      "type": "paragraph",
      "text": "repeat every 5-15 minutes up to three times"
    },
    {
      "type": "paragraph",
      "text": "Consider calling emergency"
    },
    {
      "type": "paragraph",
      "text": "response team or 911 based upon"
    },
    {
      "type": "paragraph",
      "text": "the severity of the reaction and the"
    },
    {
      "type": "paragraph",
      "text": "completeness of the response"
    },
    {
      "type": "paragraph",
      "text": "* Note: in hypotensive patients, the preferred"
    },
    {
      "type": "paragraph",
      "text": "route of epinephrine delivery is IV, as the"
    },
    {
      "type": "paragraph",
      "text": "extremities may not be perfused sufficiently to"
    },
    {
      "type": "paragraph",
      "text": "allow for adequate absorption of IM"
    },
    {
      "type": "paragraph",
      "text": "administered drug."
    },
    {
      "type": "image",
      "assetId": "asset_e40116e8e1",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 3: MANAGEMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "110"
    },
    {
      "type": "paragraph",
      "text": "HYPOTENSION"
    },
    {
      "type": "paragraph",
      "text": "(systolic blood pressure< 90 mm Hg)"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "All forms"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "Pulse oximeter"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "O2 by mask"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 L/min"
    },
    {
      "type": "paragraph",
      "text": "Elevate legs at least 60 degrees"
    },
    {
      "type": "paragraph",
      "text": "IV fluids 0.9% normal saline"
    },
    {
      "type": "paragraph",
      "text": "1,000 mL rapidly"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Lactated Ringers"
    },
    {
      "type": "paragraph",
      "text": "1,000 mL rapidly"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Hypotension with bradycardia (pulse < 60 bpm) (Vasovagal reaction)"
    },
    {
      "type": "paragraph",
      "text": "If mild"
    },
    {
      "type": "paragraph",
      "text": "No other treatment usually necessary"
    },
    {
      "type": "paragraph",
      "text": "If severe"
    },
    {
      "type": "paragraph",
      "text": "(patient remains symptomatic despite above measures)"
    },
    {
      "type": "paragraph",
      "text": "In addition to above measures: Atropine (IV)"
    },
    {
      "type": "paragraph",
      "text": "0.6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "1.0 mg; administer into a running IV infusion"
    },
    {
      "type": "paragraph",
      "text": "of fluids; can repeat up to 3 mg total"
    },
    {
      "type": "paragraph",
      "text": "Consider calling the emergency response team"
    },
    {
      "type": "paragraph",
      "text": "or 911"
    },
    {
      "type": "paragraph",
      "text": "Hypotension with tachycardia (pulse > 100 bpm) (Anaphylactoid reaction)"
    },
    {
      "type": "paragraph",
      "text": "If hypotension persists"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IV)*"
    },
    {
      "type": "paragraph",
      "text": "IV 1 mL of 0.1 mg/mL (1:10,000) dilution (0.1"
    },
    {
      "type": "paragraph",
      "text": "mg); administer slowly into a running IV infusion"
    },
    {
      "type": "paragraph",
      "text": "of fluids; can repeat every few minutes as needed"
    },
    {
      "type": "paragraph",
      "text": "up to 10 mL (1 mg) total"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine (IM)*"
    },
    {
      "type": "paragraph",
      "text": "IM 0.3 mL of 1.0 mg/mL (1:1,000) dilution (0.3"
    },
    {
      "type": "paragraph",
      "text": "mg); can repeat every 5-15 minutes up to 1 mL (1"
    },
    {
      "type": "paragraph",
      "text": "mg) total"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine auto-injector (EpiPen(R) or"
    },
    {
      "type": "paragraph",
      "text": "equivalent) (0.3 mL of 1.0 mg/mL (1:1,000)"
    },
    {
      "type": "paragraph",
      "text": "dilution, fixed [0.3mg]); can repeat every 5-15"
    },
    {
      "type": "paragraph",
      "text": "minutes up to three times"
    },
    {
      "type": "paragraph",
      "text": "Consider calling emergency response team or"
    },
    {
      "type": "paragraph",
      "text": "911 based upon the severity of the reaction and"
    },
    {
      "type": "paragraph",
      "text": "the completeness of the response"
    },
    {
      "type": "paragraph",
      "text": "* Note: in hypotensive patients, the preferred route"
    },
    {
      "type": "paragraph",
      "text": "of epinephrine delivery is IV, as the extremities"
    },
    {
      "type": "paragraph",
      "text": "may not be perfused sufficiently to allow for"
    },
    {
      "type": "paragraph",
      "text": "adequate absorption of IM administered drug."
    },
    {
      "type": "image",
      "assetId": "asset_f881038d5f",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 3: MANAGEMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "111"
    },
    {
      "type": "paragraph",
      "text": "HYPERTENSIVE CRISIS"
    },
    {
      "type": "paragraph",
      "text": "(diastolic BP> 120mmHg; systolic blood pressure > 200mm Hg; symptoms of endorgan compromise)"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "All forms"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "Pulse oximeter"
    },
    {
      "type": "paragraph",
      "text": "O2 by mask"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 L/min"
    },
    {
      "type": "paragraph",
      "text": "Labetalol (IV)"
    },
    {
      "type": "paragraph",
      "text": "20 mg IV; administer slowly, over 2 min; can double the"
    },
    {
      "type": "paragraph",
      "text": "dose every 10 min (e.g., 40 mg 10 min later, then 80 mg 10"
    },
    {
      "type": "paragraph",
      "text": "min after that)"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "(if labetalol not available)"
    },
    {
      "type": "paragraph",
      "text": "Nitroglycerin tablet (SL)"
    },
    {
      "type": "paragraph",
      "text": "0.4 mg tablet; can repeat every 5"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 min"
    },
    {
      "type": "paragraph",
      "text": "and"
    },
    {
      "type": "paragraph",
      "text": "Furosemide (Lasix(R)) (IV)"
    },
    {
      "type": "paragraph",
      "text": "20"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "40 mg IV; administer slowly over 2 min"
    },
    {
      "type": "paragraph",
      "text": "Call emergency response team or 911"
    },
    {
      "type": "paragraph",
      "text": "PULMONARY EDEMA"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "O2 by mask"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 L/min"
    },
    {
      "type": "paragraph",
      "text": "Pulse oximeter"
    },
    {
      "type": "paragraph",
      "text": "Elevate head of bed, if possible"
    },
    {
      "type": "paragraph",
      "text": "Furosemide (Lasix(R))"
    },
    {
      "type": "paragraph",
      "text": "20"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "40 mg IV; administer slowly over 2 min"
    },
    {
      "type": "paragraph",
      "text": "Call emergency response team or 911"
    },
    {
      "type": "image",
      "assetId": "asset_2e9de3c3d6",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 3: MANAGEMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "112"
    },
    {
      "type": "paragraph",
      "text": "SEIZURES/CONVULSIONS"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Observe and protect the patient"
    },
    {
      "type": "paragraph",
      "text": "Turn patient on side to avoid aspiration"
    },
    {
      "type": "paragraph",
      "text": "Suction airway, as needed"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "Pulse oximeter"
    },
    {
      "type": "paragraph",
      "text": "O2 by mask"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 L/min"
    },
    {
      "type": "paragraph",
      "text": "If unremitting"
    },
    {
      "type": "paragraph",
      "text": "Call emergency response team or 911"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Lorazepam (IV)"
    },
    {
      "type": "paragraph",
      "text": "IV 2"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "4 mg IV; administer slowly to maximum dose of 4 mg"
    },
    {
      "type": "paragraph",
      "text": "HYPOGLYCEMIA"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "O2 by mask"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "10 L/min"
    },
    {
      "type": "paragraph",
      "text": "If patient is able to swallow safely"
    },
    {
      "type": "paragraph",
      "text": "Oral glucose"
    },
    {
      "type": "paragraph",
      "text": "Two sugar packets or 15 g of glucose tablet/gel or"
    },
    {
      "type": "paragraph",
      "text": "cup (4 oz) of fruit juice"
    },
    {
      "type": "paragraph",
      "text": "If patient is unable to swallow safely and IV"
    },
    {
      "type": "paragraph",
      "text": "access available"
    },
    {
      "type": "paragraph",
      "text": "Dextrose 50% (IV)"
    },
    {
      "type": "paragraph",
      "text": "D50W 1 ampule (25 grams) IV administer over 2"
    },
    {
      "type": "paragraph",
      "text": "min"
    },
    {
      "type": "paragraph",
      "text": "D5W or D5NS (IV) as adjunct therapy Administer at a rate of 100 mL/hour"
    },
    {
      "type": "paragraph",
      "text": "If no IV access is available"
    },
    {
      "type": "paragraph",
      "text": "Glucagon (IM)"
    },
    {
      "type": "paragraph",
      "text": "IM 1 mg"
    },
    {
      "type": "paragraph",
      "text": "ANXIETY (PANIC ATTACK)"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Diagnosis of exclusion"
    },
    {
      "type": "paragraph",
      "text": "Assess patient for developing signs and symptoms that might indicate another type of reaction"
    },
    {
      "type": "paragraph",
      "text": "Preserve IV access"
    },
    {
      "type": "paragraph",
      "text": "Monitor vitals"
    },
    {
      "type": "paragraph",
      "text": "Pulse oximeter"
    },
    {
      "type": "paragraph",
      "text": "If no identifiable manifestations and normal oxygenation, consider this diagnosis"
    },
    {
      "type": "paragraph",
      "text": "Reassure patient"
    },
    {
      "type": "image",
      "assetId": "asset_d96968e2e0",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 3: MANAGEMENT OF ACUTE REACTIONS TO CONTRAST MEDIA IN ADULTS"
    },
    {
      "type": "paragraph",
      "text": "113"
    },
    {
      "type": "paragraph",
      "text": "REACTION REBOUND PREVENTION"
    },
    {
      "type": "paragraph",
      "text": "Treatment"
    },
    {
      "type": "paragraph",
      "text": "Dosing"
    },
    {
      "type": "paragraph",
      "text": "Note: While IV corticosteroids may help prevent a short-term"
    },
    {
      "type": "paragraph",
      "text": "recurrence of an allergic-like reaction, they are not useful in the"
    },
    {
      "type": "paragraph",
      "text": "acute treatment of any reaction. However, these may be"
    },
    {
      "type": "paragraph",
      "text": "considered for patients having severe allergic-like manifestations"
    },
    {
      "type": "paragraph",
      "text": "prior to transportation to an Emergency Department or inpatient"
    },
    {
      "type": "paragraph",
      "text": "unit."
    },
    {
      "type": "paragraph",
      "text": "Hydrocortisone"
    },
    {
      "type": "paragraph",
      "text": "(Solu-Cortef(R)) (IV)"
    },
    {
      "type": "paragraph",
      "text": "IV 5 mg / kg; administer over 1-2 min"
    },
    {
      "type": "paragraph",
      "text": "or"
    },
    {
      "type": "paragraph",
      "text": "Methylprednisolone"
    },
    {
      "type": "paragraph",
      "text": "(Solu-Medrol(R)) (IV)"
    },
    {
      "type": "paragraph",
      "text": "IV 1 mg / kg; administer over 1-2 min"
    },
    {
      "type": "paragraph",
      "text": "Revision History"
    },
    {
      "type": "paragraph",
      "text": "14 October 2020: Minor revisions"
    },
    {
      "type": "paragraph",
      "text": "28 August 2015: Major revisions"
    },
    {
      "type": "paragraph",
      "text": "15 April 2013: Major revisions"
    },
    {
      "type": "paragraph",
      "text": "26 June 2012: Minor revisions"
    },
    {
      "type": "paragraph",
      "text": "23 June 2010: Major revisions"
    },
    {
      "type": "paragraph",
      "text": "15 March 2004: First version"
    },
    {
      "type": "image",
      "assetId": "asset_f08d5083cb",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 4: EQUIPMENT FOR CONTRAST REACTIONS KITS IN RADIOLOGY"
    },
    {
      "type": "paragraph",
      "text": "114"
    },
    {
      "type": "paragraph",
      "text": "Facilities should be equipped with basic emergency equipment and medications needed to assess patients and treat contrast"
    },
    {
      "type": "paragraph",
      "text": "reactions. Equipment that can help assess a patients clinical status include a stethoscope, blood pressure and pulse monitor"
    },
    {
      "type": "paragraph",
      "text": ","
    },
    {
      "type": "paragraph",
      "text": "and a pulse oximeter. While no standard contrast reaction kit exists, sites should consider making key medications available"
    },
    {
      "type": "paragraph",
      "text": "for prompt reaction management. This would include epinephrine 1 mg/1 mL for intramuscular injection (this includes"
    },
    {
      "type": "paragraph",
      "text": "standard Epinephrine auto-injectors), albuterol, and an antihistamine. Additional medications and equipment are listed in"
    },
    {
      "type": "paragraph",
      "text": "Table 4"
    },
    {
      "type": "paragraph",
      "text": ". Due to financial and operational constraints related to frequent replacement of medications with a relatively short"
    },
    {
      "type": "paragraph",
      "text": "shelf life, many practices are choosing to stock only essential medications separate from standard code carts. A periodic"
    },
    {
      "type": "paragraph",
      "text": "monitoring program to ensure equipment functionality and medication shelf life is recommended."
    },
    {
      "type": "paragraph",
      "text": "Depending on the size and function of an imaging site, it may be sufficient to have one treatment cart designed for both"
    },
    {
      "type": "paragraph",
      "text": "contrast reactions and cardiopulmonary arrest. Other facilities may find it more cost-effective to have separate contrast"
    },
    {
      "type": "paragraph",
      "text": "reaction kits and code carts. Smaller distributed contrast reaction kits focused on the most frequently used or urgently needed"
    },
    {
      "type": "paragraph",
      "text": "items can enable rapid implementation of treatment at considerably lower expense. In general, code carts designed for"
    },
    {
      "type": "paragraph",
      "text": "treatment of cardiopulmonary arrest have more equipment than necessary for radiologists to use, and facilities may find the"
    },
    {
      "type": "paragraph",
      "text": "suggestions below helpful in designing a dedicated reaction treatment cart that can be used to manage patients experiencing a"
    },
    {
      "type": "paragraph",
      "text": "contrast reaction."
    },
    {
      "type": "paragraph",
      "text": "The contact phone number of the local emergency response team (if one is available) should be clearly posted within or near"
    },
    {
      "type": "paragraph",
      "text": "any room in which contrast media is to be injected. If there is no emergency response team, the emergency external phone"
    },
    {
      "type": "paragraph",
      "text": "number to be used (e.g., 911) should be displayed instead."
    },
    {
      "type": "paragraph",
      "text": "The following equipment is suggested to be readily available and within or nearby any room in which contrast media is to be"
    },
    {
      "type": "paragraph",
      "text": "injected. Adult or pediatric sizes are optional for facilities that do not inject adult or pediatric patients, respectively. Sites may"
    },
    {
      "type": "paragraph",
      "text": "opt to stock less equipment and medications if emergency response teams or ambulance support is readily available."
    },
    {
      "type": "paragraph",
      "text": "The following minimum equipment should be within or near any room in which contrast media is to be injected:"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Access to oxygen"
    },
    {
      "type": "paragraph",
      "text": "*"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Defibrillator or automated external defibrillator (AED)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Blood pressure and pulse monitor"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Pulse oximeter"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Stethoscope"
    },
    {
      "type": "paragraph",
      "text": "* Although oxygen can be administered in a variety of ways, use of non-rebreather masks is preferred because of their ability to deliver a larger dose"
    },
    {
      "type": "paragraph",
      "text": "of oxygen to the patient."
    },
    {
      "type": "paragraph",
      "text": "The following minimum medications should be within or near any room in which contrast media is to be injected:"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine IM 1mg/1mL (auto-injector or vials with needle and syringe for use)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Inhaled short-acting beta-agonist (inhaler or nebulizer)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Anti-histamine"
    },
    {
      "type": "paragraph",
      "text": "Table4:"
    },
    {
      "type": "paragraph",
      "text": "EQUIPMENT FOR CONTRAST REACTION KITS IN RADIOLOGY"
    },
    {
      "type": "paragraph",
      "text": "Last updated: January 2020"
    },
    {
      "type": "image",
      "assetId": "asset_3ca9e2746b",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "TABLE 4: EQUIPMENT FOR CONTRAST REACTIONS KITS IN RADIOLOGY"
    },
    {
      "type": "paragraph",
      "text": "115"
    },
    {
      "type": "paragraph",
      "text": "The following discretionary medications and equipment may be considered for inclusion within or near any room in which"
    },
    {
      "type": "paragraph",
      "text": "contrast media is to be injected:"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Equipment"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Suction: wall-mounted or portable; tubing and catheters"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Ambu(R)"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "type bag"
    },
    {
      "type": "paragraph",
      "text": "-valve-mask device; masks in adult and pediatric sizes; protective barriers for mouth-to-"
    },
    {
      "type": "paragraph",
      "text": "mouth respiration optional if bag-valve-mask device is stocked"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Normal saline (0.9%) and tubing"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Syringes and IV cannulas: variety of sizes; tourniquets"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Needle(s) for IM drug administration"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Medications"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Epinephrine IV 1mg/10mL, 10-mL preloaded syringe"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Atropine IV, 1mg/10mL, 10-mL preloaded syringe"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Corticosteroid IV"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Nitroglycerin sublingual, 0.4 mg tab"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Aspirin per oral, 325 mg (for chest pain where myocardial ischemia is a consideration)"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Lasix IV, 20"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "40 mg (for pulmonary edema)"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Labetalol IV, 20 mg (for hypertensive emergency)"
    },
    {
      "type": "paragraph",
      "text": "o"
    },
    {
      "type": "paragraph",
      "text": "Dextrose IV, 50% 25g/50mL syringe (for hypoglycemia)"
    },
    {
      "type": "image",
      "assetId": "asset_0efdd66e87",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "APPENDIX A: CONTRAST MEDIA SPECIFICATION"
    },
    {
      "type": "paragraph",
      "text": "116"
    },
    {
      "type": "paragraph",
      "text": "INTRAVASCULAR"
    },
    {
      "type": "paragraph",
      "text": "Product"
    },
    {
      "type": "paragraph",
      "text": "Generic name (concentration in mg"
    },
    {
      "type": "paragraph",
      "text": "contrast/ml)"
    },
    {
      "type": "paragraph",
      "text": "Ionicity"
    },
    {
      "type": "paragraph",
      "text": "Iodine+"
    },
    {
      "type": "paragraph",
      "text": "(mg/ml)"
    },
    {
      "type": "paragraph",
      "text": "Viscosity+"
    },
    {
      "type": "paragraph",
      "text": "25C"
    },
    {
      "type": "paragraph",
      "text": "(cp or mPa.s)"
    },
    {
      "type": "paragraph",
      "text": "Viscosity+37C"
    },
    {
      "type": "paragraph",
      "text": "(cp or mPa.s)"
    },
    {
      "type": "paragraph",
      "text": "Osmolality"
    },
    {
      "type": "paragraph",
      "text": "(mOsm/kgH2O)"
    },
    {
      "type": "paragraph",
      "text": "Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "140 (GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "Iohexol 302"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "140"
    },
    {
      "type": "paragraph",
      "text": "2.3*"
    },
    {
      "type": "paragraph",
      "text": "1.5"
    },
    {
      "type": "paragraph",
      "text": "322"
    },
    {
      "type": "paragraph",
      "text": "Conray"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "30 (Covidien)"
    },
    {
      "type": "paragraph",
      "text": "iothalamate (300)"
    },
    {
      "type": "paragraph",
      "text": "Ionic"
    },
    {
      "type": "paragraph",
      "text": "141"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "1.5"
    },
    {
      "type": "paragraph",
      "text": "600"
    },
    {
      "type": "paragraph",
      "text": "Ultravist(R) 150 (Bayer HealthCare)"
    },
    {
      "type": "paragraph",
      "text": "iopromide"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "150"
    },
    {
      "type": "paragraph",
      "text": "2.3*"
    },
    {
      "type": "paragraph",
      "text": "1.5"
    },
    {
      "type": "paragraph",
      "text": "328"
    },
    {
      "type": "paragraph",
      "text": "Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "180 (GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "iohexol (388)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "180"
    },
    {
      "type": "paragraph",
      "text": "3.1*"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "408"
    },
    {
      "type": "paragraph",
      "text": "Isovue(R)-200 (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "iopamidol (408)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "200"
    },
    {
      "type": "paragraph",
      "text": "3.3*"
    },
    {
      "type": "paragraph",
      "text": "2.0"
    },
    {
      "type": "paragraph",
      "text": "413"
    },
    {
      "type": "paragraph",
      "text": "Conray"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "43 (Covidien)"
    },
    {
      "type": "paragraph",
      "text": "iothalamate (430)"
    },
    {
      "type": "paragraph",
      "text": "Ionic"
    },
    {
      "type": "paragraph",
      "text": "202"
    },
    {
      "type": "paragraph",
      "text": "3"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "1000"
    },
    {
      "type": "paragraph",
      "text": "Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "240 (GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "iohexol (518)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "240"
    },
    {
      "type": "paragraph",
      "text": "5.8*"
    },
    {
      "type": "paragraph",
      "text": "3.4"
    },
    {
      "type": "paragraph",
      "text": "520"
    },
    {
      "type": "paragraph",
      "text": "Optiray"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "240 (Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "ioversol (509)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "240"
    },
    {
      "type": "paragraph",
      "text": "4.6"
    },
    {
      "type": "paragraph",
      "text": "3.0"
    },
    {
      "type": "paragraph",
      "text": "502"
    },
    {
      "type": "paragraph",
      "text": "Ultravist(R) 240 (Bayer Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "iopromide"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "240"
    },
    {
      "type": "paragraph",
      "text": "4.9*"
    },
    {
      "type": "paragraph",
      "text": "2.8"
    },
    {
      "type": "paragraph",
      "text": "483"
    },
    {
      "type": "paragraph",
      "text": "Isovue(R) 250 (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "iopamidol (510)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "250"
    },
    {
      "type": "paragraph",
      "text": "5.1*"
    },
    {
      "type": "paragraph",
      "text": "3.0"
    },
    {
      "type": "paragraph",
      "text": "524"
    },
    {
      "type": "paragraph",
      "text": "Visipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "270 (GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "iodixanol (550)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "270"
    },
    {
      "type": "paragraph",
      "text": "12.7*"
    },
    {
      "type": "paragraph",
      "text": "6.3"
    },
    {
      "type": "paragraph",
      "text": "290"
    },
    {
      "type": "paragraph",
      "text": "Conray"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "(Covidien)"
    },
    {
      "type": "paragraph",
      "text": "iothalamate (600)"
    },
    {
      "type": "paragraph",
      "text": "Ionic"
    },
    {
      "type": "paragraph",
      "text": "282"
    },
    {
      "type": "paragraph",
      "text": "6"
    },
    {
      "type": "paragraph",
      "text": "4"
    },
    {
      "type": "paragraph",
      "text": "1400"
    },
    {
      "type": "paragraph",
      "text": "Isovue(R) 300 (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "iopamidol (612)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "300"
    },
    {
      "type": "paragraph",
      "text": "8.8*"
    },
    {
      "type": "paragraph",
      "text": "4.7"
    },
    {
      "type": "paragraph",
      "text": "616"
    },
    {
      "type": "paragraph",
      "text": "Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "300 (GE Health care)"
    },
    {
      "type": "paragraph",
      "text": "iohexol (647)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "300"
    },
    {
      "type": "paragraph",
      "text": "11.8*"
    },
    {
      "type": "paragraph",
      "text": "6.3"
    },
    {
      "type": "paragraph",
      "text": "672"
    },
    {
      "type": "paragraph",
      "text": "Optiray"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "300 (Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "ioversol (640)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "300"
    },
    {
      "type": "paragraph",
      "text": "8.2"
    },
    {
      "type": "paragraph",
      "text": "5.5"
    },
    {
      "type": "paragraph",
      "text": "651"
    },
    {
      "type": "paragraph",
      "text": "Oxilan(R) 300 (Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "ioxilan (623)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "300"
    },
    {
      "type": "paragraph",
      "text": "9.4*"
    },
    {
      "type": "paragraph",
      "text": "5.1"
    },
    {
      "type": "paragraph",
      "text": "610"
    },
    {
      "type": "paragraph",
      "text": "Ultravist(R) 300 (Bayer Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "iopromide"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "300"
    },
    {
      "type": "paragraph",
      "text": "9.2*"
    },
    {
      "type": "paragraph",
      "text": "4.9"
    },
    {
      "type": "paragraph",
      "text": "607"
    },
    {
      "type": "paragraph",
      "text": "Hexabrix"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "*** (Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "Ioxaglate meglumine/sodium (589)"
    },
    {
      "type": "paragraph",
      "text": "Ionic"
    },
    {
      "type": "paragraph",
      "text": "320"
    },
    {
      "type": "paragraph",
      "text": "15.7*"
    },
    {
      "type": "paragraph",
      "text": "7.5"
    },
    {
      "type": "paragraph",
      "text": "600"
    },
    {
      "type": "paragraph",
      "text": "Optiray"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "320 (Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "ioversol (680)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "320"
    },
    {
      "type": "paragraph",
      "text": "9.9"
    },
    {
      "type": "paragraph",
      "text": "5.8"
    },
    {
      "type": "paragraph",
      "text": "702"
    },
    {
      "type": "paragraph",
      "text": "Visipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "320 (GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "iodixanol (652)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "320"
    },
    {
      "type": "paragraph",
      "text": "26.6"
    },
    {
      "type": "paragraph",
      "text": "11.8"
    },
    {
      "type": "paragraph",
      "text": "290"
    },
    {
      "type": "paragraph",
      "text": "Optiray"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "350 (Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "ioversol (740)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "350"
    },
    {
      "type": "paragraph",
      "text": "14.3"
    },
    {
      "type": "paragraph",
      "text": "9.0"
    },
    {
      "type": "paragraph",
      "text": "792"
    },
    {
      "type": "paragraph",
      "text": "Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "350 (GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "iohexol (755)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "350"
    },
    {
      "type": "paragraph",
      "text": "20.4*"
    },
    {
      "type": "paragraph",
      "text": "10.4"
    },
    {
      "type": "paragraph",
      "text": "844"
    },
    {
      "type": "paragraph",
      "text": "Oxilan(R) 350 (Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "ioxilan (727)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "350"
    },
    {
      "type": "paragraph",
      "text": "16.3*"
    },
    {
      "type": "paragraph",
      "text": "8.1"
    },
    {
      "type": "paragraph",
      "text": "721"
    },
    {
      "type": "paragraph",
      "text": "Isovue(R) 370 (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "iopamidol (755)"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "370"
    },
    {
      "type": "paragraph",
      "text": "20.9*"
    },
    {
      "type": "paragraph",
      "text": "9.4"
    },
    {
      "type": "paragraph",
      "text": "796"
    },
    {
      "type": "paragraph",
      "text": "MD-76"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "R (Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "diatrizoate/ meglumine/sodium (760)"
    },
    {
      "type": "paragraph",
      "text": "Ionic"
    },
    {
      "type": "paragraph",
      "text": "370"
    },
    {
      "type": "paragraph",
      "text": "16.4"
    },
    {
      "type": "paragraph",
      "text": "10.5"
    },
    {
      "type": "paragraph",
      "text": "1551"
    },
    {
      "type": "paragraph",
      "text": "Ultravist(R) 370 (Bayer Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "Ioprokoi98mide"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "370"
    },
    {
      "type": "paragraph",
      "text": "22.0*"
    },
    {
      "type": "paragraph",
      "text": "10.0"
    },
    {
      "type": "paragraph",
      "text": "774"
    },
    {
      "type": "paragraph",
      "text": "Appendix A"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA SPECIFICATIONS"
    },
    {
      "type": "paragraph",
      "text": "Last updated: March 2023"
    },
    {
      "type": "image",
      "assetId": "asset_6bed3b26d2",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "APPENDIX A: CONTRAST MEDIA SPECIFICATION"
    },
    {
      "type": "paragraph",
      "text": "117"
    },
    {
      "type": "paragraph",
      "text": "+ Data from product package inserts, product brochures, technical information services and Rohrer, M, et al., Comparison of Magnetic Properties of MRI Contrast Media"
    },
    {
      "type": "paragraph",
      "text": "Solutions at Different Field Strengths. Investigative Radiology 2005;40:715-724."
    },
    {
      "type": "paragraph",
      "text": "* Measured at 20"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "** Data on file with Covidien"
    },
    {
      "type": "paragraph",
      "text": "*** Hexabrix is a registered trademark of Guerbet, S.A. and is co-marketed in the U.S. by Guerbet LLC and Covidien."
    },
    {
      "type": "paragraph",
      "text": "o Viscosities of most products intended for oral administration are not reported by manufacturers."
    },
    {
      "type": "paragraph",
      "text": "# Barium concentrations are expressed as percent by weight (%w/w) and percent weight-in volume (% w/v). Percent by weight is the number of grams of barium sulfate per 100"
    },
    {
      "type": "paragraph",
      "text": "grams of final suspension. For barium powders, percent by weight is the proportion of total powder weight that is pure barium, and the remainder is additives (Ex., barium"
    },
    {
      "type": "paragraph",
      "text": "100% w/w is pure barium with no additives). Percent weight-in volume is the number of grams of barium sulfate per 100 mL of final suspension"
    },
    {
      "type": "paragraph",
      "text": "1 Adopted from Reiter et al. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012; 14(1): 31."
    },
    {
      "type": "paragraph",
      "text": "Cond 7.4 refers to value at physiologic pH of 7.4."
    },
    {
      "type": "paragraph",
      "text": "Appendix A"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA SPECIFICATIONS (continued)"
    },
    {
      "type": "paragraph",
      "text": "GASTROINTESTINAL"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Non-Barium Oral Contrast"
    },
    {
      "type": "paragraph",
      "text": "Product"
    },
    {
      "type": "paragraph",
      "text": "Generic name"
    },
    {
      "type": "paragraph",
      "text": "(concentration in mg"
    },
    {
      "type": "paragraph",
      "text": "contrast/ml)"
    },
    {
      "type": "paragraph",
      "text": "Ionicity"
    },
    {
      "type": "paragraph",
      "text": "Iodine+"
    },
    {
      "type": "paragraph",
      "text": "(mg/ml)"
    },
    {
      "type": "paragraph",
      "text": "Viscosity+ 25C"
    },
    {
      "type": "paragraph",
      "text": "(cp or mPa.s)"
    },
    {
      "type": "paragraph",
      "text": "Viscosity+"
    },
    {
      "type": "paragraph",
      "text": "37C"
    },
    {
      "type": "paragraph",
      "text": "(cp or mPa.s)"
    },
    {
      "type": "paragraph",
      "text": "Osmolality"
    },
    {
      "type": "paragraph",
      "text": "(mOsm/kg"
    },
    {
      "type": "paragraph",
      "text": "H2O)"
    },
    {
      "type": "paragraph",
      "text": "Gastrografin(R) (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "diatrizoate meglumine"
    },
    {
      "type": "paragraph",
      "text": "sodium (660)"
    },
    {
      "type": "paragraph",
      "text": "Ionic"
    },
    {
      "type": "paragraph",
      "text": "367"
    },
    {
      "type": "paragraph",
      "text": "MD-Gastroview"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "(Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "diatrizoate meglumine"
    },
    {
      "type": "paragraph",
      "text": "sodium (660)"
    },
    {
      "type": "paragraph",
      "text": "Ionic"
    },
    {
      "type": "paragraph",
      "text": "367"
    },
    {
      "type": "paragraph",
      "text": "Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "180 (GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "iohexol (388) pediatric use"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "180"
    },
    {
      "type": "paragraph",
      "text": "3.1*"
    },
    {
      "type": "paragraph",
      "text": "2.0"
    },
    {
      "type": "paragraph",
      "text": "331"
    },
    {
      "type": "paragraph",
      "text": "Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "240 (GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "iohexol (518) pediatric use"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "240"
    },
    {
      "type": "paragraph",
      "text": "5.8*"
    },
    {
      "type": "paragraph",
      "text": "3.4"
    },
    {
      "type": "paragraph",
      "text": "520"
    },
    {
      "type": "paragraph",
      "text": "Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "300 (GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "iohexol (647) pediatric use"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "300"
    },
    {
      "type": "paragraph",
      "text": "11.8*"
    },
    {
      "type": "paragraph",
      "text": "6.3"
    },
    {
      "type": "paragraph",
      "text": "672"
    },
    {
      "type": "paragraph",
      "text": "Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "350 (GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "iohexol (755) adult use"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "350"
    },
    {
      "type": "paragraph",
      "text": "20.4*"
    },
    {
      "type": "paragraph",
      "text": "10.4"
    },
    {
      "type": "paragraph",
      "text": "844"
    },
    {
      "type": "paragraph",
      "text": "Gastromark"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "(Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "Discontinued in US"
    },
    {
      "type": "paragraph",
      "text": "ferrous-ferric oxide"
    },
    {
      "type": "paragraph",
      "text": "ferumoxsil"
    },
    {
      "type": "paragraph",
      "text": "NA"
    },
    {
      "type": "paragraph",
      "text": "NA"
    },
    {
      "type": "paragraph",
      "text": "250"
    },
    {
      "type": "paragraph",
      "text": "GASTROINTESTINAL"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "Barium-Based Oral Contrast"
    },
    {
      "type": "paragraph",
      "text": "Product"
    },
    {
      "type": "paragraph",
      "text": "Chemical Structure"
    },
    {
      "type": "paragraph",
      "text": "Concentration"
    },
    {
      "type": "paragraph",
      "text": "(w/v or w/w)#"
    },
    {
      "type": "paragraph",
      "text": "E-Z-HD (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "barium sulfate"
    },
    {
      "type": "paragraph",
      "text": "98% w/w"
    },
    {
      "type": "paragraph",
      "text": "Liquid Polibar Plus (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "barium sulfate"
    },
    {
      "type": "paragraph",
      "text": "105% w/v or 58% w/w"
    },
    {
      "type": "paragraph",
      "text": "Liquid Polibar (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "barium sulfate"
    },
    {
      "type": "paragraph",
      "text": "105% w/v"
    },
    {
      "type": "paragraph",
      "text": "E-Z-Paque / Pilibar ACB (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "barium Sulfate"
    },
    {
      "type": "paragraph",
      "text": "96% w/w"
    },
    {
      "type": "paragraph",
      "text": "Liquid E-Z-Paque (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "barium sulfate"
    },
    {
      "type": "paragraph",
      "text": "60% w/v or 41% w/w"
    },
    {
      "type": "paragraph",
      "text": "Readi-cat 2 (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "barium sulfate"
    },
    {
      "type": "paragraph",
      "text": "2.1% w/v"
    },
    {
      "type": "paragraph",
      "text": "E-Z-Paste (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "barium sulfate"
    },
    {
      "type": "paragraph",
      "text": "60% w/w"
    },
    {
      "type": "paragraph",
      "text": "Entero Vu (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "barium sulfate"
    },
    {
      "type": "paragraph",
      "text": "24% w/v"
    },
    {
      "type": "paragraph",
      "text": "Tagitol"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "(Bracco)"
    },
    {
      "type": "paragraph",
      "text": "barium sulfate"
    },
    {
      "type": "paragraph",
      "text": "40% w/v or 30% w/w"
    },
    {
      "type": "paragraph",
      "text": "Varibar(R) (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "Barium sulfate in variable consistency"
    },
    {
      "type": "paragraph",
      "text": "40% w/v"
    },
    {
      "type": "paragraph",
      "text": "E-Z-HD (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "barium sulfate"
    },
    {
      "type": "paragraph",
      "text": "98% w/w"
    },
    {
      "type": "paragraph",
      "text": "NeuLumEX"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "(E-Z-EM Inc/Bracco)"
    },
    {
      "type": "paragraph",
      "text": "barium sulfate"
    },
    {
      "type": "paragraph",
      "text": "0.1% w/v or 0.1% w/w"
    },
    {
      "type": "image",
      "assetId": "asset_6f69759ce5",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "APPENDIX A: CONTRAST MEDIA SPECIFICATION"
    },
    {
      "type": "paragraph",
      "text": "118"
    },
    {
      "type": "paragraph",
      "text": "+ Data from product package inserts, product brochures, technical information services and Rohrer, M, et al., Comparison of Magnetic Properties of MRI"
    },
    {
      "type": "paragraph",
      "text": "Contrast Media Solutions at Different Field Strengths. Investigative Radiology 2005;40:715-724."
    },
    {
      "type": "paragraph",
      "text": "* Measured at 20"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "** Data on file with Covidien"
    },
    {
      "type": "paragraph",
      "text": "*** Hexabrix is a registered trademark of Guerbet, S.A. and is co-marketed in the U.S. by Guerbet LLC and Covidien."
    },
    {
      "type": "paragraph",
      "text": "o Viscosities of most products intended for oral administration are not reported by manufacturers."
    },
    {
      "type": "paragraph",
      "text": "# Barium concentrations are expressed as percent by weight (%w/w) and percent weight-in volume (% w/v). Percent by weight is the number of grams of barium"
    },
    {
      "type": "paragraph",
      "text": "sulfate per 100 grams of final suspension. For barium powders, percent by weight is the proportion of total powder weight that is pure barium and the remainder"
    },
    {
      "type": "paragraph",
      "text": "is additives (Ex., barium 100% w/w is pure barium with no additives). Percent weight-in volume is the number of grams of barium sulfate per 100 mL of final"
    },
    {
      "type": "paragraph",
      "text": "suspension"
    },
    {
      "type": "paragraph",
      "text": "1 Adopted from Reiter et al. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012; 14(1):"
    },
    {
      "type": "paragraph",
      "text": "31. Cond 7.4 refers to value at physiologic pH of 7.4."
    },
    {
      "type": "paragraph",
      "text": "Appendix A"
    },
    {
      "type": "paragraph",
      "text": "-"
    },
    {
      "type": "paragraph",
      "text": "CONTRAST MEDIA SPECIFICATIONS (continued)"
    },
    {
      "type": "paragraph",
      "text": "GENITOURINARY"
    },
    {
      "type": "paragraph",
      "text": "Product"
    },
    {
      "type": "paragraph",
      "text": "Generic name (concentration in mg"
    },
    {
      "type": "paragraph",
      "text": "contrast/ml)"
    },
    {
      "type": "paragraph",
      "text": "Ionicity"
    },
    {
      "type": "paragraph",
      "text": "Iodine+"
    },
    {
      "type": "paragraph",
      "text": "(mg/ml)"
    },
    {
      "type": "paragraph",
      "text": "Viscosity+"
    },
    {
      "type": "paragraph",
      "text": "25C"
    },
    {
      "type": "paragraph",
      "text": "(cp or mPa.s)"
    },
    {
      "type": "paragraph",
      "text": "Viscosity+"
    },
    {
      "type": "paragraph",
      "text": "37C"
    },
    {
      "type": "paragraph",
      "text": "(cp or mPa.s)"
    },
    {
      "type": "paragraph",
      "text": "Osmolality"
    },
    {
      "type": "paragraph",
      "text": "(mOsm/kg"
    },
    {
      "type": "paragraph",
      "text": "H2O"
    },
    {
      "type": "paragraph",
      "text": ")"
    },
    {
      "type": "paragraph",
      "text": "Cystografin(R) (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "diatrizoate"
    },
    {
      "type": "paragraph",
      "text": "Ionic"
    },
    {
      "type": "paragraph",
      "text": "141"
    },
    {
      "type": "paragraph",
      "text": "Cysto-Conray"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "II (Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "iothalamate (172)"
    },
    {
      "type": "paragraph",
      "text": "(Only for retrograde cystography and"
    },
    {
      "type": "paragraph",
      "text": "cystourethrography)"
    },
    {
      "type": "paragraph",
      "text": "Ionic"
    },
    {
      "type": "paragraph",
      "text": "81"
    },
    {
      "type": "paragraph",
      "text": "(Only for retrograde cystography"
    },
    {
      "type": "paragraph",
      "text": "and cystourethrography)"
    },
    {
      "type": "paragraph",
      "text": "~400"
    },
    {
      "type": "paragraph",
      "text": "Conray"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "43 (Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "iothalamate (430)"
    },
    {
      "type": "paragraph",
      "text": "Ionic"
    },
    {
      "type": "paragraph",
      "text": "202"
    },
    {
      "type": "paragraph",
      "text": "3"
    },
    {
      "type": "paragraph",
      "text": "2"
    },
    {
      "type": "paragraph",
      "text": "1000"
    },
    {
      "type": "paragraph",
      "text": "Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "Can be diluted for"
    },
    {
      "type": "paragraph",
      "text": "retrograde use. See package insert"
    },
    {
      "type": "paragraph",
      "text": "iohexol"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "INTRATHECAL"
    },
    {
      "type": "paragraph",
      "text": "Product"
    },
    {
      "type": "paragraph",
      "text": "Generic name"
    },
    {
      "type": "paragraph",
      "text": "(concentration in mg"
    },
    {
      "type": "paragraph",
      "text": "contrast/ml)"
    },
    {
      "type": "paragraph",
      "text": "Ionicity"
    },
    {
      "type": "paragraph",
      "text": "Iodine+"
    },
    {
      "type": "paragraph",
      "text": "(mg/ml)"
    },
    {
      "type": "paragraph",
      "text": "Viscosity+"
    },
    {
      "type": "paragraph",
      "text": "25C"
    },
    {
      "type": "paragraph",
      "text": "(cp or mPa.s)"
    },
    {
      "type": "paragraph",
      "text": "Viscosity+"
    },
    {
      "type": "paragraph",
      "text": "37C"
    },
    {
      "type": "paragraph",
      "text": "(cp or mPa.s)"
    },
    {
      "type": "paragraph",
      "text": "Osmolality"
    },
    {
      "type": "paragraph",
      "text": "(mOsm/kg H2O"
    },
    {
      "type": "paragraph",
      "text": ")"
    },
    {
      "type": "paragraph",
      "text": "Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "180 (GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "iohexol"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "180"
    },
    {
      "type": "paragraph",
      "text": "3.1*"
    },
    {
      "type": "paragraph",
      "text": "2.0"
    },
    {
      "type": "paragraph",
      "text": "408"
    },
    {
      "type": "paragraph",
      "text": "Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "240 (GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "iohexol"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "240"
    },
    {
      "type": "paragraph",
      "text": "5.8*"
    },
    {
      "type": "paragraph",
      "text": "3.4"
    },
    {
      "type": "paragraph",
      "text": "520"
    },
    {
      "type": "paragraph",
      "text": "Omnipaque"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "300 (GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "iohexol"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "300"
    },
    {
      "type": "paragraph",
      "text": "11.8*"
    },
    {
      "type": "paragraph",
      "text": "6.3"
    },
    {
      "type": "paragraph",
      "text": "672"
    },
    {
      "type": "paragraph",
      "text": "Isovue-M(R) 200 (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "iopamidol"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "200"
    },
    {
      "type": "paragraph",
      "text": "3.3*"
    },
    {
      "type": "paragraph",
      "text": "2.0"
    },
    {
      "type": "paragraph",
      "text": "413"
    },
    {
      "type": "paragraph",
      "text": "Isovue-M(R) 300 (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "iopamidol"
    },
    {
      "type": "paragraph",
      "text": "Nonionic"
    },
    {
      "type": "paragraph",
      "text": "300"
    },
    {
      "type": "paragraph",
      "text": "8.8*"
    },
    {
      "type": "paragraph",
      "text": "4.7"
    },
    {
      "type": "paragraph",
      "text": "616"
    },
    {
      "type": "image",
      "assetId": "asset_66a828e4c9",
      "alt": "background image"
    },
    {
      "type": "paragraph",
      "text": "APPENDIX A: CONTRAST MEDIA SPECIFICATION"
    },
    {
      "type": "paragraph",
      "text": "119"
    },
    {
      "type": "paragraph",
      "text": "GADOLINIUM-BASED INTRAVASCULAR"
    },
    {
      "type": "paragraph",
      "text": "Revision History"
    },
    {
      "type": "paragraph",
      "text": "September 2020: Minor Revision"
    },
    {
      "type": "paragraph",
      "text": "April 2023: Minor Revision"
    },
    {
      "type": "paragraph",
      "text": "Product"
    },
    {
      "type": "paragraph",
      "text": "Chemical Structure"
    },
    {
      "type": "paragraph",
      "text": "and Class"
    },
    {
      "type": "paragraph",
      "text": "Anion"
    },
    {
      "type": "paragraph",
      "text": "Cation"
    },
    {
      "type": "paragraph",
      "text": "Viscosity+"
    },
    {
      "type": "paragraph",
      "text": "25C"
    },
    {
      "type": "paragraph",
      "text": "(cp or mPa.s)"
    },
    {
      "type": "paragraph",
      "text": "Viscosity+"
    },
    {
      "type": "paragraph",
      "text": "37C"
    },
    {
      "type": "paragraph",
      "text": "(cp or mPa.s)"
    },
    {
      "type": "paragraph",
      "text": "Relaxivity"
    },
    {
      "type": "paragraph",
      "text": "1.5T (3T)"
    },
    {
      "type": "paragraph",
      "text": "Osmolality"
    },
    {
      "type": "paragraph",
      "text": "(mOsm/kg H2O) Log k Therm"
    },
    {
      "type": "paragraph",
      "text": "(cond7.4)"
    },
    {
      "type": "paragraph",
      "text": "Elucirem(R) (Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "Vueway(R) (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "Macrocyclic Non-ionic"
    },
    {
      "type": "paragraph",
      "text": "Gadopiclenol****"
    },
    {
      "type": "paragraph",
      "text": "None"
    },
    {
      "type": "paragraph",
      "text": "12.6*"
    },
    {
      "type": "paragraph",
      "text": "7.6"
    },
    {
      "type": "paragraph",
      "text": "12.8 (11.6)"
    },
    {
      "type": "paragraph",
      "text": "850"
    },
    {
      "type": "paragraph",
      "text": "18.7"
    },
    {
      "type": "paragraph",
      "text": "Magnevist(R)"
    },
    {
      "type": "paragraph",
      "text": "(Bayer Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "Gd-DTPA"
    },
    {
      "type": "paragraph",
      "text": "Linear Ionic"
    },
    {
      "type": "paragraph",
      "text": "Gadopentetate"
    },
    {
      "type": "paragraph",
      "text": "Dimeglumine"
    },
    {
      "type": "paragraph",
      "text": "4.9*"
    },
    {
      "type": "paragraph",
      "text": "2.9"
    },
    {
      "type": "paragraph",
      "text": "4.1 (3.7)"
    },
    {
      "type": "paragraph",
      "text": "1960"
    },
    {
      "type": "paragraph",
      "text": "22.5 (18.4)"
    },
    {
      "type": "paragraph",
      "text": "Prohance(R) (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "Gd-HP-D03A"
    },
    {
      "type": "paragraph",
      "text": "Macrocyclic Non-ionic"
    },
    {
      "type": "paragraph",
      "text": "Gadoteridol"
    },
    {
      "type": "paragraph",
      "text": "None"
    },
    {
      "type": "paragraph",
      "text": "2.0*"
    },
    {
      "type": "paragraph",
      "text": "1.3"
    },
    {
      "type": "paragraph",
      "text": "4.1 (3.7)"
    },
    {
      "type": "paragraph",
      "text": "630"
    },
    {
      "type": "paragraph",
      "text": "23.8 (17.2)"
    },
    {
      "type": "paragraph",
      "text": "Multihance(R) (Bracco)"
    },
    {
      "type": "paragraph",
      "text": "Gd-BOPTA"
    },
    {
      "type": "paragraph",
      "text": "Linear Ionic"
    },
    {
      "type": "paragraph",
      "text": "Gadobenate"
    },
    {
      "type": "paragraph",
      "text": "Dimeglumine"
    },
    {
      "type": "paragraph",
      "text": "9.2*"
    },
    {
      "type": "paragraph",
      "text": "5.3"
    },
    {
      "type": "paragraph",
      "text": "6.3 (5.5)"
    },
    {
      "type": "paragraph",
      "text": "1970"
    },
    {
      "type": "paragraph",
      "text": "22.6 (18.4)"
    },
    {
      "type": "paragraph",
      "text": "Omniscan"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "(GE Healthcare) Gd-DTPA-BMA"
    },
    {
      "type": "paragraph",
      "text": "Linear Non-ionic"
    },
    {
      "type": "paragraph",
      "text": "Gadodiamide"
    },
    {
      "type": "paragraph",
      "text": "None"
    },
    {
      "type": "paragraph",
      "text": "2.0"
    },
    {
      "type": "paragraph",
      "text": "1.4"
    },
    {
      "type": "paragraph",
      "text": "4.3 (4)"
    },
    {
      "type": "paragraph",
      "text": "789"
    },
    {
      "type": "paragraph",
      "text": "16.9 (14.9)"
    },
    {
      "type": "paragraph",
      "text": "Optimark"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "(Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "Gd-DTPA-BMEA"
    },
    {
      "type": "paragraph",
      "text": "Linear Non-ionic"
    },
    {
      "type": "paragraph",
      "text": "Gadoversetamide"
    },
    {
      "type": "paragraph",
      "text": "None"
    },
    {
      "type": "paragraph",
      "text": "2.8**"
    },
    {
      "type": "paragraph",
      "text": "2.0"
    },
    {
      "type": "paragraph",
      "text": "4.7 (4.5)"
    },
    {
      "type": "paragraph",
      "text": "1110"
    },
    {
      "type": "paragraph",
      "text": "16.8 (15)"
    },
    {
      "type": "paragraph",
      "text": "EOVIST/Primovist(R)"
    },
    {
      "type": "paragraph",
      "text": "(Bayer Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "Gd-EOB-DTPA"
    },
    {
      "type": "paragraph",
      "text": "Linear Ionic"
    },
    {
      "type": "paragraph",
      "text": "Gadoxetate"
    },
    {
      "type": "paragraph",
      "text": "Disodium"
    },
    {
      "type": "paragraph",
      "text": "1.19"
    },
    {
      "type": "paragraph",
      "text": "6.9 (6.2)"
    },
    {
      "type": "paragraph",
      "text": "688"
    },
    {
      "type": "paragraph",
      "text": "23.5 (18.7)"
    },
    {
      "type": "paragraph",
      "text": "Gadavist/Gadovost"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "(Bayer Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "Gd-BT-D03A"
    },
    {
      "type": "paragraph",
      "text": "Macrocyclic Non Ionic"
    },
    {
      "type": "paragraph",
      "text": "Gadobutrol"
    },
    {
      "type": "paragraph",
      "text": "None"
    },
    {
      "type": "paragraph",
      "text": "4.96"
    },
    {
      "type": "paragraph",
      "text": "5.2 (5)"
    },
    {
      "type": "paragraph",
      "text": "1603"
    },
    {
      "type": "paragraph",
      "text": "21.8 (15.5)"
    },
    {
      "type": "paragraph",
      "text": "Dotarem(R) (Guerbet)"
    },
    {
      "type": "paragraph",
      "text": "Clariscan"
    },
    {
      "type": "paragraph",
      "text": "TM"
    },
    {
      "type": "paragraph",
      "text": "(GE Healthcare)"
    },
    {
      "type": "paragraph",
      "text": "Gd-DOTA"
    },
    {
      "type": "paragraph",
      "text": "Macrocyclic Ionic"
    },
    {
      "type": "paragraph",
      "text": "Gadoterate"
    },
    {
      "type": "paragraph",
      "text": "Meglumine"
    },
    {
      "type": "paragraph",
      "text": "3.4*"
    },
    {
      "type": "paragraph",
      "text": "2.4"
    },
    {
      "type": "paragraph",
      "text": "3.6 (3.5)"
    },
    {
      "type": "paragraph",
      "text": "1350"
    },
    {
      "type": "paragraph",
      "text": "25.6 (19.3)"
    },
    {
      "type": "paragraph",
      "text": "Data from product package inserts, product brochures, technical information services and Rohrer, M, et al., Comparison of Magnetic Properties of MRI Contrast Media Solutions"
    },
    {
      "type": "paragraph",
      "text": "at Different Field Strengths. Investigative Radiology 2005; 40:715-724."
    },
    {
      "type": "paragraph",
      "text": "* Measured at 20"
    },
    {
      "type": "paragraph",
      "text": "."
    },
    {
      "type": "paragraph",
      "text": "** Data on file with Covidien"
    },
    {
      "type": "paragraph",
      "text": "*** Hexabrix is a registered trademark of Guerbet, S.A. and is co-marketed in the U.S. by Guerbet LLC and Covidien."
    },
    {
      "type": "paragraph",
      "text": "o Viscosities of most products intended for oral administration are not reported by manufacturers."
    },
    {
      "type": "paragraph",
      "text": "# Barium concentrations are expressed as percent by weight (%w/w) and percent weight-in volume (% w/v). Percent by weight is the number of grams of barium sulfate per 100"
    },
    {
      "type": "paragraph",
      "text": "grams of final suspension. For barium powders, percent by weight is the proportion of total powder weight that is pure barium, and the remainder is additives (Ex., barium 100%"
    },
    {
      "type": "paragraph",
      "text": "w/w is pure barium with no additives). Percent weight-in volume is the number of grams of barium sulfate per 100 mL of final suspension"
    },
    {
      "type": "paragraph",
      "text": "1 Adopted from Reiter et al. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012; 14(1): 31. Cond 7.4 refers"
    },
    {
      "type": "paragraph",
      "text": "to value at physiologic pH of 7.4"
    },
    {
      "type": "paragraph",
      "text": "****Gadopiclenol demonstrates kinetic stability and a long dissociation half-life that are comparable to other Group II macrocyclic agents. Based on the most recent scientific and"
    },
    {
      "type": "paragraph",
      "text": "clinical evidence, the ACR Committee on Drugs and Contrast Media considers the risk of NSF among patients exposed to standard or lower than standard doses of Gadopiclenol is"
    },
    {
      "type": "paragraph",
      "text": "sufficiently low or possibly nonexistent such that it has been classified as a Group II agent."
    }
  ]
}
